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A B S T R A C T
Background
Liver resection is a major surgery with significant mortality and morbidity. Specialists have tested various methods in attempts to
limit blood loss, transfusion requirements, and morbidity during elective liver resection. These methods include different approaches
(anterior versus conventional approach), use of autologous blood donation, cardiopulmonary interventions such as hypoventilation,
low central venous pressure, different methods of parenchymal transection, different methods of management of the raw surface of
the liver, different methods of vascular occlusion, and different pharmacological interventions. A surgeon typically uses only one of
the methods from each of these seven categories. The optimal method to decrease blood loss and transfusion requirements in people
undergoing liver resection is unknown.
Objectives
To assess the effects of different interventions for decreasing blood loss and blood transfusion requirements during elective liver resection.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and Science Citation Index
Expanded to September 2015 to identify randomised clinical trials. We also searched trial registers and handsearched the references
lists of identified trials.
Selection criteria
We included only randomised clinical trials (irrespective of language, blinding, or publication status) comparing different methods of
decreasing blood loss and blood transfusion requirements in people undergoing liver resection.
1Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Two review authors independently identified trials and collected data. We assessed the risk of bias using Cochrane domains. We
conducted a Bayesian network meta-analysis using the Markov chain Monte Carlo method in WinBUGS 1.4, following the guidelines
of the National Institute for Health and Care Excellence Decision Support Unit guidance documents. We calculated the odds ratios
(OR) with 95% credible intervals (CrI) for the binary outcomes, mean differences (MD) with 95% CrI for continuous outcomes, and
rate ratios with 95% CrI for count outcomes, using a fixed-effect model or random-effects model according to model-fit. We assessed
the evidence with GRADE.
Main results
We identified 67 randomised clinical trials involving a total of 6197 participants. All the trials were at high risk of bias. A total of 5771
participants from 64 trials provided data for one or more outcomes included in this review. There was no evidence of differences in
most of the comparisons, and where there was, these differences were in single trials, mostly of small sample size. We summarise only
the evidence that was available in more than one trial below. Of the primary outcomes, the only one with evidence of a difference
from more than one trial under the pair-wise comparison was in the number of adverse events (complications), which was higher with
radiofrequency dissecting sealer than with the clamp-crush method (rate ratio 1.85, 95% CrI 1.07 to 3.26; 250 participants; 3 studies;
very low-quality evidence). Among the secondary outcomes, the only differences we found frommore than one trial under the pair-wise
comparison were the following: blood transfusion (proportion) was higher in the low central venous pressure group than in the acute
normovolemic haemodilution plus low central venous pressure group (OR 3.19, 95% CrI 1.56 to 6.95; 208 participants; 2 studies;
low-quality evidence); blood transfusion quantity (red blood cells) was lower in the fibrin sealant group than in the control (MD−0.53
units, 95% CrI −1.00 to −0.07; 122 participants; 2; very low-quality evidence); blood transfusion quantity (fresh frozen plasma)
was higher in the oxidised cellulose group than in the fibrin sealant group (MD 0.53 units, 95% CrI 0.36 to 0.71; 80 participants; 2
studies; very low-quality evidence); blood loss (MD −0.34 L, 95% CrI −0.46 to −0.22; 237 participants; 4 studies; very low-quality
evidence), total hospital stay (MD−2.42 days, 95% CrI −3.91 to−0.94; 197 participants; 3 studies; very low-quality evidence), and
operating time (MD −15.32 minutes, 95% CrI −29.03 to −1.69; 192 participants; 4 studies; very low-quality evidence) were lower
with low central venous pressure than with control. For the other comparisons, the evidence for difference was either based on single
small trials or there was no evidence of differences. None of the trials reported health-related quality of life or time needed to return to
work.
Authors’ conclusions
Paucity of data meant that we could not assess transitivity assumptions and inconsistency for most analyses. When direct and indirect
comparisons were available, network meta-analysis provided additional effect estimates for comparisons where there were no direct
comparisons. However, the paucity of data decreases the confidence in the results of the network meta-analysis. Low-quality evidence
suggests that liver resection using a radiofrequency dissecting sealer may be associated with more adverse events than with the clamp-
crush method. Low-quality evidence also suggests that the proportion of people requiring a blood transfusion is higher with low central
venous pressure than with acute normovolemic haemodilution plus low central venous pressure; very low-quality evidence suggests
that blood transfusion quantity (red blood cells) was lower with fibrin sealant than control; blood transfusion quantity (fresh frozen
plasma) was higher with oxidised cellulose than with fibrin sealant; and blood loss, total hospital stay, and operating time were lower
with low central venous pressure than with control. There is no evidence to suggest that using special equipment for liver resection is
of any benefit in decreasing the mortality, morbidity, or blood transfusion requirements (very low-quality evidence). Radiofrequency
dissecting sealer should not be used outside the clinical trial setting since there is low-quality evidence for increased harm without any
evidence of benefits. In addition, it should be noted that the sample size was small and the credible intervals were wide, and we cannot
rule out considerable benefit or harm with a specific method of liver resection.
P L A I N L A N G U A G E S U M M A R Y
Surgical methods to decrease blood loss during liver surgery
Background
Many cancerous and non-cancerous growths that develop in the liver are treated by removing part of the liver (liver resection), which
is major surgery with high risk of complications, including blood loss during division of the liver tissue. Specialists have tested several
methods to decrease blood loss during liver resection. These include lowering the pressure in the liver veins (low central venous
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pressure) or decreasing the amount of air that enters and leaves the lungs (hypoventilation), again aimed at decreasing central venous
pressure; different ways of cutting the liver, for example, without any special equipment or using ultrasound waves or high-frequency
(radiofrequency); applying glue to decrease bleeding from the cut surface; blocking the blood supply to the liver during the operation,
a process known as vascular occlusion, which could be performed continuously or intermittently. In addition, medical treatments that
improve clotting of blood can be given to decrease blood loss. A surgeon typically uses one or more methods to decrease blood loss
during liver surgery. The optimal method is unknown. We sought to identify the best methods of decreasing blood loss during liver
surgery by performing a literature search that included all studies reported until September 2015. We used special statistical methods,
so-called network meta-analyses. to compare the different treatments simultaneously as compared to the traditional Cochrane method
of comparing two treatments at a time as there are multiple treatment strategies.
Study characteristics
We identified 67 randomised clinical trials involving a total of 6197 participants that met our inclusion criteria. However, we were only
able to include 5771 participants from 64 trials since investigators either did not include the remaining participants in the analysis or
did not report any outcomes of interest.
Source of funding: 24 trials (35.8%) were funded by parties with no financial interest in obtaining positive results for the treatment
being evaluated. The remaining trials received funding from either parties who would gain financially from the results of the study or
did not report the funding.
Quality of evidence
All the trials were at high risk of bias, that is, investigators may have overestimated the benefits or underestimated the harms of one
method or the other because of the way that the studies were conducted. Many trials included few participants, and there was a good
chance of arriving at the wrong conclusions because of this. The overall quality of evidence was low or very low.
Key results
There was no evidence of differences in most of the comparisons, and where there was, these differences were in single trials, mostly
of small sample size. Such evidence is unreliable. So, we mention only the evidence that was available in more than one trial. Of the
primary outcomes, the only one where there was evidence of difference was in the number of adverse events, which was higher with
radiofrequency dissecting sealer than with clamp-crush method. Among the secondary outcomes, the only evidence of difference was
in the following:
Blood transfusion (percentage): higher in the low central venous pressure group than in the acute normovolemic haemodilution (diluting
the blood by giving fluids during operation) plus low central venous pressure group.
Blood transfusion amount: lower in the fibrin sealant group (a type of glue applied to the cut surface of the liver) than in the control.
Blood transfusion (fresh frozen plasma − a component of blood): higher in the oxidised cellulose (another type of glue applied to the
cut surface of the liver) group than in the fibrin sealant group.
Blood loss, total hospital stay, and operating time: lower with the low central venous pressure group than control.
For other comparisons, the evidence for difference was based on single small trials, or there was no evidence of differences. None of
the trials reported health-related quality of life or time needed to return to work. There is no evidence to suggest that using special
equipment for liver resection is of any benefit.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
M ethods to decrease blood loss during liver resection: a network meta-analysis. Primary outcomes
Patient or population: people undergoing liver resect ion
Settings: secondary or tert iary sett ing
Intervention and control: various treatments
Follow-up: unt il discharge or 1 month (except for mortality (long-term follow-up) which was reported at 1 year
Outcomes Anterior approach
versus conventional
approach
Autologous
blood donation ver-
sus control
Cardiopulmonary
interventions
M eth-
ods of parenchymal
transection
M ethods of dealing
with cut surface
M ethods of vascu-
lar occlusion
Pharmacological
interventions
Treatments
The f irst treatment
listed is the control.
The remaining are
intervent ions
1. Convent ional
approach
2. Anterior
approach
1. Control
2. Autologous
blood donat ion
1. Control
2. Acute
normovolemic
haemodilut ion plus
low central venous
pressure
3. Hypovent ilat ion
4. Low central
venous pressure
1. Clamp-crush
method
2. Cavitron
ultrasonic surgical
aspirator
3. Hydrojet
4. Radiof requency
dissect ing sealer
5. Sharp
transect ion method
6. Stapler
1. Control
2. Argon beam
3. Collagen
4. Cyanoacrylate
5. Fibrin sealant
6. Fibrin sealant
plus collagen
7. Oxidised
cellulose
8. Plasmajet
1. Control
2. Cont inuous
hepat ic vascular
exclusion
3. Continuous
portal triad
clamping
4. Continuous
select ive hepat ic
vascular exclusion
5. Continuous
select ive portal
triad clamping
6. Interm it tent
portal triad
clamping
7. Interm it tent
select ive portal
triad clamping
1. Control
2. Ant i-thrombin
III
3. Recombinant
factor VIIa
4. Tranexamic
acid
Link for detailed
’Summary of Find-
ings tables’
Table 14 Table 15 Table 16 Table 17 Table 18 Table 19 Table 20
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Mortality (periopera-
t ive)
There was no evi-
dence of dif f erences
in perioperat ive mor-
tality between the 2
groups
Quality of evidence
= very low1,2,3.
There was no evi-
dence of dif f erences
in perioperat ive mor-
tality between the
two groups
Quality of evidence
= very low1,2,3.
There was no evi-
dence of dif f erences
in perioperat ive mor-
tality for any of the
comparisons
Quality of evidence
= very low1,2,3.
There was no evi-
dence of dif f erences
in perioperat ive mor-
tality for any of the
comparisons
Quality of evidence
= very low1,2,3.
There was no evi-
dence of dif f erences
in perioperat ive mor-
tality for any of the
comparisons
Quality of evidence
= very low1,2,3.
There was no evi-
dence of dif f erences
in perioperat ive mor-
tality for any of the
comparisons
Quality of evidence
= very low1,2,3.
There was no evi-
dence of dif f erences
in perioperat ive mor-
tality for any of the
comparisons
Quality of evidence
= very low1,2,3.
Mortality (longest
follow-up)
None of the trials
reported this out-
come.
There was no evi-
dence of dif f erences
in mortality at 1
year between the 2
groups. Quality of
evidence = very low)
1,2,3.
None of the trials
reported this out-
come.
None of the trials
reported this out-
come.
None of the trials
reported this out-
come.
None of the trials
reported this out-
come.
None of the trials
reported this out-
come.
Serious adverse
events (proport ion)
There was no evi-
dence of dif f erences
in the proport ion of
part icipants experi-
encing serious ad-
verse events be-
tween the 2 groups
Quality of evidence
= very low1,2,3.
None of the trials
reported this out-
come.
There was no evi-
dence of dif f erences
in the proport ion of
part icipants experi-
encing serious ad-
verse events (for any
of the comparisons
Quality of evidence
= very low1,2,3.
There was no evi-
dence of dif f erences
in the proport ion of
part icipants experi-
encing serious ad-
verse events for any
of the comparisons
Quality of evidence
= very low1,2,3.
There was no evi-
dence of dif f erences
in the proport ion of
part icipants experi-
encing serious ad-
verse events for any
of the comparisons
Quality of evidence
= very low1,2,3.
The proport ion of
part icipants experi-
encing serious ad-
verse eventsa was
lower in cont inuous
select ive portal triad
clamping than con-
t inuous portal triad
clamping
• Proport ion with
serious adverse
events in
cont inuous portal
triad clamping: 367
per 1000
• Proport ion with
serious adverse
events in
cont inuous
There was no evi-
dence of dif f erences
in the proport ion of
part icipants experi-
encing serious ad-
verse events for any
of the comparisons
Quality of evidence
= very low1,2,3.
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select ive portal
triad clamping: 154
per 1000 (66 to 352)
• Relat ive ef fect:
OR 0.42, 95% CrI 0.
18 to 0.96
• 120
part icipants; 1
study.
• Quality of
evidence = very low
1,2,3.
There was no evi-
dence of dif f erences
in other compar-
isons.
Quality of evidence
= very low1,2,3
Serious adverse
events (number)
None of the trials
reported this out-
come.
None of the trials
reported this out-
come.
There was no evi-
dence of dif f erences
in the number of se-
rious adverse events
for any of the com-
parisons
Quality of evidence
= very low1,2,3.
The number of seri-
ous
adverse events was
higher in radiof re-
quency dissect ing
sealer than clamp-
crush method
• Serious
adverse rate in
clamp-crush
method: 53 per
1000
• Serious
adverse rate in
radiof requency
dissect ing sealer:
193 per 1000 (66 to
740)
The number of seri-
ous adverse events
was higher in f ibrin
sealant than argon
beam
• Serious
adverse event rate
in argon beam: 65
per 1000
• Serious
adverse event rate
in f ibrin sealant:
313 per 1000 (112
to 1138)
• Relat ive ef fect:
rate rat io 4.81, 95%
CrI 1.73 to 17.5.
The number of seri-
ous adverse events
was lower in inter-
m it tent portal triad
clamping than con-
t inuous portal triad
clamping
• Serious
adverse event rate
in cont inuous portal
triad clamping: 136
per 1000
• Serious
adverse event rate
in interm it tent
portal triad
clamping: 12 per
There was no evi-
dence of dif f erences
in the number of se-
rious adverse events
for any of the com-
parisons
Quality of evidence
= very low1,2,3.
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• Relat ive ef fect:
rate rat io 3.64, 95%
CrI 1.25 to 13.97.
• 130
part icipants; 2
studies.
• Quality of
evidence = low1,2.
There was no evi-
dence of dif f erences
in other compar-
isons.
Quality of evidence
= very low1,2,3.
• 121
part icipants; 1
study.
• Quality of
evidence = low1,2.
There was no evi-
dence of dif f erences
in other compar-
isons.
Quality of evidence
= very low1,2,3.
1000 (0 to 76)
• Relat ive ef fect:
rate rat io 0.09, 95%
CrI 0.00 to 0.56
• 86
part icipants; 1
study.
• Quality of
evidence = low1,2.
There was no evi-
dence of dif f erences
in other compar-
isons
Quality of evidence
= very low1,2,3.
Health-related qual-
ity of lif e
None of the trials
reported this out-
come.
None of the trials
reported this out-
come.
None of the trials re-
ported this outcome
at any t ime point.
None of the trials re-
ported this outcome
at any t ime point.
None of the trials re-
ported this outcome
at any t ime point.
None of the trials re-
ported this outcome
at any t ime point.
None of the trials re-
ported this outcome
at any t ime point.
CrI: credible intervals; OR: odds rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias was unclear or high in the trial(s) (downgraded by 1 point).
2 Sample size was low (total number of part icipants fewer than 400 for cont inuous outcomes and fewer than 300 events in
total in both groups for other outcomes) (downgraded by 1 point).
3 Credible intervals spanned no ef fect and clinically signif icant ef fect (20% relat ive risk reduct ion for binary outcomes;
standardised mean dif ference of 0.5 for health-related quality of lif e) (downgraded by 1 point).
a Network meta-analysis was performed for this outcome because of the availability of direct and indirect comparisons in the
network. The remaining outcomes were analysed by direct comparisons.
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B A C K G R O U N D
Description of the condition
Liver resection refers to removal of part of the liver. Every year,
an average of 2400 people undergo liver resections in England
(HSCIC 2015), 11,000 in the USA (Asiyanbola 2008), and 7200
in France (Farges 2012). In the West, the main indication for
liver resection is colorectal liver metastases. Colorectal cancer is
the third most common cancer in the world. Approximately 1.36
million people develop colorectal cancer each year (IARC 2012),
and 50% to 60% will have colorectal liver metastases (Garden
2006). Liver resection, the only curative option for people with
colorectal liver metastases, is indicated in 20% to 30% of people
in whom the metastasis is confined to the liver (Garden 2006).
Five-year survival for people with colorectal liver metastases who
undergo liver resection is about 45% (Garden 2006; Nordlinger
2013).
The second most common reason for liver resection is hepato-
cellular carcinoma. Hepatocellular carcinoma is one of the most
common cancers, with a worldwide annual incidence of 780,000
people (IARC 2012). Most hepatocellular carcinomas develop in
cirrhotic livers (Llovet 2005). Liver resection and liver transplanta-
tion are themain curative treatments (Llovet 2005;Taefi 2013).Of
people who present with hepatocellular carcinoma, about 5% are
candidates for liver resection (Chen 2006). Survival after surgery
depends on the stage of cancer and the severity of the underly-
ing chronic liver disease. People with early-stage disease (cancers
smaller than 5 cm) have a five-year survival of about 50%, whereas
people with more advanced disease have a five-year survival of
about 30% (Chen 2006; Navadgi 2016). Screening programmes
in theory should lead to a diagnosis at an earlier stage, when surgery
is feasible and associated with better outcomes.
Liver resection may also be performed for benign liver tumours
(Belghiti 1993).
The liver can be subdivided into eight segments (Couinaud 1999),
which can be removed individually or by right hemi-hepatectomy
(Couinaud segments 5 to 8), left hemi-hepatectomy (segments 2
to 4), right trisectionectomy (segments 4 to 8), or left trisectionec-
tomy (segments 2 to 5 and 8 ± 1) (Strasberg 2000). Although every
liver resection is considered major surgery, only resection of three
or more segments is considered a major liver resection (Belghiti
1993).
Blood loss during liver resection is an important factor affecting
complications and mortality in people undergoing liver resection
(Shimada 1998; Yoshimura 2004; Ibrahim 2006). Estimates of
blood loss have ranged from 200mL to 2 L per patient (Gurusamy
2009a). Major blood loss during surgery or in the immediate post-
operative period may result in death of the patient. Major blood
loss can be defined based on the Advanced Trauma Life Support
(ATLS definition of class 3 or class 4 shock, where there is a loss of
30% or more of blood volume) (ATLS 2008). During liver resec-
tion, the liver parenchyma is transected at the plane of resection.
The blood vessels and the bile duct branches in the plane of resec-
tion (cut surface) are then sealed by different methods to prevent
blood or bile leakage.
Description of the intervention
Specialists have tested various interventions in attempts to decrease
blood loss during liver resection. These interventions include an-
terior approach as compared to the standard (conventional) surgi-
cal approach (Capussotti 2012); autologous blood donation with
an aim of decreasing the use of others’ blood (heterologous blood
transfusion) (Kajikawa 1994), various cardiopulmonary interven-
tions such as acute normovolemic haemodilution (ANH), low
central venous pressure (central venous pressure), and hypoven-
tilation that can be used either alone or in combination to de-
crease blood loss (Gurusamy 2012; Table 1); different methods of
liver parenchymal transection (the way that the liver parenchyma
is divided), such as the clamp-crush method, the cavitron ultra-
sonic surgical aspirator, or the radiofrequency dissecting sealer
(Gurusamy 2009b; Table 2); different methods of management
of the cut surface of the liver (the way that the resection plane of
the remnant liver is managed), such as use of fibrin sealant, argon
beamer, or electrocautery and suture material (Frilling 2005; Table
3); temporary occlusion of the blood vessels that supply the liver
(Gurusamy 2009a; Table 4); and various pharmacological inter-
ventions such as recombinant factor VIIa, antithrombin III, and
tranexamic acid (Gurusamy 2009c).
Interventions selected to decrease blood loss can be used alone or in
various combinations. Usually surgeons at different centres follow
their own protocol for decreasing blood loss. The finger-fracture
and clamp-crush techniques do not involve specialist equipment.
The minimum and standard method of managing the cut surface
involves electrocautery for sealing small vessels and suturing larger
vessels. Altogether, the goal of these interventions is to decrease
blood loss and the associated morbidity and mortality.
How the intervention might work
Temporarily occluding the vessels that supply blood to the liver
may reduce the blood loss from the cut vessels. Different methods
of liver transection are used to identify major vessels and allow
them to be sutured and divided. This might result in clear visuali-
sation of the blood vessels, which canbe clamped and thendivided.
Different topical methods of managing the cut surface attempt to
seal the blood vessels on the resection plane, preventing blood loss.
Cardiopulmonary interventions decrease the amount of blood lost
by dilution of blood or reducing the pressure in the hepatic veins
(low central venous pressure). Autologous blood donation involves
venesection of the patient prior to surgery and storage of blood
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which can be replaced if required during or after surgery with the
aim of reducing homologous blood transfusion. Pharmacological
interventions work by increasing the clotting of blood with a view
to decreasing the blood loss. The anterior approach is a surgical
technique that involves occluding the inflow and outflow vessels
and performing parenchymal transection prior to mobilisation of
the right liver (Liu 2006). The potential advantage of anterior ap-
proach over the conventional approach, in which liver is mobilised
first, is that inadvertent injury to the blood vessels and the result-
ing bleeding can be avoided since the blood vessels are occluded
before liver mobilisation in the anterior approach. Blood vessels
may also be occluded first in conventional approach if one of the
methods of vascular occlusion is used.
Why it is important to do this review
Liver resection is a major surgical procedure with significant mor-
tality (estimated at 3.5%) and morbidity (estimated around 40%)
(Finch 2007; Reissfelder 2011). Interventions that decrease blood
loss may improve outcomes of liver resection. Previous system-
atic reviews have assessed some of the categories of interven-
tions (Gurusamy 2009a; Gurusamy 2009b; Gurusamy 2009c;
Gurusamy 2012). We also performed a network meta-analysis
assessing the combination of a method of vascular occlusion,
parenchymal transection, and method of dealing with raw surface
as a package (Simillis 2014).However, in that review,we found that
most authors did not report the different aspects of the method of
liver resection other than the factor being randomised or allowed
surgeons to choose how to deal with the other factors according to
their preference. Since that review excluded such trials, reviewers
could only include a few studies. In this updated review, we have
covered all the different aspects of the methods to decrease blood
loss and blood transfusion requirements during liver resection.We
included trials where at least one of the methods to decrease blood
loss and blood transfusion requirements during liver resection was
included in a randomised comparison with the other aspects either
not reported or allowed to vary according to surgeons’ preference.
This systematic review is intended as a useful guide for patients
and healthcare providers as they seek to understand the role of
different methods in decreasing blood loss and blood transfusion
requirements in people undergoing elective liver resection.
O B J E C T I V E S
To assess the effects of different interventions for decreasing blood
loss and blood transfusion requirements during elective liver re-
section.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only randomised clinical trials for this network
meta-analysis. We excluded studies of other designs.
Types of participants
We included randomised clinical trials in which participants un-
derwent elective liver resection using different types of vascular oc-
clusion or no vascular occlusion, irrespective of themethod of vas-
cular occlusion or the nature of the background liver (i.e. normal
or cirrhotic), different types of parenchymal transection, different
types of management of cut surface, or whether pharmacological
interventions were used. We excluded randomised clinical trials in
which participants underwent liver resection combined with other
major surgical procedures (e.g. one-stage liver and bowel resection
for synchronous metastases from colorectal tumours).
Types of interventions
We included randomised clinical trials that assessed one or more
of the following interventions in this review.
1. Anterior approach versus conventional approach.
2. Autologous blood donation versus control.
3. Cardiopulmonary interventions.
4. Methods of liver parenchymal transection.
5. Methods of management of the raw surface (resection
plane) of the liver.
6. Methods of vascular occlusion (including no vascular
occlusion).
7. Pharmacological interventions.
The surgeon (and hence the trialists) may use a particular combi-
nationof each of the above. For example, one surgeonmay perform
liver resection using intermittent vascular occlusion, clamp-crush
technique as the method of liver parenchymal transection, and a
fibrin sealant on the cut surface, while another surgeon may per-
form liver resection without using any method of vascular occlu-
sion, with the cavitron ultrasonic surgical aspirator as the method
of liver parenchymal transection, without any fibrin sealant on the
cut surface, or any additional pharmacological intervention.
Commonly used surgical techniques under each of the above cat-
egories are listed in Table 1, Table 2, Table 3, and Table 4. In
practice, surgeons can use any intervention in Table 1 in combi-
nation with an intervention from Table 2, Table 3, or Table 4.
Any intervention in Table 2 can be used in combination with an
intervention from Table 3 or Table 4. Any intervention in Table 3
can be used in combination with an intervention in Table 4. Any
of these combinations can be used in combination with anterior
or conventional approach, with autologous blood donation, and
with or without a pharmacological intervention.
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Types of outcome measures
We assessed the comparative effectiveness of available treatment
strategies that aimed to decrease blood loss during liver resection
for the following outcomes.
Primary outcomes
1. Mortality.
i) Peri-operative (30-day mortality or postoperative
mortality). We used in-hospital mortality as defined in the
included trials.
ii) Long-term (at longest follow-up).
2. Adverse events. We defined an adverse event as any
untoward medical occurrence not necessarily having a causal
relationship with the treatment but resulting in a dose reduction
or discontinuation of treatment (ICH-GCP 1997). We
considered a serious adverse event to be any event that would
increase mortality; was life-threatening; required inpatient
hospitalisation; resulted in persistent or significant disability;
might have jeopardised the person; or required intervention to
prevent it. Serious adverse events correspond approximately to
grade III or above of the Clavien-Dindo classification - the only
validated system for classifying postoperative complications
(Dindo 2004; Clavien 2009;Table 5). In cases where the authors
did not classify the severity of adverse events, we followed the
criteria provided in Table 5 to classify the severity. We analysed
the following information.
i) Proportion of participants experiencing serious adverse
events.
ii) Number of serious adverse events.
iii) Proportion of participants experiencing adverse events.
iv) Number of adverse events.
3. Quality of life as defined in the included trials.
i) Short-term (30 days, three months).
ii) Long-term (longest follow-up).
Secondary outcomes
1. Blood transfusion requirements.
i) Number of participants who required red blood cells
or whole blood heterologous blood transfusion.
ii) Quantity of blood transfusion (heterologous red blood
cells or whole blood product, platelet, or fresh frozen plasma).
iii) Total operative blood loss.
iv) Number of participants who had major operative
blood loss.
2. Hospital stay.
i) Length of total hospital stay (including re-admissions).
ii) Intensive therapy unit stay.
3. Operating time.
4. Time needed to return to work.
Search methods for identification of studies
Electronic searches
We aimed to identify all relevant randomised clinical trials regard-
less of language or publication status (published, unpublished, in
press, or in progress) (Royle 2003).
We searched the following databases up to 23 September 2015.
• The Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 9) in the Cochrane Library.
• MEDLINE via PubMed (from 1947).
• EMBASE via Ovid SP (from 1974).
• Science Citation Index Expanded via Web of Science (from
1975).
We also searched the World Health Organization International
Clinical Trials Registry Platform search portal (www.who.int/
ictrp), which searches various trial registers, including ISRCTN
and ClinicalTrials.gov, to identify further trials (searched 23
September 2015). Because existing Cochrane systematic reviews
have comprehensively assessed subsets of all available interventions
on this topic, we also used these reviews as a way to identify tri-
als(Gurusamy 2009a; Gurusamy 2009b). We present full search
strategies in Appendix 1.
Searching other resources
We searched the references of the identified trials for additional
trials eligible for inclusion.
Data collection and analysis
Selection of studies
Two review authors (EM and KG) independently screened the ti-
tles and abstracts of all records retrieved. We sought full text for
any references that at least one of the authors identified as poten-
tially eligible. We assessed the full text for inclusion and listed the
reasons for the excluding trials in the Characteristics of excluded
studies tables. We listed any ongoing trials in Characteristics of
ongoing studies for further follow-up in updates of the reviews.
We resolved discrepancies through discussion.
Data extraction and management
Two review authors (KG and EM) independently extracted the
following data.
1. Year and language of publication.
2. Country in which investigators recruited the participants.
3. Year(s) in which the trial took place.
4. Inclusion and exclusion criteria.
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5. Participant characteristics such as age, sex, underlying
disease, comorbidity, number and proportion of participants
with cirrhosis, and number and proportion of participants
undergoing major versus minor liver resection.
6. Details of the intervention and treatment strategy that
aimed to decrease blood loss and blood transfusion requirements
(e.g. surgical technique, procedure and co-intervention,
concurrent surgery, and medications).
7. Outcomes (Primary outcomes; Secondary outcomes).
8. Follow-up time points.
9. Risk of bias (Assessment of risk of bias in included studies).
We sought unclear or missing information by contacting the au-
thors of the individual trials. If there had been any doubt whether
trials shared the same participants - completely or partially (by
identifying common authors and centres) - we would have con-
tacted the authors of the trials to clarify whether the trial report
was duplicated. We resolved any differences in opinion through
discussion.
Assessment of risk of bias in included studies
We followed the guidance in the Cochrane Handbook for System-
atic Reviews of Intervention and those described in the Cochrane
Hepato-Biliary GroupModule to assess the risk of bias in included
studies (Higgins 2011; Gluud 2013). Specifically, we assessed the
risk of bias in included trials for the following domains (Schulz
1995; Moher 1998; Kjaergard 2001; Wood 2008; Lundh 2012;
Savovic 2012a; Savovic 2012b).
Allocation sequence generation
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, and throwing
dice were adequate if an independent adjudicator performed
them.
• Uncertain risk of bias: authors described the trial as
randomised but did not specify the method of sequence
generation.
• High risk of bias: the sequence generation method was not,
or may not have been, random. Quasi-randomised studies (those
using dates, names, or admittance numbers to allocate
participants) were inadequate, and we excluded them for the
assessment of benefits butof harms.
Allocation concealment
• Low risk of bias: allocation was controlled by a central and
independent randomisation unit and involved sequentially
numbered, opaque, sealed envelopes, or something similar, so
that neither participants nor investigators could have foreseen
intervention allocations in advance of or during enrolment.
• Uncertain risk of bias: authors described the trial as
randomised but did not describe the method used to conceal the
allocation, so participants or operators may have been able to
foresee intervention allocations in advance of, or during,
enrolment.
• High risk of bias: the investigators who assigned
participants were aware of the allocation sequence, or the study
was quasi-randomised. We excluded quasi-randomised studies
for assessment of benefits but not of harms.
Blinding of participants and personnel
• Low risk of bias: blinding was performed adequately, or the
outcome measurement was not likely to be influenced by lack of
blinding.
• Uncertain risk of bias: information was insufficient to allow
assessment of whether the type of blinding used was likely to
induce bias on the estimate of effect.
• High risk of bias: no blinding or incomplete blinding and
the outcome or the outcome measurements were likely to be
influenced by lack of blinding.
Blinding of outcome assessors
• Low risk of bias: blinding was performed adequately, or the
outcome measurement was not likely to be influenced by lack of
blinding.
• Uncertain risk of bias: information was insufficient to allow
assessment of whether the type of blinding used was likely to
induce bias on the estimate of effect.
• High risk of bias: no blinding or incomplete blinding and
the outcome or the outcome measurements were likely to be
influenced by lack of blinding.
Incomplete outcome data
• Low risk of bias: the underlying reasons for missing data
were unlikely to make treatment effects depart from plausible
values, or proper methods were employed to handle missing data.
• Uncertain risk of bias: information was insufficient to allow
assessment of whether the missing data mechanism in
combination with the method used to handle missing data was
likely to induce bias on the estimate of effect.
• High risk of bias: the crude estimate of effects (e.g.
complete case estimate) were clearly biased because of the
underlying reasons for missing data, and the methods used to
handle missing data were unsatisfactory.
Selective outcome reporting
• Low risk of bias: authors reported pre-defined or clinically
relevant and reasonably expected outcomes (mortality and
serious adverse events).
• Uncertain risk of bias: authors did not fully report all pre-
defined or clinically relevant and reasonably expected outcomes,
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or it was unclear whether authors recorded data on these
outcomes.
• High risk of bias: authors failed to report one or more
clinically relevant and reasonably expected outcomes; data on
these outcomes were likely to have been recorded.
Vested interest bias
• Low risk of bias: a party with no vested interests in the
outcome (i.e. a party that would not benefit from the results of
the trial) conducted the trial.
• Uncertain risk of bias: it was not clear if those conducting
the trial had a vested interest in its outcome.
• High risk of bias: a party with vested interests in the
outcome of the trial (such as a drug manufacturer) conducted
the trial.
We considered a trial to be at low risk of bias if we assessed it as
being at low risk of bias for all domains. We considered a trial at
low risk of bias for an outcome if we assessed it as being at low risk
of bias for all study level domains, as well as for outcome-specific
domains (e.g. blinding, incomplete outcome data). Otherwise, we
considered trials with uncertain or high risk of bias regarding one
or more domains to be trials at high risk of bias.
Measures of treatment effect
For dichotomous variables (short-term mortality, serious adverse
events, participants requiring blood transfusion), we calculated the
odds ratio (OR) with 95% credible interval (CrI). For continuous
variables, such as quantity of blood transfused, blood loss, hospital
stay, and operating time, we calculated the mean difference (MD)
with 95% CrI. When trials reported the blood transfusion as mL
or L rather than units, we converted these into units by considering
that each unit of whole blood or red blood cell transfusion was 400
mL and each unit of fresh frozen plasma was 250 mL.We planned
to useMD and 95%CrI for time needed to return to work, but we
did not use this because none of the included trials reported this
outcome. We planned to use standardised mean difference (SMD)
with 95%CrI for quality of life if trials used different scales, but we
did not plan to combine the quality of life at different time points.
For time-to-event data, such as long-term survival, we planned to
use the hazard ratio (HR) with 95% CrI.
Relative ranking
We estimated the probabilities for each intervention of being at
each possible rank. Then we obtained a treatment hierarchy using
the probability of each intervention being the best treatment by
using the surface under the cumulative ranking curve (SUCRA)
(Salanti 2011).
Unit of analysis issues
The unit of analysis was the person undergoing elective liver re-
section according to the intervention group to which they were
randomly assigned.
Dealing with missing data
We performed an intention-to-treat analysis whenever possible
(Newell 1992). Otherwise, we used data that were available to us
(e.g. a trial may have reported only per protocol analysis results).
As per protocol analyses may be biased, we planned to conduct
best-worst case scenario and worst-best case scenario analyses as
sensitivity analyses, if there was a possibility that authors could
have judged a treatment as effective because of attrition bias.
For continuous outcomes, we imputed the standard deviation
from P values according to guidance in the Cochrane Handbook
for Systematic Reviews of Intervention (Higgins 2011). If the data
were likely to be normally distributed and the mean was not avail-
able, we used the median for meta-analysis. If it was not possi-
ble to calculate the standard deviation from the P value or the
confidence intervals, we imputed the standard deviation using the
largest standard deviation in other trials for that outcome. This
form of imputation may decrease the weight of the study for cal-
culation of mean differences and may bias the effect estimate to
no effect for calculation of SMDs (Higgins 2011).
Assessment of heterogeneity
We assessed clinical andmethodological heterogeneity by carefully
examining the characteristics and design of included trials. Major
sources of clinical heterogeneity included cirrhotic compared to
non-cirrhotic livers and major compared to minor liver resections.
In addition, we anticipated considerable heterogeneity in the way
the intervention was performed. For example, surgeons may per-
form intermittent portal triad clamping with different time pe-
riods of occlusion and non-occlusion. In addition, they may use
different doses of fibrin sealant. Different study design and risk of
bias may contribute to methodological heterogeneity.
We used the residual deviance and Deviance Information Criteria
(DIC) for assessing between-study heterogeneity as per the guid-
ance from the National Institute for Health and Care Excellence
(NICE) Decision Support Unit (DSU) Technical Support Docu-
ments (Dias 2012b; Dias 2013a). We also calculated the between-
trial standard deviation and reported this if we used a random-ef-
fects model. See Data synthesis for further details regarding resid-
ual deviance, DIC, and choice of model.
If we identified substantial heterogeneity - clinical, methodologi-
cal, or statistical - we planned to explore and address it in a sub-
group analysis (see section on Subgroup analysis and investigation
of heterogeneity).
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Assessment of reporting biases
We planned to use visual asymmetry on a funnel plot to explore
reporting bias in case at least 10 trials were included for the out-
come (Egger 1997; Macaskill 2001). In the presence of hetero-
geneity that we could explain by subgroup analysis, we planned to
perform the funnel plot for each subgroup in the presence of the
adequate number of trials. We planned to perform the linear re-
gression approach described by Egger 1997 to determine the fun-
nel plot asymmetry in the presence of at least 10 trials for the direct
comparison. However, we did not perform this because there were
not enough trials.
We also considered selective reporting as evidence of reporting
bias.
Data synthesis
We applied classifications described in Table 1, Table 2, Table
3, and Table 4 to categorise cardiopulmonary interventions,
parenchymal transection methods, methods of dealing with cut
surface, and different vascular occlusion methods. Each category
in the table is broadly defined to encompass a relatively homo-
geneous group of interventions, although we noted variations in
the way each method is carried out. For example, surgeons may
perform intermittent portal triad clamping with different time pe-
riods of occlusion and non-occlusion. We categorised them under
intermittent portal triad clamping regardless of the time intervals.
Likewise, we did not distinguish different maximum periods for
continuous vascular occlusion (Clavien 1996). These practice vari-
ations might be a source of heterogeneity; however, evidence was
insufficient to suggest that they could affect the outcome. For the
comparisons of anterior approach versus conventional approach
and autologous blood donation versus control, there are only two
treatments for each comparison. For pharmacological interven-
tions, we treated each pharmacological treatment as a separate cat-
egory.
In liver resection, a surgeon typically uses one item each fromTable
1, Table 2, Table 3, and Table 4. Liver resection is usually per-
formed using conventional approach without autologous blood
donation or any pharmacological agent. Compared to the previ-
ous version of the review (Simillis 2014), where we considered
a combination of one method each from Table 2, Table 3, and
Table 4 as a treatment strategy, in this review, we considered each
of these interventions (different methods of cardiopulmonary in-
terventions, parenchymal transection methods, methods of deal-
ing with raw surface, vascular occlusion methods, and pharmaco-
logical interventions) as separate networks. This approach was in
response to the lack of information on the details of co-interven-
tions in the trials and the design of the trials, which limited the
number of trials included in the previous analysis. In many of the
trials, the surgeons involved were allowed to choose their method
of liver resection apart from the factor being randomised, based
on the assumption that the factors are independent of each other
(i.e. there is no interaction between the factors, or the choice of
one factor is independent of the choice of other factors). There is
no evidence to support or refute this assumption. However, if we
had included only trials that reported all the intervention variables
adequately, and none were left to the choice of the surgeons, this
would have resulted in inclusion of fewer trials than the previous
version, as we have now included all the interventions aimed at
decreasing blood loss and blood transfusion requirements during
liver resection.
Direct comparison
We performed pair-wise meta-analyses using WinBUGS by
Bayesian analysis using the same codes and methods described im-
mediately below in the network meta-analysis section (i.e. same
burn-in, number of simulations, choice of initial values, and choice
of models). In addition, we performed the meta-analysis using
frequentist methods with Review Manager 5 (RevMan 2014), in
accordance with recommendations of Higgins 2011 and those de-
scribed in the Cochrane Hepato-Biliary Group Module (Gluud
2013). For frequentist analyses, we presented the results of the
model that was used for Bayesian analysis (which was determined
by the model fit).
Network meta-analysis
We conducted network meta-analyses to compare multiple inter-
ventions simultaneously for each of the outcomes listed in the
Types of outcome measures section. Network meta-analysis com-
bines direct evidence within trials and indirect evidence across tri-
als (Mills 2012).
We obtained a network plot to ensure that the trials were con-
nected by treatments using Stata/IC 11 (StataCorp LP). We per-
formed a network meta-analysis only when it was possible to com-
pare the direct and indirect estimates. This is because one cannot
assess whether there is consistency between the direct and indirect
estimates unless both are available. We planned to exclude any
trials that were not connected to the network. We conducted a
Bayesian network meta-analysis using the Markov chain Monte
Carlo method in WinBUGS 1.4. We modelled the treatment
contrast (e.g. log OR for binary outcomes, MD for continuous
outcomes) for any two interventions (’functional parameters’) as
a function of comparisons between each individual intervention
and an arbitrarily selected reference group (’basic parameters’) (Lu
2006). We used inconsistency models to assess this consistency
assumption (Dias 2013e). The reference groups selected for the
different comparisons are as follows.
• Anterior approach versus conventional approach:
conventional approach.
• Autologous blood donation versus control: inactive control.
• Cardiopulmonary interventions: inactive control.
• Methods of parenchymal transection: clamp-crush method.
• Methods of dealing with raw surface: inactive control.
13Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Methods of vascular occlusion: no vascular occlusion.
• Pharmacological interventions: inactive control.
We performed the network analysis as per the guidance from the
NICEDSU documents (Dias 2013a; Dias 2013c). Further details
of the codes used, the raw data, and the technical details of how
we performed the analysis are in Appendix 2, Appendix 3, and
Appendix 4. We tested the codes on simulated data (Appendix
5) using predetermined effect estimates with no inconsistency be-
tween direct and indirect comparisons. This simulation testing
demonstrated that the codes produced similar effect estimates as
the predetermined effect estimates (allowing for some variability
because of simulation) and that the effect estimates obtained using
these codes were almost identical to the effect estimates obtained
by direct estimates using RevMan (Appendix 6).
The codes allow handling of trials with multiple arms to be dealt
in the same way as two-armed trials, that is, one can enter the data
from all the intervention arms in a trial as number of events and
the number of people exposed to the event for binary outcomes;
for continuous outcomes, one can enter the mean and standard
error for all intervention arms in the trial. The choice between
the fixed-effect model and random-effects model was based on the
model fit as per the guidelines of the NICE TSU (a difference of
three to five for deviance information criterion (DIC)) is impor-
tant (Dias 2013a; Dias 2013c); we used a difference of three as
important). We reported the treatment contrasts (i.e. log ORs for
binary outcomes andMDs for continuous outcomes) of the differ-
ent treatments in relation to the reference treatment, the deviance
residuals, the number of effective parameters, and DIC for the
fixed-effect model and random-effects model for each outcome.
We also reported the parameters used to assess the model fit (i.e.
deviance residuals, number of effective parameters, and DIC) for
the inconsistency model in Table 6, Table 7, and Table 8.
We reported estimates of treatment effects (ORs for binary out-
comes, MDs for continuous outcomes, and rate ratios for count
outcomes). We calculated the 95% credible intervals of treatment
effects (e.g. odd ratios for binary outcomes, mean differences for
continuous outcomes, and so on) in the Bayesian meta-analysis
and indicate that the average effect in the population lies within
the credible intervals with 95% probability. We used the posterior
median as the point estimate of treatment effect, the posterior 2.5
percentile as the lower bounds of its 95% credible interval, and the
97.5 percentile as the upper bounds, and we reported the effect
estimates and associated 95% credible intervals for each pair-wise
comparison in a table. We presented these in Table 9, Table 10,
and Table 11. We also presented the cumulative probability of the
treatment ranks (i.e. the probability that the treatment is within
the top two, top three, etc.) in SUCRA graphs (Salanti 2011).
We also plotted the probability of each rank for each treatment
(rankograms), which are generally considered more informative
(Salanti 2011; Dias 2012a; Dias 2013b).
Sample size calculations and imprecision
To control for the risk of random errors, we interpreted the infor-
mation with caution when the accrued sample size in the meta-
analysis was less than the required sample size (required informa-
tion size). For calculation of the required information size, please
see Appendix 7.We considered a 20% relative risk reduction as the
minimal clinically important difference for binary outcomes and
count outcomes. For continuous outcomes, we used or planned
to use the following minimal clinically important differences: a
standardised mean difference of 0.5 for health-related quality of
life, a mean difference of one unit for blood transfusion quantity,
a mean difference of 500 mL for blood loss, a mean difference of
one day of hospital stay and time-to-return to activity, and a mean
difference of 15 minutes for operating time.
Subgroup analysis and investigation of heterogeneity
Weplanned to assess the differences in the effect estimates between
the following subgroups using meta-regression with the help of
the WinBUGS code if we included a sufficient number of trials
(Appendix 8). We planned to use study level co-variates for meta-
regression.
1. Trials at low risk of bias compared to trials at
2. high risk of bias.
3. Participants with cirrhosis compared to those without
cirrhosis.
4. Participants undergoing major liver resections compared to
those undergoing minor liver resections.
We planned to calculate the interaction term (Dias 2012b; Dias
2013d). If the 95% credible intervals of the interaction term did
not cross zero, we planned to consider this statistically significant.
We did not perform any of the above because of the paucity of
data.
Sensitivity analysis
We performed a sensitivity analysis when we imputed the mean,
the standard deviation, or both.
Summary of findings table
We presented a ’Summary of findings’ table, similar to the ones
used in direct comparisons. We modified the table from the origi-
nal format because of the presence of many comparisons andmany
outcomes. We presented only the comparisons in which there was
evidence of differences with the illustrative examples. For other
comparisons, we simply mentioned that there was no evidence of
differences. This is to ensure that the most important information
is available in the table. We provided links in the table to specific
tables using more a traditional format.
In addition to this ’Summary of findings’ table, we also provided
the ’Summary of findings’ table for network meta-analysis in a
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graphical format (in the form of forest plots along with the qual-
ity of evidence), in which we used the methodology of grading
the quality of evidence in network meta-analysis suggested by the
GRADE Working group (Puhan 2014). The first step was to es-
timate the evidence from direct and indirect effect estimates. Fur-
ther steps included rating the quality of evidence from direct and
indirect effect estimates, presenting the estimate combined from
the direct estimate and indirect estimate, and rating the quality
of the network meta-analysis effect estimates (Puhan 2014). Al-
though codes are available for node splitting, they resulted in nu-
merical errors because of the data. So we calculated the direct es-
timates (including only the trials which compared the specific in-
tervention and control) and indirect estimates (after removing the
trials which compared the specific intervention and control).
R E S U L T S
Description of studies
Results of the search
We identified 2938 references through electronic searches ofCEN-
TRAL (N = 342), MEDLINE (N = 1431), Embase (N = 445),
Science Citation Index Expanded (N = 641), WHO ICTRP (N =
47), and ClinicalTrials.gov (N = 32). We excluded 893 duplicates
and 1883 clearly irrelevant references through screening titles and
reading abstracts. We retrieved 162 references for further assess-
ment. We did not identify any references by scanning reference
lists of the identified randomised trials. We excluded 76 references
(67 studies) for the reasons listed in the Characteristics of excluded
studies table. In total, 83 references for 67 completed randomised
clinical trials met the inclusion criteria. Two references were for
ongoing studies (Schmidt 2008; Chen 2015). We were unable to
obtain one reference (Franceschi 2006). We included three stud-
ies under ’Studies awaiting classification’ because there were no
separate data for people who underwent liver resection, that is,
the studies included a number of different surgical procedures,
and information on people who underwent liver resection was not
available (Chapman 2006; Bochicchio 2015; Wright 2015). This
is summarised in the study flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
We describe the treatments used in the 67 randomised clinical
trials in the Characteristics of included studies table and in Table
12.
Two trials compared anterior approach versus conventional ap-
proach (Liu 2006; Capussotti 2012). Two trials compared
autologous blood donation versus control (Kajikawa 1994;
Kostopanagiotou 2007). Ten trials compared different methods
of cardiopulmonary interventions (Hasegawa 2002; Matot 2002;
El-Kharboutly 2004; Wang 2006; Yao 2006; Choi 2007; Jarnagin
2008; Kato 2008; Guo 2013; Guo 2014). Twelve trials different
compared methods of parenchymal transection (Takayama 2001;
Rau 2001; Arita 2005; Koo2005; Lesurtel 2005; Smyrniotis 2005;
Lupo 2007; Ikeda 2009; Doklestic 2012; Savlid 2013; Muratore
2014; Rahbari 2014). Seventeen trials compared different meth-
ods of dealing with raw surface (Kohno 1992; Liu 1993; Noun
1996; Chapman 2000; Frilling 2005; Franceschi 2006; Figueras
2007; Fischer 2011;Gugenheim 2011;DeBoer 2012; Porte 2012;
Kakaei 2013; Koea 2013; Ollinger 2013; Bektas 2014; Genyk
2014; Moench 2014). Eighteen trials compared different meth-
ods of vascular occlusion (Belghiti 1996; Clavien 1996; Man
1997; Belghiti 1999; Wu 2002; Capussotti 2003; Man 2003;
Chouker 2004; Figueras 2005; Capussotti 2006; Chen 2006;
Liang 2009; Dayangac 2010; Pietsch 2010; Lee 2012; Park 2012;
Ni 2013; Si-Yuan 2014). Six trials compared different pharma-
cological interventions (Shimada 1994; Lentschener 1997; Wong
2003; Lodge 2005; Shao 2006; Wu 2006).
All the trials assessed different methods of open liver resection.
Four trials were three-armed trials (Yao 2006; Doklestic 2012;
Kakaei 2013; Guo 2014), one trial was a four-armed trial of which
we included three arms (Lesurtel 2005), and the remaining trials
were two-armed trials. The 67 trials involved a total of 6197 par-
ticipants. After exclusion of 133 participants after randomisation
and 293 participants in three trials that did not provide any in-
formation about the outcomes included in this review (Franceschi
2006; Porte 2012; Koea 2013), we included 5771 participants
who contributed to one or more outcomes of interest in this re-
view.
Excluded studies
Of the 64 excluded studies, we excluded 6 because they were com-
ments on included or excluded studies (Gonzalez 2009; Petras
2009; Schilling 2009; Strobel 2012; Strobel 2014;Hamady 2015);
19 because they were not randomised clinical trials (Le Treut
1995;Man 2002; Yin 2003; Azoulay 2005; Arru 2007; Kim2008;
Nagano 2009; Wang 2010; Wang 2011; Bellolio 2012; Beppu
2012; Narita 2012; NCT01651182; Palibrk 2012; Yang 2012;
Dominioni 2014; Vlad 2014; Li 2015; Takatsuki 2015); 7 be-
cause of inadequate randomisation (Rau 1995; Smyrniotis 2002;
Smyrniotis 2003a; Smyrniotis 2003b; Richter 2009; Obiekwe
2014; Shu 2014); 6 because they were comparisons of interven-
tions that were not of interest to this review (Figueras 2003;
Grobmyer 2009; Harimoto 2011; Levit 2012; Correa-Gallego
2015; Feldheiser 2015); 18 since they were trials comparing vari-
ations within the treatments included in this review (for example,
different periods of intermittent vascular occlusion or different
methods of achieving low central venous pressure) (Standl 1998;
Esaki 2006; Saiura 2006; Chapman 2007; Hashimoto 2007; Kim
2007; Torzilli 2008; El-Moghazy 2009; Ryu 2010; Broek 2011;
Rahbari 2011; Dello 2012; Zhu 2012; Frankel 2013; Kaibori
2013; Yang 2013; Saiura 2014;Zhang2014); and8because the co-
interventions were not used equally in the intervention and con-
trol (Schwartz 2004; Petrowsky 2006; Smyrniotis 2006; Si-Yuan
2011; Li 2013; Lu 2014; Gotohda 2015; Hanyong 2015).
Risk of bias in included studies
We summarise the risk of bias in the included trials in Figure 2
and Figure 3. Overall, we judged all trials to be at high risk of bias.
The risk of bias according to the type of comparison is shown in
Table 13.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Twenty-four trials (35.8%) were at low risk of bias in the ’se-
quence generation’ domain (Lentschener 1997; Chapman 2000;
Hasegawa 2002;Matot 2002; Capussotti 2003; Arita 2005; Lodge
2005; Capussotti 2006; Figueras 2007; Lupo 2007; Kato 2008;
Ikeda 2009; Dayangac 2010; Capussotti 2012; De Boer 2012; Lee
2012; Park 2012; Kakaei 2013; Koea 2013; Savlid 2013; Bektas
2014;Moench 2014;Muratore 2014;Rahbari 2014). Eighteen tri-
als (26.9%) were at low risk of bias in the ’allocation concealment’
domain (Hasegawa 2002; Arita 2005; Lodge 2005; Figueras 2007;
Kato 2008; Dayangac 2010; Fischer 2011; De Boer 2012; Lee
2012; Park 2012; Koea 2013; Ni 2013; Savlid 2013; Bektas 2014;
Moench 2014;Muratore 2014; Rahbari 2014; Si-Yuan 2014). Fif-
teen trials (22.4%) were at low risk of bias in the ’both sequence
generation and allocation concealment’ domains and were free
from selection bias (Hasegawa 2002; Arita 2005; Lodge 2005;
Figueras 2007; Kato 2008; Dayangac 2010; De Boer 2012; Lee
2012; Park 2012; Koea 2013; Savlid 2013; Bektas 2014; Moench
2014; Muratore 2014; Rahbari 2014).
Blinding
Four trials (6.0%) were at low risk of bias in the ’blinding of partic-
ipants and healthcare providers’ domain (Hasegawa 2002; Wong
2003; Lodge 2005; Wu 2006). Six trials (9.0%) were at low risk of
bias in the ’blinding of outcome assessors’ domain (Lentschener
1997; Wong 2003; Lodge 2005; Wu 2006; Dayangac 2010;
Rahbari 2014). Three trials (4.5%) were at low risk of bias in both
the ’blinding of participants and healthcare providers’ and ’blind-
ing of outcome assessors’ domains and were free fromperformance
and detection bias (Wong 2003; Lodge 2005; Wu 2006).
Incomplete outcome data
Thirty-three trials (49.3%) were at low risk of bias in the ’miss-
ing outcome bias’ domain (Kohno 1992; Liu 1993; Man 1997;
Belghiti 1999; Takayama 2001; Hasegawa 2002;Matot 2002;Wu
2002; Capussotti 2003; Man 2003; Arita 2005; Figueras 2005;
Frilling 2005; Lesurtel 2005; Smyrniotis 2005; Capussotti 2006;
Wu 2006; Figueras 2007; Lupo 2007; Kato 2008; Ikeda 2009;
Liang 2009; Dayangac 2010; Gugenheim 2011; De Boer 2012;
Lee 2012; Ni 2013; Ollinger 2013; Savlid 2013; Bektas 2014;
Muratore 2014; Rahbari 2014; Si-Yuan 2014).
Selective reporting
Twenty-five trials (37.3%) reported mortality and serious adverse
events and hence were considered to be at low risk of bias in the
’selective reporting bias’ domain (Kohno 1992; Takayama 2001;
Wu 2002; Capussotti 2003; Arita 2005; Frilling 2005; Lesurtel
2005; Lodge 2005; Chen 2006; Figueras 2007; Jarnagin 2008;
Ikeda 2009; Liang 2009; Fischer 2011; Capussotti 2012; De
Boer 2012; Doklestic 2012; Lee 2012; Ni 2013; Ollinger 2013;
Savlid 2013; Bektas 2014;Moench 2014;Muratore 2014; Rahbari
2014).
Other potential sources of bias
Twenty-four trials (35.8%) were at low risk of bias in the ’source of
funding bias’ domain (Clavien 1996; Man 1997; Hasegawa 2002;
Matot 2002; Wu 2002; Wong 2003; Arita 2005; Figueras 2005;
Chen 2006; Liu 2006; Figueras 2007; Lupo 2007; Ikeda 2009;
Liang 2009; Dayangac 2010; Capussotti 2012; Doklestic 2012;
Lee 2012; Park 2012; Guo 2013; Kakaei 2013; Ni 2013; Guo
2014; Muratore 2014).
We did not identify any other bias in the trials.
Effects of interventions
See: Summary of findings for the main comparison
We provide the data used in network meta-analysis in Appendix 3;
the data used for direct comparisons in Data and analyses; and the
overall results in Summary of findings for the main comparison,
Appendix 9, andAppendix 10.Wepresent the data in the following
format for each comparison.
• Outcome.
◦ Different methods of measuring the outcome.
⋄ Direct comparison.
⋄ Network meta-analysis (when applicable).
⋄ Differences between direct comparison and
network meta-analysis (when applicable).
• Differences between Bayesian and frequentist meta-analysis.
• An overall summary for the comparison.
In addition, we also provide an overall summary for each outcome
across all interventions at the end.
Anterior approach versus conventional approach
Two trials compared anterior approach versus conventional ap-
proach (Liu 2006; Capussotti 2012). Since this comparison only
involved two treatments, we did not perform network meta-anal-
ysis.
Quality of evidence
The quality of evidence was very low for all the outcomes. This was
because of high risk of bias in the trials (downgraded by one point),
imprecision due to small sample size (downgraded by one point),
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and wide credible intervals for all outcomes (downgraded by one
point) as well as considerable heterogeneity for blood transfusion
(proportion) and major blood loss (proportion) (downgraded by
two points).
Mortality
Mortality (perioperative)
Two trials reported perioperative mortality (Liu 2006; Capussotti
2012). The unadjusted proportions of perioperative mortality are
as follows.
• Conventional approach: 7/92 (7.6%).
• Anterior approach: 2/93 (2.2%).
Based on the DIC, we chose the fixed-effect model. There was
no evidence of differences in perioperative mortality between the
two groups (OR 0.23, 95% CrI 0.03 to 1.08; 185 participants; 2
studies).
Mortality (longest follow-up)
None of the trials reported this outcome.
Adverse events
Serious adverse events (proportion)
One trial reported serious adverse events as a proportion of par-
ticipants who experienced one or more (Capussotti 2012). The
unadjusted proportions of serious adverse events are as follows.
• Conventional approach: 4/32 (12.5%).
• Anterior approach: 5/33 (15.2%).
There was no evidence of differences in the proportion of partici-
pants experiencing serious adverse events between the two groups
(OR 1.27, 95% CrI 0.29 to 5.89; 65 participants; 1 study).
Serious adverse events (number)
None of the trials reported this outcome.
Adverse events (proportion)
Two trials reported adverse events as a proportion (Liu 2006;
Capussotti 2012). The unadjusted proportions of adverse events
are as follows.
• Conventional approach: 33/92 (35.9%).
• Anterior approach: 31/93 (33.3%).
Based on the DIC, we chose the fixed-effect model. There was no
evidence of differences in the proportion of participants experi-
encing adverse events between the two groups (OR 0.89, 95%CrI
0.48 to 1.64; 185 participants; 2 studies).
Adverse events (number)
One trial reported the number of adverse events (Capussotti2012).
The unadjusted rates of adverse events (number) are as follows.
• Conventional approach: 18/32 (56.3 per 100 participants).
• Anterior approach: 17/33 (51.5 per 100 participants).
There was no evidence of differences in the number of adverse
events between the two groups (rate ratio 0.91, 95% CrI 0.47 to
1.78; 65 participants; 2 studies).
Health-related quality of life
None of the trials reported this outcome at any time point.
Blood transfusion requirements
Blood transfusion (proportion)
Two trials reported blood transfusion as a proportion of partici-
pants requiring one (Liu 2006; Capussotti 2012). The unadjusted
proportions of participants receiving a blood transfusion are as
follows.
• Conventional approach: 20/92 (21.7%).
• Anterior approach: 10/93 (10.8%).
Based on the DIC, we chose the random-effects model. The be-
tween-study standard deviation was 2.60. There was no evidence
of differences in the proportion of participants receiving a blood
transfusion between the two groups (OR 0.57, 95% CrI 0.01 to
50.91; 185 participants; 2 studies).
Blood transfusion (quantity)
None of the trials reported the quantity of blood transfusion in
red blood cells, platelets, fresh frozen plasma, or cryoprecipitate.
Blood loss
Two trials reported blood loss (Liu 2006; Capussotti 2012). The
median blood loss reported for each treatment in the two trials are
as follows.
• Conventional approach: 0.5 L and 1 L.
• Anterior approach: 0.437 L and 0.8 L.
We did not perform meta-analysis since both trials reported the
median blood loss rather than the mean and standard deviation of
blood loss. There was no evidence of differences in blood loss in
either trial (Liu 2006; Capussotti 2012).
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Major blood loss (proportion)
Two trials reportedmajor blood loss as a proportion of participants
experiencing it (Liu 2006; Capussotti 2012). One trial defined
major blood loss as more than one litre of blood loss (Capussotti
2012), while the other trial defined it as more than two litres (Liu
2006). The unadjusted proportions of major blood loss (propor-
tion) are as follows.
• Conventional approach: 22/92 (23.9%).
• Anterior approach: 12/93 (12.9%).
Based on the DIC, we chose the random-effects model. The be-
tween-study standard deviation was 2.3. There was no evidence of
differences in the proportion of participants experiencing major
blood loss between the two groups (OR 0.54, 95% CrI 0.01 to
34.54; 185 participants; 2 studies).
Hospital stay
Total hospital stay
Two trials reported hospital stay (Liu 2006; Capussotti 2012). The
median hospital stay reported for each treatment in the two trials
are as follows.
• Conventional approach: 11.5 days (d) and 12.5 d.
• Anterior approach: 10 d and 11 d.
We did not perform meta-analysis since both trials reported the
median hospital stay rather than the mean and standard deviation
of hospital stay. There was no evidence of differences in hospital
stay in either trial (Liu 2006; Capussotti 2012).
Intensive therapy unit (ITU) stay
One trial reported ITU stay (Liu 2006). The median ITU stay
reported for each treatment is as follows.
• Conventional approach: 2 d.
• Anterior approach: 1.5 d.
We did not perform meta-analysis since the trial reported the me-
dian ITU stay rather than themean and standard deviation of ITU
stay. There was no evidence of differences in ITU stay in this trial
(Liu 2006).
Operating time
Two trials reported operating time (Liu 2006; Capussotti 2012).
The median operating times reported for each treatment are as
follows.
• Conventional approach: 312.8 minutes (min) and 415 min.
• Anterior approach: 295.8 min and 420 min.
We did not perform meta-analysis since both trials reported the
median operating time rather than the mean and standard devi-
ation of operating time. There was no evidence of differences in
operating time in either trial.
Time needed to return to work
None of the trials reported this outcome.
Difference between Bayesian and frequentist meta-analysis
The interpretation of information and conclusions did not alter
by using the frequentist meta-analysis.
Overall summary
There was no evidence of differences between the anterior ap-
proach and conventional approach in any of the reported out-
comes of interest for this review.
Autologous blood donation versus control
Two trials compared autologous blood donation versus control
(Kajikawa 1994; Kostopanagiotou 2007). As this comparison only
included two treatments, we did not perform network meta-anal-
ysis.
Quality of evidence
The quality of evidence was very low for all the outcomes and
comparisons unless specifically indicated within the results. This
was because of unclear or high risk of bias in the trials (downgraded
by one point), imprecision due to small sample size (downgraded
by one point), and wide credible intervals (downgraded by one
point) for all outcomes with very low quality of evidence.
Mortality
Mortality (perioperative)
One trial (28 participants) reported perioperative mortality (
Kostopanagiotou 2007); there was none in either group.
Mortality (longest follow-up)
One trial (28 participants) reported mortality at longest follow-up
(Kostopanagiotou 2007). There was no mortality in either group
after a follow-up period of one year.
Adverse events
Serious adverse events (proportion)
None of the trials reported this outcome.
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Serious adverse events (number)
None of the trials reported this outcome.
Adverse events (proportion)
One trial reported adverse events as a proportion of participants
experiencing at least one (Kostopanagiotou 2007). The unadjusted
proportions of participants experiencing an adverse event are as
follows.
• Control: 5/13 (38.5%).
• Autologous blood donation: 5/15 (33.3%).
There was no evidence of differences in the proportion of partici-
pants experiencing adverse events between groups (OR 0.79, 95%
CrI 0.15 to 3.98; 28 participants; 1 study).
Adverse events (number)
None of the trials reported this outcome.
Health-related quality of life
None of the trials reported this outcome at any time point.
Blood transfusion requirements
Blood transfusion (proportion)
One trial reported the proportion of participants requiring a blood
transfusion (Kajikawa 1994). The unadjusted proportions are as
follows.
• Control: 13/21 (61.9%).
• Autologous blood donation: 5/21 (23.8%).
The proportion of participants requiring a blood transfusion was
lower in the autologous blood donation group than in the control
(OR 0.18, 95% CrI 0.04 to 0.66; 42 participants; 1 study; low-
quality evidence: downgraded one point for unclear or high risk
of bias and one point for small sample size).
Blood transfusion (red blood cells)
One trial reported blood transfusion quantity in red blood cells
(Kostopanagiotou 2007). The mean blood transfusion quantities
reported for each treatment are as follows.
• Control: 1.7 units.
• Autologous blood donation: 1.6 units.
There was no evidence of differences in blood transfusion quantity
(red blood cells) between the groups (MD−0.10 units, 95% CrI
−0.59 to 0.38; 28 participants; 1 study).
Blood transfusion (platelets)
None of the trials reported this outcome.
Blood transfusion (fresh frozen plasma)
None of the trials reported this outcome.
Blood transfusion (cryoprecipitate)
None of the trials reported this outcome.
Blood loss
Two trials reported blood loss (Kajikawa 1994; Kostopanagiotou
2007). The mean blood loss reported for each treatment are as
follows.
• Control: 0.78 L and 1.193 L
• Autologous blood donation: 0.68 L and 1.272 L
Based on the DIC, we chose the fixed-effect model. There was
no evidence of differences in blood loss between the groups (MD
−0.02 L, 95% CrI −0.37 to 0.34; 70 participants; 2 studies).
Major blood loss (proportion)
One trial reported the proportion of participants experiencing
major blood loss, defined as the loss of more than two litres (
Kajikawa 1994). The unadjusted proportions of participants with
major blood loss are as follows.
• Control: 2/21 (9.5%).
• Autologous blood donation: 4/21 (19.0%).
There was no evidence of differences in the proportion of par-
ticipants experiencing major blood loss between the groups (OR
2.44, 95% CrI 0.39 to 21.5; 42 participants; 1 study).
Hospital stay
Total hospital stay
One trial reported total hospital stay (Kostopanagiotou 2007).
Themean hospital stays reported for each treatment are as follows.
• Control: 10 d.
• Autologous blood donation: 11 d.
There was no evidence of differences in hospital stay between the
groups (MD 0.99 d, 95% CrI −0.92 to 2.91; 28 participants; 1
study).
ITU stay
None of the trials reported this outcome.
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Operating time
Two trials reported operating time (Kajikawa 1994;
Kostopanagiotou 2007). The mean operating times reported for
each treatment are as follows.
• Control: 190 min and 290 min.
• Autologous blood donation: 175 min and 318 min.
Based on the DIC, we chose the fixed-effect model. There was
no evidence of differences in operating times between the groups
(MD 1.78 min, 95% CrI −28.13 to 31.68; 70 participants; 2
studies).
Time needed to return to work
None of the trials reported this outcome.
Difference between Bayesian and frequentist meta-analysis
The interpretation of information and conclusions did not alter
by using the frequentist meta-analysis.
Overall summary
There was no evidence of difference between autologous blood
donation and control in any of the reported outcomes of interest
for this review other than the proportion of people who required
blood transfusion, which was lower in the autologous blood do-
nation group than control (OR 0.18, 95% CrI 0.04 to 0.66; 42
participants; 1 study).
Cardiopulmonary interventions
Ten trials compared different methods of cardiopulmonary in-
terventions (Hasegawa 2002; Matot 2002; El-Kharboutly 2004;
Wang 2006; Yao 2006; Choi 2007; Jarnagin 2008; Kato 2008;
Guo 2013; Guo 2014).We performed networkmeta-analysis only
for blood transfusion quantity (red blood cells) and blood loss
since direct comparison and indirect comparison effect estimates
(which would enable assessment of inconsistency) were available
only for these outcomes. We present only direct comparison re-
sults for other outcomes.
Quality of evidence
The quality of evidence was very low for all the outcomes and
comparisons unless specifically indicated within the results. This
was because of unclear or high risk of bias in the trials (downgraded
by one point), imprecision due to small sample size (downgraded
by one point), and wide credible intervals (downgraded by one
point) for all outcomes with very low quality of evidence.
Mortality
Mortality (perioperative)
Four trials reported perioperative mortality (Hasegawa 2002;
Matot 2002; Jarnagin 2008; Kato 2008). These studies used four
treatments in 372 participants. The unadjusted proportions of pe-
rioperative mortality are as follows.
• Control: 0/81 (0.0%).
• Acute normovolemic haemodilution plus low central
venous pressure: 1/102 (1.0%).
• Hypoventilation: 0/40 (0.0%).
• Low central venous pressure: 3/149 (2.0%).
There was no evidence of differences in perioperative mortality
for any of the comparisons.
Mortality (longest follow-up)
None of the trials reported this outcome.
Adverse events
Serious adverse events (proportion)
Two trials reported the proportion of participants experiencing
serious adverse events (Hasegawa 2002; Jarnagin 2008). A total of
four treatments were used in a total of 209 participants in these
studies. The unadjusted proportions of participants with serious
adverse events are as follows.
• Control: 1/39 (2.6%).
• Acute normovolemic haemodilution plus low central
venous pressure: 19/63 (30.2%).
• Hypoventilation: 2/40 (5.0%).
• Low central venous pressure: 19/67 (28.4%).
There was no evidence of differences in the proportion of partic-
ipants experiencing serious adverse events for any of the compar-
isons.
Serious adverse events (number)
Two trials reported the total number of serious adverse events
(Matot 2002; El-Kharboutly 2004). These studies used three treat-
ments in 118 participants. The unadjusted rates of serious adverse
events (number) are as follows.
• Control: 2/20 (10.0 per 100 participants).
• Acute normovolemic haemodilution plus low central
venous pressure: 4/39 (10.3 per 100 participants).
• Low central venous pressure: 3/59 (5.1 per 100
participants).
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There was no evidence of differences in the number of serious
adverse events observed for any of the comparisons.
Adverse events (proportion)
Four trials reported the proportionof participants experiencing ad-
verse events (Hasegawa 2002; Matot 2002; Wang 2006; Jarnagin
2008). These studies used four treatments in 337 participants.
The unadjusted proportions of participants experiencing adverse
events are as follows.
• Control: 19/64 (29.7%).
• Acute normovolemic haemodilution plus low central
venous pressure: 37/102 (36.3%).
• Hypoventilation: 16/40 (40.0%).
• Low central venous pressure: 35/131 (26.7%).
There was no evidence of differences in the proportion of partici-
pants experiencing adverse events for any of the comparisons.
Adverse events (number)
Two trials reported adverse events (number) (Matot 2002; El-
Kharboutly 2004). These studies used three treatments in 118
participants. The unadjusted rates of adverse events (number) are
as follows.
• Control: 6/20 (30.0 per 100 participants).
• Acute normovolemic haemodilution plus low central
venous pressure: 12/39 (30.8 per 100 participants).
• Low central venous pressure: 15/59 (25.4 per 100
participants).
There was no evidence of differences in adverse events (number)
for any of the comparisons.
Health-related quality of life
None of the trials reported this outcome at any time point.
Blood transfusion requirements
Blood transfusion (proportion)
Six trials reported the proportion of participants requiring a blood
transfusion (Hasegawa 2002; Matot 2002; El-Kharboutly 2004;
Wang 2006; Jarnagin 2008; Kato 2008). These studies used four
treatments in 462 participants. The unadjusted proportions of
participants requiring a blood transfusion are as follows.
• Control: 29/126 (23.0%).
• Acute normovolemic haemodilution plus low central
venous pressure: 12/102 (11.8%).
• Hypoventilation: 3/40 (7.5%).
• Low central venous pressure: 48/194 (24.7%).
Based on the DIC, we chose the fixed-effect model. The propor-
tion of participants requiring a blood transfusion was higher in
the low central venous pressure group than in the group receiving
acute normovolemic haemodilution plus low central venous pres-
sure (OR 3.19, 95% CrI 1.56 to 6.95; 208 participants; 2; low-
quality evidence: downgraded by one point for unclear or high
risk of bias in the trials and one more point for small sample size).
There was no evidence of differences in other comparisons.
Blood transfusion (red blood cells)
Six trials reported blood transfusion quantity (as red blood cells) (
Matot 2002; El-Kharboutly 2004;Wang 2006; Yao2006; Jarnagin
2008; Guo 2013), testing five treatments in 358 participants. The
median and range of the mean blood transfusion quantity (red
blood cells) reported for each treatment are as follows.
• Control: 1.38 units (range 0.88 to 3.22).
• Acute normovolemic haemodilution: 0.17 units (range 0.17
to 0.17).
• Acute normovolemic haemodilution plus hypotension:
0.00 units (range 0.00 to 0.00).
• Acute normovolemic haemodilution plus low central
venous pressure: 0.44 (range 0.00 to 1.15).
• Low central venous pressure: 0.61 (range 0.00 to 1.31).
Direct comparison
Based on the DIC, we chose the fixed-effect model. The blood
transfusion quantity (in red blood cells) was lower in the group
receiving acute normovolemic haemodilution (MD −1.25 units,
95%CrI−1.75 to−0.74; 20 participants; 1 study; low-quality ev-
idence: downgraded by one point for unclear or high risk of bias in
the trials and one more point for small sample size) and acute nor-
movolemic haemodilution plus hypotension (MD −1.67 units,
95% CrI −2.06 to −1.32; 20 participants; 1 study; low-quality
evidence: downgraded by one point for unclear or high risk of bias
in the trials and one more point for small sample size) than con-
trol.The blood transfusion quantity (red blood cells) was higher
inthe acute normovolemic haemodilution plus low central venous
pressure group than in the control group (MD 0.27 units, 95%
CrI 0.01 to 0.52; 30 participants; 1 study). There was no evidence
of differences in other comparisons. We imputed either the mean
or standard deviation in two trials (Matot 2002; Jarnagin 2008).
Excluding these trials did not alter the conclusions.
Network meta-analysis
We present the network plots in Figure 4. Based on the DIC,
we chose the random-effects model. There was no evidence of
differences in blood transfusion quantity (red blood cells) for any
of the comparisons. Excluding the trials in which we imputed
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the mean or standard deviation (Matot 2002; Jarnagin 2008),
we could not assess whether the direct and indirect evidence was
consistent. We show the probability of each treatment being best,
second best, third best, and so on in Figure 5 and the cumulative
probability of a treatment being best in Figure 6.
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Figure 4. The network plot showing the comparisons in the trials included in the comparison of
cardiopulmonary interventions in which network meta-analysis was performed. The size of the node (circle)
provides a measure of the number of trials in which the particular treatment was included as one of the arms.
The thickness of the line provides a measure of the number of direct comparisons between two nodes
(treatments).ANH: acute normovolemic haemodilution; CVP: central venous pressure; RBC: red blood cells.
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Figure 5. Probability of best treatment: probability of being best, second best, third best, etc. for each
treatment for blood transfusion (red blood cells) (cardiopulmonary interventions). A probability of more than
90% is a reliable indicator that a treatment is best with regards to the specific outcome. A probability of less
than 90% is less reliable. None of the treatments have a 90% probability of being best treatment.ANH: acute
normovolemic haemodilution; CVP: central venous pressure; RBC: red blood cells.
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Figure 6. Cumulative probability of being best treatment: cumulative probability of being best for each
treatment for cardiopulmonary interventions. Rank 1 indicates the probability that a treatment is best, rank 2
indicates the probability that a treatment is in the two best treatments, rank 3 indicates the probability that a
treatment is in the three best treatments, and so on.ANH: acute normovolemic haemodilution; CVP: central
venous pressure; RBC: red blood cells.
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Direct evidence compared to network meta-analysis
We compare the information on direct evidence to network meta-
analysis in Figure 7. The mean effect goes in opposite directions
in the indirect and direct estimates, suggesting that there may be
discrepancies (incongruence or inconsistency) between direct and
indirect estimates. Direct evidence appears to be preferable over
indirect evidence and network meta-analysis based on the quality
of evidence.
Figure 7. Cardiopulmonary intervention: blood transfusion (red blood cells) Forest plot of the comparisons
in which direct and indirect estimates were available. The mean effect is in opposite directions in the indirect
estimate and the direct estimates, thus suggesting that there may be discrepancies between direct and indirect
estimates. Direct evidence appears to be preferable over indirect evidence and network meta-analysis based
on the quality of evidence.1 Risk of bias was unclear or high in the trial(s) (downgraded by 1 point).2 Sample
size was low (downgraded by 1 point).3Confidence intervals spanned no effect and clinically significant effect
(downgraded by 1 point).4There was substantial or considerable heterogeneity (downgraded by 2 points).
Blood transfusion (platelets)
None of the trials reported this outcome.
Blood transfusion (fresh frozen plasma)
Two trials reported blood transfusion quantity (as fresh frozen
plasma) (Wang 2006; Jarnagin 2008), testing three interventions
in 180 participants. The mean blood transfusion quantities (fresh
frozen plasma) reported for each treatment are as follows.
• Control: 4.23 units.
• Acute normovolemic haemodilution plus low central
venous pressure: 0.17 units.
• Low central venous pressure: 0.28 and 1.75 units.
The blood transfusion quantity (fresh frozen plasma) was lower in
the low central venous pressure group than the control group (MD
−2.48 units, 95% CrI −3.58 to −1.37; 50 participants; 1 study;
low-quality evidence: downgraded by one point for unclear or high
risk of bias in the trials and one more point for small sample size).
There was no evidence of differences in the other comparison (low
central venous pressure versus acute normovolemic haemodilution
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plus low central venous pressure) (MD0.11 units, 95%CrI−0.79
to 1.01; 130 participants; 1 study). We imputed the standard
deviation in one of the trials (Jarnagin 2008). Excluding this trial
did not alter the outcome.
Blood transfusion (cryoprecipitate)
One trial reported blood transfusion quantity (cryoprecipitate)
(Hasegawa 2002). The mean blood transfusion quantities (cryo-
precipitate) are as follows.
• Control: 0.076 units.
• Hypoventilation: 0.052 units.
There was no evidence of differences in blood transfusion quantity
(cryoprecipitate) between the groups (MD−0.02 units, 95% CrI
−0.12 to 0.07; 79 participants; 1 study).
Blood loss
Nine trials reported blood loss (Hasegawa 2002; Matot 2002;
El-Kharboutly 2004; Wang 2006; Yao 2006; Choi 2007; Jarnagin
2008; Kato 2008; Guo 2013),testing six interventions in 584 par-
ticipants. The median and range of the mean blood loss reported
for each treatment are as follows.
• Control: 0.711 L (range 0.584 to 2.329).
• Acute normovolemic haemodilution: 0.654 L (one trial
only).
• Acute normovolemic haemodilution plus hypotension:
0.404 L (one trial only).
• Acute normovolemic haemodilution plus low central
venous pressure: 0.75 L (range 0.735 to 0.8).
• Hypoventilation: 0.63 L (one trial only).
• Low central venous pressure: 0.6445 L (range 0.49 to
0.904).
Direct comparison
Based on the DIC, we chose the fixed-effect model. The blood
loss was lower in the acute normovolemic haemodilution plus hy-
potension group (MD −0.25 L; 95% CrI −0.37 to −0.13; 20
participants; 1 study) and the low central venous pressure group
than in the control (MD−0.34 L, 95% CrI−0.46 to−0.22; 237
participants; 4 studies).The blood loss was lower for acute normo-
volemic haemodilution plus hypotension than for acute normov-
olemic haemodilution (MD −0.25 L; 95% CrI−0.40 to−0.10;
20 participants; 1 study). There was no evidence of differences in
other comparisons. We imputed either the mean or standard devi-
ation in four trials (Hasegawa 2002; Matot 2002; Jarnagin 2008;
Kato 2008). Excluding these trials did not alter the conclusions.
Network meta-analysis
We present the network plots in Figure 4. Based on the DIC, we
chose the random-effects model. There was no evidence of differ-
ences in blood loss for any of the comparisons. Excluding the trials
in which we imputed the mean or standard deviation (Hasegawa
2002; Matot 2002; Jarnagin 2008; Kato 2008) meant that there
would be no evidence from direct and indirect evidence, which
would allow the assessment of whether the direct and indirect ev-
idence was consistent. We show the probability of each treatment
being the best, second best, third best, and so on in Figure 8. The
cumulative probability of a treatment being best is shown in Figure
6.
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Figure 8. Probability of best treatment: probability of being best, second best, third best, etc. for each
treatment for blood loss (cardiopulmonary interventions). A probability of more than 90% is a reliable
indicator that a treatment is best with regards to the specific outcome. A probability of less than 90% is less
reliable. None of the treatments have a 90% probability of being best treatment.ANH: acute normovolemic
haemodilution; CVP: central venous pressure.
Direct evidence compared to network meta-analysis
We show the information on direct evidence compared to net-
work meta-analysis in Figure 9. There does not appear to be any
discrepancy between the direct and indirect estimates, although
the indirect estimates have wide credible intervals. Direct evidence
appears to be preferable over indirect evidence and network meta-
analysis based on the quality of evidence.
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Figure 9. Cardiopulmonary intervention: blood loss Forest plot of the comparisons in which direct and
indirect estimates were available. There does not appear to be any discrepancy between the direct and
indirect estimates, although the indirect estimates have wide credible intervals.Direct evidence appears to be
preferable over indirect evidence and network meta-analysis based on the quality of evidence.ANH: acute
normovolemic haemodilution; CVP: central venous pressure.1Risk of bias was unclear or high in the trial(s)
(downgraded by 1 point).2Sample size was low (downgraded by 1 point).3Confidence intervals spanned no
effect and clinically significant effect (downgraded by 1 point).4There was substantial or considerable
heterogeneity (downgraded by 2 points).
Major blood loss (proportion)
One trial reported the proportion of participants experiencing
major blood loss (Jarnagin 2008), defined as more than 0.8 L.
The unadjusted proportions of of participants experiencing major
blood loss are as follows.
• Acute normovolemic haemodilution plus low central
venous pressure: 33/63 (52.4%).
• Low central venous pressure: 29/67 (43.3%).
There was no evidence of differences in the proportion of par-
ticipants experiencing major blood loss between the groups (OR
0.69, 95% CrI 0.34 to 1.38; 130 participants; 1 study).
Hospital stay
Total hospital stay
Five trials reported hospital stay (Hasegawa 2002; Wang 2006;
Choi 2007; Jarnagin 2008; Kato 2008). They used four treatments
in 406 participants. The median length and range of the mean or
median hospital stay reported for each treatment are as follows.
• Control: 21 d (range 14 to 30).
• Acute normovolemic haemodilution plus low central
venous pressure: 7 d (one trial only).
• Hypoventilation: 20 d (one trial only).
• Low central venous pressure: 15 d (range 7 to 26).
Based on the DIC, we chose the fixed-effect modelwhen there
were two or more trials under the comparison. The total hospital
stay was lower in the low central venous pressure group than in
the control group (MD −2.42 d, 95% CrI −3.91 to−0.94; 197
participants; 3 studies). There was no evidence of differences in
the remaining comparisons. In three trials, either the mean or the
standard deviation was not available (Hasegawa 2002; Jarnagin
2008; Kato 2008), so we did not perform a meta-analysis. Exclu-
sion of these three trials did not alter the conclusions.
ITU stay
None of the trials reported this outcome.
Operating time
Seven trials reported operating time (Hasegawa 2002;Matot 2002;
El-Kharboutly 2004;Wang 2006; Choi 2007; Jarnagin 2008;Guo
2014). They used four treatments in 499 participants. Themedian
and range of themean operating times reported for each treatment
are as follows.
• Control: 246 min (range 190 to 498).
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• Acute normovolemic haemodilution plus low central
venous pressure: 255 min (range 179 to 293).
• Hypoventilation: 498 min (one trial only).
• Low central venous pressure: 244 min (range 164 to 321).
Based on the DIC, we chose the fixed-effect model. The operating
timewas lower in the low central venous pressure group than in the
control group (MD−15.32 min, 95%CrI−29.03 to−1.69; 192
participants; 4 studies). There was no evidence of differences in
other comparisons. Two trials failed to report the mean, standard
deviation, or both (Hasegawa 2002; Jarnagin 2008). Excluding
these trials did not alter the conclusions.
Time needed to return to work
None of the trials reported this outcome.
Difference between Bayesian and frequentist meta-analysis
The interpretation of information and conclusions did not alter
by using the frequentist meta-analysis.
Overall summary
There was no evidence of differences between different cardiopul-
monary interventions in any of the reported outcomes of interest
for this review other than the following.
• The proportion of participants requiring a blood
transfusion was higher in those receiving low central venous
pressure than in those receiving acute normovolemic
haemodilution plus low central venous pressure (OR 3.19, 95%
CrI 1.56 to 6.95; 208 participants; 2 studies).
• The blood transfusion quantity (red blood cells) was lower
in the acute normovolemic haemodilution group (MD −1.25
units, 95% CrI −1.75 to −0.74; 20 participants; 1 study) and
the acute normovolemic haemodilution plus hypotension group
(MD −1.67 units, 95% CrI −2.06 to −1.32; 20 participants; 1
study) than in the control group. The blood transfusion quantity
(red blood cells) was higher in the acute normovolemic
haemodilution plus low central venous pressure group than in
the control group (MD 0.27 units, 95% CrI 0.01 to 0.52; 30
participants; 1 study).
• The blood transfusion quantity (fresh frozen plasma) was
lower for low central venous pressure than for control (MD
−2.48 units, 95% CrI −3.58 to −1.37; 50 participants; 1
study).
• The blood loss was lower in the acute normovolemic
haemodilution plus hypotension group (MD −0.25 L; 95% CrI
−0.37 to −0.13; 20 participants; 1 study) and the low central
venous pressure group than in the control (MD −0.34 L, 95%
CrI −0.46 to −0.22; 237 participants; 4 studies). The blood loss
was lower in the acute normovolemic haemodilution plus
hypotension group than in the acute normovolemic
haemodilution group (MD −0.25; 95% CrI −0.40 to −0.10;
20 participants; 1 study).
• The total hospital stay was lower in the low central venous
pressure group than in the control (MD −2.42 d, 95% CrI
−3.91 to −0.94; 197 participants; 3 studies).
• The operating time was lower in the low central venous
pressure group than in the control (MD −15.32 min, 95% CrI
−29.03 to −1.69; 192 participants; 4 studies).
Methods of parenchymal transection
Twelve trials compared different methods of parenchymal transec-
tion (Rau 2001; Takayama 2001; Arita 2005; Koo 2005; Lesurtel
2005; Smyrniotis 2005; Lupo 2007; Ikeda 2009; Doklestic 2012;
Savlid 2013; Muratore 2014; Rahbari 2014). We performed net-
work meta-analysis only for adverse events (proportion), adverse
events (number), and proportion requiring blood transfusion,
since direct comparison and indirect comparison effect estimates
(which would enable assessment of inconsistency) were available
only for these outcomes. We present only direct comparison re-
sults for other outcomes.
Quality of evidence
The quality of evidence was very low for all the outcomes and com-
parisons unless specifically indicated within the results. This was
because of unclear or high risk of bias in the trials (downgraded by
one point), imprecision due to small sample size (downgraded by
one point), and wide credible intervals (downgraded by one point)
for all outcomes with very low-quality of evidence. In addition,
we downgraded the outcome of blood transfusion (proportion) by
two points because of the presence of substantial or considerable
heterogeneity in the pair-wise comparison or in the network.
Mortality
Mortality (perioperative)
Eleven trials reported perioperative mortality (Rau 2001;
Takayama 2001; Arita 2005; Lesurtel 2005; Smyrniotis 2005;
Lupo 2007; Ikeda 2009; Doklestic 2012; Savlid 2013; Muratore
2014; Rahbari 2014). They used six treatments in 990 partici-
pants. The unadjusted proportions of perioperative mortality are
as follows.
• Clamp-crush method: 4/368 (1.1%).
• Cavitron ultrasonic surgical aspirator: 3/191 (1.6%).
• Hydrojet: 3/56 (5.4%).
• Radiofrequency dissecting sealer: 4/219 (1.8%).
• Sharp transection method: 0/41 (0.0%).
• Stapler: 4/115 (3.5%).
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Based on the DIC, the fixed-effect model was chosen for all com-
parisons involving two or more trials. There was no evidence of
differences in perioperative mortality for any of the comparisons.
Mortality (longest follow-up)
None of the trials reported this outcome.
Adverse events
Serious adverse events (proportion)
Seven trials reported the proportion of participants experiencing
serious adverse events (Rau 2001; Takayama 2001; Arita 2005;
Smyrniotis 2005; Ikeda 2009; Doklestic 2012; Rahbari 2014).
They used six treatments in 665 participants. The unadjusted
proportions of participants experiencing serious adverse events are
as follows.
• Clamp-crush method: 28/292 (9.6%).
• Cavitron ultrasonic surgical aspirator: 6/116 (5.2%).
• Hydrojet: 2/31 (6.5%).
• Radiofrequency dissecting sealer: 6/120 (5.0%).
• Sharp transection method: 4/41 (9.8%).
• Stapler: 19/65 (29.2%).
Based on the DIC, we chose the fixed-effect model for all com-
parisons involving two or more trials. There was no evidence of
differences in serious adverse events (proportion) for any of the
comparisons.
Serious adverse events (number)
Five trials reported the number of serious adverse events (
Takayama 2001; Arita 2005; Lesurtel 2005; Lupo 2007; Savlid
2013). They used five treatments in 437 participants. The unad-
justed rates of serious adverse events (number) are as follows.
• Clamp-crush method: 7/132 (5.3 per 100 participants).
• Cavitron ultrasonic surgical aspirator: 13/141 (9.2 per 100
participants).
• Hydrojet: 3/25 (12.0 per 100 participants).
• Radiofrequency dissecting sealer: 16/89 (18.0 per 100
participants).
• Stapler: 12/50 (24.0 per 100 participants)..
Based on the DIC, we chose the fixed-effect model for all compar-
isons involving two or more trials. The number of serious adverse
events was higher in the radiofrequency dissecting sealer group
than in the clamp-crush method group (rate ratio 3.64, 95% CrI
1.25 to 13.97; 130 participants; 2 studies; low-quality evidence:
downgraded by one point for unclear or high risk of bias in the
trials and one more point for small sample size). There was no
evidence of differences in other comparisons.
Adverse events (proportion)
Eight trials reported the proportion of participants experiencing
adverse events (Rau 2001; Takayama 2001; Arita 2005; Koo 2005;
Smyrniotis 2005;Doklestic 2012;Muratore 2014; Rahbari 2014).
They used six treatments in 695 participants. The unadjusted pro-
portions of participants experiencing adverse events are as follows.
• Clamp-crush method: 116/307 (37.8%).
• Cavitron ultrasonic surgical aspirator: 60/141 (42.6%).
• Hydrojet: 3/31 (9.7%).
• Radiofrequency dissecting sealer: 37/110 (33.6%).
• Sharp transection method: 17/41 (41.5%).
• Stapler: 31/65 (47.7%).
Direct comparison
Based on the DIC, we chose the fixed-effect model for all com-
parisons involving two or more trials. There was no evidence of
differences in adverse events (proportion) for any of the compar-
isons.
Network meta-analysis
We show the network plots in Figure 10. Based on the DIC, we
chose the random-effects model. The between-study standard de-
viation was 2.44. There was no evidence of differences in the pro-
portion of participants experiencing adverse events for any of the
comparisons. We show the probability of each treatment being
best, second best, third best, and so on in Figure 11 and the cu-
mulative probability of a treatment being best in Figure 12.
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Figure 10. The network plot showing the comparisons in the trials included in the comparison of methods
for parenchymal transection in which network meta-analysis was performed. The size of the node (circle)
provides a measure of the number of trials in which the particular treatment was included as one of the arms.
The thickness of the line provides a measure of the number of direct comparisons between two nodes
(treatments).CUSA: cavitron ultrsonic surgical aspirator; RFDS: radiofrequency dissecting sealer.
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Figure 11. Probability of best treatment: probability of being best, second best, third best, etc. for each
treatment for adverse events (proportion) (parenchymal transection methods). A probability of more than
90% is a reliable indicator that a treatment is best with regards to the specific outcome. A probability of less
than 90% is less reliable. None of the treatments have a 90% probability of being best treatment.CUSA:
cavitron ultrsonic surgical aspirator; RFDS: radiofrequency dissecting sealer.
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Figure 12. Cumulative probability of being best treatment: cumulative probability of being best for each
treatment for parenchymal transection methods. Rank 1 indicates the probability that a treatment is best,
rank 2 indicates the probability that a treatment is in the two best treatments, rank 3 indicates the probability
that a treatment is in the three best treatments, and so on.CUSA: cavitron ultrsonic surgical aspirator; RFDS:
radiofrequency dissecting sealer.
Direct evidence compared to network meta-analysis
Figure 13 shows the information on direct evidence compared to
network meta-analysis. There does not appear to be any discrep-
ancy between the direct and indirect estimates, although the indi-
rect estimates have wide credible intervals. Direct evidence appears
to be preferable over indirect evidence and network meta-analysis
based on the quality of evidence.
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Figure 13. Parenchymal transection: adverse events (proportion) Forest plot of the comparisons in which
direct and indirect estimates were available. There does not appear to be any discrepancy between the direct
and indirect estimates, although the indirect estimates have wide credible intervals.Direct evidence appears to
be preferable over indirect evidence and network meta-analysis based on the quality of evidence.CUSA:
cavitron ultrsonic surgical aspirator; RFDS: radiofrequency dissecting sealer.1Risk of bias was unclear or high
in the trial(s) (downgraded by 1 point).2Sample size was low (downgraded by 1 point).3Confidence intervals
spanned no effect and clinically significant effect (downgraded by 1 point).4There was substantial or
considerable heterogeneity (downgraded by 2 points).
Adverse events (number)
Seven trials reported the number of adverse events (Takayama
2001; Arita 2005; Lesurtel 2005; Smyrniotis 2005; Lupo 2007;
Ikeda 2009; Savlid 2013). They used six treatments in 639 par-
ticipants. The unadjusted rates of adverse events (number) are as
follows.
• Clamp-crush method: 52/233 (22.3 per 100 participants).
• Cavitron ultrasonic surgical aspirator: 52/141 (36.9 per 100
participants).
• Hydrojet: 7/25 (28.0 per 100 participants).
• Radiofrequency dissecting sealer: 45/149 (30.2 per 100
participants).
• Sharp transection method: 18/41 (43.9 per 100
participants)
• Stapler: 22/50 (44.0 per 100 participants).
Direct comparison
Based on the DIC, we chose the fixed-effect model for all compar-
isons involving two or more trials. There was evidence for a higher
adverse events (number)with radiofrequency dissecting sealer than
with the clamp-crush method (rate ratio 1.85, 95% CrI 1.07 to
3.26; 250 participants; 3 studies). There was no evidence of differ-
ences in the number of adverse events for any of the comparisons.
Network meta-analysis
Figure 10 shows the network plots. Based on the DIC, we chose
the fixed-effect model. There was evidence of more adverse events
(number) with the radiofrequency dissecting sealer method than
with the clamp-crush method (rate ratio 1.84, 95% CrI 1.13 to
3.06). There was no evidence of differences in other comparisons.
Figure 14 shows the probability of each treatment being best, sec-
ond best, third best, and so on, and Figure 12 shows the cumula-
tive probability of a treatment being best.
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Figure 14. Probability of best treatment: probability of being best, second best, third best, etc. for each
treatment for adverse events (number) (parenchymal transection methods). A probability of more than 90% is
a reliable indicator that a treatment is best with regards to the specific outcome. A probability of less than 90%
is less reliable. None of the treatments have a 90% probability of being best treatment.CUSA: cavitron
ultrsonic surgical aspirator; RFDS: radiofrequency dissecting sealer.
Direct evidence compared to network meta-analysis
Figure 15 shows the information on direct evidence compared to
network meta-analysis. There does not appear to be any discrep-
ancy between the direct and indirect estimates. Direct evidence
appears to be preferable over indirect evidence and network meta-
analysis based on the quality of evidence.
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Figure 15. Parenchymal transection: adverse events (number) Forest plot of the comparisons in which
direct and indirect estimates were available. There does not appear to be any discrepancy between the direct
and indirect estimates.Direct evidence appears to be preferable over indirect evidence and network meta-
analysis based on the quality of evidence.CUSA: cavitron ultrsonic surgical aspirator; RFDS: radiofrequency
dissecting sealer.1Risk of bias was unclear or high in the trial(s) (downgraded by 1 point).2Sample size was low
(downgraded by 1 point).3Confidence intervals spanned no effect and clinically significant effect (downgraded
by 1 point).
Health-related quality of life
None of the trials reported this outcome at any time point.
Blood transfusion requirements
Blood transfusion (proportion)
Eight trials reported the proportion of participants requiring a
blood transfusion (Takayama 2001; Arita 2005; Lesurtel 2005;
Smyrniotis 2005; Lupo 2007; Ikeda 2009; Doklestic 2012;
Muratore 2014). They used five treatments in 699 participants.
The unadjusted proportions of blood transfusion (proportion) are
as follows.
• Clamp-crush method: 46/303 (15.2%).
• Cavitron ultrasonic surgical aspirator: 12/111 (10.8%).
• Hydrojet: 8/25 (32.0%).
• Radiofrequency dissecting sealer: 37/219 (16.9%).
• Sharp transection method: 13/41 (31.7%).
Direct comparison
Based on theDIC,we chose the fixed-effectmodel for comparisons
involving two or more trials. There was no evidence of differences
in the proportion of participants requiring a blood transfusion for
any of the comparisons.
Network meta-analysis
Figure 10 shows the network plots. Based on the DIC, we chose
the fixed-effect model. There was no evidence of differences in
the proportion of participants requiring a blood transfusion for
any of the comparisons. Figure 16 shows the probability of each
treatment being best, second best, third best, and so on. Figure 12
shows the cumulative probability of a treatment being best.
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Figure 16. Probability of best treatment: probability of being best, second best, third best, etc. for each
treatment for blood transfusion (proportion) (parenchymal transection methods). A probability of more than
90% is a reliable indicator that a treatment is best with regards to the specific outcome. A probability of less
than 90% is less reliable. None of the treatments have a 90% probability of being best treatment.CUSA:
cavitron ultrsonic surgical aspirator; RFDS: radiofrequency dissecting sealer.
Direct evidence compared to network meta-analysis
Figure 17 shows the information on direct evidence compared to
network meta-analysis. There does not appear to be any discrep-
ancy between the direct and indirect estimates, although the indi-
rect estimates have wide credible intervals for some comparisons.
There was little apparent difference in the quality of evidence be-
tween direct, indirect estimates, and networkmeta-analysis; so, we
could not choose one estimate over the others based on the quality
of evidence.
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Figure 17. Parenchymal transection:blood transfusion (proportion) Forest plot of the comparisons in which
direct and indirect estimates were available. There does not appear to be any discrepancy between the direct
and indirect estimates, although the indirect estimates have wide credible intervals for some comparisons.
There was little apparent difference in the quality of evidence between direct, indirect estimates, and network
meta-analysis; so, we could not choose one estimate over the others based on the quality of evidence.CUSA:
cavitron ultrsonic surgical aspirator; RFDS: radiofrequency dissecting sealer.1Risk of bias was unclear or high
in the trial(s) (downgraded by 1 point).2Sample size was low (downgraded by 1 point).3Confidence intervals
spanned no effect and clinically significant effect (downgraded by 1 point).
Blood transfusion (red blood cells)
Four trials reported blood transfusion quantity (in red blood cells)
(Rau 2001; Smyrniotis 2005; Savlid 2013; Rahbari 2014). They
used five treatments in 373 participants. The median or mean
blood transfusion quantity (red blood cells) reported for each treat-
ment are as follows.
• Clamp-crush method: 0.00 and 1.20 units (two trials only).
• Cavitron ultrasonic surgical aspirator: 2.48 and 4.00 units
(two trials only).
• Hydrojet: 1.50 units (one trial only).
• Sharp transection method: 0.00 units (one trial only).
• Stapler: 1.10 and 4.00 units (two trials only).
The blood transfusion quantity (red blood cells) was lower in the
hydrojet group than in the cavitron ultrasonic surgical aspirator
group (MD −0.98 units, 95% CrI −1.90 to −0.06; 61 partici-
pants; 1 study). There was no evidence of difference in blood trans-
fusion quantity (red blood cells) in the remaining comparisons.
Either mean or standard deviation or both were not available in
two trials (Smyrniotis 2005; Savlid 2013). Excluding these two
trials did not change the conclusion.
Blood transfusion (platelets)
None of the trials reported this outcome.
Blood transfusion (fresh frozen plasma)
One trial reported blood transfusionquantity (fresh frozenplasma)
(Rahbari 2014). It used two treatments in 130 participants in
these studies. The mean blood transfusion quantity (fresh frozen
plasma) reported for each treatment are as follows.
• Clamp-crush method: 0.5 units.
• Stapler: 0.3 units.
There was no evidence of differences in blood transfusion quantity
(fresh frozen plasma) between the groups (MD−0.20 units, 95%
CrI −0.66 to 0.26; 130 participants;1 study).
Blood transfusion (cryoprecipitate)
None of the trials reported this outcome.
Blood loss
Ten trials reported blood loss (Rau 2001; Takayama 2001; Arita
2005; Koo 2005; Smyrniotis 2005; Ikeda 2009; Doklestic 2012;
Savlid 2013; Muratore 2014; Rahbari 2014). They used six treat-
ments in 915 participants. The median or mean blood loss re-
ported for each treatment are as follows.
• Clamp-crush method: 0.56 L (range 0.2 to 1.05).
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• Cavitron ultrasonic surgical aspirator: 0.875 L (range 0.15
to 1.797).
• Hydrojet: 1.479 L (range 1.479 to 1.479).
• Radiofrequency dissecting sealer: 0.47 L (range 0.15 to
0.665).
• Sharp transection method: 0.5 L (range 0.5 to 0.5).
• Stapler: 0.9625 L (range 0.925 to 1).
Of the 10 trials, 8 did not provide either the mean, the standard
deviation or both (Takayama 2001; Arita 2005; Smyrniotis 2005;
Ikeda 2009;Doklestic 2012; Savlid 2013;Muratore 2014;Rahbari
2014), so we performed the analysis only for two trials (Rau 2001;
Koo 2005). There was no evidence of differences in blood loss for
any of the comparisons.
Major blood loss (proportion)
None of the trials reported this outcome.
Hospital stay
Total hospital stay
Ten trials reported hospital stay (Doklestic 2012; Takayama 2001;
Arita 2005; Lesurtel 2005; Smyrniotis 2005; Lupo 2007; Ikeda
2009; Savlid 2013; Muratore 2014; Rahbari 2014). They used six
treatments in 929 participants. The mean and range of the mean
hospital stays reported for each treatment are as follows.
• Clamp-crush method: 11 d (range 7 to 18).
• Cavitron ultrasonic surgical aspirator: 11.95 d (range 8.5 to
17).
• Hydrojet: 9 d (one trial only).
• Radiofrequency dissecting sealer: 10.5 d (range 8 to 16).
• Sharp transection method: 11 d (one trial only).
• Stapler: 10 to 14.9 d (two trials only).
All 10 trials failed to provide themean, standard deviation or both.
There was no evidence of differences in total hospital stay for any
of the comparisons.
ITU stay
Four trials reported ITU stay (Lesurtel 2005; Smyrniotis 2005;
Doklestic 2012; Rahbari 2014). They used six treatments in 347
participants. The median ITU stays reported for each treatment
are as follows.
• Clamp-crush method: 1 d (range 0 to 1.5).
• Cavitron ultrasonic surgical aspirator: 0 and 1 d (two trials
only).
• Hydrojet: 1 d (one trial only).
• Radiofrequency dissecting sealer: 1 d (two trials only).
• Sharp transection method: 1 d (one trial only).
• Stapler: 0 d (one trial only).
Either themean, the standard deviation, or both were not available
in all the four trials. There was no evidence of differences in ITU
stay for any of the comparisons.
Operating time
Six trials reported operating time (Koo 2005; Smyrniotis 2005;
Lupo 2007; Doklestic 2012; Savlid 2013; Rahbari 2014). They
used five treatments in 472 participants. The median or mean
operating time reported for each treatment are as follows.
• Clamp-crush method: 231 min (range 211 to 278).
• Cavitron ultrasonic surgical aspirator: 270 min (range 259
to 298).
• Radiofrequency dissecting sealer: 292 and 295 min (two
trials only).
• Sharp transection method: 205 min (one trial only).
• Stapler: 190 and 272 min (two trials only).
Based on the DIC, we chose the fixed-effect model when there
were two or more studies in a comparison. There was no evidence
of differences in operating time in any of the comparisons. We
imputed either the mean or the standard deviation in two trials
(Lupo 2007; Doklestic 2012). Excluding this trial did not alter
the results.
Time needed to return to work
None of the trials reported this outcome.
Difference between Bayesian and frequentist meta-analysis
The interpretation of information and conclusions did not change
upon use of the frequentist meta-analysis except for the following.
Adverse events (number): the number of adverse events was higher
in the radiofrequency dissecting sealer group than in the group re-
ceiving the clamp-crush method with Bayesian meta-analysis (rate
ratio 1.85, 95% CrI 1.07 to 3.26; 250 participants; 3 studies),
while there was no evidence of difference in adverse events (num-
ber) in any comparisons by frequentist meta-analysis (rate ratio
1.67, 95% CI 0.95 to 2.94; 250 participants; 3 studies).
Operating time: there was no evidence of difference in operating
time in any comparisons by Bayesian meta-analysis (stapler re-
section versus clamp-crush method: MD −27.99 min, 95% CrI
−56.91 to 1.02; 130 participants; 1 study), while the operating
time was lower in stapler resection than clamp-crush method with
frequentist meta-analysis (MD −31.00 min, 95% CI −60.40 to
−1.60; 130 participants; 1 study).
Overall summary
There was no evidence of differences between different parenchy-
mal transection methods in any of the reported outcomes of in-
terest for this review other than the following.
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• The adverse events (number) was higher with the
radiofrequency dissecting sealer than with the clamp-crush
method (rate ratio 1.85, 95% CrI 1.07 to 3.26; 250 participants;
3 studies) (Bayesian analysis only: both direct and network meta-
analysis).
• The blood transfusion quantity (red blood cells) was lower
in the hydrojet group than with the cavitron ultrasonic surgical
aspirator group (MD −0.98 units, 95% CrI−1.90 to−0.06; 61
participants; 1 study).
• The operating time was lower with stapler resection than
with the clamp-crush method with frequentist meta-analysis
(MD −31.00 min, 95% CI −60.40 to −1.60; 130 participants;
1 study) (frequentist analysis only).
Methods of dealing with cut surface
Seventeen trials compared different methods of dealing with cut
surface (Kohno 1992; Liu 1993; Noun 1996; Chapman 2000;
Frilling 2005; Franceschi 2006; Figueras 2007; Fischer 2011;
Gugenheim 2011; De Boer 2012; Porte 2012; Kakaei 2013; Koea
2013; Ollinger 2013; Bektas 2014; Genyk 2014; Moench 2014).
We did not perform network meta-analysis since direct compari-
son and indirect comparison effect estimates (which would enable
assessment of inconsistency) were not available for any of the out-
comes.
Quality of evidence
The quality of evidence was very low for all the outcomes and com-
parisons unless specifically indicated within the results. This was
because of unclear or high risk of bias in the trials (downgraded by
one point), imprecision due to small sample size (downgraded by
one point), and wide credible intervals (downgraded by one point)
for all outcomes with very low quality of evidence. In addition,
some of the pair-wise comparisons in blood transfusion propor-
tion and blood transfusion (red blood cells) were downgraded by
two points because of the presence of substantial or considerable
heterogeneity.
Mortality
Mortality (perioperative)
Ten trials reported perioperative mortality (Kohno 1992;
Chapman 2000; Frilling 2005; Figueras 2007; Fischer 2011;
Gugenheim 2011; De Boer 2012; Ollinger 2013; Bektas 2014;
Moench 2014). They used seven interventions in 1271 partici-
pants. The unadjusted proportions of perioperative mortality are
as follows.
• Control: 4/339 (1.2%).
• Argon beam: 6/114 (5.3%).
• Collagen: 4/122 (3.3%).
• Fibrin sealant: 23/485 (4.7%).
• Fibrin sealant plus collagen: 6/150 (4.0%).
• Oxidised cellulose: 1/32 (3.1%).
• Plasmajet: 2/29 (6.9%).
Based on the DIC, we chose the fixed-effect model when there
were two or more trials. There was no evidence of differences in
perioperative mortality for any of the comparisons.
Mortality (longest follow-up)
None of the trials reported this outcome.
Adverse events
Serious adverse events (proportion)
Seven trials reported the proportion of participants experiencing
serious adverse events (Noun 1996; Fischer 2011; Gugenheim
2011;De Boer 2012;Ollinger 2013; Bektas 2014;Moench 2014).
They used six interventions in 798 participants. The unadjusted
proportions of serious adverse events (proportion) are as follows.
• Control: 43/231 (18.6%).
• Argon beam: 14/52 (26.9%).
• Collagen: 16/62 (25.8%).
• Fibrin sealant: 90/392 (23.0%).
• Oxidised cellulose: 10/32 (31.3%).
• Plasmajet: 1/29 (3.4%).
Based on the DIC, we chose the fixed-effect model when there
were two or more trials. There was no evidence of differences in
serious adverse events (proportion) for any of the comparisons.
Serious adverse events (number)
Six trials reported the number of serious adverse events (Kohno
1992; Frilling 2005; Figueras 2007; Kakaei 2013; Bektas 2014;
Moench 2014). They used seven interventions in 725 participants.
The unadjusted rates of serious adverse events (number) are as
follows.
• Control: 39/185 (21.1 per 100 participants).
• Argon beam: 4/62 (6.5 per 100 participants).
• Collagen: 30/93 (32.3 per 100 participants).
• Cyanoacrylate: 1/15 (6.7 per 100 participants).
• Fibrin sealant: 72/205 (35.1 per 100 participants).
• Fibrin sealant plus collagen: 29/150 (19.3 per 100
participants).
• Oxidised cellulose: 4/15 (26.7 per 100 participants).
Based on the DIC, we chose the fixed-effect model when there
were two or more trials. The serious adverse events (number) was
higher in the fibrin sealant group than in the argon beam group
(rate ratio 4.81, 95% CrI 1.73 to 17.5; 121 participants; 1 study;
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low-quality evidence: downgraded one point for unclear or high
risk of bias in the trial and one more point for small sample size).
There was no evidence of differences in other comparisons.
Adverse events (proportion)
Nine trials reported the proportion of participants experiencing
adverse events (Noun 1996; Frilling 2005; Figueras 2007; Fischer
2011; De Boer 2012; Ollinger 2013; Bektas 2014; Genyk 2014;
Moench 2014). They used six interventions in 1385 participants.
The unadjusted proportions of adverse events (proportion) are as
follows.
• Control: 166/381 (43.6%).
• Argon beam: 52/114 (45.6%).
• Collagen: 38/62 (61.3%).
• Fibrin sealant: 227/536 (42.4%).
• Fibrin sealant plus collagen: 35/150 (23.3%).
• Oxidised cellulose: 27/142 (19.0%).
Based on the DIC, we chose the fixed-effect model when there
were two or more trials. There was no evidence of differences in
adverse events (proportion) for any of the comparisons.
Adverse events (number)
Five trials reported the number of adverse events (Kohno 1992;
Frilling 2005; Kakaei 2013; Bektas 2014; Moench 2014). They
used six interventions in 425 participants. The unadjusted rates
of adverse events (number) are as follows.
• Control: 89/35 (254.3 per 100 participants).
• Argon beam: 47/62 (75.8 per 100 participants).
• Collagen: 135/93 (145.2 per 100 participants).
• Cyanoacrylate: 2/15 (13.3 per 100 participants).
• Fibrin sealant: 302/205 (147.3 per 100 participants).
• Oxidised cellulose: 7/15 (46.7 per 100 participants).
Based on the DIC, we chose the fixed-effect model when there
were two or more trials. There was no evidence of differences in
adverse events (number) for any of the comparisons.
Health-related quality of life
None of the trials reported this outcome at any time point.
Blood transfusion requirements
Blood transfusion (proportion)
Four trials reported the proportion of participants requiring a
blood transfusion (Noun 1996; Figueras 2007; De Boer 2012;
Kakaei 2013). They used five interventions in 737 participants.
The unadjusted proportions of participants requiring a blood
transfusion are as follows.
• Control: 62/348 (17.8%).
• Cyanoacrylate: 2/15 (13.3%).
• Fibrin sealant: 38/209 (18.2%).
• Fibrin sealant plus collagen: 40/150 (26.7%).
• Oxidised cellulose: 4/15 (26.7%).
Based on the DIC, we chose the fixed-effect model when there
were two or more trials. There was no evidence of differences in
blood transfusion (proportion) for any of the comparisons.
Blood transfusion (red blood cells)
Five trials reported blood transfusion (red blood cells) (Liu 1993;
Noun 1996; Figueras 2007; Kakaei 2013; Ollinger 2013). They
used five interventions in 517 participants. The median and range
of the mean blood transfusion (red blood cells) reported for each
treatment are as follows.
• Control: 3.50 units (range 0.31 to 8.13).
• Cyanoacrylate: 2.13 units (one trial only).
• Fibrin sealant: 4.30 units (range 3.00 to 5.94).
• Fibrin sealant plus collagen: 0.30 units (one trial only).
• Oxidised cellulose: 1.86 and 4.35 units (two trials only).
Based on theDIC, we chose the fixed-effectmodel for the compar-
ison of fibrin sealant versus control and the random-effects model
for the comparison of oxidised cellulose versus fibrin sealant. The
remaining comparisons had only one trial. The blood transfusion
quantity (red blood cells) was lower in the fibrin sealant group than
in the control (MD −0.53 units, 95% CrI −1.00 to −0.07; 122
participants; 2 studies). The blood transfusion quantity (red blood
cells) was higher in the fibrin sealant group than the cyanoacrylate
group (MD 2.20 units; 95% CrI 1.59 to 2.81; 30 participants; 1
study; low-quality evidence: downgraded one point for unclear or
high risk of bias in the trial and one more point for small sample
size). There was no evidence of differences in other comparisons.
Blood transfusion (platelets)
None of the trials reported this outcome.
Blood transfusion (fresh frozen plasma)
Two trials reported blood transfusion quantity (fresh frozen
plasma) (Kakaei 2013;Ollinger 2013). They used three treatments
in 95 participants. The median blood transfusion quantities (fresh
frozen plasma) reported for each treatment are as follows.
• Cyanoacrylate: 0.80 units (one trial only).
• Fibrin sealant: 0.00 and 17.64 units (two trials only).
• Oxidised cellulose: 0.53 and 20.12 units (two trials only).
Based on the DIC, we chose the fixed-effect model when there
were two or more trials. The blood transfusion quantity (fresh
frozen plasma) was lower in the fibrin sealant group than in the
cyanoacrylate group (MD−0.81 units, 95%CrI−1.04 to−0.62;
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30 participants; 1 study). The blood transfusion quantity (fresh
frozen plasma) was higher with oxidised cellulose than with fibrin
sealant (MD 0.53 units, 95% CrI 0.36 to 0.71; 80 participants;
2 studies). There was no evidence of differences in other compar-
isons.
Blood transfusion (cryoprecipitate)
None of the trials reported this outcome.
Blood loss
Five trials reported blood loss (Kohno 1992; Liu 1993; Figueras
2007; De Boer 2012; Kakaei 2013). They usedsix interventions
in 757 participants. The median and range of the mean blood loss
reported for each treatment are as follows.
• Control: 0.82 L (range 0.55 to 4.052).
• Collagen: 1.027 L (one trial only).
• Cyanoacrylate: 0.653 L (one trial only).
• Fibrin sealant: 0.9325 L (range 0.675 to 3.047).
• Fibrin sealant plus collagen: 0.884 L (one trial only).
• Oxidised cellulose: 0.573 L (one trial only).
Based on the DIC, we chose the fixed-effect model when there
were two or more trials. There was no evidence of differences in
blood loss for any of the comparisons. Excluding the trial for which
the mean and standard deviation were not available did not alter
the conclusions (De Boer 2012).
Major blood loss (proportion)
None of the trials reported this outcome.
Hospital stay
Total hospital stay
Four trials reported hospital stay (Noun 1996; Figueras 2007;
Kakaei 2013; Ollinger 2013). They used five interventions in 477
participants. The median and range of the mean hospital stay
reported for each treatment are as follows.
• Control: 11.3 d and 12.6 d (two trials only).
• Cyanoacrylate: 8.8 d (one trial only).
• Fibrin sealant: 10.8 d (range 7.5 to 18.5).
• Fibrin sealant plus collagen: 13.3 d (one trial only).
• Oxidised cellulose: 8.1 d, 15.2 d (two trials only).
Based on the DIC, we chose the fixed-effect model when there
were two or more trials. There was no evidence of differences in
hospital stay for any of the comparisons.
ITU stay
One trial (50 participants) reported ITU stay (Ollinger 2013).
The median ITU stay reported for each treatment are as follows.
• Fibrin sealant: 2.2 d (one trial only).
• Oxidised cellulose: 2.8 d (one trial only).
There was no evidence of differences in ITU stay for any of the
comparisons.
Operating time
Five trials reported operating time (Kohno 1992; Liu 1993; Noun
1996; Figueras 2007;Ollinger 2013). They used five interventions
in 534 participants. The median and range of the mean operating
time reported for each treatment are as follows.
• Control: 263 min (range 258 to 343).
• Collagen: 169 min (one trial only).
• Fibrin sealant: 245 min (range 165 to 295).
• Fibrin sealant plus collagen: 282 min (one trial only).
• Oxidised cellulose: 253 min (one trial only).
Based on the DIC, we chose the fixed-effect model when there
were two or more trials. The operating time was higher in the
group receiving fibrin sealant and collagen than in the control
group (MD19.72min, 95%CrI 2.93 to 36.57; 300participants; 1
study). There was no evidence of differences in other comparisons.
Time needed to return to work
None of the trials reported this outcome.
Difference between Bayesian and frequentist meta-analysis
The interpretation of information and conclusions did not alter
by using the frequentist meta-analysis.
Overall summary
There was no evidence of differences between different methods
of dealing with cut surface in any of the reported outcomes of
interest for this review other than the following.
• The serious adverse events (number) was higher in the
fibrin sealant group than in the argon beam group (rate ratio
4.81, 95% CrI 1.73 to 17.5; 121 participants; 1 study).
• The blood transfusion quantity (red blood cells) was lower
in the fibrin sealant group than in the control (MD −0.53 units,
95% CrI −1.00 to −0.07; 122 participants; 2 studies). The
blood transfusion quantity (red blood cells) was higher in fibrin
sealant than cyanoacrylate (MD 2.20 units; 95% CrI 1.59 to
2.81; 30 participants; 1 study).
• The blood transfusion quantity (fresh frozen plasma) was
lower with fibrin sealant than with cyanoacrylate (MD −0.81
units, 95% CrI −1.04 to −0.62; 30 participants; 1 study). The
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blood transfusion quantity (fresh frozen plasma) was higher with
oxidised cellulose than with fibrin sealant (MD 0.53 units, 95%
CrI 0.36 to 0.71; 80 participants; 2 studies).
• The operating time was higher with fibrin sealant and
collagen than with control (MD 19.72 min, 95% CrI 2.93 to
36.57; 300 participants; 1 study).
Methods of vascular occlusion
Eighteen trials compared different methods of vascular occlu-
sion (Belghiti 1996; Clavien 1996; Man 1997; Belghiti 1999;
Wu 2002; Capussotti 2003; Man 2003; Chouker 2004; Figueras
2005; Capussotti 2006; Chen 2006; Liang 2009; Dayangac 2010;
Pietsch 2010; Lee 2012; Park 2012; Ni 2013; Si-Yuan 2014). We
performed network meta-analysis only for serious adverse events
(proportion), adverse events (proportion), blood transfusion (pro-
portion), and blood transfusion quantity (red blood cells) since di-
rect comparison and indirect comparison effect estimates (which
would enable assessment of inconsistency) were not available for
the other outcomes. We present only direct comparison results for
other outcomes.
Quality of evidence
The quality of evidence was very low for all the outcomes and com-
parisons unless specifically indicated within the results. This was
because of unclear or high risk of bias in the trials (downgraded by
one point), imprecision due to small sample size (downgraded by
one point), and wide credible intervals (downgraded by one point)
for all outcomes with very low quality of evidence. In addition,
we downgraded the evidence for blood transfusion quantity (red
blood cells), blood loss, and operating time by two points because
of the presence of substantial or considerable heterogeneity in the
pair-wise comparison or in the network.
Mortality
Mortality (perioperative)
Fourteen trials reported perioperative mortality (Belghiti 1996;
Clavien 1996; Man 1997; Belghiti 1999; Wu 2002; Capussotti
2003; Man 2003; Figueras 2005; Capussotti 2006; Chen 2006;
Liang 2009; Lee 2012; Ni 2013; Si-Yuan 2014). They used seven
treatments in 1196 participants. The unadjusted proportions of
perioperative mortality are as follows.
• Control: 5/203 (2.5%).
• Continuous hepatic vascular exclusion: 0/88 (0.0%).
• Continuous portal triad clamping: 6/290 (2.1%).
• Continuous selective hepatic vascular exclusion: 0/80
(0.0%).
• Continuous selective portal triad clamping: 0/100 (0.0%).
• Intermittent portal triad clamping: 3/364 (0.8%).
• Intermittent selective portal triad clamping: 1/71 (1.4%).
Based on the DIC, we chose the fixed-effect model for all compar-
isons with two or more trials. There was no evidence of differences
in perioperative mortality for any of the comparisons.
Mortality (longest follow-up)
None of the trials reported this outcome.
Adverse events
Serious adverse events (proportion)
Eight trials reported the proportion of participants experiencing
serious adverse events (Capussotti 2003; Capussotti 2006; Chen
2006; Liang 2009; Lee 2012; Park 2012; Ni 2013; Si-Yuan 2014).
They used six treatments in 815 participants. The unadjusted
proportions of participants experiencing serious adverse events are
as follows.
• Control: 15/151 (9.9%).
• Continuous hepatic vascular exclusion: 3/60 (5.0%).
• Continuous portal triad clamping: 30/216 (13.9%).
• Continuous selective hepatic vascular exclusion: 0/80
(0.0%).
• Continuous selective portal triad clamping: 13/100
(13.0%).
• Intermittent portal triad clamping: 23/208 (11.1%).
Direct comparison
Based on the DIC, we chose the fixed-effect model for all compar-
isons with two or more trials. The serious adverse events (propor-
tion) was lower in the group receiving continuous selective portal
triad clamping than in the continuous portal triad clamping group
(OR0.42, 95%CrI 0.18 to 0.96; 120 participants; 1 study). There
was no evidence of differences in other comparisons.
Network meta-analysis
The network plots are shown in Figure 18. Based on the DIC, we
chose the fixed-effect model. There was no evidence of differences
in adverse events (proportion) for any of the comparisons. Figure
19 shows the probability of each treatment being best, second best,
third best, and so on. Figure 20 shows the cumulative probability
of a treatment being best.
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Figure 18. The network plot showing the comparisons in the trials included in the comparison of methods
for vascular occlusion in which network meta-analysis was performed. The size of the node (circle) provides a
measure of the number of trials in which the particular treatment was included as one of the arms. The
thickness of the line provides a measure of the number of direct comparisons between two nodes
(treatments).Con: continuous; Int: intermittent; HVE: hepatic vascular exclusion; PTC: portal triad clamping;
RBC: red blood cells.
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Figure 19. Probability of best treatment: probability of being best, second best, third best, etc. for each
treatment for serious adverse events (proportion) (vascular occlusion methods). A probability of more than
90% is a reliable indicator that a treatment is best with regards to the specific outcome. A probability of less
than 90% is less reliable. None of the treatments have a 90% probability of being best treatment.Con:
continuous; Int: intermittent; HVE: hepatic vascular exclusion; PTC: portal triad clamping.
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Figure 20. Cumulative probability of being best treatment: cumulative probability of being best for each
treatment for vascular occlusion methods. Rank 1 indicates the probability that a treatment is best, rank 2
indicates the probability that a treatment is in the two best treatments, rank 3 indicates the probability that a
treatment is in the three best treatments, and so on.Con: continuous; Int: intermittent; HVE:hepatic vascular
exclusion; PTC: portal triad clamping.
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Direct evidence compared to network meta-analysis
Figure 21 shows the information on direct evidence compared
to network meta-analysis. Although there is overlap of credible
intervals, the mean indirect estimate seems to be quite different
from the direct estimate (sometimes suggesting an opposite effect),
thus suggesting that there may be discrepancies between direct
and indirect estimates. There was little apparent difference in the
quality of evidence between direct, indirect estimates, and network
meta-analysis; so, we could not choose one estimate over the others
based on the quality of evidence.
Figure 21. Methods of vascular occlusion: serious adverse events (proportion) Forest plot of the
comparisons in which direct and indirect estimates were available. Although there is overlap of confidence
intervals, the mean indirect estimate seems to be quite different from the direct estimate (sometimes,
suggesting an opposite effect), thus suggesting that there may be discrepancies between direct and indirect
estimates.There was little apparent difference in the quality of evidence between direct, indirect estimates,
and network meta-analysis; so, we could not choose one estimate over the others based on the quality of
evidence.1Risk of bias was unclear or high in the trial(s) (downgraded by 1 point).2Sample size was low
(downgraded by 1 point).3Confidence intervals spanned no effect and clinically significant effect (downgraded
by 1 point).
Serious adverse events (number)
Five trials reported the number of serious adverse events (Belghiti
1996; Man 1997; Belghiti 1999; Wu 2002; Figueras 2005). They
used five treatments in 376 participants. The unadjusted rates of
serious adverse events (number) are as follows.
• Control: 4/50 (8.0 per 100 participants).
• Continuous hepatic vascular exclusion: 5/28 (17.9 per 100
participants).
• Continuous portal triad clamping: 9/66 (13.6 per 100
participants).
• Intermittent portal triad clamping: 16/161 (9.9 per 100
participants).
• Intermittent selective portal triad clamping: 12/71 (16.9
per 100 participants).
Based on the DIC, we chose the fixed-effect model for all compar-
isonswith two ormore trials. The number of serious adverse events
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was lower in the intermittent portal triad clamping group than in
the continuous portal triad clamping group (rate ratio 0.09, 95%
CrI 0.00 to 0.56; 86 participants; 1 study; low-quality evidence:
downgraded one point for unclear or high risk of bias in trial and
one more point for small sample size). There was no evidence of
differences in other comparisons.
Adverse events (proportion)
Twelve trials reported the proportion of participants experiencing
adverse events (Man 1997; Belghiti 1999; Wu 2002; Capussotti
2003; Man 2003; Figueras 2005; Capussotti 2006; Chen 2006;
Liang 2009; Lee 2012; Ni 2013; Si-Yuan 2014). They used seven
treatments in 1129 participants. The unadjusted proportions of
adverse events (proportion) are as follows.
• Control: 55/196 (28.1%).
• Continuous hepatic vascular exclusion: 19/60 (31.7%).
• Continuous portal triad clamping: 75/258 (29.1%).
• Continuous selective hepatic vascular exclusion: 9/80
(11.3%).
• Continuous selective portal triad clamping: 22/100
(22.0%).
• Intermittent portal triad clamping: 109/364 (29.9%).
• Intermittent selective portal triad clamping: 22/71 (31.0%).
Direct comparison
Based on the DIC, we chose the fixed-effect model for compar-
isons with two or more studies. The proportion of participants
experiencing adverse events was lower in the continuous selective
portal triad clamping group than in the continuous portal triad
clamping group (OR 0.41, 95% CrI 0.18 to 0.90; 120 partic-
ipants; 1 study). There was no evidence of differences in other
comparisons.
Network meta-analysis
Figure 18 shows the network plots. Based on the DIC, we chose
the fixed-effect model. There was no evidence of differences in the
proportion of participants experiencing adverse events for any of
the comparisons. Figure 22 shows the probability of each treatment
being best, second best, third best, and so on. Figure 20 shows the
cumulative probability of a treatment being best.
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Figure 22. Probability of best treatment: probability of being best, second best, third best, etc. for each
treatment for adverse events (proportion) (vascular occlusion methods). A probability of more than 90% is a
reliable indicator that a treatment is best with regards to the specific outcome. A probability of less than 90%
is less reliable. None of the treatments have a 90% probability of being best treatment.Con: continuous; Int:
intermittent; HVE: hepatic vascular exclusion; PTC: portal triad clamping.
Direct evidence compared to network meta-analysis
Figure 23 shows the information on direct evidence compared to
network meta-analysis. There do not appear to be any discrepan-
cies between direct and indirect estimates. Direct evidence appears
to be preferable over indirect evidence and network meta-analysis
based on the quality of evidence.
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Figure 23. Methods of vascular occlusion: adverse events (proportion) Forest plot of the comparisons in
which direct and indirect estimates were available. There does not appear to be any discrepancies between
direct and indirect estimates. Direct evidence appears to be preferable over indirect evidence and network
meta-analysis based on the quality of evidence.1Risk of bias was unclear or high in the trial(s) (downgraded by
1 point).2Sample size was low (downgraded by 1 point).3Confidence intervals spanned no effect and clinically
significant effect (downgraded by 1 point).
Adverse events (number)
Six trials reported the number of adverse events (Belghiti 1996;
Man 1997; Belghiti 1999; Wu 2002; Figueras 2005; Lee 2012).
They used five in 502 participants. The unadjusted rates of adverse
events (number) are as follows.
• Control: 47/113 (41.6 per 100 participants).
• Continuous hepatic vascular exclusion: 19/28 (67.9 per
100 participants).
• Continuous portal triad clamping: 28/66 (42.4 per 100
participants).
• Intermittent portal triad clamping: 97/224 (43.3 per 100
participants).
• Intermittent selective portal triad clamping: 36/71 (50.7
per 100 participants).
Based on theDIC,we chose the fixed-effectmodel for comparisons
with two or more studies. There was no evidence of differences in
adverse events (number) for any of the comparisons.
Health-related quality of life
None of the trials reported this outcome at any time point.
Blood transfusion requirements
Blood transfusion (proportion)
Thirteen trials reported the proportion of participants requir-
ing a blood transfusion (Man 1997; Belghiti 1999; Wu 2002;
Capussotti 2003; Man 2003; Chouker 2004; Figueras 2005;
Capussotti 2006; Chen 2006; Liang 2009; Lee 2012; Ni 2013;
Si-Yuan 2014). They used seven treatments in 1163 participants.
The unadjusted proportions of participants requiring a blood
transfusion are as follows.
• Control: 64/211 (30.3%).
• Continuous hepatic vascular exclusion: 8/60 (13.3%).
• Continuous portal triad clamping: 71/277 (25.6%).
• Continuous selective hepatic vascular exclusion: 13/80
(16.3%).
• Continuous selective portal triad clamping: 21/100
(21.0%).
• Intermittent portal triad clamping: 101/364 (27.7%).
• Intermittent selective portal triad clamping: 11/71 (15.5%).
Direct comparison
Based on the DIC, we used the random-effects model for compar-
isons with two or more studies for intermittent portal triad clamp-
ing versus continuous portal triad clamping and the fixed-effect
model for the remaining comparisons with two or more studies.
The proportion of participants requiring a blood transfusion was
lower in the continuous portal triad clamping group than in the
control (OR 0.06, 95% CrI 0.00 to 0.49; 34 participants; 1 study;
low-quality evidence: downgraded one point for unclear or high
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risk of bias in trial and one more point for small sample size). The
blood transfusion (proportion) was higher in continuous portal
triad clamping than continuous hepatic vascular exclusion (OR
5.90, 95%CrI 2.45 to 15.58; 118 participants; 1 study; low-qual-
ity evidence: downgraded one point for unclear or high risk of bias
in trial and one more point for small sample size). There was no
evidence of differences in other comparisons.
Network meta-analysis
Figure 18 shows the network plots. Based on the DIC, we chose
the random-effects model. There was no evidence of differences
in the proportion of participants requiring a blood transfusion for
any of the comparisons. Figure 24 shows the probability of each
treatment being best, second best, third best, and so on. Figure 20
shows the cumulative probability of a treatment being the best.
Figure 24. Probability of best treatment: probability of being best, second best, third best, etc. for each
treatment for blood transfusion (proportion) (vascular occlusion methods). A probability of more than 90% is
a reliable indicator that a treatment is best with regards to the specific outcome. A probability of less than 90%
is less reliable. None of the treatments have a 90% probability of being best treatment.Con: continuous; Int:
intermittent; HVE: hepatic vascular exclusion; PTC: portal triad clamping.
Direct evidence compared to network meta-analysis
Figure 25 shows the information on direct evidence compared to
network meta-analysis. Although the credible intervals overlap,
there appears to be some discrepancies between direct and indirect
estimates for continuous portal triad clamping versus control, in-
termittent portal triad clamping versus control, and intermittent
portal triad clamping versus continuous portal triad clamping. Di-
rect evidence appears to be preferable over indirect evidence and
network meta-analysis based on the quality of evidence.
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Figure 25. Methods of vascular occlusion: blood transfusion (proportion) Forest plot of the comparisons in
which direct and indirect estimates were available. Although the confidence intervals overlap, there appear to
be some discrepancies between direct and indirect estimates for continuous portal triad clamping versus
control, intermittent portal triad clamping versus control, and intermittent portal triad clamping versus
continuous portal triad clamping. Direct evidence appears to be preferable over indirect evidence and network
meta-analysis based on the quality of evidence.1Risk of bias was unclear or high in the trial(s) (downgraded by
1 point).2Sample size was low (downgraded by 1 point).3Confidence intervals spanned no effect and clinically
significant effect (downgraded by 1 point).4There was substantial or considerable heterogeneity (downgraded
by 2 points).
Blood transfusion (red blood cells)
Ten trials reported blood transfusion quantity (red blood cells)
(Belghiti 1996; Clavien 1996; Man 1997; Belghiti 1999; Wu
2002; Capussotti 2003; Figueras 2005; Liang 2009; Ni 2013;
Si-Yuan 2014). They usedseven treatments in 786 participants.
The median and range of the mean blood transfusion quantity
(red blood cells) reported for each treatment are as follows.
• Control: 1.50 units and 1.90 units (two trials only).
• Continuous hepatic vascular exclusion: 2.50 units (one trial
only).
• Continuous portal triad clamping: 1.80 units (range 0.50
to 30).
• Continuous selective hepatic vascular exclusion: 1.00 unit
(one trial only).
• Continuous selective portal triad clamping: 1.20 units and
1.37 units (two trials only).
• Intermittent portal triad clamping: 0.99125 units (range
0.00 to 2.54).
• Intermittent selective portal triad clamping: 0.34 units,
2.24 units (two trials only).
Direct comparison
Based on the DIC, we chose the fixed-effect model for compar-
isons with two or more studies. The blood transfusion quantity
(red blood cells) was lower in the group receiving intermittent por-
tal triad clamping than in the control (−1.50, 95% CrI−2.75 to
−0.26; 100 participants; 1 study). The blood transfusion quan-
tity (red blood cells) was lower in the group receiving continuous
selective hepatic vascular exclusion than in the continuous por-
tal triad clamping group (MD −1.20 units, 95% CrI −2.37 to
−0.04; 160 participants; 1 study). The blood transfusion quan-
tity (red blood cells) was lower in the continuous selective portal
triad clamping group than in the continuous portal triad clamp-
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ing group (MD−0.20 units, 95% CrI−0.31 to−0.09; 120 par-
ticipants; 1 study). There was no evidence of differences in other
comparisons. Exclusion of four trials in which we calculated the
mean, standard deviation, or both did not change the conclusions
(Man 1997; Belghiti 1999; Wu 2002; Si-Yuan 2014).
Network meta-analysis
Figure 18 shows the network plots. Based on the DIC, we chose
the fixed-effect model. Compared with the control group, there
was evidence for a lower blood transfusion quantity (red blood
cells) with continuous portal triad clamping (MD −1.25 units,
95% CrI −2.39 to −0.10), continuous selective hepatic vascular
exclusion (MD −2.45 units, 95% CrI −4.08 to −0.82), contin-
uous selective portal triad clamping (MD −1.45 units, 95% CrI
−2.59 to−0.31), intermittent portal triad clamping (MD−1.36
units, 95% CrI −2.48 to −0.23), and intermittent selective por-
tal triad clamping (MD−1.43 units, 95% CrI−2.61 to−0.24).
There was no evidence of differences in other comparisons. On
excluding the trials in which either mean or standard deviation
was not available, there was no evidence of differences in any of the
comparisons. Figure 26 shows the probability of each treatment
being best, second best, third best, and so on. Figure 20 shows the
cumulative probability of a treatment being best.
Figure 26. Probability of best treatment: probability of being best, second best, third best, etc. for each
treatment for blood transfusion (red blood cells) (vascular occlusion methods). A probability of more than 90%
is a reliable indicator that a treatment is best with regards to the specific outcome. A probability of less than
90% is less reliable. Intermittent selective portal triad clamping has about 90% probability of being best
treatment. However, other random and systematic errors make this finding unreliable.Con: continuous; Int:
intermittent; HVE: hepatic vascular exclusion; PTC: portal triad clamping.
Direct evidence compared to network meta-analysis
Figure 27 shows the information on direct evidence compared to
network meta-analysis. There do not appear to be any discrepan-
cies between direct and indirect estimates, although the credible
intervals are different (the direct evidence had narrower credible
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intervals in four of the five comparisons above) resulting in the
differences in the comparisons in which there was evidence for
difference. Direct evidence appears to be preferable over indirect
evidence and network meta-analysis based on the quality of evi-
dence for the comparison ’continuous selective portal triad clamp-
ing versus continuous portal triad clamping’. Indirect evidence
and network meta-analysis appear to be preferable over direct evi-
dence for the comparison ’continuous portal triad clamping versus
control’. Direct evidence and network meta-analysis appear to be
preferable over indirect evidence for the comparison ’intermittent
portal triad clamping versus control’. There was little apparent
difference in the quality of evidence between direct, indirect es-
timates, and network meta-analysis; so, we could not choose one
estimate over the others based on the quality of evidence.
Figure 27. Methods of vascular occlusion:blood transfusion (red blood cells) Forest plot of the comparisons
in which direct and indirect estimates were available. There do not appear to be any discrepancies between
direct and indirect estimates, although the credible intervals are different (the direct evidence had narrower
credible intervals in four of the five comparisons above) resulting in the differences in the comparisons in
which there was evidence for difference. Direct evidence appears to be preferable over indirect evidence and
network meta-analysis based on the quality of evidence for the comparison ’continuous selective portal triad
clamping versus continuous portal triad clamping’. Indirect evidence and network meta-analysis appear to be
preferable over direct evidence for the comparison ’continuous portal triad clamping versus control’. Direct
evidence and network meta-analysis appear to be preferable over indirect evidence for the comparison
’intermittent portal triad clamping versus control’. There was little apparent difference in the quality of
evidence between direct, indirect estimates, and network meta-analysis; so, we could not choose one estimate
over the others based on the quality of evidence.1Risk of bias was unclear or high in the trial(s) (downgraded
by 1 point).2Sample size was low (downgraded by 1 point).3Confidence intervals spanned no effect and
clinically significant effect (downgraded by 1 point).
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Blood transfusion (platelets)
None of the trials reported this outcome.
Blood transfusion (fresh frozen plasma)
None of the trials reported this outcome.
Blood transfusion (cryoprecipitate)
None of the trials reported this outcome.
Blood loss
Sixteen trials reported blood loss (Belghiti 1996; Man 1997;
Belghiti 1999; Wu 2002; Capussotti 2003; Chouker 2004;
Figueras 2005; Capussotti 2006; Chen 2006; Liang 2009;
Dayangac 2010; Pietsch 2010; Lee 2012; Park 2012; Ni 2013;
Si-Yuan 2014). They used seven interventions in 1322 partici-
pants. The median and range of the mean blood loss reported for
each treatment are as follows.
• Control: 0.489 L (range 0.204 to 2.17).
• Continuous hepatic vascular exclusion: 0.42 L and 1.195 L
(two trials only).
• Continuous portal triad clamping: 0.77 L (range 0.2 to
1.38).
• Continuous selective hepatic vascular exclusion: 0.529 L
(one trial only).
• Continuous selective portal triad clamping: 0.3 L and
0.649 L (two trials only).
• Intermittent portal triad clamping: 0.671 L (range 0.184 to
1.685).
• Intermittent selective portal triad clamping: 0.735 L and
1.159 L (two trials only)..
Direct comparison
Based on theDIC, we chose the fixed-effectmodel for intermittent
portal triad clamping versus continuous portal triad clamping and
the random-effectsmodel for the remaining comparisonswith two
or more studies. There was no evidence of differences in blood
loss for any of the comparisons. Either the mean, the standard
deviation, or both were not available in six trials (Man 1997; Wu
2002; Capussotti 2006; Pietsch 2010; Ni 2013; Si-Yuan 2014).
Excluding these trials did not alter the conclusions.
Network meta-analysis
Figure 18 shows the network plots. Based on the DIC, we chose
the random-effects model. There was no evidence of differences
in blood loss for any of the comparisons. Excluding the six trials in
which either the mean, the standard deviation, or both were not
available did not alter the results (Man 1997;Wu2002; Capussotti
2006; Pietsch 2010; Ni 2013; Si-Yuan 2014). Figure 28 shows
the probability of each treatment being best, second best, third
best, and so on. Figure 20 shows the cumulative probability of a
treatment being best.
60Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 28. Probability of best treatment: probability of being best, second best, third best, etc. for each
treatment for blood loss (vascular occlusion methods). A probability of more than 90% is a reliable indicator
that a treatment is best with regards to the specific outcome. A probability of less than 90% is less reliable.
None of the treatments have a 90% probability of being best treatment.Con: continuous; Int: intermittent;
HVE: hepatic vascular exclusion; PTC: portal triad clamping.
Direct evidence compared to network meta-analysis
Figure 29 shows the information on direct evidence compared to
network meta-analysis. There do not appear to be any discrepan-
cies between direct and indirect estimates, although the credible
intervals are different (the direct evidence had narrower credible
intervals in three of the five comparisons above). Direct evidence
appears to be preferable over indirect evidence and network meta-
analysis based on the quality of evidence.
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Figure 29. Methods of vascular occlusion:blood loss Forest plot of the comparisons in which direct and
indirect estimates were available. There does not appear to be any discrepancies between direct and indirect
estimates, although the credible intervals are different (the direct evidence had narrower credible intervals in
three of the five comparisons above). Direct evidence appears to be preferable over indirect evidence and
network meta-analysis based on the quality of evidence.1Risk of bias was unclear or high in the trial(s)
(downgraded by 1 point).2 Sample size was low (downgraded by 1 point).3Confidence intervals spanned no
effect and clinically significant effect (downgraded by 1 point).Ç4There was substantial or considerable
heterogeneity (downgraded by 2 points).
Major blood loss (proportion)
Three trials reported the proportion of participants experiencing
major blood loss (Lee 2012; Ni 2013; Si-Yuan 2014), defined
as more than one litre in Lee 2012 and Ni 2013 and as more
than two litres in Si-Yuan 2014. The trials used five interventions
in 406 participants. The unadjusted proportions of participants
experiencing major blood loss are as follows.
• Control: 4/63 (6.3%).
• Continuous portal triad clamping: 8/140 (5.7%).
• Continuous selective hepatic vascular exclusion: 2/80
(2.5%).
• Continuous selective portal triad clamping: 0/60 (0.0%).
• Intermittent portal triad clamping: 5/63 (7.9%).
There was only one trial for each comparison. There was no ev-
idence of differences in major blood loss (proportion) for any of
the comparisons.
Hospital stay
Total hospital stay
Ten trials reported total hospital stay (Belghiti 1996; Man 1997;
Belghiti 1999; Wu 2002; Figueras 2005; Capussotti 2006; Liang
2009; Lee 2012; Park 2012; Si-Yuan 2014). They used seven treat-
ments in 918 participants. The medians and ranges of the mean
hospital stay reported for each treatment are as follows.
• Control: 9 d (range 7 to 19).
• Continuous hepatic vascular exclusion: 22 d (one trial
only).
• Continuous portal triad clamping: 14 d (range 13 to 14).
• Continuous selective hepatic vascular exclusion: 10 d (one
trial only).
• Continuous selective portal triad clamping: 10 d (one trial
only).
• Intermittent portal triad clamping: 10 d (range 8 to 16).
• Intermittent selective portal triad clamping: 8 d and 16 d
(two trials only)..
Based on the DIC, we chose the fixed-effect model for compar-
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isons with two or more studies. The total hospital stay was lower
in the continuous portal triad clamping group than in the con-
tinuous hepatic vascular exclusion group (MD−8.00 d, 95% CrI
−13.03 to−2.95; 52 participants; 1 study; low-quality evidence:
downgraded one point for unclear or high risk of bias in trial and
one more point for small sample size). The total hospital stay was
lower in the continuous selective hepatic vascular exclusion group
than in the continuous portal triad clamping group (MD −2.80
d, 95% CrI−4.13 to−1.47; 160 participants; 1 study; low-qual-
ity evidence: downgraded 1 point for unclear or high risk of bias
in trial and one more point for small sample size). There was no
evidence of differences in other comparisons. Either the mean,
the standard deviation, or both were not available in four trials
(Man 1997; Wu 2002; Capussotti 2006; Lee 2012). Excluding
these trials did not alter the conclusions except for intermittent
portal triad clamping versus control. We excluded three of the
four trials under this comparison because of the lack of availability
of either the mean, the standard deviation, or both (Man 1997;
Capussotti 2006; Lee 2012). Excluding these trials, the hospital
stay was shorter in the intermittent portal triad clamping group
than in the control (MD −3.51 d, 95% CrI −6.85 to −0.16; 50
participants; 1 study).
ITU stay
One trial reported ITU stay (Si-Yuan 2014); the mean ITU stays
reported for each treatment are as follows.
• Continuous portal triad clamping: 1.5 d.
• Continuous selective hepatic vascular exclusion: 1.2 d.
The ITU stay was lower in the continuous selective hepatic vascu-
lar exclusion group than in the continuous portal triad clamping
group (MD−0.30 d, 95%CrI−0.55 to−0.06; 160 participants;
1 study).
Operating time
Twelve trials reported operating time (Belghiti 1996; Clavien
1996; Wu 2002; Capussotti 2003; Figueras 2005; Chen 2006;
Liang 2009; Pietsch 2010; Lee 2012; Park 2012; Ni 2013; Si-
Yuan 2014). They used seven treatments in 919 participants. The
medians and ranges of the mean operating times reported for each
treatment are as follows.
• Control: 292 min (range 239 to 339).
• Continuous hepatic vascular exclusion: 133 min and 366
min (two trials only).
• Continuous portal triad clamping: 200 min (range 116 to
301).
• Continuous selective hepatic vascular exclusion: 131 min
(one trial only).
• Continuous selective portal triad clamping: 136 min and
236 min (two trials only).
• Intermittent portal triad clamping: 241 min (range 204 to
409).
• Intermittent selective portal triad clamping: 219 min and
399 min (two trials only).
Based on the DIC, we chose the fixed-effect model for continu-
ous portal triad clamping versus control and intermittent selective
portal triad clamping versus intermittent portal triad clamping,
and we used the random-effects model for the remaining compar-
isons with two or more studies. The operating time was lower in
the intermittent portal triad clamping group than in the continu-
ous selective portal triad clamping group (MD−30.53 min, 95%
CrI −49.68 to −11.29; 80 participants; 1 study). There was no
evidence of differences in other comparisons. Either the mean, the
standard deviation, or both were not available in four trials (Wu
2002; Pietsch 2010; Lee 2012; Si-Yuan 2014). Excluding these
trials did not alter the conclusions except for intermittent portal
triad clamping versus control. We excluded Lee 2012 from this
two-trial comparison because no mean or standard deviation were
available (Lee 2012; Park 2012). Excluding this trial, the operating
time was longer in the intermittent portal triad clamping group
than in the control (MD 49.63 min, 95% CrI 26.72 to 72.55;
50 participants; 1 study; low-quality evidence: downgraded one
point for unclear or high risk of bias in trial and one more point
for small sample size).
Time needed to return to work
None of the trials reported this outcome.
Difference between Bayesian and frequentist meta-analysis
The interpretation of information and conclusions did not alter
by using the frequentist meta-analysis.
Overall summary
There was no evidence of differences between the tested methods
of vascular occlusion in any of the reported outcomes of interest
for this review other than the following − and they all ought to
be considered of low or very low quality .
• The proportion of participants experiencing serious adverse
events was lower in the continuous selective portal triad clamping
group than in the continuous portal triad clamping group (OR
0.42, 95% CrI 0.18 to 0.96; 120 participants; 1 study).
• The number of serious adverse events was lower in the
intermittent portal triad clamping group than in the continuous
portal triad clamping group (rate ratio 0.09, 95% CrI 0.00 to
0.56; 86 participants; 1 study).
• The proportion of participants experiencing adverse events
was lower in the continuous selective portal triad clamping
group than in the continuous portal triad clamping group (OR
0.41, 95% CrI 0.18 to 0.90; 120 participants; 1 study).
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• The proportion of participants requiring a blood
transfusion was lower in the continuous portal triad clamping
group than in the control (OR 0.06, 95% CrI 0.00 to 0.49; 34
participants; 1 study). The proportion of participants requiring a
blood transfusion was higher in the continuous portal triad
clamping group than in the continuous hepatic vascular
exclusion group (OR 5.90, 95% CrI 2.45 to 15.58; 118
participants; 1 study).
• The blood transfusion quantity (red blood cells) was lower
with continuous portal triad clamping than in the control (MD
−1.25 units, 95% CrI −2.39 to −0.10; network meta-analysis:
786 participants; 10 studies). The blood transfusion quantity
(red blood cells) was lower in the intermittent portal triad
clamping group than in the control (−1.50, 95% CrI −2.75 to
−0.26; 100 participants; 1 study). The blood transfusion
quantity (red blood cells) was lower in the continuous selective
hepatic vascular exclusion group than in the continuous portal
triad clamping group(MD −1.20 units, 95% CrI −2.37 to
−0.04; 160 participants; 1 study). The blood transfusion
quantity (red blood cells) was lower in the continuous selective
portal triad clamping group than in the continuous portal triad
clamping group (MD −0.20, 95% CrI −0.31 to −0.09; 120
participants; 1 study).
• The hospital stay was lower in the continuous portal triad
clamping group than in the continuous hepatic vascular
exclusion group (MD −8.00 d, 95% CrI −13.03 to −2.95; 52
participants; 1 study). The hospital stay was lower in the
continuous selective hepatic vascular exclusion group than in the
continuous portal triad clamping group (MD −2.80 d, 95% CrI
−4.13 to −1.47; 160 participants; 1 study).
• The ITU stay was lower in the continuous selective hepatic
vascular exclusion group than in the continuous portal triad
clamping group (MD −0.30 d, 95% CrI −0.55 to −0.06; 160
participants; 1 study).
• The operating time was lower in the intermittent portal
triad clamping group than in the continuous selective portal
triad clamping group (MD −30.53 min, 95% CrI −49.68 to
−11.29; 80 participants; 1 study).
Pharmacological interventions
Six trials compared different pharmacological interventions (
Shimada 1994; Lentschener 1997;Wong 2003; Lodge 2005; Shao
2006;Wu 2006).We did not perform networkmeta-analysis since
direct comparison and indirect comparison effect estimates (which
would enable assessment of inconsistency) were not available for
any of the outcomes.
Quality of evidence
The quality of evidence was very low for all the outcomes and
comparisons unless specifically indicated within the results. This
was because of unclear or high risk of bias in the trials (down-
graded by one point), imprecision due to small sample size (down-
graded by one point), and wide credible intervals (downgraded by
one point) for all outcomes with very low quality of evidence. In
addition, we downgraded the quality for blood transfusion (as a
proportion of participants requiring one) by two points because
of the presence of substantial or considerable heterogeneity in the
pair-wise comparison or in the network.
Mortality
Mortality (perioperative)
Two trials reported perioperative mortality (Lodge 2005; Wu
2006). They used three treatments in 399 participants. The un-
adjusted proportions of perioperative mortality are as follows.
• Control: 3/165 (1.8%).
• Recombinant factor VIIa: 4/126 (3.2%).
• Tranexamic acid: 0/108 (0.0%).
There was no evidence of differences in perioperative mortality
for any of the comparisons.
Mortality (longest follow-up)
None of the trials reported this outcome.
Adverse events
Serious adverse events (proportion)
Three trials reported the proportion of participants experiencing
serious adverse events (Shimada 1994; Lodge 2005; Shao 2006).
They used three treatments in 456 participants. The unadjusted
proportions of participants experiencing serious adverse events are
as follows.
• Control: 59/160 (36.9%).
• Anti-thrombin III: 4/13 (30.8%).
• Recombinant factor VIIa: 111/283 (39.2%).
There was no evidence of differences in the proportion of partic-
ipants experiencing serious adverse events for any of the compar-
isons.
Serious adverse events (number)
Three trials reported the number of serious adverse events (Lodge
2005; Shao 2006; Wu 2006). They used three treatments in 646
participants. The unadjusted rates of serious adverse events (num-
ber) are as follows.
• Control: 20/255 (7.8 per 100 participants).
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• Recombinant factor VIIa: 35/283 (12.4 per 100
participants).
• Tranexamic acid: 7/108 (6.5 per 100 participants).
There was no evidence of differences in the number of serious
adverse events for any of the comparisons.
Adverse events (proportion)
Three trials reported the proportion of participants experiencing
adverse events (Shimada 1994; Shao 2006; Wu 2006). A total of
four treatments were used in a total of 470 participants in these
studies. The unadjusted proportions of adverse events (propor-
tion) are as follows.
• Control: 98/198 (49.5%)
• Anti-thrombin III: 4/13 (30.8%)
• Recombinant factor VIIa: 142/151 (94.0%)
• Tranexamic acid: 14/108 (13.0%).
There was no evidence of differences in the proportion of partici-
pants experiencing adverse events for any of the comparisons.
Adverse events (number)
Three trials reported the number of adverse events (number) (
Lodge 2005; Shao 2006;Wu 2006). They used three treatments in
646 participants. The unadjusted rates of adverse events (number)
are as follows.
• Control: 467/255 (183.1 per 100 participants).
• Recombinant factor VIIa: 824/283 (291.2 per 100
participants).
• Tranexamic acid: 19/108 (17.6 per 100 participants).
There was no evidence of differences in the number of adverse
events reported for any of the comparisons.
Health-related quality of life
None of the trials reported this outcome at any time point.
Blood transfusion requirements
Blood transfusion (proportion)
Five trials reported the proportion of participants requiring a
blood transfusion (Lentschener 1997; Wong 2003; Lodge 2005;
Shao 2006; Wu 2006). They used five treatments in 787 par-
ticipants. The unadjusted proportions of participants requiring a
blood transfusion (proportion) are as follows.
• Control: 93/320 (29.1%).
• Aprotinin: 8/48 (16.7%).
• Desmopressin: 3/30 (10.0%).
• Recombinant factor VIIa: 104/281 (37.0%).
• Tranexamic acid: 0/108 (0.0%).
The the proportion of participants requiring a blood transfusion
was lower in the aprotinin group (OR0.31, 95%CrI 0.11 to 0.78;
97 participants; 1 study; low-quality evidence: downgraded one
point for unclear or high risk of bias in trial and one more point
for small sample size) and in the tranexamic acid group than in
the control (OR 0.01, 95% CrI 0.00 to 0.13; 214 participants; 1
study; low-quality evidence: downgraded one point for unclear or
high risk of bias in trial and one more point for small sample size).
There was no evidence of differences in other comparisons.
Blood transfusion (red blood cells)
Four trials reported blood transfusion quantity (red blood cells) (
Shimada 1994; Lentschener 1997; Lodge 2005; Shao 2006). They
used four interventions in 537 participants. Themedian and range
of the mean blood transfusion quantity (red blood cells) reported
for each treatment are as follows.
• Control: 2.07 units (range 0.00 to 4.40).
• Anti-thrombin III: 4.80 units (one trial only).
• Aprotinin: 0.63 units (one trial only).
• Recombinant factor VIIa: 0.40 and 3.00 units (two trials
only).
We did not perform meta-analysis since none of the studies pro-
vided both the mean and the standard deviation. The blood trans-
fusion quantity (red blood cells) was lower in the aprotinin group
than in the control (MD−0.94 units; P = 0.015; 97 participants;
1 study). There was no evidence of differences in other compar-
isons.
Blood transfusion (platelets)
Two trials reported blood transfusion quantity (platelets) (
Lentschener 1997; Shao 2006). They used three treatments in 328
participants. No participants received a platelets transfusion in
Lentschener 1997 (aprotinin versus control). Themedian platelets
transfused was 0 in both groups in the other trial (Shao 2006;
recombinant factor VIIa versus control).
Blood transfusion (fresh frozen plasma)
Three trials reported blood transfusion quantity (fresh frozen
plasma) (Lentschener 1997; Wong 2003; Shao 2006). They used
four treatments in 388 participants. The median and range of the
mean or median blood transfusion quantity (fresh frozen plasma)
reported for each treatment are as follows.
• Control: 0.45 units (range 0.00 to 0.80).
• Aprotinin: 0.04 units (one trial only).
• Desmopressin: 0.20 units (one trial only).
• Recombinant factor VIIa: 0.00 units (one trial only).
We did not perform meta-analysis since either mean or standard
deviation was not available in two trials (Lentschener 1997; Shao
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2006). There was no evidence of differences in blood transfusion
quantity (fresh frozen plasma) for any of the comparisons.
Blood transfusion (cryoprecipitate)
None of the trials reported this outcome.
Blood loss
Six trials reported blood loss (Shimada 1994; Lentschener 1997;
Wong 2003; Lodge 2005; Shao 2006; Wu 2006). They used six
treatments in 810 participants. Themedian and range of themean
blood loss reported for each treatment are as follows.
• Control: 1.10 L (range 0.50 to 1.65).
• Anti-thrombin III: 1.86 L (one trial only).
• Aprotinin: 1.22 L (one trial only).
• Desmopressin: 0.83 L (one trial only).
• Recombinant factor VIIa: 0.65 L and 1.23 L (two trials
only).
• Tranexamic acid: 0.30 L (one trial only).
We did not perform meta-analysis since we imputed the mean,
standard deviation, or both in five trials (Shimada 1994; Wong
2003; Lodge 2005; Shao 2006; Wu 2006). The blood loss was
lower in the tranexamic acid group than in the control (difference
in median:−0.30 L, P < 0.001; 214 participants; 1 study). There
was no evidence of any difference in other comparisons.
Major blood loss (proportion)
None of the trials reported this outcome.
Total hospital stay
Hospital stay
One trial (214 participants) reported hospital stay (Wu 2006). The
median hospital stays reported for each treatment are as follows.
• Control: 9 d (one trial only).
• Tranexamic acid: 8 d (one trial only).
There was no evidence of difference in median hospital stay be-
tween the groups.
ITU stay
None of the trials reported this outcome.
Operating time
Five trials reported operating time (Shimada 1994; Lentschener
1997; Wong 2003; Lodge 2005; Wu 2006). They used six treat-
ments in 580 participants. The medians and ranges of the mean
operating times reported for each treatment are as follows.
• Control: 261 min (range 233 to 435).
• Anti-thrombin III: 233 min (one trial only).
• Aprotinin: 232 min (one trial only).
• Desmopressin: 405 min (one trial only).
• Recombinant factor VIIa: 230 min (one trial only).
• Tranexamic acid: 254min (one trial only).
Themean, standard deviation or both were not available from four
studies (Shimada 1994;Wong 2003; Lodge 2005;Wu 2006). The
operating time was lower in the tranexamic acid group than in
the control group (difference in medians −52.20 min; P = 0.003;
214 participants; 1 study; low-quality evidence: downgraded one
point for unclear or high risk of bias in trial and onemore point for
small sample size). There was no evidence of differences in other
comparisons.
Time needed to return to work
None of the trials reported this outcome.
Difference between Bayesian and frequentist meta-analysis
The interpretation of information and conclusions did not alter
by using the frequentist meta-analysis.
Overall summary
There was no evidence of differences between different pharma-
cological interventions in any of the reported outcomes of interest
for this review other than the following.
• The proportion of participants requiring a blood
transfusion was lower in the aprotinin group (OR 0.31, 95% CrI
0.11 to 0.78; 97 participants; 1 study) and in the tranexamic
acid group (OR 0.01, 95% CrI 0.00 to 0.13; 214 participants; 1
study) than in the control.
• The blood transfusion quantity (red blood cells) was lower
in the aprotinin group than in the control (MD−0.94 units; P =
0.015; 97 participants; 1 study).
• The blood loss was lower in the tranexamic acid group than
in the control (difference in median: −0.3 L, P < 0.001; 214
participants; 1 study).
• The operating time was lower in the tranexamic acid group
than in the control (difference in medians −52.20 min; P =
0.003; 214 participants; 1 study).
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Overall summary across all interventions
Mortality (perioperative)
There was no evidence of differences in perioperative mortality for
any of the comparisons for which this information was available.
Mortality at longest follow-up
There was no evidence of differences inmortality at longest follow-
up for any of the comparisons for which this information was
available.
Serious adverse events (proportion)
• The proportion of participants experiencing serious adverse
events was lower in the continuous selective portal triad clamping
group than in the continuous portal triad clamping group (OR
0.42, 95% CrI 0.18 to 0.96; 120 participants; 1 study).
• There was no evidence of differences in other comparisons
for which this information was available.
Serious adverse events (number)
• The number of serious adverse events was higher in the
fibrin sealant group than in the argon beam group (rate ratio
4.81, 95% CrI 1.73 to 17.5; 121 participants; 1 study).
• The number of serious adverse events was lower in the
intermittent portal triad clamping group than in the continuous
portal triad clamping group (rate ratio 0.09, 95% CrI 0.00 to
0.56; 86 participants; 1 study).
• There was no evidence of differences in other comparisons
for which this information was available.
Adverse events (proportion)
• The proportion of participants experiencing adverse events
was lower in the continuous selective portal triad clamping
group than in the continuous portal triad clamping group (OR
0.41, 95% CrI 0.18 to 0.90; 120 participants; 1 study).
• There was no evidence of differences in other comparisons
for which this information was available.
Adverse events (number)
• The number of adverse events was higher with
radiofrequency dissecting sealer than with the clamp-crush
method (rate ratio 1.85, 95% CrI 1.07 to 3.26; 250 participants;
3 studies) (Bayesian analysis only: both direct and network meta-
analysis).
• There was no evidence of differences in other comparisons
for which this information was available.
Health-related quality of life
None of the trials reported this outcome.
Blood transfusion (proportion)
• The proportion of participants requiring a blood
transfusion was lower in the group receiving an autologous blood
donation than in the control (OR 0.18, 95% CrI 0.04 to 0.66;
42 participants; 1 study).
• The proportion of participants requiring a blood
transfusion was higher in the low central venous pressure group
than in the acute normovolemic haemodilution plus low central
venous pressure group (OR 3.19, 95% CrI 1.56 to 6.95; 208
participants; 2 studies).
• The proportion of participants requiring a blood
transfusion was lower in the continuous portal triad clamping
group than in the control (OR 0.06, 95% CrI 0.00 to 0.49; 34
participants; 1 study). The proportion of participants requiring a
blood transfusion was higher in the continuous portal triad
clamping group than in the continuous hepatic vascular
exclusion group (OR 5.90, 95% CrI 2.45 to 15.58; 118
participants; 1 study).
• The proportion of participants requiring a blood
transfusion was lower in the aprotinin group (OR 0.31, 95% CrI
0.11 to 0.78; 97 participants; 1 study) and in the tranexamic
acid group than in the control (OR 0.01, 95% CrI 0.00 to 0.13;
214 participants; 1 study).
• There was no evidence of differences in other comparisons
for which this information was available.
Blood transfusion (red blood cells)
• Compared to control, the blood transfusion quantity (red
blood cells) was lower in the acute normovolemic haemodilution
group (MD −1.25 units, 95% CrI −1.75 to −0.74; 20
participants; 1 study) and in the acute normovolemic
haemodilution plus hypotension group (MD −1.67 units, 95%
CrI −2.06 to −1.32; 20 participants; 1 study). The blood
transfusion quantity (red blood cells) was higher in the acute
normovolemic haemodilution plus low central venous pressure
group than in the control (MD 0.27 units, 95% CrI 0.01 to
0.52; 30 participants; 1 study).
• The blood transfusion quantity (red blood cells) was lower
in the hydrojet group than in the cavitron ultrasonic surgical
aspirator group (MD −0.98 units, 95% CrI−1.90 to−0.06; 61
participants; 1 study).
• The blood transfusion quantity (red blood cells) was lower
in the fibrin sealant group than in the control (MD −0.53 units,
95% CrI −1.00 to −0.07; 122 participants; 2 studies). The
blood transfusion quantity (red blood cells) was higher in the
fibrin sealant group than in the cyanoacrylate group (MD 2.20
units; 95% CrI 1.59 to 2.81; 30 participants; 1 study).
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• The blood transfusion quantity (red blood cells) was lower
with continuous portal triad clamping than control (MD −1.25
units, 95% CrI −2.39 to −0.10; network meta-analysis: 786
participants; 10 studies). The blood transfusion quantity (red
blood cells) was lower in the intermittent portal triad clamping
group than in the control (−1.50, 95% CrI −2.75 to −0.26;
100 participants; 1 study). The blood transfusion quantity (red
blood cells) was lower in the continuous selective hepatic vascular
exclusion group than in the continuous portal triad clamping
group (MD −1.20 units, 95% CrI −2.37 to −0.04; 160
participants; 1 study). The blood transfusion quantity (red blood
cells) was lower in the continuous selective portal triad clamping
group than in the continuous portal triad clamping group (MD
−0.20, 95% CrI −0.31 to −0.09; 120 participants; 1 study).
• The blood transfusion quantity (red blood cells) was lower
in the aprotinin group than in the control (MD −0.94; P =
0.015; 97 participants; 1 study).
• There was no evidence of differences in other comparisons
for which this information was available.
Blood transfusion (platelets)
There was no evidence of differences in blood transfusion quantity
(platelets) in any of the comparisons for which this information
was available.
Blood transfusion (fresh frozen plasma)
• The blood transfusion quantity (fresh frozen plasma) was
lower in the low central venous pressure group than in the
control (MD −2.48 units, 95% CrI −3.58 to −1.37; 50
participants; 1 study).
• The blood transfusion quantity (fresh frozen plasma) was
lower in the fibrin sealant group than in the cyanoacrylate group
(MD −0.81 units, 95% CrI −1.04 to −0.62; 30 participants; 1
study). The blood transfusion quantity (fresh frozen plasma) was
higher in the oxidised cellulose group than in the fibrin sealant
group (MD 0.53 units, 95% CrI 0.36 to 0.71; 80 participants; 2
studies).
• There was no evidence of differences in other comparisons
for which this information was available.
Blood transfusion (cryoprecipitate)
There was no evidence of differences in blood transfusion quantity
(cryoprecipitate) in any of the comparisons for which this infor-
mation was available.
Blood loss
• The blood loss was lower in the acute normovolemic
haemodilution plus hypotension group (MD −0.25 L; 95% CrI
−0.37 to −0.13; 20 participants; 1 study) and in the low central
venous pressure group than in the control (MD −0.34 L, 95%
CrI −0.46 to −0.22; 237 participants; 4 studies). The blood loss
was lower in the acute normovolemic haemodilution plus
hypotension group than in the acute normovolemic
haemodilution group (MD −0.25; 95% CrI −0.40 to −0.10;
20 participants; 1 study).
• The blood loss was lower in the tranexamic acid group than
in the control (difference in median: −0.3 L, P < 0.001; 214
participants; 1 study).
• There was no evidence of differences in other comparisons
for which this information was available.
Major blood loss (proportion)
There was no evidence of differences in the proportion of partici-
pants experiencing major blood loss in any of the comparisons for
which this information was available.
Hospital stay
• The total hospital stay was lower in the low central venous
pressure group than in the control (MD −2.42 d, 95% CrI
−3.91 to −0.94; 197 participants; 3 studies).
• The total hospital stay was lower in the continuous portal
triad clamping group than in the continuous hepatic vascular
exclusion group (MD −8.00 d, 95% CrI −13.03 to −2.95; 52
participants; 1 study). The total hospital stay was lower in the
continuous selective hepatic vascular exclusion group than in the
continuous portal triad clamping group (MD −2.80 d, 95% CrI
−4.13 to −1.47; 160 participants; 1 study).
• There was no evidence of differences in other comparisons
for which this information was available.
ITU stay
• The ITU stay was lower in the continuous selective hepatic
vascular exclusion group than in the continuous portal triad
clamping group (MD −0.30 d, 95% CrI −0.55 to −0.06; 160
participants; 1 study).
• There was no evidence of differences in other comparisons
for which this information was available.
Operating time
• The operating time was lower in the low central venous
pressure group than in the control (MD −15.32 min, 95% CrI
−29.03 to −1.69; 192 participants; 4 studies).
• The operating time was lower in the stapler resection group
than in the clamp-crush method group with frequentist meta-
analysis (MD −31.00 min, 95% CI −60.40 to −1.60; 130
participants; 1 study) (frequentist analysis only).
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• The operating time was higher in the fibrin sealant and
collagen group than in the control (MD 19.72 min, 95% CrI
2.93 to 36.57; 300 participants; 1 study).
• The operating time was lower in the intermittent portal
triad clamping group than in the continuous selective portal
triad clamping group (MD −30.53 min, 95% CrI −49.68 to
−11.29; 80 participants; 1 study).
• The operating time was lower in the tranexamic acid group
than in the control (difference in medians −52.20 min; P =
0.003; 214 participants; 1 study).
• There was no evidence of differences in other comparisons
for which this information was available.
Time needed to return to work
None of the trials reported this outcome.
Subgroup analysis
We did not perform subgroup analyses because of the paucity of
data.
Reporting bias
For outcomes with 10 or more trials, we explored reporting bias
using funnel plots. There were nine comparisons with at least 10
trials. Of these, there was no evidence of funnel plot asymmetry on
visualisation for perioperative mortality for methods of parenchy-
mal transection, methods of dealing with cut surface, or methods
of vascular occlusion. There was funnel plot asymmetry in the re-
maining six comparisons, all of which fall under the comparison
of different methods of vascular occlusion: adverse events (pro-
portion), blood transfusion (proportion), blood transfusion (red
blood cells), blood loss, hospital stay, and operating time. The
funnels plots of blood transfusion (proportion), blood transfusion
(red blood cells), and blood loss are shown in Figure 30, Figure
31, and Figure 32.
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Figure 30. Funnel plot of blood transfusion (proportion): The funnel plot shows funnel plot asymmetry (i.e.
some trials with large variance with large effects favouring one treatment were not matched by other trials
with similarly large variance with large effects favouring the other treatment). This may be evidence of
reporting bias or could be because of heterogeneity between the studies.
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Figure 31. Funnel plot of blood transfusion (red blood cells): The funnel plot shows funnel plot asymmetry
(i.e. some trials with large variance with large effects favouring one treatment were not matched by other
trials with similarly large variance with large effects favouring the other treatment). This may be evidence of
reporting bias or could be because of heterogeneity between the studies.
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Figure 32. Funnel plot of blood loss: The funnel plot shows funnel plot asymmetry (i.e. some trials with
large variance with large effects favouring one treatment were not matched by other trials with similarly large
variance with large effects favouring the other treatment). This may be evidence of reporting bias or could be
because of heterogeneity between the studies.
Since none of the comparisons had 10 or more trials, we did not
perform Egger’s test to assess the funnel plot asymmetry.
D I S C U S S I O N
Summary of main results
In this updated network meta-analysis, we compared all the in-
terventions aimed at decreasing blood loss and blood transfusion
requirements in people undergoing liver resection. We included
67 randomised clinical trials involving 6197 participants in this
review. A total of 5771 participants from 64 trials provided data
for one or more outcomes assessed.
In order to perform a network meta-analysis, it is necessary to sat-
isfy the transitivity assumption, that is, the participants had to be
sufficiently similar across the pair-wise comparisons. While some
trials restricted their participant recruitment to thosewith cirrhotic
livers or those who were undergoing major liver resections, others
did not. Although there is no clear evidence for an interaction
between the presence of cirrhosis or extent of liver resection and
the treatment effect, lack of evidence supporting an interaction
does not mean that one does not exist. For example, experimen-
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tal research has shown that cirrhotic livers are more susceptible
to ischaemia than normal livers (Figueras 1997; Jang 2008). So
vascular occlusion may be beneficial in limiting blood loss in peo-
ple without cirrhosis while the same treatment may be harmful in
people with cirrhotic liver.When different trials use different types
of participants (with regards to the presence of cirrhosis), this may
lead to problems with clinical heterogeneity in pair-wise compar-
isons and undermine the transivitiy assumption in network meta-
analysis. Similarly, a method of treating the cut surface may be
more beneficial in people undergoing major liver resections with
larger cut surfaces than in those undergoing minor liver resections
with smaller cut surfaces that bleed. In the presence of sufficient
data, we could have assessed the interaction between the treatment
effects and the presence of cirrhosis and the extent of liver resec-
tion; however, this was not possible because of paucity of data.
So we are unable to comment on the transitivity assumption. We
performed network meta-analyses only when direct and indirect
effect estimates for one of more comparisons in a network. This
allowed us to evaluate inconsistency in the network. Although we
did not find any inconsistency in the networks, lack of evidence
of inconsistency did not indicate that the results were consistent.
With the paucity of data due to few trials and few participants
under each comparison, we were unable to make any firm conclu-
sions about inconsistency. Likewise, the paucity of data decreases
the confidence in the results of the network meta-analysis. As a
result of these limitations, readers should interpret our network
meta-analysis with caution. Nevertheless, these results provide rel-
ative estimates between treatments that have not been compared
in head-to-head comparisons.
We present the summary of findings in the Summary of findings
for the main comparison, Appendix 9, and Appendix 10, as well
as in the Results section. There was no evidence of differences
in most of the comparisons, and where such differences existed,
they were in single trials, mostly of small sample size. Without
confirmation of the findings in additional trials, combined with
lack of reporting in some (possibly because of selective outcome
reporting), the evidence from these single trials is not reliable. So
we discuss only the evidence that was available in more than one
trial below. Of the primary outcomes, the only comparison show-
ing evidence of a difference was in the number of adverse events,
which was higher with radiofrequency dissecting sealer than with
the clamp-crush method (rate ratio 1.85, 95% CrI 1.07 to 3.26;
250 participants; 3 studies). However, even for this comparison,
the credible intervals overlap a clinically non-significant difference
(i.e. < 20% difference). So, there is significant uncertainty in the
difference in the number of adverse events between those oper-
ated on with the radiofrequency dissecting sealer compared to the
clamp-crush method due to imprecision in addition to the uncer-
tainty caused by the risk of bias in the trials.
There was no evidence of a reduction inmortality for any of the in-
terventions.Major blood lossmay causemultiorgan failure leading
to sepsis and death. Mortality was generally low in all the groups
compared to that reported in previous studies (Finch 2007). This
may be because of the careful selection of participants included in
randomised clinical trials compared to a consecutive patient series,
which report the results of all liver resections. We have provided
the sample size calculations based on the mortality observed in
the control groups of 1.8%. To demonstrate a significant 20%
relative reduction in mortality (20% relative risk reduction) from
1.8% to 1.4%, approximately 38,000 participants are required for
a single direct comparison with one intervention. As shown in the
Appendix 7, the effective sample size in an indirect comparison
involving just three treatments is only a fraction of the number
of participants included in the trials. For example, 10,000 partic-
ipants included in the indirect comparisons is equivalent to fewer
than 2000 ’direct’ participants in the absence of heterogeneity and
fewer than 1000 ’direct’ participants in the presence of moderate
heterogeneity. Even without these complicated calculations, one
can easily observe that the credible intervals were very wide, mean-
ing that we cannot rule out a significant benefit or harm for dif-
ferent treatments in terms of mortality. Approximately 16.7% of
people in the control group (as defined above) developed serious
adverse events. To demonstrate a significant 20% relative reduc-
tion in serious adverse events (20% relative risk reduction) from
16.7% to 13.4%, approximately 3592 participants are required
for a single direct comparison with a specific intervention. This
critical mass of information has not been reached, and there is a
significant risk of both type I (alpha) and type II (beta) random
errors, that is, there is a significant risk of making false positive
and false negative conclusions. Given the number of participants
required to show a significant benefit of treatment with relation
to mortality and serious adverse events, it is unlikely that trials of
the adequate magnitude will be funded.
Of the secondary outcomes, the main outcome measure of the
included trials was blood loss and transfusion requirement. The
only comparisons with more than one trial where there was evi-
dence of difference were the following: the proportion of partici-
pants requiring a blood transfusion was higher in the low central
venous pressure group than in the acute normovolemic haemod-
ilution plus low central venous pressure group; blood transfusion
(red blood cells) was lower in the fibrin sealant group than in the
control; blood transfusion (fresh frozen plasma) was higher in the
oxidised cellulose group than in the fibrin sealant group; and blood
loss, total hospital stay, and operating time were lower with low
central venous pressure than in the control. Trials measured blood
loss in different ways. Most reports did not specify whether they
measured the amount of blood obtained in the suction, weighed
the swabs, or measured the decrease in haemoglobin. In any case,
this is only important if the intervention decreases the blood trans-
fusion requirements, operating time, or serious adverse events. Ex-
cept for low central venous pressure, which decreases blood loss,
operating time, and hospital stay, none of the interventions con-
sistently lowered the blood transfusion requirements or improved
other clinical outcomes.
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Approximately 21.8% of people in the control group required
a blood transfusion. Decreasing this need can reduce transfu-
sion-related anaphylactic reactions and transmission of transfu-
sion-related diseases. In addition, there are significant costs associ-
ated with blood transfusion, so this is an important outcome. To
demonstrate a (significant) 20% relative reduction in serious ad-
verse events (20% relative risk reduction) from 21.8% to 17.4%,
approximately 2600 participants are required for a single direct
comparisonwith a specific intervention. This critical mass of in-
formation has not been reached, and there is significant risk of
both alpha and beta random errors in secondary outcomes also.
None of the trials reported quality of life, which is an impor-
tant outcome used to assess the cost-effectiveness of a treatment
in a state-funded healthcare system. Given that the quality of life
would depend upon various factors including perioperative com-
plications, length of hospital stay, and time to return to work, it is
likely to be easier to demonstrate a significant difference in qual-
ity of life if the treatment is effective than to demonstrate a dif-
ference in mortality or serious adverse events. Future randomised
clinical trials should use a validated quality of life measure as one
of the outcomes. Serious adverse events are likely to result in de-
creased quality of life for patients and increased costs to the health-
care provider and are, therefore, more important endpoints than a
modest decrease in blood transfusion. Length of total hospital stay
and intensive therapy unit stay are important to the patients, their
carers, and the healthcare funders. These should be reported in
future trials assessing interventions to decrease blood loss or blood
transfusion requirements. None of the trials reported time taken
to return to work, which is an important outcome for the patient
and their carers in the absence of significant sickness benefit and
is an important outcome for the healthcare provider in a state-
funded healthcare system with significant sickness benefits.
The major purpose of using different methods of liver resection
is to limit blood loss and blood transfusion requirements. Some
methods do not require any additional equipment (e.g. vascular
occlusion), while other methods do (e.g. cavitron ultrasonic sur-
gical aspirator or radiofrequency dissecting sealer). None of the
interventions that require special equipment were better than the
clamp-crush method in terms of blood transfusion requirements
or other important patient-oriented outcomes and hence cannot
be recommended over the standard. However, as mentioned pre-
viously, there is a significant risk of random errors because of the
small sample sizes and possibly important benefits or harms.
Overall completeness and applicability of
evidence
The participants included in this trial underwent elective open
liver resection and were generally anaesthetically fit. The findings
of this review are applicable only to such patients.
Quality of the evidence
The overall quality of evidence was low or very low as shown in
Summary of findings for the main comparison, Appendix 9, and
Appendix 10. The risk of bias was high in many of the domains
in the trials. Using appropriate methods of randomisation and
reporting the method of randomisation adequately will decrease
selection bias. While surgeons who perform the surgery cannot
be blinded to the treatments, it is possible to blind the surgeons
who are involved in the day-to-day postoperative management of
the patient. While it may be difficult to blind the anaesthetist to
the treatment groups, using objective criteria for transfusion may
overcome the problem of bias due to lack of blinding with regards
to intraoperative blood transfusion (NHS Blood and Transplant
2007). The intensivist involved in the postoperative care of the
patient can be easily blinded. Objective criteria for detection of
complications along with the postoperative management of the
patient by a healthcare team not involved in the operation can
decrease detection and performance bias. Even if blinding of par-
ticipants and healthcare providers was excluded as a criterion to
classify a trial as being at low risk of bias (i.e. even if we considered
that trials were at low risk of bias if they were classified as low
risk of bias in all domains other than blinding of participants and
healthcare providers), we would not have classified any of the trials
as being at low risk of bias. With regards to dropouts, randomising
the participants after confirming that the tumour can be removed
can avoid postrandomisation dropouts due to metastatic spread
identified at the time of laparotomy. This can decrease attrition
bias. Reporting all the important clinical outcomes can decrease
selective reporting bias.
There was heterogeneity in some of the comparisons, which re-
sulted in downgrading the level of evidence, but we did not ob-
serve heterogeneity in most of the comparisons in which there
were two or more trials. However, it was not possible to assess
the consistency of evidence in many comparisons because of the
presence of single trials.
The effect estimates were wide with the credible intervals span-
ning either 0.80 (a 20% reduction) or 1.20 (a 20% increase),
which both can be considered clinically significant effects. The
total number of participants included in the analysis was only a
small fraction of the required sample size even without adjustment
for heterogeneity. These findings indicate that there is significant
risk of imprecision in all the comparisons. Future trials should be
adequately powered to decrease the risk of random errors. There
was no indirectness of evidence for any of the outcomes. Although
we did not find any reporting bias since the paucity of trials pre-
cluded the creation of funnel plots, many of the trials did not ad-
equately report a number of important outcomes. Only 25 trials
(37.3%) reported mortality and serious adverse events, although
these outcomes ought to be routinelymeasured in trials comparing
interventions aimed at limiting blood loss. This suggests indirect
evidence of reporting bias.
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Potential biases in the review process
We selected a range of databases without any language restrictions
and conducted the meta-analysis according to the NICE TSU
(Dias 2012a; Dias 2012b; Dias 2012c; Dias 2013a; Dias 2013b;
Dias 2013c; Dias 2013d; Dias 2013e). We performed network
meta-analysis only when the treatments were connected to each
other and only when it was possible to obtain the direct and in-
direct estimates for a comparison. This allowed us to evaluate the
quality of evidence of direct estimates, indirect estimates, and net-
work meta-analysis estimates, choosing the estimates with the best
quality of evidence. These are the strengths of the review process.
The major potential source of bias was that we considered each of
these interventions (different methods of cardiopulmonary inter-
ventions, parenchymal transection methods, methods of dealing
with raw surface, vascular occlusion methods, and pharmacolog-
ical interventions) as separate networks. This was due to the lack
of sufficient information in the trials (which resulted in very few
trials in the previous version) and the design of the trials. In many
of the trials, the surgeons involved in the trial were allowed to
choose their method of liver resection apart from the factor being
randomised. This design is based on the assumption that the other
factors are independent of each other, that is, there is no interaction
between the factors, or the choice of one factor is not dependent
upon the choice of another factor. There is no evidence to support
or refute this assumption. However, if we planned to include only
trials in which all the factors were included, we would not even
have been able to include as many trials as we did in the previ-
ous version, as we have now included all the interventions aimed
at limiting blood loss and blood transfusion requirements during
liver resection. Each of the factors are independent of other, i.e. the
method of parenchymal transection does not affect the method of
vascular occlusion that the surgeons use. However, it is quite pos-
sible that there were interactions between the different methods.
For example, when a parenchymal transection method with high
blood loss was chosen, additional interventions such as fibrin glue
may have been used to deal with the cut surface (although there is
currently no evidence that fibrin glue is effective). Such use may
not necessarily mean that there was an interaction unless there
was a systematic difference in the use of the other methods for
limiting blood loss between the intervention and control. How-
ever, it is only possible to assess this if there are details about all
the methods to decrease blood loss from the trial report. Future
trials should describe the methods used for reducing blood loss
even if it was not the factor being randomised. It is only possible
to assess the presence of interaction (i.e. the intervention is more
effective or less effective depending upon the presence or absence
of a second factor) in well-designed factorial trials. However, the
sample size required to detect interaction is much higher than the
usual primary analysis of the ’margins’. It is highly unlikely that
trials powered to measure interactions can be conducted because
of this very large sample size.
We excluded studies that compared variations in themethods listed
in Table 1, Table 2, Table 3, and Table 4 and treated variations
in the method as single treatment. For example, we included in-
termittent portal triad clamping of differing durations as a single
treatment and did not include comparisons of different methods
of intermittent portal triad clamping, unless trials compared them
with a different method of vascular occlusion. Hence, this review
does not provide information on whether one variation is better
than another.We imputed the standard deviations when theywere
not available from the trials. We performed a sensitivity analysis
in all these situations, and there were no changes in results.
Another major limitation of the review was the paucity of data.
Many of the networks had few closed loops (i.e. where direct and
indirect evidence was available for a particular comparison). Along
with this, there were few trials included under each comparison.
This also makes the assessment of inconsistency underpowered.
Lack of evidence of inconsistency should not be considered the
same as lack of inconsistency. This paucity of data decreases the
confidence in the results of the network meta-analysis.
Different interventions may have different effects based on on
the extent of liver resection and whether the underlying liver was
diseased. However, we were unable to assess this because of paucity
of data.
We included only randomised clinical trials in this review. While
this is the best way to prevent arriving at biased false conclusions
on the benefits of a treatment, the harms of treatment may not
be fully captured. This is because of the highly selected group of
people who enter into randomised clinical trials compared to clin-
ical practice. In addition, randomised clinical trials may not report
rare or late serious adverse events, simply due to their generally
small sample size and short duration of follow-up.
Agreements and disagreements with other
studies or reviews
This is an update of ourfirst network meta-analysis on methods
to reduce blood loss during liver resection from 2014 (Simillis
2014). In that review, we concluded that liver resection using a ra-
diofrequency dissecting sealer without vascular occlusion or fibrin
sealant may increase serious adverse events. In that review as well,
we highlighted the paucity of data. Previously, we also compared
individual components included in this review and concluded that
intermittent vascular occlusion and the clamp-crush method may
decrease blood loss (Gurusamy 2009a; Gurusamy 2009b). In this
review, we concluded that there is no evidence for any significant
advantage of different methods of liver resection with regards to
blood loss. The differences in conclusion may be because of the
decreased importance that we have given to single trials of small
sample size and inclusion of trials in which the methods were not
reported or when the other aspects of liver resection other than
the component being compared were chosen in a non-random
manner.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Paucity of data meant that we could not assess the transitivity
assumption or inconsistency for most analyses. When direct and
indirect comparisons were available, network meta-analysis pro-
vided additional effect estimates for comparisons where there were
no direct comparisons. However, the paucity of data decreases the
confidence in the results of the network meta-analysis. Low-qual-
ity evidence suggests that liver resection using a radiofrequency
dissecting sealer may be associated with more adverse events than
with the clamp-crush method. Low-quality evidence also suggests
that the proportion of participants requiring a blood transfusion
was higher in the groups receiving low central venous pressure than
in those receiving acute normovolemic haemodilution plus low
central venous pressure; very low-quality evidence suggests that
blood transfusion quantity (red blood cells) was lower in the fib-
rin sealant group than in the control; blood transfusion quantity
(fresh frozen plasma) was higher in the oxidised cellulose group
than in the fibrin sealant group; and blood loss, total hospital stay,
and operating time were lower with low central venous pressure
than control. There is no evidence to suggest that using special
equipment for liver resection is of any benefit in decreasing the
mortality,morbidity, or blood transfusion requirements (very low-
quality evidence). Radiofrequency dissecting sealer should not be
used outside the clinical trial setting since there is low-quality ev-
idence for increased harm without any evidence of benefits. In
addition, it should be noted that the sample size was small and
the credible intervals were wide, and considerable benefit or harm
with a specific method of liver resection cannot be ruled out.
Implications for research
Trials need to be conducted and reported according to the
SPIRIT (Standard Protocol Items: Recommendations for Inter-
ventional Trials) statement (www.spirit-statement.org/) and the
CONSORT (Consolidated Standards for Reporting of Trials)
statement (www.consort-statement.org). Future randomised clin-
ical trials ought to include people at higher anaesthetic risk eligible
for liver resection and to blind outcome assessors.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arita 2005
Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 80
Postrandomisation dropouts: 0 (0%)
Revised sample size: 80
Average age: 67 years
Women: 20 (25%)
Number of cirrhotics: 21 (26.3%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): not stated
Further details of methods of liver resection
1. Vascular occlusion: variable
2. Parenchymal transection: factor being randomised
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients undergoing liver resection
2. Age 20-79 years
3. An acceptable clotting profile
Exclusion criteria: inflow occlusion at the hepatic hilumproved impossible at laparotomy
Interventions Participants were randomly assigned to 2 groups.
Group 1: radiofrequency dissecting sealer (n = 40)
Group 2: clamp-crush method (n = 40)
Radiofrequency dissecting sealer: Tissue Link (Valley Lab)
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, number of serious adverse events, proportion of people with any adverse
events, number of adverse events, operative blood loss, proportion of people requiring
blood transfusion, and length of hospital stay
Notes Authors provided replies in March 2016.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization was done by the minimization
procedure with stratification by age (less than 65 versus 65
years or more), indocyanine green retention rate at 15 min
(ICG-R15) (less than 20 versus 20 per cent or more) and
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Arita 2005 (Continued)
type of resection (minor ormajor). Resection of two or more
Couinaud segments was defined as ’major”’
Allocation concealment (selection bias) Low risk Quote: “The assignments were done by an internet-accessed
registration system administered by the independent ran-
domization service University Hospital Medical Informa-
tion Network in Japan”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (author replies): “Patients were informed just of a
study plan, but did not knowwhich cohort they belonged to.
However, surgeons, of course, could not be blinded because
of the nature of study”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The outcome assessors were not blinded”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Low risk Quote: “This work was supported by a grant from the Kanae
Foundation for Life-Socio-medical service”
Other bias Low risk Comment: no other bias
Bektas 2014
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 70
Postrandomisation dropouts: not stated
Revised sample size: 70
Average age: 57 years
Women: 31 (44.3%)
Number of cirrhotics: 2 (2.9%)
Number of major liver resections: 33 (47.1%)
Number of right hepatectomies: not stated
Follow-up (months): 1
Further details of methods of liver resection
1. Vascular occlusion: intermittent portal triad clamping
2. Parenchymal transection: different types of liver resection
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
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1. Adult patients undergoing elective liver resection
2. Requirement for additional haemostatic measures because of persistent oozing
from cut surface
Exclusion criteria: arterial or venous bleeding
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = 35)
Group 2: control (n = 35)
Fibrin sealant: TISSEEL (Baxter Health Corporation) Spray; 5 mL of fibrinogen with
synthetic aprotinin and 5 mL of thrombin (500 IU/mL)
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, number of serious adverse events, proportion of people with any adverse
events, and number of adverse events
Notes Authors provided replies in March 2016.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “ Subjects were randomized at a ratio of 1:1 to re-
ceive either FS or MC according to a predetermined ran-
domization scheme stratified by study center using the ran-
dom number generator algorithm of Wichmann and Hill as
modified by McLeod”
Comment: FS: fibrin sealant; MC: manual compression.
Allocation concealment (selection bias) Low risk Quote: “On the day of surgery, the randomization envelope
number was obtained from an electronic data capture sys-
tem. The randomization envelope assigned was opened in
the operating room after confirmation of the intraoperative
eligibility criteria and clamping of the hilar vessels in the
hepatoduodenal ligament (i.e., Pringle maneuver)”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (author reply): “the patient was blinded to the treat-
ment administered. Blinding of the investigator (surgeon)
was not possible due to the difference in procedures (spray
administration of fibrin sealant vs.manual compressionwith
a surgical gauze swab”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (author reply): “The investigator assessed intra-oper-
ative time to hemostasis and other outcome measures, i.e.,
outcome was assessed unblinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all patients were included for the clinical out-
comes
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
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Vested interest bias High risk Quote: “This clinical research was sponsored by Baxter In-
novations GmbH, Vienna, Austria”
Other bias Low risk Comment: no other bias
Belghiti 1996
Methods Randomised clinical trial
Participants Country: France
Number randomised: 52
Postrandomisation dropouts: 8 (15.4%)
Revised sample size: 44
Average age: 46 years
Women: 31 (70.5%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: 44 (100%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: clamp-crush or cavitron ultrasonic surgical aspirator
3. Fibrin glue: yes
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients undergoing elective major liver resections
2. Non-cirrhotic livers
Exclusion criteria: encasement of blood vessels
.
Interventions Participants were randomly assigned to 2 groups.
Group 1: continuous portal triad clamping (n = 24)
Group 2: continuous hepatic vascular exclusion (n = 28)
Hepatic vascular exclusion by encircling the entire retrohepatic inferior vena cava
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
number of adverse events, operative blood loss, quantity of blood transfused (red cell
transfusion or whole blood), length of hospital stay, and operating time
Notes Reasons for postrandomisation dropouts: cross-over to other group (n = 4 in each group)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Belghiti 1999
Methods Randomised clinical trial
Participants Country: France
Number randomised: 86
Postrandomisation dropouts: 0 (0%)
Revised sample size: 86
Average age: 51 years
Women: 39 (45.3%)
Number of cirrhotics: not stated
Number of major liver resections: 39 (45.3%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: cavitron ultrasonic surgical aspirator
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: low central venous pressure
6. Autologous transfusion: not stated
Inclusion criteria
1. Elective resections
2. Total vascular exclusion not required because of involvement of the
cavosuprahepatic junction or the inferior vena cava
3. No simultaneous bilioenteric anastomosis or associated gastro- intestinal
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procedures
Interventions Participants were randomly assigned to 2 groups.
Group 1: continuous portal triad clamping (n = 42)
Group 2: intermittent portal triad clamping (n = 44)
Continuous portal triad clamping: until end of transection
Intermittent portal triad clamping: 15 min on and 5 min off until hepatectomy
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
proportion of people with any adverse events, number of adverse events, operative blood
loss, proportion of people requiring blood transfusion, quantity of blood transfused (red
cell transfusion or whole blood), and length of hospital stay
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Capussotti 2003
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 35
Postrandomisation dropouts: not stated
Revised sample size: 35
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Average age: 63 years
Women: 8 (22.9%)
Number of cirrhotics: 35 (100%)
Number of major liver resections: 8 (22.9%)
Number of right hepatectomies: 2 (5.7%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: clamp-crush
3. Fibrin glue: fibrin glue used
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients with hepatocellular carcinoma and liver cirrhosis who underwent liver
resection
2. Age < 75 years
3. Child-Pugh class A
Interventions Participants were randomly assigned to 2 groups
Group 1: continuous portal triad clamping (n = 18)
Group 2: intermittent portal triad clamping (n = 17)
Intermittent portal triad clamping: 15 min on and 5 min off
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, operative blood loss, pro-
portion of people requiring blood transfusion, quantity of blood transfused (red cell
transfusion or whole blood), and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization to the type of clamping was as-
signed by computer generated random numbers”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Capussotti 2006
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 126
Postrandomisation dropouts: 0 (0%)
Revised sample size: 126
Average age: 64 years
Women: 51 (40.5%)
Number of cirrhotics: 19 (15.1%)
Number of major liver resections: 56 (44.4%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: clamp-crush or bipolar dissecting sealer
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: low central venous pressure
6. Autologous transfusion: not stated
Inclusion criteria: patients with resectable liver tumours
Exclusion criteria: patients requiring concomitant bowel or bile duct resection or total
vascular exclusion
Interventions Participants were randomly assigned to 2 groups.
Group 1: intermittent portal triad clamping (n = 63)
Group 2: control (n = 63)
Intermittent portal triad clamping: 15 min on and 5 min off
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, operative blood loss, pro-
portion of people requiring blood transfusion, and length of hospital stay
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “Randomization took place intraoperatively and was
performedwith a computerized random-number generator”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Capussotti 2012
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 66
Postrandomisation dropouts: 1 (1.5%)
Revised sample size: 65
Average age: 62 years
Women: 39 (60%)
Number of cirrhotics: 5 (7.7%)
Number of major liver resections: 65 (100%)
Number of right hepatectomies: 65 (100%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: clamp-crush, bipolar dissecting sealer
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients aged 18-80 years old scheduled for right hepatectomy
2. Estimated future remnant liver (FRL) before or after portal vein embolisation ≥
25 % in patients with a normal liver or ≥ 30 % in those with intense preoperative
chemotherapy or ≥ 40 % in cirrhotic patients
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3. Indocyanine green (ICG) retention rate at 15 min ≤ 10 % in cirrhotic patients
Exclusion criteria
1. Concomitant resection of segment 1 or the bile duct
2. Suspected infiltration of IVC based on preoperative imaging studies
3. Very high-risk patient according to the American Society of Anesthesiologists
(ASA) physical score (ASA score IV) and emergency surgery
Interventions Participants were randomly assigned to 2 groups.
Group 1: anterior approach (n = 33)
Group 2: control (n = 32)
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, number of adverse events,
operative blood loss, proportion of people with major blood loss, proportion of people
requiring blood transfusion, length of hospital stay, and operating time
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random sequence was performed using a comput-
erised random number generator”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Low risk Quote: “there has been no significant financial support for
this work that could have influenced its outcome”
Other bias Low risk Comment: no other bias
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Methods Randomised clinical trial
Participants Country: USA
Number randomised: 80
Postrandomisation dropouts: 13 (16.3%)
Revised sample size: 67
Average age: 58 years
Women: 38 (56.7%)
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing elective liver resection
.
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = 38)
Group 2: collagen (n = 29)
Fibrin sealant: Costasis (Cohesion Technologies) - bovine thrombin and collagen com-
bined with patient’s own plasma
Collagen: Instat (Johnson & Johnson)
Outcomes The outcomes reported were: short-term mortality, quantity of blood transfused (red
cell transfusion or whole blood), and operating time
Notes Reasons for postrandomisation dropouts: surgery cancelled (n = 8), study co-ordinator
not available (n = 1), other reasons (n = 4); 7 in intervention and 6 in control
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Thus, separate computer generated randomization
schedules of treatment group assignment placed in sealed
envelopes were used for each clinical site and for each type
of surgery”
Allocation concealment (selection bias) Unclear risk Quote: “Thus, separate computer generated randomization
schedules of treatment group assignment placed in sealed
envelopes were used for each clinical site and for each type
of surgery”.
Comment: further details of sealed envelope were not avail-
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able
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: morbidity was not reported.
Vested interest bias High risk Quote: “This workwas supported in part byCohesionTech-
nologies Inc, Palo Alto, Calif ”
Other bias Low risk Comment: no other bias
Chen 2006
Methods Randomised clinical trial
Participants Country: China
Number randomised: 118
Postrandomisation dropouts: not stated
Revised sample size: 118
Average age: 41 years
Women: 14 (11.9%)
Number of cirrhotics: 118 (100%)
Number of major liver resections: 102 (86.4%)
Number of right hepatectomies: 0 (0%)
Follow-up (months): 1
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: clamp-crush method
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria:
patients with cirrhosis and hepatocellular carcinoma undergoing minor or major right
sided liver resections
Exclusion criteria
1. Patients with extrahepatic spread or who required concomitant non-shunt
operation
2. Splenectomy
3. Multiple liver resection
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4. Extended right or left hepatectomy
Interventions Participants were randomly assigned to 2 groups.
Group 1: continuous portal triad clamping (n = 58)
Group 2: continuous hepatic vascular exclusion (n = 60)
Hepatic vascular exclusion by encircling the entire infrahepatic inferior vena cava
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, operative blood loss, pro-
portion of people requiring blood transfusion, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Low risk Quote: “This work was supported by the key clinical project
fund [No. 321 (2001)] from the Chinese Ministry of Public
Health”
Other bias Low risk Comment: no other bias
Choi 2007
Methods Randomised clinical trial
Participants Country: South Korea
Number randomised: 62
Postrandomisation dropouts: not stated
Revised sample size: 62
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Average age: 55 years
Women: 18 (29%)
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: factor being randomised
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: low central venous pressure (n = 30)
Group 2: control (n = 32)
Low central venous pressure: by restricting flow from legs
Outcomes The outcomes reported were: operative blood loss, length of hospital stay, and operating
time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Comment: this information was not available.
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Other bias Low risk Comment: no other bias
Chouker 2004
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 46
Postrandomisation dropouts: 12 (26.1%)
Revised sample size: 34
Average age: 61 years
Women: 11 (32.4%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: 8 (23.5%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Non-cirrhotic adult patients (> 18 years) undergoing elective liver resection
2. ASA status I to III
Exclusion criteria
1. History of myocardial infarction in the last 6 months
2. Haemotological disorder
3. Additional planned gastrointestinal surgery
Interventions Participants were randomly assigned to 2 groups.
Group 1: continuous portal triad clamping (n = 19)
Group 2: control (n = 15)
Outcomes The outcomes reported were: operative blood loss and proportion of people requiring
blood transfusion
Notes Reasons for postrandomisation dropouts: patients in this trial were randomised to 3
groups out of which 2 are eligible for this review. The reason for dropout in the included
groups was not available. There were 4 dropouts in intervention group and 8 dropouts
in control group
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “A blinded allocation of surgeons/anaesthesists was
not feasible”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Clavien 1996
Methods Randomised clinical trial
Participants Country: International multicentric trial
Number randomised: 17
Postrandomisation dropouts: 2 (11.8%)
Revised sample size: 15
Average age: 63 years
Women: 4 (26.7%)
Number of cirrhotics: 6 (40%)
Number of major liver resections: 15 (100%)
Number of right hepatectomies: 15 (100%)
Follow-up (months): 3 months
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing right hepatectomy
Interventions Participants were randomly assigned to 2 groups.
Group 1: continuous portal triad clamping (n = 8)
Group 2: control (n = 7)
Note: after every 1h of continuous portal triad clamping (or 30min for cirrhotic patients)
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, the clamp was released for 10 min before reclamping
Outcomes The outcomes reported were: short-term mortality, quantity of blood transfused (red
cell transfusion or whole blood), and operating time
Notes Reasons for postrandomisation dropouts: cardiac transplant patient (n = 1), haemody-
namic instability during surgery (n = 1)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: morbidity was not reported.
Vested interest bias Low risk Quote: “Supported by a grant from the Medical Research
Council of Canada and by a special grant from the Toronto
Hospital, University of Toronto, Toronto”
Other bias Low risk Comment: no other bias
Dayangac 2010
Methods Randomised clinical trial
Participants Country: Turkey
Number randomised: 72
Postrandomisation dropouts: 0 (0%)
Revised sample size: 72
Average age: 39 years.
Women: not stated
Number of cirrhotics: not stated
Number of major liver resections: 72 (100%)
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Number of right hepatectomies: 72 (100%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing right donor hepatectomy
Interventions Participants were randomly assigned to 2 groups.
Group 1: continuous portal triad clamping (n = 36)
Group 2: control (n = 36)
Outcomes The outcome reported was: operative blood loss.
Notes Authors provided replies in March 2016.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (author reply): “The patients were randomly assigned
by coin tossing”
Allocation concealment (selection bias) Low risk Quote: “Neither participants, nor investigators could foresee
the assignment, because the coin tossing was performed by
the chief operating room nurse at the time of incision”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (author reply): “Yes, all the patients and all of the
transplant nurses, coordinators, and physicians (except the
senior donor surgeon, who performed all hepatectomies)
were blinded”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (author reply): “Yes, at the end of the study, I per-
formed all the analyses on the prospectively collected data.
As the outcome assessor, I was blinded until the end of the
study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Low risk Quote (author reply): “There was no direct or indirect fi-
nancial support”
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Other bias Low risk Comment: no other bias
De Boer 2012
Methods Randomised clinical trial
Participants Country: Netherlands
Number randomised: 310
Postrandomisation dropouts: 0 (0%)
Revised sample size: 310
Average age: 62 years
Women: 151 (48.7%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: 160 (51.6%)
Number of right hepatectomies: not stated
Follow-up (months): 1
Further details of methods of liver resection
1. Vascular occlusion: with and without inflow occlusion
2. Parenchymal transection: clamp-crush, cavitron ultrasonic surgical aspirator,
electric coagulation based, combined
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: at least 1 liver segment or a nonanatomical resection
Exclusion criteria
1. Wedge resections
2. Concomitant extrahepatic bile duct resection or bowel resection
3. Cirrhosis
4. Haemostatic disorders
5. Polycystic liver disease
6. Pregnancy
7. History of hypersensitivity or allergic reaction to any plasma derived product
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = 156)
Group 2: control (n = 154)
Fibrin sealant: Quixil (Johnson & Johnson Medical) spray; 5 mL of fibrinogen and
tranexamic acid and 5 mL of thrombin
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, operative blood loss, and
proportion of people requiring blood transfusion
Notes Authors provided replies in March 2016.
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (author reply): “A statistician, who was not otherwise
involved in the conduct of the study prepared the random-
ization list, using a computer random number generator”
Allocation concealment (selection bias) Low risk Quote: “Treatment allocation employed a sequentially num-
bered opaque and sealed envelope system”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Surgeons could not be kept unaware of treatment
allocation, but patients, local investigators responsible for
data gathering, data analysts, and radiologists did remain
unaware of the study group assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Surgeons could not be kept unaware of treatment
allocation, but patients, local investigators responsible for
data gathering, data analysts, and radiologists did remain
unaware of the study group assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all patients were included for the clinical out-
comes
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias High risk Quote: “This study was supported by the Fund for Medical
Technology Assessment of the University Medical Center
Groningen and by Johnson & Johnson Medical”
Other bias Low risk Comment: no other bias
Doklestic 2012
Methods Randomised clinical trial
Participants Country: Serbia
Number randomised: 60
Postrandomisation dropouts: not stated
Revised sample size: 60
Average age: 58 years
Women: 40 (66.7%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: 20 (51.6%)
Number of right hepatectomies: not stated
Follow-up (months): 1
Further details of methods of liver resection
1. Vascular occlusion: intermittent portal triad clamping
2. Parenchymal transection: factor being randomised
3. Fibrin glue: not stated
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4. Pharmacological methods: not stated
5. Cardiopulmonary methods: low central venous pressure
6. Autologous transfusion: not stated
Inclusion criteria:
patients undergoing hepatectomy for benign or malignant tumours in patients with
adequate functional reserve of the heart, lungs, and kidneys
Exclusion criteria:
cirrhosis
Interventions Participants were randomly assigned to 3 groups.
Group 1: clamp-crush method (n = 20)
Group 2: cavitron ultrasonic surgical aspirator (n = 20)
Group 3: radiofrequency dissecting sealer (LIGASURE) (n = 20)
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, operative blood loss, pro-
portion of people requiring blood transfusion, length of hospital stay, length of intensive
therapy unit stay, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “The randomization was performed on the day prior
to surgery using the sealed envelopes; each group consisted
of 20 subjects”.
Comment: further details of sealed envelope method were
not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Low risk Quote: “This study was supported by funding by funding
from theMinistry of Education and Science of the Republic
109Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Doklestic 2012 (Continued)
of Serbia”
Other bias Low risk Comment: no other bias
El-Kharboutly 2004
Methods Randomised clinical trial
Participants Country: Egypt
Number randomised: 40
Postrandomisation dropouts: not stated
Revised sample size: 40
Average age: 51 years
Women: 17 (42.5%)
Number of cirrhotics: 40 (100%)
Number of major liver resections: 25 (62.5%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: intermittent portal triad clamping
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: factor being randomised
6. Autologous transfusion: not stated
Inclusion criteria: cirrhotic patients undergoing liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: control (n = 20)
Group 2: low central venous pressure (n = 20)
Low central venous pressure: nitroglycerine
Outcomes The outcomes reportedwere: number of serious adverse events, number of adverse events,
operative blood loss, proportion of people requiring blood transfusion, quantity of blood
transfused (red cell transfusion or whole blood), and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomly (closed envelope method)
”.
Comment: further details of sealed envelope method were
not available
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Figueras 2005
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 80
Postrandomisation dropouts: 0 (0%)
Revised sample size: 80
Average age: 62 years
Women: 21 (26.3%)
Number of cirrhotics: 39 (48.8%)
Number of major liver resections: 0 (0%)
Number of right hepatectomies: 0 (0%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing minor liver resection
Exclusion criteria: patients requiring concomitant bowel resection or contralateral hep-
atic resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: intermittent portal triad clamping (n = 39)
Group 2: intermittent selective portal triad clamping (n = 41)
Intermittent clamping: 15 min on and 5 min off
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Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
proportion of people with any adverse events, number of adverse events, operative blood
loss, proportion of people requiring blood transfusion, quantity of blood transfused (red
cell transfusion or whole blood), length of hospital stay, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “Randomization was performed using sealed en-
velopes”.
Comment: further details of sealed envelope method were
not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Low risk Quote: “This is study was partially supported by a grant
from ’August Pi i Sunyer Foundation’, Ciutat Sanitaria i
Universitaria de Bellvitge, Barcelona, Spain; and by a grant
from ’Fundacio August Pi i Sunyer’, Hospital Universitario
de Bellvitge, Barcelona, Spain”
Other bias Low risk Comment: no other bias
Figueras 2007
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 300
Postrandomisation dropouts: 0 (0%)
Revised sample size: 300
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Average age: 61 years
Women: 195 (65%)
Number of cirrhotics: 21 (7%)
Number of major liver resections: 181 (60.3%)
Number of right hepatectomies: 112 (37.3%)
Follow-up (months): 6
Further details of methods of liver resection
1. Vascular occlusion: intermittent portal triad or selective clamping
2. Parenchymal transection: cavitron ultrasonic surgical aspirator
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria:patients undergoing liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant plus collagen (n = 150)
Group 2: control (n = 150)
Fibrin sealant spray: Tissucol
Collagen: collagen sponge (Johnson & Johnson)
Note: in both groups, bleeding from raw surface was controlled using argon beam co-
agulator or Tissuelink
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
proportion of people with any adverse events, operative blood loss, proportion of people
requiring blood transfusion, quantity of blood transfused (red cell transfusion or whole
blood), length of hospital stay, and operating time
Notes Authors provided replies in March 2016.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (author reply): “Random list was generated by a com-
puter”
Allocation concealment (selection bias) Low risk Quote (author reply): “For patient allocation among groups
we used consecutive sealed opaque envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The patients were blinded as well as the healthcare
providers. After finishing the liver resection the envelope
was opened and the surgeon applied the technique of the
allocated group”.
Comment: further details of blinding were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The data manager and assessors were also blinded”.
Comment: further details of blinding were not available.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Low risk Quote (author reply): “Supported in part by a grant from
Fundacio Bellvitge, Barcelona, Spain. The study was not
funded because the hemostatic product was approved by the
agencia española del medicamento”
Other bias Low risk Comment: no other bias
Fischer 2011
Methods Randomised clinical trial
Participants Country: European multicentre trial
Number randomised: 119
Postrandomisation dropouts: 13 (10.9%)
Revised sample size: 106
Average age: 61 years
Women: 49 (46.2%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: a mixture of approaches
2. Parenchymal transection: a mixture of approaches
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients > 18 years of age
2. Elective liver resection
3. Women of child-bearing potential use adequate contraception (contraceptive pill
or intrauterine device)
4. At least segmental resection (anatomic/nonanatomic) of the liver
Exclusion criteria
1. Only minor (i.e. oozing) or moderate haemorrhage persisting after primary
operative haemostatic procedures
2. Evidence of coagulation disorders including haemophilia A or B and von
Willebrand disease
3. History of allergic reactions after application of human fibrinogen, human
thrombin, and/or collagen of any origin
4. Evidence of cirrhosis
5. Emergency operation
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6. Present drug or alcohol abuse
7. Pregnant or breastfeeding woman
8. Participation in a clinical trial < 30 d before inclusion in present trial
9. Participation in a clinical trial concomitantly with present trial
10. Serious operative complications
11. Prior portal vein embolisation
12. Any fibrin glue haemostatic (including tachocombs) or coagulation method
having been used before randomisation
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = 54)
Group 2: argon beam coagulator (n = 52)
Fibrin sealant: Tachosil (Nycomed)
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events and proportion of people with any adverse events
Notes Reasons for postrandomisation dropouts: lost to follow-up or discontinued (6 inTachoSil
group and 7 in control group)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “Clinical monitoring, centralized telephone ran-
domization, data management, and statistics were done by
Quintiles Ltd”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “This trial was open, because blinding for surgeons
and outcome assessors was not possible owing to the nature
of the interventions and the primary end point”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “This trial was open, because blinding for surgeons
and outcome assessors was not possible owing to the nature
of the interventions and the primary end point”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias High risk Quote: “This study was fully sponsored by Nycomed”.
Other bias Low risk Comment: no other bias
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Methods Randomised clinical trial
Participants Country: USA
Number randomised: 153
Postrandomisation dropouts: not stated
Revised sample size: 153
Average age: not stated
Women: not stated
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): 1
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = not stated)
Group 2: collagen (n = not stated)
Fibrin sealant: CryoSeal FS
Collagen: Instat (Ethicon)
Outcomes None of the outcomes of interest were reported
Notes Number of participants in each groupwas not stated. There were no significant difference
in blood loss, operating time, hospital stay, or complications
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Frilling 2005
Methods Randomised clinical trial
Participants Country: European multicentre trial
Number randomised: 121
Postrandomisation dropouts: 0 (0%)
Revised sample size: 121
Average age: not stated
Women: not stated
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: a mixture of approaches
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing elective liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = 59)
Group 2: argon beam coagulator (n = 62)
Fibrin sealant: Tachosil
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
proportion of people with any adverse events, and number of adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
117Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Frilling 2005 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “Allocation was concealed by the use of sealed treat-
ment code envelopes, which were opened when the patients
had fulfilled the eligibility criteria”.
Comment: further details of sealed envelope method were
not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The trial was open, since the appearance of TachoSil
precluded blinding”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The trial was open, since the appearance of TachoSil
precluded blinding”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Genyk 2014
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 224
Postrandomisation dropouts: not stated
Revised sample size: 224
Average age: not stated
Women: not stated
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing liver resection with minor to moderate bleeding
from the resection area after primary control of arterial bleeding or major venous haem-
orrhage
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Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = 114)
Group 2: oxidised cellulose (n = 110)
Fibrin sealant: Tachosil
Oxidised cellulose: Surgicel
Outcomes The outcomes reported were: proportion of people with any adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Gugenheim 2011
Methods Randomised clinical trial
Participants Country: France
Number randomised: 58
Postrandomisation dropouts: not stated
Revised sample size: 58
Average age: 62 years
Women: 31 (53.4%)
Number of cirrhotics: 9 (15.5%)
Number of major liver resections: 31 (53.4%)
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Number of right hepatectomies: 20 (34.5%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: cavitron ultrasonic surgical aspirator
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients undergoing elective open liver resection
2. Raw liver surface > 16 square cm
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = 29)
Group 2: plasmajet coagulator (n = 29)
Fibrin sealant: fibrin glue (no further details)
Outcomes The outcomes reportedwere: short-termmortality and proportion of people with serious
adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “Random assignment was done by opening an en-
velope in which allotted treatment was hidden”.
Comment: further details of sealed envelope method were
not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: morbidity was not reported adequately.
Vested interest bias Unclear risk Comment: this information was not available.
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Other bias Low risk Comment: no other bias
Guo 2013
Methods Randomised clinical trial
Participants Country: China
Number randomised: 30
Postrandomisation dropouts: not stated
Revised sample size: 30
Average age: 65 years
Women: 8 (26.7%)
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: factor being randomised
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients under liver resection for cancer
2. ASA
-
3. Aged 60-70 years with body weight of 45-74 kg
4. No severe dysfunction of liver, kidney, or coagulation system
5. No severe pulmonary or cardiovascular diseases
6. No anticoagulation medication in the previous 2 weeks
7. Preoperative haematocrit (HCT) > 35%
8. Haemoglobin (HB) > 120 g/L
Interventions Participants were randomly assigned to 2 groups.
Group 1: acute normovolemic haemodilution plus low central venous pressure (n = 15)
Group 2: control (n = 15)
Acute normovolemic dilution plus low central venous pressure: blood withdrawn to a
target of 28% haemocrit and replaced with fluid; target for central venous pressure was
not reported
Outcomes The outcomes reported were: operative blood loss and quantity of blood transfused (red
cell transfusion or whole blood)
Notes -
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Low risk Quote: “The study is supported by Ningbo Medical Tech-
nology Foundation 200612”
Other bias Low risk Comment: no other bias
Guo 2014
Methods Randomised clinical trial
Participants Country: China
Number randomised: 60
Postrandomisation dropouts: not stated
Revised sample size: 60
Average age: 50 years
Women: 22 (36.7%)
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: factor being randomised
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients undergoing liver resection
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2. Age 35-71
3. BMI 18-28 kg/m2
4. Haematocrit ≥ 35%
5. Haemoglobin ≥ 110 g/L
6. Normal endocrine and coagulation function before operation
7. No portal hypertension
8. No disease of the brain, heart, lung, or kidney
Interventions Participants were randomly assigned to 3 groups.
Group 1: control (n = 20)
Group 2: low central venous pressure (n = 20)
Group 3: low central venous pressure + acute normovolemic haemodilution (n = 20)
Low central venous pressure: fluid restriction and nitroglycerine
Acute normovolemic haemodilution plus low central venous pressure: withdrawal of
blood to a target haematocrit of 30% and replacement with colloids
Outcomes The outcomes reported were: operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Low risk Quote: “The study is supported by Outstanding Leaders
Training Program of Pudong Health Bureau of Shanghai
Grant no:PWR12013-03 and funded by Disciplines Group
Construction Project of Pudong Health Bureau of Shanghai
Grant no:PWZxq2014-06”
Other bias Low risk Comment: no other bias.
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Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 80
Postrandomisation dropouts: 1 (1.3%)
Revised sample size: 79
Average age: 65 years
Women: not stated
Number of cirrhotics: 35 (44.3%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: intermittent portal triad clamping or selective occlusion
2. Parenchymal transection: clamp-crush or cavitron ultrasonic surgical aspirator
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: factor being randomised
6. Autologous transfusion: none
Inclusion criteria: patients scheduled to undergo hepatic resection for the removal of
tumours were entered into this trial
Exclusion criteria: patients with severe pulmonary dysfunction (< 70% vital capacity, or
1 second forced expiratory volume divided by forced vital capacity < 60%)
Interventions Participants were randomly assigned to 2 groups.
Group 1: control (n = 39)
Group 2: hypoventilation (n = 40)
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, operative blood loss, pro-
portion of people requiring blood transfusion, quantity of blood transfused (cryoprecip-
itate), length of hospital stay, and operating time
Notes Authors provided replies in March 2016.
Reasons for postrandomisation dropouts: did not undergo liver resection
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “In the operating room, eligible patients were ran-
domly assigned to the normoventilation or hypoventilation
groups by the minimization method.”
Allocation concealment (selection bias) Low risk Quote: “In the operating room, eligible patients were ran-
domly assigned to the normoventilation or hypoventilation
groups by the minimization method ”
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (author reply): “Only 2 investigators (K.H. and R.
O.), who were not involved in the hepatic resections, had
seen the results of the randomization procedure, and they
were able to decide to alter the respiratory conditions with-
out consulting with the surgeon. The intervention of this
studywas hypoventilation during liver parenchyma division,
while the control was normoventilation. Both are done by
anesthesiologists, which could be blinded to the surgeons
and the enrolled patients”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (author reply): “Outcome assessors were not blinded.
The outcome measures including blood loss and central ve-
nous pressure were evaluated by nurses and anesthesiologists
as the outcome assessors”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there was 1 postrandomisation dropout. This
was because the patient did not undergo liver resection. This
postrandomisation dropout is unlikely to affect the effect
estimates for people undergoing liver resection
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Low risk Quote: “This work was supported by a grant-in-aid for sci-
entific research from the Ministry of Education, Science,
and Culture of Japan (grant 12470252) (Drs Kubota and
Makuuchi)”
Other bias Low risk Comment: no other bias
Ikeda 2009
Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 120
Postrandomisation dropouts: 0 (0%)
Revised sample size: 120
Average age: 66 years
Women: 39 (32.5%)
Number of cirrhotics: 27 (22.5%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: intermittent portal triad clamping or hemihepatic occlusion
2. Parenchymal transection: factor being randomised
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
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5. Cardiopulmonary methods: not stated
6. Autologous transfusion: no
Inclusion criteria
1. Patients undergoing liver resection
2. Age 20-85 years
3. An acceptable clotting profile
Exclusion criteria
1. Requirement for bilioenteric anastomoses
2. Cases where inflow occlusion is not possible
Interventions Participants were randomly assigned to 2 groups.
Group 1: radiofrequency dissecting sealer (n = 60)
Group 2: clamp-crush method (n = 60)
Radiofrequency dissecting sealer: ligasure
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, number of adverse events, operative blood loss, proportion of people
requiring blood transfusion, and length of hospital stay
Notes Authors provided replies in March 2016.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the assignments were generated by an internet-ac-
cessed randomization system supported by Mebix Inc.”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “In this study, results of assignment were not
blinded”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “In this study, results of assignment were not
blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Low risk Quote: “Supported by grants from the Public Trust Surgery
Research Fund, the Japanese Clinical Oncology Fund, the
Public Trust Haraguchi Memorial Cancer Research Fund,
the JSPS Fujita Memorial Fund for Medical Research; and a
grant-in-aid for Scientific Research from theMinistry of Ed-
ucation, Culture, Sports, Science and Technology of Japan
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(grant 18790955)”
Other bias Low risk Comment: no other bias
Jarnagin 2008
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 135
Postrandomisation dropouts: 5 (3.7%)
Revised sample size: 130
Average age: 53 years
Women: 61 (46.9%)
Number of cirrhotics: not stated
Number of major liver resections: 130 (100%)
Number of right hepatectomies: 53 (40.8%)
Follow-up (months): 3
Further details of methods of liver resection
1. Vascular occlusion: intermittent portal triad clamping
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: factor being randomised
6. Autologous transfusion: not stated
Inclusion criteria
1. Adult patients (> 18 years) undergoing elective major liver resection
2. Preoperative Hb ≥ 11 g/dL for men and ≥ 10 g/dL for women
Exclusion criteria
1. Active coronary artery disease (exceptions for cardiac stress study showing no
reversible ischaemia within 30 d)
2. History of cerebrovascular disease
3. History of congestive heart failure
4. Uncontrolled hypertension
5. Restrictive or obstructive pulmonary disease (COPD)
6. Renal dysfunction
7. Abnormal coagulation parameters
8. Presence of active infection
9. Evidence of hepatic metabolic disorder
10. Preoperative autologous blood donation
Interventions Participants were randomly assigned to 2 groups.
Group 1: acute normovolemic haemodilution plus low central venous pressure (n = 63)
Group 2: low central venous pressure (n = 67)
Acute normovolemic haemodilution: blood was withdrawn and replaced by colloids and
crystalloids to reach a haemocrit target of 8 gm/dL
Low central venous pressure was maintained < 5 H20 using fluid restriction and phar-
macologic manipulation
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Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, operative blood loss, pro-
portion of people with major blood loss, proportion of people requiring blood trans-
fusion, quantity of blood transfused (red cell transfusion or whole blood), quantity of
blood transfused (fresh frozen plasma), length of hospital stay, and operating time
Notes Reasons for postrandomisation dropouts: not clearly stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The generation of the randomization sequences was
performed in the Office of Clinical Research at Memorial
Sloan-Kettering Cancer Center (MSKCC) by a statistician
completely blinded to patient clinical data ”.
Comment: the method of random sequence generation was
not reported
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Kajikawa 1994
Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 42
Postrandomisation dropouts: not stated
Revised sample size: 42
Average age: not stated
Women: not stated
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Number of cirrhotics: 42 (100%)
Number of major liver resections: 12 (28.6%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: factor being randomised
Inclusion criteria: cirrhotic patients undergoing liver resection for HCC
Interventions Participants were randomly assigned to 2 groups.
Group 1: autologous blood donation (n = 21)
Group 2: control (n = 21)
Note: autologous blood donation group was further randomised to recombinant ery-
thropoietin and no erythropoietin
Outcomes The outcomes reported were: operative blood loss, proportion of people with major
blood loss, proportion of people requiring blood transfusion, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
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Methods Randomised clinical trial
Participants Country: Iran
Number randomised: 45
Postrandomisation dropouts: not stated
Revised sample size: 45
Average age: 48 years
Women: 27 (60%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge.
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: clamp-crush method
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients aged 18-75 years old undergoing liver resection for resectable
mass
Exclusion criteria
1. Patients with chronic liver disease
2. Coagulopathy not corrected with treatment before the surgery
3. Death during surgery
4. Operation discontinuation due to severe acidosis or coagulopathy
5. Acute liver failure diagnosed with severe acidosis and severe uncontrolled INR
Patients in need of resurgery due to bleeding or bile leak from liver other than resection
site
Interventions Participants were randomly assigned to 3 groups.
Group 1: fibrin sealant (n = 15)
Group 2: oxidised cellulose (n = 15)
Group 3: cyanoacrylate (n = 15)
Oxidised cellulose: Surgicel (Ethicon Inc)
Fibrin sealant: Tachosil (Takeda Pharmaceuticals)
Cyanoacrylate: Glubran 2 (GEM S.R.L.)
Outcomes The outcomes reported were: number of serious adverse events, number of adverse
events, operative blood loss, proportion of people requiring blood transfusion, quantity
of blood transfused (red cell transfusion or whole blood), quantity of blood transfused
(fresh frozen plasma), and length of hospital stay
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned to these 3 groups
by a web-based calculator available in this web address: http:
//www.randomizer.org”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Blinding for surgeons was not possible owing to the
nature of the used materials’ consistency (spongy TachoSil
knitted fabric Surgicel and liquid Glubran 2) and their pack-
ages”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The postoperative assessors were completely
blinded to which agents were used for each patient”.
Comment: it is not clear how the assessment was done if the
surgeons were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality was not reported.
Vested interest bias Low risk Quote: “This research was financially supported by the Vice
Chancellor for Research, Tabriz University of Medical Sci-
ences, Iran”
Other bias Low risk Comment: no other bias
Kato 2008
Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 85
Postrandomisation dropouts: 0 (0%)
Revised sample size: 85
Average age: 66 years
Women: not stated
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): not stated
Further details of methods of liver resection
1. Vascular occlusion: intermittent portal triad clamping
2. Parenchymal transection: cavitron ultrasonic surgical aspirator
3. Fibrin glue: fibrin glue used
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: factor being randomised
6. Autologous transfusion: not stated
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Inclusion criteria: patients undergoing liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: low central venous pressure (n = 43)
Group 2: control (n = 42)
Low central venous pressure: by inferior IVC clamping
Outcomes The outcomes reported were: short-term mortality, operative blood loss, proportion of
people requiring blood transfusion, length of hospital stay
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eighty-five patients who underwent hepatic resec-
tion between June 2002 and May 2006 were randomly as-
signed to an IVC clamping or an IVC nonclamping group
by the minimization method ”
Allocation concealment (selection bias) Low risk Quote: “Eighty-five patients who underwent hepatic resec-
tion between June 2002 and May 2006 were randomly as-
signed to an IVC clamping or an IVC nonclamping group
by the minimization method ”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: morbidity was not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
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Koea 2013
Methods Randomised clinical trial
Participants Country: European and Australian multicentre trial
Number randomised: 84
Postrandomisation dropouts: 0 (0%)
Revised sample size: 84
Average age: 65 years
Women: 36 (42.9%)
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: older than 18 years of age and required urgent or elective hepatic
resection and were able to provide written, informed consent
Exclusion criteria
1. Admitted for trauma surgery
2. Undergoing a liver transplant for fulminant hepatic failure
3. Active sepsis around the liver
4. Known tolerance to blood products or one of the components of the fibrin pad
5. Unwilling to receive blood products
6. Known and current alcohol or drug abuser
7. Pregnant or breastfeeding
8. Participated in another investigational drug or device research study within the
previous 30 d
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = 45)
Group 2: oxidised cellulose (n = 39)
Fibrin sealant: Fibrin Pad
Oxidised cellulose: no further details
Outcomes None of the outcomes of interest were reported.
Notes Authors provided replies in March 2016.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random allocation of patients to the FP or SoC
groups was generated by a computer program and validated
by a secondary statistician”.
133Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Koea 2013 (Continued)
Comment: FP: Fibrin Pad; SoC: standard of care.
Allocation concealment (selection bias) Low risk Quote: “The allocation was on sequentially numbered con-
cealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (author reply): “The patients were blinded regard-
ing the treatment, but health care providers can’t be blinded
given the obvious difference in the nature of the test prod-
ucts”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (author reply): “Outcomes assessor for outcomes not
specific for research may include hospital staff which may
not be aware of the research nor the treatment assignment.
The collection of the outcomes information for analysis was
done by research staff that is aware of the treatment assign-
ment. However, the information collected is verified with
the hospital source documents”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: although the authors call this intention-to-treat
analysis, only an ’as-treated’ analysis is presented
Selective reporting (reporting bias) High risk Comment: none of the outcomes of interest were presented
for the randomised patients
Vested interest bias High risk Quote: “Financial and product support was provided by
Ethicon Inc, Sommervile, New Jersey, USA”
Other bias Low risk Comment: no other bias
Kohno 1992
Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 62
Postrandomisation dropouts: 0 (0%)
Revised sample size: 62
Average age: 62 years
Women: 14 (22.6%)
Number of cirrhotics: 46 (74.2%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): not stated
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
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5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: collagen (n = 31)
Group 2: fibrin sealant (n = 31)
Collagen: Avitene (Alcon Inc)
Fibrin sealant: Beriplast P (Beringwerke AB)
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
number of adverse events, operative blood loss, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Koo 2005
Methods Randomised clinical trial
Participants Country: South Korea
Number randomised: 50
Postrandomisation dropouts: not stated
Revised sample size: 50
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Average age: 53 years
Women: 14 (28%)
Number of cirrhotics: not stated
Number of major liver resections: 38 (76%)
Number of right hepatectomies: 27 (54%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: No vascular occlusion.
2. Parenchymal transection: factor being randomised
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: adults scheduled for elective hepatectomy
Exclusion criteria
1. Known cardiopulmonary diseases
2. Patients with dysphagia
3. Hiatal hernia
4. Oesophageal disease
Interventions Participants were randomly assigned to 2 groups.
Group 1: clamp-crush method (n = 25)
Group 2: cavitron ultrasonic surgical aspirator (n = 25)
Outcomes The outcomes reported were: proportion of people with any adverse events, operative
blood loss, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “Randomization was performed by opening a sealed
envelope before induction of anaesthesia”.
Comment: further information on sealed envelope system
were not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Kostopanagiotou 2007
Methods Randomised clinical trial
Participants Country: Greece
Number randomised: 35
Postrandomisation dropouts: 7 (20%)
Revised sample size: 28
Average age: 52 years
Women: 11 (39.3%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: 16 (57.1%)
Number of right hepatectomies: 11 (39.3%)
Follow-up (months): 12
Further details of methods of liver resection
1. Vascular occlusion: hepatic vascular exclusion
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: factor being randomised
Inclusion criteria
1. Non-cirrhotic patients undergoing elective liver resections
2. ASA II or III
Exclusion criteria: receiving immunosuppressive drugs
Interventions Participants were randomly assigned to 2 groups.
Group 1: autologous blood donation (n = 15)
Group 2: control (n = 13)
Autologous blood donation: 2 units of blood were withdrawn before surgery
Outcomes The outcomes reported were: short-term mortality, long-term mortality, proportion of
people with any adverse events, operative blood loss, quantity of blood transfused (red
cell transfusion or whole blood), length of hospital stay, and operating time
Notes Reasons for postrandomisation dropouts: requirement of allogenic transfusion in autol-
ogous group or did not require any transfusion (4 in intervention group and 3 in control
group)
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Lee 2012
Methods Randomised clinical trial
Participants Country: Hong Kong, China
Number randomised: 126
Postrandomisation dropouts: 0 (0%)
Revised sample size: 126
Average age: 59 years
Women: 32 (25.4%)
Number of cirrhotics: 54 (42.9%)
Number of major liver resections: 62 (49.2%)
Number of right hepatectomies: 39 (31%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: cavitron ultrasonic surgical aspirator
3. Fibrin glue: yes
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: low central venous pressure
6. Autologous transfusion: not stated
Inclusion criteria:
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adult patients (> 18 years) undergoing elective open liver resection
Exclusion criteria
1. Portal vein thrombosis, portal vein embolisation, or requiring portal vein resection
2. Hepatic artery thrombosis
3. Previous transarterial chemoembolization (TACE) or chemoirradiation
4. Ruptured hepatocellular carcinoma (HCC)
5. Repeat hepatectomy
6. Patients in whom concomitant bowel or bile duct resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: intermittent portal triad clamping (n = 63)
Group 2: control (n = 63)
Intermittent portal triad clamping: 15 min on and 5 min off
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, number of adverse events,
operative blood loss, proportion of people with major blood loss, proportion of people
requiring blood transfusion, length of hospital stay, operating time
Notes Authors provided replies in March 2016.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The computer-generated numbers were kept in
sealed envelopes.”
Allocation concealment (selection bias) Low risk Quote (author reply): “The randomisation code was put in
the sealed opaque envelops with consecutive number before
the start of the study by a clerical staff not related to the
study. An envelop was provided by research assistant consec-
utively and was brought to the theatre on day of surgery. The
envelop was opened by the operation nurse or anesthetist
independent to the study when and only if the surgical team
confirm feasibility of proceeding to liver resection according
to the study protocol intra-operatively”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Patients and surgeons were not blinded to the ran-
domization result”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (author reply): “The outcome assessors for blood loss
were not blinded to the surgeons (because we felt operating
surgeons should know about the degree of intra-operative
blood loss). But the actual recording procedure were per-
formed by independent OT nurses and anaesthetists in the
particular operation. The blood loss was measure bymeasur-
ing all the blood collected in the suction bottle and weighing
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the gauzes in different phases of the operation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Low risk Quote (author reply): “The study received no external fund-
ing. It was supported by the team’s own private funding”
Other bias Low risk Comment: no other bias
Lentschener 1997
Methods Randomised clinical trial
Participants Country: France
Number randomised: 109
Postrandomisation dropouts: 12 (11%)
Revised sample size: 97
Average age: 54 years
Women: 45 (46.4%)
Number of cirrhotics: not stated
Number of major liver resections: 63 (64.9%)
Number of right hepatectomies: 34 (35.1%)
Follow-up (months): not stated
Further details of methods of liver resection
1. Vascular occlusion: intermittent portal triad clamping
2. Parenchymal transection: Kelly clamp
3. Fibrin glue: fibrin glue used
4. Pharmacological methods: factor being randomised
5. Cardiopulmonary methods: none
6. Autologous transfusion: not stated
Inclusion criteria:
adult patients undergoing elective liver resection
Exclusion criteria
1. Known allergy to aprotinin or possible previous exposure to the drug
2. Pregnancy
3. Any possible bleeding disorder or inherited bleeding disorder
4. Previous venous or arterial thrombosis or any biological abnormality likely to
induce thrombosis
5. Impaired renal function
6. Age < 18 years
Interventions Participants were randomly assigned to 2 groups.
Group 1: aprotinin (n = 48)
Group 2: control (n = 49)
Aprotinin: loading dose: 2 X 106 kIU of aprotinin over a 20 min period after induction
of anaesthesia
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Continuous infusion: 5 x 105 kIU per h administered by an infusion pump until skin
closure
Additional bolus: 5 X 105 kIU of aprotinin was infused every 3 transfused red blood cell
packs
Control: placebo
Outcomes The outcomes reported were: long-term mortality, operative blood loss, proportion of
people requiring blood transfusion, quantity of blood transfused (red cell transfusion
or whole blood), quantity of blood transfused (platelets), quantity of blood transfused
(fresh frozen plasma), and operating time
Notes Reasons for postrandomisation dropouts: tumour could not be removed (n = 6), wrong
pre-operative histological assessment (n = 5), and extension of incision to a thoracotomy
(n = 1)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “ Patients were assigned in a double blind fashion
by means of a computer-generated code to receive either
aprotinin or the equivalent volume of placebo”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: a placebo was used. It was not clear whether the
anaesthetists and surgeons performing the surgery and the
patients were aware of the groups
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “An identical-appearing placebo was prepared by a
nurse not involved in latter assessment. Each patient in the
control group received equivalent volumes of the placebo (0.
9% saline solution) at the respective times”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Unclear risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Quote: “This study was conducted independently of, but
partially supported by, Assistance Publique-Hopitaux de
Paris, Bayer Pharma France and the Associations Claude
Bernard and Mises au Point en Anesthesie-Reanimation”
Other bias Unclear risk Comment: no other bias
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Methods Randomised clinical trial
Participants Country: Switzerland
Number randomised: 75
Postrandomisation dropouts: not stated
Revised sample size: 75
Average age: 57 years
Women: 34 (45.3%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: 45 (60%)
Number of right hepatectomies: 23 (30.6%)
Follow-up (months): 3
Further details of methods of liver resection
1. Vascular occlusion: no vascular occlusion
2. Parenchymal transection: factor being randomised
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients undergoing partial liver resection for tumours
2. Acceptable coagulation profile
Exclusion criteria
1. Living liver donors
2. Cirrhotic patients
3. Cholestatic patients
Interventions Participants were randomly assigned to 3 groups.
Group 1: radiofrequency dissecting sealer (n = 25)
Group 2: cavitron ultrasonic surgical aspirator (n = 25)
Group 3: hydrojet (n = 25)
Radiofrequency dissecting sealer: Tissue Link
Hydrojet: Helix Hydro-Jet
A fourth group with clamp-crush and vascular occlusion was excluded since there was
difference in the co-intervention between the groups
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
number of adverse events, proportion of people requiring blood transfusion, length of
hospital stay, and length of intensive therapy unit stay
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
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Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias High risk Quote: “Supported in an equivalent amount byErbe (Tubin-
gen, Germany), Tissuelink (Dover, NH), and Tyco Health-
care (Mansfield, MA). Dr. Selzner and Dr. Petrowsky are the
recipients of the Novartis fellowship in HPB surgery and
liver transplantation”
Other bias Low risk Comment: no other bias
Liang 2009
Methods Randomised clinical trial
Participants Country: China
Number randomised: 80
Postrandomisation dropouts: 0 (0%)
Revised sample size: 80
Average age: 49 years
Women: 22 (27.5%)
Number of cirrhotics: 36 (45%)
Number of major liver resections: 23 (28.8%)
Number of right hepatectomies: 6 (7.5%)
Follow-up (months): 1
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: clamp-crush
3. Fibrin glue: not stated
4. Pharmacological methods: None
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients undergoing liver resection
2. Tumours confined to one half of the liver
3. Hilar dissection was feasible
143Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Liang 2009 (Continued)
Exclusion criteria: patients requiring concomitant gastrointestinal procedures or bilioen-
teric anastomosis
Interventions Participants were randomly assigned to 2 groups.
Group 1: continuous selective portal triad clamping (n = 40)
Group 2: intermittent portal triad clamping (n = 40)
Intermittent portal triad clamping: 20 min on and 5 min off
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, operative blood loss, pro-
portion of people requiring blood transfusion, quantity of blood transfused (red cell
transfusion or whole blood), length of hospital stay, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Low risk Quote: “The study was supported by the Basic Research
Foundation of Sichuan Province of China (05JY29-005-3)
”
Other bias Low risk Comment: no other bias
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Methods Randomised clinical trial
Participants Country: Taiwan
Number randomised: 40
Postrandomisation dropouts: 0 (0%)
Revised sample size: 40
Average age: 60 years
Women: 3 (7.5%)
Number of cirrhotics: 22 (55%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = 20)
Group 2: control (n = 20)
Fibrin sealant: name not available
Outcomes The outcomes reported were: operative blood loss, quantity of blood transfused (red cell
transfusion or whole blood), and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
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Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Liu 2006
Methods Randomised clinical trial
Participants Country: Hong Kong, China
Number randomised: 136
Postrandomisation dropouts: 16 (11.8%)
Revised sample size: 120
Average age: 52 years
Women: 17 (14.2%)
Number of cirrhotics: 38 (31.7%)
Number of major liver resections: 120 (100%)
Number of right hepatectomies: 120 (100%)
Follow-up (months): 20
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: cavitron ultrasonic surgical aspirator
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients undergoing right hepatectomy
2. HCC
Interventions Participants were randomly assigned to 2 groups.
Group 1: anterior approach (n = 60)
Group 2: control (n = 60)
Outcomes The outcomes reportedwere: short-termmortality, proportionof peoplewith any adverse
events, operative blood loss, proportion of people with major blood loss, proportion of
people requiring blood transfusion, length of hospital stay, length of intensive therapy
unit stay, and operating time
Notes Reasons for postrandomisation dropouts: 7 and 9 in intervention and control groups;
Non-HCC on histology (n = 8); segmentectomy (n = 1); palliative resection (n = 7)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “A total of 136 patients were randomized initially
to have either anterior approach hepatectomy (AA group)
or conventional approach resection (CA group) by drawing
consecutive sealed envelopes”.
Comment: further information on sealed envelope system
were not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The randomization was made known to the oper-
ating surgeon only when the disease was deemed suitable for
curative resection”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “All patients received the same postoperative care by
the same team of surgeons in the intensive care unit during
the early postoperative course”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Low risk Quote: “Supported by the Earmarked Research Grant of the
Research Grants Council of Hong Kong”
Other bias Low risk Comment: no other bias
Lodge 2005
Methods Randomised clinical trial
Participants Country: European multicentre trial
Number randomised: 204
Postrandomisation dropouts: 19 (9.3%)
Revised sample size: 185
Average age: 57 years
Women: 92 (49.7%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: mixture of methods
2. Parenchymal transection: not stated
3. Fibrin glue: no
4. Pharmacological methods: factor being randomised
5. Cardiopulmonary methods: not stated
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6. Autologous transfusion: no
Inclusion criteria
1. Non-cirrhotic adults (≥ 18 years of age) scheduled to undergo partial
hepatectomy for liver cancer/metastasis, benign tumors, or both
2. Planned anatomical resection of 3 or more segments of the liver or planned
nonanatomical resection of a volume equivalent to 2 or more segments of the liver
parenchyma
Exclusion criteria
1. Known hereditary bleeding disorders
2. The planned use of autologous blood transfusion
3. Low molecular weight heparin before hepatectomy
4. Tissue glue or haemodilution therapy during surgery or haemostatic drugs for
prophylactic purposes
5. Renal insufficiency requiring dialysis
6. Clinically documented portal vein or deep vein thrombosis or a history of the
latter within the preceding 6 months
7. Severe cardiovascular disease or previous myocardial/pulmonary infarction or
stroke within the preceding 6 months
8. Anticoagulation therapy not discontinued within 48 h before surgery
9. Active bleeding
10. Use of nonsteroidal antiinflammatory drugs within 7 d before surgery
Interventions Participants were randomly assigned to 2 groups.
Group 1: recombinant factor viia (n = 126)
Group 2: control (n = 59)
Recombinant factor VIIa: first dose: slow intravenous injection (20 mcg/kg or 80 mcg/
kg) within 5 min before incision. Second dose: identical dose was given 5 h after incision
if the surgery time was anticipated to exceed 6 h
Control: placebo
Outcomes The outcomes reported were: short-term mortality, long-term mortality, proportion of
people with serious adverse events, number of serious adverse events, number of adverse
events, operative blood loss, proportion of people requiring blood transfusion, quantity
of blood transfused (red cell transfusion or whole blood), and operating time
Notes Reasons for postrandomisation dropouts: did not receive drug (n = 4); did not undergo
hepatectomy (n = 15)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was computer-generated and was
performed after patient eligibility assessments on the day
of surgery by means of a central interactive voice response
system set up by Novo Nordisk A/S”
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Allocation concealment (selection bias) Low risk Quote: “Randomization was computer-generated and was
performed after patient eligibility assessments on the day
of surgery by means of a central interactive voice response
system set up by Novo Nordisk A/S”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The current randomized, controlled, double-blind,
multi-national trial was designed to evaluate the efficacy and
safety of rFVIIa in noncirrhotic patients undergoing major
liver resection. To maintain blinding, an equal volume of
trial drug per body weight was administered to all patients,
irrespective of treatment group allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The current randomized, controlled, double-blind,
multi-national trial was designed to evaluate the efficacy and
safety of rFVIIa in noncirrhotic patients undergoing major
liver resection. To maintain blinding, an equal volume of
trial drug per body weight was administered to all patients,
irrespective of treatment group allocation”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias High risk Quote: “The authors thank the patients and the hospital
staff participating in the trial, as well as Allan Blemings, M.
Sc. (Statistician), and Karsten Soendergaard, M.Sc. (Clin-
ical Researcher), both at Novo Nordisk A/S, Copenhagen,
Denmark”
Other bias Low risk Comment: no other bias
Lupo 2007
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 51
Postrandomisation dropouts: 1 (2%)
Revised sample size: 50
Average age: 62 years
Women: 14 (28%)
Number of cirrhotics: 7 (14%)
Number of major liver resections: 21 (42%)
Number of right hepatectomies: 9 (18%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: no vascular occlusion
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2. Parenchymal transection: factor being randomised
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing potentially curative liver resection for primary or
secondary liver cancers
Interventions Participants were randomly assigned to 2 groups.
Group 1: radiofrequency dissecting sealer (n = 24)
Group 2: clamp-crush method (n = 26)
Radiofrequency dissecting sealer: radionics needles
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
number of adverse events, proportion of people requiring blood transfusion, length of
hospital stay, and operating time
Notes Authors provided replies in March 2016.
Reasons for postrandomisation dropouts: did not undergo liver resection
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The patients were assigned, in the operating room,
by random-number tables to undergo RF-R (even numbers)
or resection by the clamp-crushing method (odd numbers)
”
Comment: RF-R: radiofrequency radiation
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Authors replied that patients and healthcare
providers were blinded”.
Comment: further information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Authors replied that outcome assessors were
blinded”.
Comment: further information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there was 1 postrandomisation dropout. This
was because the patient did not undergo liver resection. This
postrandomisation dropout is unlikely to affect the effect
estimates for people undergoing liver resection
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
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Vested interest bias Low risk Quote: “The authors replied that there was no external fund-
ing”
Other bias Low risk Comment: no other bias
Man 1997
Methods Randomised clinical trial
Participants Country: Hong Kong, China
Number randomised: 100
Postrandomisation dropouts: not stated
Revised sample size: 100
Average age: 56 years
Women: 19 (19%)
Number of cirrhotics: 29 (29%)
Number of major liver resections: 69 (69%)
Number of right hepatectomies: 14 (14%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: cavitron ultrasonic surgical aspirator
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
Adult patients undergoing liver resection
Exclusion criteria
Requiring concomitant bowel resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: intermittent portal triad clamping (n = 50)
Group 2: control (n = 50)
Intermittent portal triad clamping: 20 min on and 5 min off
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
proportion of people with any adverse events, number of adverse events, operative blood
loss, proportion of people requiring blood transfusion, quantity of blood transfused (red
cell transfusion or whole blood), and length of hospital stay
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Low risk Quote: “Research Grant Council of Hong Kong in funding
the study”
Other bias Low risk Comment: no other bias
Man 2003
Methods Randomised clinical trial
Participants Country: Hong Kong, China
Number randomised: 40
Postrandomisation dropouts: 0 (0%)
Revised sample size: 40
Average age: 50 years
Women: 11 (27.5%)
Number of cirrhotics: not stated
Number of major liver resections: 26 (65%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients with resectable tumours.
Interventions Participants were randomly assigned to 2 groups.
Group 1: intermittent portal triad clamping (n = 20)
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Group 2: control (n = 20)
Intermittent portal triad clamping: 20min on and 5min off (until resection is completed
or a maximum of 6 cycles)
Outcomes The outcomes reportedwere: short-termmortality, proportionof peoplewith any adverse
events, and proportion of people requiring blood transfusion
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Matot 2002
Methods Randomised clinical trial
Participants Country: Israel
Number randomised: 78
Postrandomisation dropouts: not stated
Revised sample size: 78
Average age: 57 years
Women: 47 (60.3%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: 78 (100%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
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Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: factor being randomised
6. Autologous transfusion: not stated
Inclusion criteria
1. Adults (> 18 years) undergoing major elective resection
2. Haematocrit > 36%
3. ASA I or II
4. No cardiovascular or pulmonary disease, or severe hepatic metabolic disorder
Interventions Participants were randomly assigned to 2 groups.
Group 1: acute normovolemic haemodilution + low central venous pressure (n = 39)
Group 2: low central venous pressure (n = 39)
Acute normovolemic haemodilution: blood was withdrawn and replaced by colloids to
reach a haemocrit target of 24%
Low central venous pressure was achieved by fluid restriction
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
proportion of people with any adverse events, number of adverse events, operative blood
loss, proportion of people requiring blood transfusion, quantity of blood transfused (red
cell transfusion or whole blood), and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “On admission to the operating room, patients
whomet inclusion criteria were randomly assigned (random
numbers) to one of two groups”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The anesthesiologist making decisions regarding
transfusion was not blinded to patient group assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Subsequent blood loss was estimated by assessment
of the suction bottles, sponges, and the surgical drapes and
gowns by an anesthesiologist who was not aware of the pa-
tient’s group assignment”.
Comment: Not clear whether other outcomes were assessed
by a blinded observer
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Low risk Quote: “Supported by a grant from the Joint Research Fund
of the Hebrew University and Hadassah, Jerusalem, Israel”
Other bias Low risk Comment: no other bias
Moench 2014
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 128
Postrandomisation dropouts: 1 (0.8%)
Revised sample size: 127
Average age: 61 years
Women: 53 (41.7%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): 3
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: a number of parenchymal transection techniques
3. Fibrin glue: factor being randomised
4. Pharmacological methods: none
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria:
non-cirrhotic adult patients undergoing elective open liver resection
Exclusion criteria
1. Coagulation disorders
2. Klatskin tumour
3. Participation in another clinical study within 30 d
4. Pregnancy or breastfeeding
5. Concurrent or previous therapy with systemic pharmacologic agents promoting
blood clotting (including but not limited to tranexamic acid, activated factor VIII, and
aprotinin)
6. Known allergy or hypersensitivity to human thrombin or to human fibrinogen or
to riboflavin or to proteins of bovine origin.
7. Resection area estimated by operating surgeon to be less than 16 cm2
8. An infected wound area
9. Persistent major bleeding or no bleeding after primary operative haemostatic
procedures
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Interventions Participants were randomly assigned to 2 groups.
Group 1: collagen (n = 62)
Group 2: fibrin sealant (n = 65)
Collagen: sangustop fleece (Aesculap AG)
Fibrin sealant: Tachosil (Nycomed)
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, number of serious adverse events, proportion of people with any adverse
events, and number of adverse events
Notes Authors provided replies in March 2016.
Reasons for postrandomisation dropouts: the resection area was dry
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Lists with a block size of 4 were generated for each
participating center prior to the initiation of the study using
the Software RandList of the DatInf GmbH (Tübingen,
Germany)”
Allocation concealment (selection bias) Low risk Quote: “A1:1 intraoperative randomization was performed
using identical looking, sealed, and numbered opaque en-
velopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “ESSCALIVER is a single-blinded trial, i.e., patients
were not informed about their assignment in order to in-
crease reliability of secondary outcomes, assessed during the
follow-up visits”.
Comment: healthcare providers were not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Due to the appearance of the products used and
the differences in their application, blinding of the primary
outcome assessor was not possible”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: the outcomes stated in the protocol wer reported.
Vested interest bias High risk Quote (author reply): “The study was sponsored by Aes-
culap AG (Tuttlingen , Germany). Clinical Monitoring
and data management were contracted to Centrial GmbH
(Tübingen, Germany). Statistical planning and analysis was
performed by Dr.M.Koehler GmbH (Freiburg, Germany)”
Other bias Low risk Comment: no other bias
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Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 100
Postrandomisation dropouts: 0 (0%)
Revised sample size: 100
Average age: 65 years
Women: 38 (38%)
Number of cirrhotics: not stated
Number of major liver resections: 10 (10%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: factor being randomised
3. Fibrin glue: none.
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: low central venous pressure
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients undergoing elective liver resection
2. Good hepatic function (Child Pugh - A or indocyanine green (ICG) clearance ≤
15%)
3. Good cardiac and renal function
Exclusion criteria
1. Clotting disorders
2. Requiring bile duct resection or vascular resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: clamp-crush method (n = 50)
Group 2: radiofrequency dissecting sealer (n = 50)
Radiofrequency dissecting sealer: ligasure (Covidien)
Outcomes The outcomes reportedwere: short-termmortality, proportionof peoplewith any adverse
events, operative blood loss, proportion of people requiring blood transfusion, and length
of hospital stay
Notes Authors provided replies in March 2016.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were assigned to treatment at the ratio of
1:1 according to a computer-generated randomization list
by means of STATA software (version 10©; StataCorp LP,
College Station, TX, USA)”.
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Allocation concealment (selection bias) Low risk Quote (author reply): “The details of the randomization
series were unknown to any of the invesigators and were
contained in sealed envelopes, each bearing outside the name
of the hospital and a number. After the patient was deemed
resectable in the operating room, the numbered envelope
was opened at the central office and the card inside told if the
patient was kellyclasia or ligasure group. This information
was given to the surgeon performing the operation”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (author reply): “Patients and healthcare providers
were blinded”.
Comment: further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (author reply): “Outcome assessors were not
blinded”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “There were no postrandomisation dropouts”.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Low risk Quote (author reply): “The study was funded by the partic-
ipating hospitals”
Other bias Low risk Comment: no other bias
Ni 2013
Methods Randomised clinical trial
Participants Country: China
Number randomised: 120
Postrandomisation dropouts: 0 (0%)
Revised sample size: 120
Average age: 56 years
Women: 28 (23.3%)
Number of cirrhotics: 120 (100%)
Number of major liver resections: 15 (12.5%)
Number of right hepatectomies: 3 (2.5%)
Follow-up (months): until discharge
Further details of methods of liver resection:
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: clamp-crush method
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: low central venous pressure
6. Autologous transfusion: not stated
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Inclusion criteria
1. Elective liver resection
2. No major concomitant surgical procedures such as bowel or bile duct resection
3. Total or selective vascular inflow/outflow occlusion was not required because of
the site or extent of tumour
4. Tumours which were located either in the right or left hemiliver
5. Extent of partial hepatectomy was a hemihepatectomy or less
6. Compensated cirrhosis with Child-Pugh class A or B
7. Eastern cooperative oncology group performance status 0-1
Interventions Participants were randomly assigned to 2 groups.
Group 1: continuous portal triad clamping (n = 60)
Group 2: continuous selective portal triad clamping (n = 60)
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, operative blood loss, pro-
portion of people with major blood loss, proportion of people requiring blood transfu-
sion, quantity of blood transfused (red cell transfusion or whole blood), and operating
time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “The patients were randomly assigned to the Pringle
manoeuvre group or to the hemi-hepatic vascular inflow oc-
clusion group by drawing sealed and opaque envelops from
a box containing 120 prearranged envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Low risk Quote: “This study was supported by the State Key
Project on InfectiousDiseases of China (2012ZX10002010,
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2012ZX10002016), Nature Science Fund for Creative Re-
search Groups, China (30921006,81221061,81201940)
and Innovation Program of Shanghai Municipal Education
Commission (09ZZ82)”
Other bias Low risk Comment: no other bias
Noun 1996
Methods Randomised clinical trial
Participants Country: France
Number randomised: 82
Postrandomisation dropouts: not stated
Revised sample size: 82
Average age: 51 years
Women: 39 (47.6%)
Number of cirrhotics: 7 (8.5%)
Number of major liver resections: 34 (41.5%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: varied
2. Parenchymal transection: clamp-crush method or cavitron ultrasonic surgical
aspirator
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing elective liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = 38)
Group 2: control (n = 44)
Fibrin sealant: Biocol
Outcomes The outcomes reported were: proportion of people with serious adverse events, propor-
tion of people with any adverse events, proportion of people requiring blood transfusion,
quantity of blood transfused (red cell transfusion or whole blood), length of hospital
stay, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
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Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: participants were excluded from complications
because drains were not inserted or drainage data was not
available
Selective reporting (reporting bias) High risk Comment: mortality and severity of morbidity were not
reported
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Ollinger 2013
Methods Randomised clinical trial
Participants Country: European multicentre trial
Number randomised: 50
Postrandomisation dropouts: not stated
Revised sample size: 50
Average age: 62 years
Women: 20 (40%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: 21 (42%)
Number of right hepatectomies: 15 (30%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: varied
2. Parenchymal transection: not stated
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Non-urgent, open hepatic surgery
2. Age ≥ 18 years and had a target bleeding site of generalised minor or moderate
bleeding that persisted on the cut surface of the liver in which haemostasis was not
achieved utilising conventional methods and which necessitated the use of a topical
haemostatic
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Exclusion criteria
1. Laparoscopic procedure that would require the study treatment to be applied
through a trocar
2. Were scheduled for a subsequent surgical procedure at the target bleeding site
3. Documented history of cirrhosis
4. Had severe coagulopathy
5. Had a total bilirubin level of ≥ 2.5 mg/dL
6. Had an active local infection at the target bleeding site
7. Were pregnant
8. Had a life expectancy of < 3 months
9. Had received a liver transplant
10. Had been treated with an investigational drug or device within 30 d of enrolment
11. Any incidental preoperative finding was deemed by the investigator to have
potentially jeopardised the safety or welfare of the patient
Interventions Participants were randomly assigned to 2 groups.
Group 1: oxidised cellulose (n = 32)
Group 2: fibrin sealant (n = 18)
Oxidised cellulose: Veriset (Covidien)
Fibrin sealant: Tachosil (Nycomed)
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, quantity of blood transfused
(red cell transfusion or whole blood), quantity of blood transfused (fresh frozen plasma)
, length of hospital stay, length of intensive therapy unit stay, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “This studywas a prospective, non-inferiority,multi-
centre, twoarm, randomized, patient-blinded study to com-
pare a haemostatic patch (Veriset™) with a fibrinogenand
thrombin-coated collagen patch (TachoSil®; control) in the
management of bleeding during hepatic surgery”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “This studywas a prospective, non-inferiority,multi-
centre, twoarm, randomized, patient-blinded study to com-
pare a haemostatic patch (Veriset™) with a fibrinogenand
thrombin-coated collagen patch (TachoSil®; control) in the
management of bleeding during hepatic surgery”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias High risk Quote: “This study was sponsored by Covidien, Inc. ”.
Other bias Low risk Comment: no other bias
Park 2012
Methods Randomised clinical trial
Participants Country: South Korea
Number randomised: 53
Postrandomisation dropouts: 3 (5.7%)
Revised sample size: 50
Average age: 31 years
Women: 11 (22%)
Number of cirrhotics: 0 (0%)
Number of major liver resections: 50 (100%)
Number of right hepatectomies: 50 (100%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: donors underwent right hemihepatectomy and recipients received
right hemiliver grafts
Exclusion criteria
1. Recipient had experienced fulminant hepatic failure
2. The graft-to-recipient body weight ratio (GRWR) was < 0.9%
3. A frozen biopsy sample from the donor liver showed > 30% macrovesicular
steatosis before donor hemihepatectomy
4. The transplant was ABO-incompatible
5. The recipient had previously undergone organ transplantation
6. The recipient had undergone or was scheduled to undergo multiorgan
transplantation
Interventions Participants were randomly assigned to 2 groups.
Group 1: intermittent portal triad clamping (n = 25)
Group 2: control (n = 25)
Intermittent portal triad clamping: 15 min on and 5 min off
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Outcomes The outcomes reported were: proportion of people with serious adverse events, operative
blood loss, length of hospital stay, and operating time
Notes Reasons for postrandomisation dropouts: graft-to-recipent body weight ratio < 0.9%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The donor-recipient pairs were randomized (1:1)
into 2 groups (IHIO and control groups) at the time of
anesthesia induction for donors via the extraction of a black
or white (but otherwise identical) stone from an unseen box”
Comment: IHIO: intermittent hepatic inflow occlusion
Allocation concealment (selection bias) Low risk Quote: “The donor-recipient pairs were randomized (1:1)
into 2 groups (IHIO and control groups) at the time of
anesthesia induction for donors via the extraction of a black
or white (but otherwise identical) stone from an unseen box”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported ade-
quately
Vested interest bias Low risk Quote: “This study was funded by the Clinical Research
Development Program (CRS1091811)”
Other bias Low risk Comment: no other bias
Pietsch 2010
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 25
Postrandomisation dropouts: not stated
Revised sample size: 25
Average age: 56 years
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Women: 11 (44%)
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing elective liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: continuous portal triad clamping (n = 14)
Group 2: control (n = 11)
Outcomes The outcomes reported were: operative blood loss and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
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Methods Randomised clinical trial
Participants Country: Netherlands
Number randomised: 56
Postrandomisation dropouts: not stated
Revised sample size: 56
Average age: 61 years
Women: 20 (35.7%)
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: factor being randomised
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing liver resection and having diffuse bleeding
Interventions Participants were randomly assigned to 2 groups.
Group 1: fibrin sealant (n = 39)
Group 2: gelatin (n = 17)
Fibrin sealant: Fibrocaps (ProFibrix)
Outcomes None of the outcomes of interest were reported.
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
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Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Rahbari 2014
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 130
Postrandomisation dropouts: 0 (0%)
Revised sample size: 130
Average age: 61 years
Women: 60 (46.2%)
Number of cirrhotics: 2 (1.5%)
Number of major liver resections: 73 (56.2%)
Number of right hepatectomies: 43 (33.1%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: variable
3. Fibrin glue: variable
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: low central venous pressure
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients undergoing liver resection
2. A minimum age of 18 years
3. Feasibility of stapler and clamp-crushing transection techniques based on
preoperative imaging (absence of a fairly curved or angled resection line)
Exclusion criteria
1. Concomitant extrahepatic resection was planned
2. Already participating in concurrent intervention trials
3. Expected lack of compliance were also excluded
4. Impaired mental state or language difficulties
Interventions Participants were randomly assigned to 2 groups.
Group 1: clamp-crush method (n = 65)
Group 2: stapler resection (n = 65)
Stapler: Autosuture EndoGIA stapler (Covidien)
Outcomes The outcomes reported were: short-termmortality, proportion of people with serious ad-
verse events, proportion of people with any adverse events, operative blood loss, quantity
of blood transfused (red cell transfusion or whole blood), quantity of blood transfused
(fresh frozen plasma), length of hospital stay, length of intensive therapy unit stay, and
operating time
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Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A block randomisation list is generated by the In-
stitute for Medical Biometrics and Informatics (IMBI) ap-
plying SAS (SAS™ Version 9.1., SAS Institute Inc., Cary,
USA) ”
Allocation concealment (selection bias) Low risk Quote: “Randomization was carried out during surgery us-
ing consecutively numbered opaque and sealed envelopes,
once the operating surgeon had confirmed resectability”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Patients were blinded to the study intervention.
Blinding of the staff in the operating room was not feasible”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Therefore, a third party blinded to the allocated
treatment group assessed postoperative outcomes”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias High risk Quote: “The trial was fundedby theDepartment ofGeneral,
Visceral and Transplant Surgery, University of Heidelberg,
Germany. M.K., P.S., M.W.B and J.W. received speaker’s
honoraria from Covidien”
Other bias Low risk Comment: no other bias
Rau 2001
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 61
Postrandomisation dropouts: not stated
Revised sample size: 61
Average age: 62 years
Women: 25 (41%)
Number of cirrhotics: not stated
Number of major liver resections: 24 (39.3%)
Number of right hepatectomies: not stated
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Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: portal triad clamping
2. Parenchymal transection: factor being randomised
3. Fibrin glue: variable
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Liver resection for liver metastases
2. Parenchymal hepatic resection rate < 50%
3. Child-Pugh class A
Interventions Participants were randomly assigned to 2 groups.
Group 1: cavitron ultrasonic surgical aspirator (n = 30)
Group 2: hydrojet (n = 31)
Hydrojet: jet cutter
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, operative blood loss, quan-
tity of blood transfused (red cell transfusion or whole blood)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: severity of postoperative morbidity was not re-
ported
Vested interest bias Unclear risk Comment: this information was not available.
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Other bias Low risk Comment: no other bias
Savlid 2013
Methods Randomised clinical trial
Participants Country: Sweden
Number randomised: 100
Postrandomisation dropouts: 0 (0%)
Revised sample size: 100
Average age: 65 years
Women: 41 (41%)
Number of cirrhotics: 2 (2%)
Number of major liver resections: 71 (71%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: variable
2. Parenchymal transection: factor being randomised
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients undergoing elective liver resection (removal of 2 or more segments)
2. Feasible to use cavitron ultrasonic surgical aspirator or stapler
Interventions Participants were randomly assigned to 2 groups.
Group 1: cavitron ultrasonic surgical aspirator (n = 50)
Group 2: stapler resection (n = 50)
Stapler: Endostapler (Covidien)
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
number of adverse events, operative blood loss, quantity of blood transfused (red cell
transfusion or whole blood), length of hospital stay, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization was completed by the use of
opaque, sealed envelopes with computer-generated random
numbers in blocks of 10 (5:5)”
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Allocation concealment (selection bias) Low risk Quote: “The randomization was completed by the use of
opaque, sealed envelopes with computer-generated random
numbers in blocks of 10 (5:5)”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias High risk Quote: “This study was supported by an unconditional re-
search grant by Covidien Sweden AB ”
Other bias Low risk Comment: no other bias
Shao 2006
Methods Randomised clinical trial
Participants Country: Asian multicentre trial
Number randomised: 235
Postrandomisation dropouts: 14 (6%)
Revised sample size: 221
Average age: 52 years
Women: 38 (17.2%)
Number of cirrhotics: 231 (104.5%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: factor being randomised
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: cirrhotic patients (> 21 years of age) scheduled for partial hepatectomy
as a result of liver cancer or benign tumors (> 5 cm, involving ≥ 2 segments or located
centrally)
Exclusion criteria
1. History of portal vein thrombosis
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2. Documented deep vein thrombosis
3. Symptoms of severe cardiovascular disease
4. Previous myocardial/pulmonary infarction or stroke
5. Renal insufficiency requiring dialysis
6. Use of anticoagulation therapy within 48 h of surgery
7. Life expectancy of less than 1 month owing to known metastasis
8. Other major abdominal surgery planned during the partial hepatectomy
9. Synchronous liver and intestinal resections
10. Previous partial hepatectomy
Interventions Participants were randomly assigned to 2 groups.
Group 1: control (n = 76)
Group 2: recombinant factor via (n = 155)
Recombinant factor VIIa: brand not stated
Dose: 50 or 100 mcg/kg before skin incision over 2 min and repeated every 2 h until a
maximum of 4 doses
Control: placebo
Outcomes The outcomes reported were: proportion of people with serious adverse events, number
of serious adverse events, proportion of people with any adverse events, number of adverse
events, operative blood loss, proportion of people requiring blood transfusion, quantity
of blood transfused (red cell transfusion or whole blood), quantity of blood transfused
(platelets), and quantity of blood transfused (fresh frozen plasma)
Notes Reasons for postrandomisation dropouts: did not receive intervention (n = 11); lost-to
follow-up (n = 2); withdrew consent (n = 1)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Amulticenter, randomized, double-blind, placebo-
controlled trial”.
Comment: further information on blinding was not avail-
able.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “a multicenter, randomized, double-blind, placebo-
controlled trial”.
Comment: further information on blinding was not avail-
able.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
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Selective reporting (reporting bias) High risk Comment: mortality was not reported.
Vested interest bias High risk Comment: one of the co-authors belonged to a pharmaceu-
tical industry
Other bias Low risk Comment: no other bias
Shimada 1994
Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 24
Postrandomisation dropouts: not stated
Revised sample size: 24
Average age: 63 years
Women: 4 (16.7%)
Number of cirrhotics: 13 (54.2%)
Number of major liver resections: 10 (41.7%)
Number of right hepatectomies: 9 (37.5%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: factor being randomised
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients with hepatocellular carcinoma undergoing liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: antithrombin iii (n = 13)
Group 2: control (n = 11)
Antithrombin concentrate: 1500 IU IV over 30 min: immediately before the operation,
just before hepatic division, and immediately after operation
Outcomes The outcomes reported were: proportion of people with serious adverse events, propor-
tion of people with any adverse events, operative blood loss, quantity of blood transfused
(red cell transfusion or whole blood), and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
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Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality and severity of morbidity were nor
reported
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Si-Yuan 2014
Methods Randomised clinical trial
Participants Country: China
Number randomised: 160
Postrandomisation dropouts: 0 (0%)
Revised sample size: 160
Average age: 49 years
Women: 36 (22.5%)
Number of cirrhotics: 98 (61.3%)
Number of major liver resections: 112 (70%)
Number of right hepatectomies: 53 (33.1%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: factor being randomised
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: low central venous pressure
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients who were surgically fit to receive partial hepatectomy
2. Resectable tumour which had invaded one or more major hepatic vein or was
adjacent to the hepatocaval junction
3. No other concomitant major surgical procedures such as bowel or bile duct
resection
4. No tumour invasion of IVC
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5. Child-Pugh class A or B
6. Patient aged between 16 and 65 years
Interventions Participants were randomly assigned to 2 groups.
Group 1: continuous portal triad clamping (n = 80)
Group 2: continuous selective hepatic vascular exclusion (n = 80)
Outcomes The outcomes reported were: short-termmortality, proportion of people with serious ad-
verse events, proportion of people with any adverse events, operative blood loss, propor-
tion of people with major blood loss, proportion of people requiring blood transfusion,
quantity of blood transfused (red cell transfusion or whole blood), length of hospital
stay, length of intensive therapy unit stay, operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “All eligible patients were randomly assigned to
the Pringle manoeuvre and selective hepatic vascular oc-
clusion group by drawing sealed, consecutively numbered,
and opaque envelopes after abdominal exploration had con-
firmed resectability”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
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Methods Randomised clinical trial
Participants Country: Greece
Number randomised: 82
Postrandomisation dropouts: 0 (0%)
Revised sample size: 82
Average age: 64 years
Women: 17 (20.7%)
Number of cirrhotics: 12 (14.6%)
Number of major liver resections: 60 (73.2%)
Number of right hepatectomies: 31 (37.8%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: selective hepatic vascular exclusion
2. Parenchymal transection: factor being randomised
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: low central venous pressure
6. Autologous transfusion: not stated
Inclusion criteria: patients who underwent liver resection for benign or malignant tu-
mours
Interventions Participants were randomly assigned to 2 groups.
Group 1: sharp transection (n = 41)
Group 2: clamp-crush method (n = 41)
Sharp transection: using scalpel
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, proportion of people with any adverse events, number of adverse events,
operative blood loss, proportion of people requiring blood transfusion, quantity of blood
transfused (red cell transfusion or whole blood), length of hospital stay, length of intensive
therapy unit stay, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
Takayama 2001
Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 132
Postrandomisation dropouts: 0 (0%)
Revised sample size: 132
Average age: 62 years
Women: not stated
Number of cirrhotics: 45 (34.1%)
Number of major liver resections: 43 (32.6%)
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: intermittent total or selective portal triad clamping
2. Parenchymal transection: factor being randomised
3. Fibrin glue: used
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria
1. Partial hepatectomy for tumor resection or graft harvest
2. Hepatic function of Child-Pugh class A or B
3. Acceptable clotting profile
4. Adequate functional reserve of the heart, lungs, and kidneys
Interventions Participants were randomly assigned to 2 groups.
Group 1: cavitron ultrasonic surgical aspirator (n = 66)
Group 2: clamp-crush method (n = 66)
Outcomes The outcomes reported were: short-term mortality, proportion of people with serious
adverse events, number of serious adverse events, proportion of people with any adverse
events, number of adverse events, operative blood loss, proportion of people requiring
blood transfusion, length of hospital stay
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Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Unclear risk Comment: mortality and morbidity were reported.
Vested interest bias Unclear risk Quote: “This work was supported in part by a grant-in-aid
for cancer research from theMinistry of Health andWelfare,
Tokyo, Japan”.
Comment: only part of the funding information was avail-
able.
Other bias Low risk Comment: no other bias
Wang 2006
Methods Randomised clinical trial
Participants Country: China
Number randomised: 52
Postrandomisation dropouts: 2 (3.8%)
Revised sample size: 50
Average age: 46 years
Women: 10 (20%)
Number of cirrhotics: 29 (58%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: varied
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2. Parenchymal transection: clamp-crush
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: factor being randomised
6. Autologous transfusion: not stated
Inclusion criteria: patients with hepatocellular carcinoma undergoing liver resection
Interventions Participants were randomly assigned to 2 groups.
Group 1: low central venous pressure (n = 25)
Group 2: control (n = 25)
Low central venous pressure: by limiting fluid, nitroglycerine, and furosemide
Outcomes The outcomes reported were: proportion of people with any adverse events, operative
blood loss, proportionof people requiring blood transfusion, quantity of blood transfused
(red cell transfusion or whole blood), quantity of blood transfused (fresh frozen plasma)
, length of hospital stay, and operating time
Notes Reasons for postrandomisation dropouts: hepatectomy was not performed because of
cardiac arrest or because it was not possible to demarcate the tumour
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “By the sealed envelope method, the patients were
blindly randomized into Lcentral venous pressure group (n
= 25) and control group (n = 27) at the beginning of the
operation”.
Comment: further details of sealed envelope method were
not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality and severity of morbidity were not
reported
Vested interest bias Unclear risk Comment: this information was not available.
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Other bias Low risk Comment: no other bias
Wong 2003
Methods Randomised clinical trial
Participants Country: Hong Kong, China
Number randomised: 60
Postrandomisation dropouts: 0 (0%)
Revised sample size: 60
Average age: 51 years
Women: 23 (38.3%)
Number of cirrhotics: 23 (38.3%)
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: varied
2. Parenchymal transection: cavitron ultrasonic surgical aspirator
3. Fibrin glue: not stated
4. Pharmacological methods: factor being randomised
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria:
adult patients scheduled for hepatectomy
Exclusion criteria
1. Patients with coronary artery disease
2. Congenital or acquired coagulation disorders other than liver cirrhosis
3. Blood sodium level < 130 mmol/L
4. Non-steroidal anti-inflammatory drug or aspirin ingestion within seven d of
scheduled surgery
5. History of thrombovascular disorders or pulmonary thromboembolism
Interventions Participants were randomly assigned to 2 groups.
Group 1: desmopressin (n = 30)
Group 2: control (n = 30)
Desmopressin: 30 mcg/kg shortly after induction
Control: placebo
Outcomes The outcomes reported were: operative blood loss, proportion of people requiring blood
transfusion, quantity of blood transfused (fresh frozen plasma), and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
180Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wong 2003 (Continued)
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “Patient randomization was by drawing a sealed en-
velope specifying a prescription for either desmopressin or
placebo, which was then prepared by an independent inves-
tigator and blinded to the patient, attending anesthesiologist
and surgeon”.
Comment: further details of sealed envelope method were
not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patient randomization was by drawing a sealed en-
velope specifying a prescription for either desmopressin or
placebo, which was then prepared by an independent inves-
tigator and blinded to the patient, attending anesthesiologist
and surgeon”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patient randomization was by drawing a sealed en-
velope specifying a prescription for either desmopressin or
placebo, which was then prepared by an independent inves-
tigator and blinded to the patient, attending anesthesiologist
and surgeon”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 1 patient who had heavy bleeding in control
group was excluded for blood loss
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Low risk Quote: “This study was supported by a Hong Kong Univer-
sity CRCG grant (10202115/20013/20100/323/01)”
Other bias Low risk Comment: no other bias
Wu 2002
Methods Randomised clinical trial
Participants Country: Taiwan
Number randomised: 58
Postrandomisation dropouts: 0 (0%)
Revised sample size: 58
Average age: 55 years
Women: 10 (17.2%)
Number of cirrhotics: 58 (100%)
Number of major liver resections: 20 (34.5%)
Number of right hepatectomies: 0 (0%)
Follow-up (months): until discharge
Further details of methods of liver resection
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1. Vascular occlusion: factor being randomised
2. Parenchymal transection: clamp-crush method
3. Fibrin glue: not stated
4. Pharmacological methods: not stated
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: cirrhotic patients who had no previous biliary operations and no
preoperative therapies and whose main tumour was located at the central portion of the
liver (defined as Couinaud segments 4, 5, and 8) without having directly invaded the
hepatic hilar plate
Exclusion criteria
1. Patients requiring extended right or left hepatectomy
2. Patients requiring hepatic vascular exclusion
Interventions Participants were randomly assigned to 2 groups.
Group 1: intermittent portal triad clamping (n = 28)
Group 2: intermittent selective portal triad clamping (n = 30)
Intermittent portal triad clamping: 15 min on and 5 min off
Intermittent selective portal triad clamping: 30 min on and 5 min off
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
proportion of people with any adverse events, number of adverse events, operative blood
loss, proportion of people requiring blood transfusion, quantity of blood transfused (red
cell transfusion or whole blood), length of hospital stay, and operating time
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “If the tumour condition and procedures fulfilled the
aforementioned criteria, randomization was performed by
opening a sealed envelope after the abdomen was explored”.
Comment: further details of sealed envelope method were
not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
182Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wu 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity were reported.
Vested interest bias Low risk Quote: “This study was supported in part by grant NSC
902314-075A-018 from the National Science Council,
Taipei, Taiwan”
Other bias Low risk Comment: no other bias
Wu 2006
Methods Randomised clinical trial
Participants Country: Taiwan
Number randomised: 217
Postrandomisation dropouts: 3 (1.4%)
Revised sample size: 214
Average age: 60 years
Women: 57 (26.6%)
Number of cirrhotics: 110 (51.4%)
Number of major liver resections: 38 (17.8%)
Number of right hepatectomies: 18 (8.4%)
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: varied
2. Parenchymal transection: clamp-crush method
3. Fibrin glue: not stated
4. Pharmacological methods: factor being randomised
5. Cardiopulmonary methods: not stated
6. Autologous transfusion: not stated
Inclusion criteria: patients undergoing liver resections
Interventions Participants were randomly assigned to 2 groups.
Group 1: tranexamic acid (n = 108)
Group 2: control (n = 106)
Tranexamic acid: 500 mg just before the surgery followed by 250 4 times a day for 3 d
Outcomes The outcomes reported were: short-term mortality, number of serious adverse events,
proportion of people with any adverse events, number of adverse events, operative blood
loss, proportion of people requiring blood transfusion, length of hospital stay, and op-
erating time
Notes Reasons for postrandomisation dropouts: liver resection not completed because of pres-
ence of more extensive disease
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “The randomization was double-blinded in a sealed
envelope”.
Comment: further details of sealed envelope method were
not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Neither surgeons nor medical staffs knew whether
patients were enrolled in group A or group B ”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Neither surgeons nor medical staffs knew whether
patients were enrolled in group A or group B ”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: although there were 3 postrandomisation drop-
outs, this was because liver resection could not be carried
out
Selective reporting (reporting bias) High risk Comment: severity of morbidity was not reported.
Vested interest bias Unclear risk Quote: “Supported in part by a grant fromNational Science
Council, Taiwan (No. 92-2314-B-075A-006) ”.
Comment: only part of the funding information was avail-
able.
Other bias Low risk Comment: no other bias
Yao 2006
Methods Randomised clinical trial
Participants Country: China
Number randomised: 30
Postrandomisation dropouts: not stated
Revised sample size: 30
Average age: not stated
Women: 14 (46.7%)
Number of cirrhotics: not stated
Number of major liver resections: not stated
Number of right hepatectomies: not stated
Follow-up (months): until discharge
Further details of methods of liver resection
1. Vascular occlusion: not stated
2. Parenchymal transection: not stated
3. Fibrin glue: not stated
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4. Pharmacological methods: not stated
5. Cardiopulmonary methods: factor being randomised
6. Autologous transfusion: not stated
Inclusion criteria
1. Patients undergoing liver resection for tumours
2. Good heart, liver, kidney, and coagulation function
Interventions Participants were randomly assigned to 3 groups.
Group 1: acute normovolemic haemodilution (n = 10)
Group 2: acute normovolemic haemodilution with hypotension (n = 10)
Group 3: control (n = 10)
Acute normovolemic haemodilution: withdrawal of blood and replacement with fluids
to maintain a target haematocrit of 30%
Acute normovolemic haemodilution With controlled hypotension: in addition to acute
normovolemic haemodilution, sodium nitroprusside was used; target blood pressure not
known
Outcomes The outcomes reported were: operative blood lossand quantity of blood transfused (red
cell transfusion or whole blood)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality and morbidity were not reported.
Vested interest bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias
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ABO: blood group incompatible; ASA: American Society of Anesthesiologists; HCC: hepatocellular carcinoma; INR: international
normalised ratio; IU: international unit; IVC: infrahepatic inferior vena cava; kIU: kilo international units.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arru 2007 Not a randomised clinical trial
Azoulay 2005 Not a randomised clinical trial
Bellolio 2012 Not a randomised clinical trial
Beppu 2012 Not a randomised clinical trial
Broek 2011 Comparison of 2 methods of intermittent Pringle manoeuvre of different duration
Chapman 2007 Variations of thrombin
Correa-Gallego 2015 Not an intervention targeted at decreasing blood loss
Dello 2012 Comparison of 2 different methods of intermittent portal triad clamping
Dominioni 2014 Not a randomised clinical trial
El-Moghazy 2009 Comparison of minor variations of same transection method
Esaki 2006 Comparison of 2 different methods of intermittent portal triad clamping
Feldheiser 2015 Not an intervention targeted at decreasing blood loss
Figueras 2003 Not a comparison with main focus on blood loss
Frankel 2013 Different methods of selection for acute normovolemic haemodilution
Gonzalez 2009 Comment on Figueras 2007
Gotohda 2015 Different methods of treatment of raw surface were allowed in control group
Grobmyer 2009 The intervention was started 1 day after operation and used only in selected patients undergoing surgery
Hamady 2015 Comment on an excluded trial (Rahbari 2011)
Hanyong 2015 Vascular occlusion was used in only method of parenchymal transection
Harimoto 2011 Different methods of suturing on the raw surface of the liver
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Hashimoto 2007 Different methods of autologous blood donation (pre-operative or pre-operative + intra-operative)
Kaibori 2013 Variations in cavitron ultrasonic surgical aspirator technique
Kim 2007 Comparison of 2 different methods of intermittent portal triad clamping
Kim 2008 Not a randomised clinical trial
Le Treut 1995 Not a randomised clinical trial
Levit 2012 Comparison of interventions that were not of interest for this review
Li 2013 In the control group, 2 different forms of vascular occlusion were used
Li 2015 Not a randomised clinical trial
Lu 2014 Low central venous pressure was used in fast-track group, but this was combined with a number of other
measures in the intervention group only
Man 2002 Not a randomised clinical trial
Nagano 2009 Not a randomised clinical trial
Narita 2012 Not a randomised clinical trial
NCT01651182 Not a randomised clinical trial
Obiekwe 2014 Quasi-randomised study (alternate assignment)
Palibrk 2012 Not a randomised clinical trial
Petras 2009 Comment on Richter 2009
Petrowsky 2006 Ischaemic preconditioning was applied only in 1 group
Rahbari 2011 Different methods of achieving low central venous pressure
Rau 1995 Started as a randomised clinical trial but did not continue because of problems with nozzles of jet cutter. So,
the report consisted of non-randomised patients
Richter 2009 In this randomised clinical trial, if the patients did not undergo liver resection, the envelopes were resealed
and returned to the pool of sealed envelopes. The allocation concealment is not adequate in this trial
Ryu 2010 Comparison of different methods of low central venous pressure
Saiura 2006 Comparison of variations in clamp-crush method
Saiura 2014 Comparison of variations in clamp-crush method
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Schilling 2009 Comment on Richter 2009
Schwartz 2004 In the control group a number of topical haemostatic agents were used
Shu 2014 In this study, patients were divided into 4 groups - people who received blood transfusion and ulinastatin,
people who received blood transfusion but not ulinastatin, people who received ulinastatin but not blood
transfusion, andpeoplewhodidnot receive blood transfusionor ulinastatin. Although the authors randomised
patients to ulinastatin or control, they ensured that the number of patients in each group was the same, i.
e. the number of people in ulinastatin group who received blood transfusion was 50% and the number of
people in control group who received blood transfusion was 50%. This would have seriously impaired the
randomisation to the extent that we feel that this is not a randomised clinical at all
Si-Yuan 2011 Used continuous and intermittent portal triad clamping depending upon transection time with vascular
occlusion being the factor randomised
Smyrniotis 2002 Quasi-randomised (random sequence generated by hospital number)
Smyrniotis 2003a Quasi-randomised (random sequence generated by hospital number)
Smyrniotis 2003b Quasi-randomised (random sequence generated by hospital number)
Smyrniotis 2006 Ischaemic preconditioning was applied to only one of the groups
Standl 1998 Variations in autologous blood donation
Strobel 2012 Commentary on Lee 2012
Strobel 2014 Commentary on Rahbari 2014
Takatsuki 2015 Not a randomised clinical trial
Torzilli 2008 Variations in clamp-crush method
Vlad 2014 Not a randomised clinical trial
Wang 2010 Not a randomised clinical trial
Wang 2011 Not a randomised clinical trial
Yang 2012 Not a randomised clinical trial
Yang 2013 Variations in selective hepatic vascular exclusion
Yin 2003 Not a randomised clinical trial
Zhang 2014 Variations in portal triad clamping
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Zhu 2012 Different methods of low central venous pressure
Characteristics of studies awaiting assessment [ordered by study ID]
Bochicchio 2015
Methods Randomised clinical trial
Participants Patients undergoing different types of surgical procedures
Interventions Fibrin sealant versus gelatin
Outcomes Adverse events
Notes Attempts were made to contact the authors in September 2016.
Chapman 2006
Methods Randomised clinical trial
Participants Patients undergoing different types of surgical procedures
Interventions Recombinant thrombin versus placebo
Outcomes Adverse events
Notes Attempts were made to contact the authors in September 2016.
Wright 2015
Methods Randomised clinical trial
Participants Adult patients undergoing major oncologic surgery
Interventions Pre-operative tranexamic acid
Outcomes Proportion requiring transfusion
Notes We were unable to obtain further contact details of the author from the institution
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Characteristics of ongoing studies [ordered by study ID]
Chen 2015
Trial name or title Usefulness of BiClamp forceps for liver resection: a randomized clinical trial
Methods Randomised clinical trial
Participants Inclusion criteria
1. Above 18 years of age
2. Elective hepatic resection due to benign or malignant hepatobiliary disease
3. Child-Pugh class A or B liver function
4. Informed consent
Exclusion criteria
1. Participation in concurrent intervention trials with interference in the outcome of this study.
Laparoscopic hepatectomy.
2. Preoperative liver function evaluation: Child-Pugh class C
3. Lack of compliance
4. Pregnancy or lactation
Interventions BiClamp forceps versus clamp-crush methods for liver parenchymal transection
Outcomes Primary outcome: total intraoperative blood loss
Secondary outcomes
• Operation time
• Duration of postoperative hospital stay
• Mortality
• Postoperative morbidity
Starting date 1 October 2014
Contact information Jiang-ming Chen (email: chenjm10@126.com)
Notes NCT02197481
Schmidt 2008
Trial name or title Influence of two different resection techniques (conventional liver resection versus anterior approach) of
liver metastases from colorectal cancer on hematogenous tumor cell dissemination - prospective randomized
multicenter trial
Methods Randomised clinical trial
Participants Inclusion criteria
• Patients being considered for a potentially curative (R0) right hepatectomy, extended right
hepatectomy, or right trisegmentectomy for colorectal liver metastases
• Age ≥ 18 years
• Absence of any psychological, familial, sociological or geographical condition potentially hampering
compliance with the study protocol, follow-up schedules or from signing informed consent
• No evidence of active or former concurrent malignant diseases (except non-melanous skin cancer)
Exclusion criteria
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• Any extrahepatic disease, even if this will be resected concomitantly
• Liver cirrhosis
• Grossly positive lymph nodes in the hepatoduodenal ligament
• Positive margins after liver resection (R1)
• Patients with an intraoperative blood loss of ≥ 2000 cc will be excluded from the analysis of tumour
cell detection in blood samples but will be included in the rest of the analyses
Interventions Anterior approach versus conventional approach
Outcomes • Overall survival
• Blood loss
• Duration time of resection
• Number of blood products transfused
• Postoperative complications
Starting date Not stated
Contact information J Weitz (email: jeurgen.weitz@med.uni-heidelberg.ed
Notes ISN45066244
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D A T A A N D A N A L Y S E S
Comparison 1. Anterior approach vs conventional approach
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (perioperative) 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Anterior approach vs
conventional approach
2 185 Odds Ratio (M-H, Fixed, 95% CI) 0.27 [0.05, 1.32]
2 Serious adverse events
(proportion)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Anterior approach vs
conventional approach
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events (proportion) 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Anterior approach vs
conventional approach
2 185 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.48, 1.64]
4 Adverse events (number) 1 Rate Ratio (Fixed, 95% CI) Totals not selected
4.1 Anterior approach vs
conventional approach
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Blood transfusion (proportion) 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Anterior approach vs
conventional approach
2 185 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.05, 6.74]
6 Major blood loss (proportion) 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Anterior approach vs
conventional approach
2 185 Odds Ratio (M-H, Random, 95% CI) 0.56 [0.09, 3.41]
Comparison 2. Autologous blood donation vs control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events (proportion) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Autologous blood
donation vs control
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Blood transfusion (proportion) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Autologous blood
donation vs control
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion (red blood
cell)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Autologous blood
donation vs control
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Blood loss 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Autologous blood
donation vs control
2 70 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.37, 0.34]
5 Major blood loss (proportion) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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5.1 Autologous blood
donation vs control
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Total hospital stay 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Autologous blood
donation vs control
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Operating time 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Autologous blood
donation vs control
2 70 Mean Difference (IV, Fixed, 95% CI) -3.79 [-34.28, 26.
70]
Comparison 3. Cardiopulmonary interventions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (perioperative) 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Hypoventilation vs control 1 79 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Low central venous
pressure vs control
1 85 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
2 208 Odds Ratio (M-H, Fixed, 95% CI) 2.91 [0.29, 28.70]
2 Serious adverse events
(proportion)
2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Hypoventilation vs control 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Serious adverse events (number) 2 Rate Ratio (Fixed, 95% CI) Totals not selected
3.1 Low central venous
pressure vs control
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events (proportion) 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Hypoventilation vs control 1 79 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.53, 3.34]
4.2 Low central venous
pressure vs control
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.21, 3.03]
4.3 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
2 208 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.37, 1.23]
5 Adverse events (number) 2 Rate Ratio (Fixed, 95% CI) Totals not selected
5.1 Low central venous
pressure vs control
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
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5.2 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Blood transfusion (proportion) 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Hypoventilation vs control 1 79 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.15, 3.40]
6.2 Low central venous
pressure vs control
3 175 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.21, 1.13]
6.3 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
2 208 Odds Ratio (M-H, Fixed, 95% CI) 3.09 [1.49, 6.42]
7 Blood transfusion (red blood
cell)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Acute normovolemic
haemodilution vs control
1 20 Mean Difference (IV, Fixed, 95% CI) -1.25 [-1.74, -0.75]
7.2 Acute normovolemic
haemodilution plus
hypotension vs control
1 20 Mean Difference (IV, Fixed, 95% CI) -1.66 [-2.05, -1.28]
7.3 Acute normovolemic
haemodilution plus low central
venous pressure vs control
1 30 Mean Difference (IV, Fixed, 95% CI) 0.27 [0.02, 0.51]
7.4 Low central venous
pressure vs control
2 90 Mean Difference (IV, Fixed, 95% CI) -1.60 [-2.26, -0.93]
7.5 Acute normovolemic
haemodilution plus
hypotension vs acute
normovolemic haemodilution
1 20 Mean Difference (IV, Fixed, 95% CI) -0.42 [-0.74, -0.10]
7.6 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
2 208 Mean Difference (IV, Fixed, 95% CI) 0.16 [-0.63, 0.95]
8 Blood transfusion (fresh frozen
plasma)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Low central venous
pressure vs control
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Blood transfusion
(cryoprecipitate)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Hypoventilation vs control 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Blood loss 9 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 Acute normovolemic
haemodilution vs control
1 20 Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.10, 0.11]
10.2 Acute normovolemic
haemodilution plus
hypotension vs control
1 20 Mean Difference (IV, Fixed, 95% CI) -0.25 [-0.36, -0.14]
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10.3 Acute normovolemic
haemodilution plus low central
venous pressure vs control
1 30 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.03, 0.08]
10.4 Hypoventilation vs
control
1 79 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.12, 1.12]
10.5 Low central venous
pressure vs control
4 237 Mean Difference (IV, Fixed, 95% CI) -0.34 [-0.47, -0.22]
10.6 Acute normovolemic
haemodilution plus
hypotension vs acute
normovolemic haemodilution
1 20 Mean Difference (IV, Fixed, 95% CI) -0.25 [-0.39, -0.11]
10.7 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
2 208 Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.32, 0.15]
11 Major blood loss (proportion) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
11.1 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Hospital stay 5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 Hypoventilation vs
control
1 79 Mean Difference (IV, Fixed, 95% CI) 0.0 [-3.79, 3.79]
12.2 Low central venous
pressure vs control
3 197 Mean Difference (IV, Fixed, 95% CI) -2.43 [-3.93, -0.94]
12.3 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
1 130 Mean Difference (IV, Fixed, 95% CI) 0.0 [-2.96, 2.96]
13 Operating time 7 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 Acute normovolemic
haemodilution plus low central
venous pressure vs control
1 40 Mean Difference (IV, Fixed, 95% CI) -17.0 [-42.78, 8.78]
13.2 Hypoventilation vs
control
1 79 Mean Difference (IV, Fixed, 95% CI) 0.0 [-88.21, 88.21]
13.3 Low central venous
pressure vs control
4 192 Mean Difference (IV, Fixed, 95% CI) -17.41 [-31.14, -3.
67]
13.4 Low central venous
pressure vs acute normovolemic
haemodilution plus low central
venous pressure
3 248 Mean Difference (IV, Fixed, 95% CI) 13.63 [-4.11, 31.38]
195Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 4. Methods of parenchymal transection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (perioperative) 11 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Cavitron ultrasonic
surgical aspirator vs
clamp-crush method
2 172 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 4.01]
1.2 Radiofrequency dissecting
sealer vs clamp-crush method
5 390 Odds Ratio (M-H, Fixed, 95% CI) 1.85 [0.38, 8.97]
1.3 Sharp transection method
vs clamp-crush method
1 82 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Stapler vs clamp-crush
method
1 130 Odds Ratio (M-H, Fixed, 95% CI) 2.07 [0.36, 11.69]
1.5 Hydrojet vs cavitron
ultrasonic surgical aspirator
2 111 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.19, 5.17]
1.6 Radiofrequency dissecting
sealer vs cavitron ultrasonic
surgical aspirator
2 90 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.11, 4.05]
1.7 Stapler vs cavitron
ultrasonic surgical aspirator
1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.8 Radiofrequency dissecting
sealer vs hydrojet
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 4.04]
2 Serious adverse events
(proportion)
7 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Cavitron ultrasonic
surgical aspirator vs
clamp-crush method
2 172 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.09, 1.35]
2.2 Radiofrequency dissecting
sealer vs clamp-crush method
3 240 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.27, 2.63]
2.3 Sharp transection method
vs clamp-crush method
1 82 Odds Ratio (M-H, Fixed, 95% CI) 2.11 [0.36, 12.20]
2.4 Stapler vs clamp-crush
method
1 130 Odds Ratio (M-H, Fixed, 95% CI) 1.26 [0.58, 2.75]
2.5 Hydrojet vs cavitron
ultrasonic surgical aspirator
1 61 Odds Ratio (M-H, Fixed, 95% CI) 0.62 [0.10, 4.00]
2.6 Radiofrequency dissecting
sealer vs cavitron ultrasonic
surgical aspirator
1 40 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 17.18]
3 Serious adverse events (number) 5 Rate Ratio (Fixed, 95% CI) Subtotals only
3.1 Cavitron ultrasonic
surgical aspirator vs
clamp-crush method
1 132 Rate Ratio (Fixed, 95% CI) 0.67 [0.11, 3.99]
3.2 Radiofrequency dissecting
sealer vs clamp-crush method
2 130 Rate Ratio (Fixed, 95% CI) 3.34 [1.08, 10.31]
3.3 Hydrojet vs cavitron
ultrasonic surgical aspirator
1 50 Rate Ratio (Fixed, 95% CI) 1.50 [0.25, 8.98]
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3.4 Radiofrequency dissecting
sealer vs cavitron ultrasonic
surgical aspirator
1 50 Rate Ratio (Fixed, 95% CI) 1.50 [0.25, 8.98]
3.5 Stapler vs cavitron
ultrasonic surgical aspirator
1 100 Rate Ratio (Fixed, 95% CI) 1.33 [0.56, 3.16]
3.6 Radiofrequency dissecting
sealer vs hydrojet
1 50 Rate Ratio (Fixed, 95% CI) 1.0 [0.20, 4.95]
4 Adverse events (proportion) 8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Cavitron ultrasonic
surgical aspirator vs
clamp-crush method
3 222 Odds Ratio (M-H, Fixed, 95% CI) 1.30 [0.73, 2.34]
4.2 Radiofrequency dissecting
sealer vs clamp-crush method
3 220 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.51, 1.64]
4.3 Sharp transection method
vs clamp-crush method
1 82 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.46, 2.68]
4.4 Stapler vs clamp-crush
method
1 130 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.53, 2.12]
4.5 Hydrojet vs cavitron
ultrasonic surgical aspirator
1 61 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.07, 1.24]
4.6 Radiofrequency dissecting
sealer vs cavitron ultrasonic
surgical aspirator
1 40 Odds Ratio (M-H, Fixed, 95% CI) 1.86 [0.52, 6.61]
5 Adverse events (number) 7 Rate Ratio (Fixed, 95% CI) Subtotals only
5.1 Cavitron ultrasonic
surgical aspirator vs
clamp-crush method
1 132 Rate Ratio (Fixed, 95% CI) 1.56 [0.83, 2.93]
5.2 Radiofrequency dissecting
sealer vs clamp-crush method
3 250 Rate Ratio (Fixed, 95% CI) 1.67 [0.95, 2.94]
5.3 Sharp transection method
vs clamp-crush method
1 82 Rate Ratio (Fixed, 95% CI) 1.12 [0.57, 2.21]
5.4 Hydrojet vs cavitron
ultrasonic surgical aspirator
1 50 Rate Ratio (Fixed, 95% CI) 0.88 [0.32, 2.41]
5.5 Radiofrequency dissecting
sealer vs cavitron ultrasonic
surgical aspirator
1 50 Rate Ratio (Fixed, 95% CI) 1.12 [0.43, 2.92]
5.6 Stapler vs cavitron
ultrasonic surgical aspirator
1 100 Rate Ratio (Fixed, 95% CI) 1.16 [0.63, 2.14]
5.7 Radiofrequency dissecting
sealer vs hydrojet
1 50 Rate Ratio (Fixed, 95% CI) 1.29 [0.48, 3.45]
6 Blood transfusion (proportion) 8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Cavitron ultrasonic
surgical aspirator vs
clamp-crush method
2 172 Odds Ratio (M-H, Fixed, 95% CI) 1.37 [0.29, 6.59]
6.2 Radiofrequency dissecting
sealer vs clamp-crush method
5 390 Odds Ratio (M-H, Fixed, 95% CI) 1.13 [0.63, 2.03]
6.3 Sharp transection method
vs clamp-crush method
1 82 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.32, 2.01]
6.4 Hydrojet vs cavitron
ultrasonic surgical aspirator
1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.30, 3.28]
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6.5 Radiofrequency dissecting
sealer vs cavitron ultrasonic
surgical aspirator
2 90 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.29, 2.09]
6.6 Radiofrequency dissecting
sealer vs hydrojet
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.15, 1.93]
7 Blood transfusion (red blood
cell)
4 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Sharp transection method
vs clamp-crush method
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Stapler vs clamp-crush
method
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Hydrojet vs cavitron
ultrasonic surgical aspirator
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Stapler vs cavitron
ultrasonic surgical aspirator
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Blood transfusion (fresh frozen
plasma)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Stapler vs clamp-crush
method
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Blood loss 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Cavitron ultrasonic
surgical aspirator vs
clamp-crush method
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Hydrojet vs cavitron
ultrasonic surgical aspirator
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Operating time 6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 Cavitron ultrasonic
surgical aspirator vs
clamp-crush method
2 90 Mean Difference (IV, Fixed, 95% CI) 27.47 [-2.87, 57.81]
10.2 Radiofrequency
dissecting sealer vs clamp-crush
method
2 90 Mean Difference (IV, Fixed, 95% CI) 16.11 [-11.45, 43.
67]
10.3 Sharp transection
method vs clamp-crush method
1 82 Mean Difference (IV, Fixed, 95% CI) -6.0 [-90.85, 78.85]
10.4 Stapler vs clamp-crush
method
1 130 Mean Difference (IV, Fixed, 95% CI) -31.0 [-60.40, -1.60]
10.5 Radiofrequency
dissecting sealer vs cavitron
ultrasonic surgical aspirator
1 40 Mean Difference (IV, Fixed, 95% CI) 25.0 [-96.48, 146.
48]
10.6 Stapler vs cavitron
ultrasonic surgical aspirator
1 100 Mean Difference (IV, Fixed, 95% CI) -26.0 [-87.12, 35.
12]
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Comparison 5. Methods of dealing with cut surface
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (perioperative) 10 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Fibrin sealant vs control 2 380 Odds Ratio (M-H, Fixed, 95% CI) 3.56 [0.73, 17.35]
1.2 Fibrin sealant and collagen
vs control
1 300 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.61, 15.53]
1.3 Fibrin sealant vs argon
beam
2 227 Odds Ratio (M-H, Fixed, 95% CI) 1.37 [0.46, 4.03]
1.4 Fibrin sealant vs collagen 3 256 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.24, 3.32]
1.5 Oxidised cellulose vs
fibrin sealant
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.55 [0.03, 9.33]
1.6 Plasmajet vs fibrin sealant 1 58 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.10, 4.16]
2 Serious adverse events
(proportion)
7 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Fibrin sealant vs control 3 457 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.64, 1.65]
2.2 Fibrin sealant vs argon
beam
1 106 Odds Ratio (M-H, Fixed, 95% CI) 0.62 [0.25, 1.55]
2.3 Fibrin sealant vs collagen 1 127 Odds Ratio (M-H, Fixed, 95% CI) 1.57 [0.73, 3.38]
2.4 Oxidised cellulose vs
fibrin sealant
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.17, 1.87]
2.5 Plasmajet vs fibrin sealant 1 58 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.22]
3 Serious adverse events (number) 6 Rate Ratio (Fixed, 95% CI) Subtotals only
3.1 Fibrin sealant vs control 1 70 Rate Ratio (Fixed, 95% CI) 0.94 [0.48, 1.86]
3.2 Fibrin sealant and collagen
vs control
1 300 Rate Ratio (Fixed, 95% CI) 1.32 [0.76, 2.29]
3.3 Fibrin sealant vs argon
beam
1 121 Rate Ratio (Fixed, 95% CI) 4.47 [1.50, 13.27]
3.4 Fibrin sealant vs collagen 2 189 Rate Ratio (Fixed, 95% CI) 1.22 [0.76, 1.98]
3.5 Fibrin sealant vs
cyanoacrylate
1 30 Rate Ratio (Fixed, 95% CI) 1.0 [0.06, 15.99]
3.6 Oxidised cellulose vs
cyanoacrylate
1 30 Rate Ratio (Fixed, 95% CI) 4.00 [0.45, 35.79]
3.7 Oxidised cellulose vs
fibrin sealant
1 30 Rate Ratio (Fixed, 95% CI) 4.00 [0.45, 35.79]
4 Adverse events (proportion) 9 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Fibrin sealant versus
control
3 457 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.55, 1.17]
4.2 Fibrin sealant and collagen
vs control
1 300 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.59, 1.71]
4.3 Fibrin sealant vs argon
beam
2 227 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.58, 1.64]
4.4 Fibrin sealant vs collagen 1 127 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.46, 1.93]
4.5 Oxidised cellulose vs
fibrin sealant
2 274 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.30, 2.01]
5 Adverse events (number) 5 Rate Ratio (Fixed, 95% CI) Subtotals only
5.1 Fibrin sealant vs control 1 70 Rate Ratio (Fixed, 95% CI) 1.01 [0.75, 1.36]
5.2 Fibrin sealant vs argon
beam
1 121 Rate Ratio (Fixed, 95% CI) 1.12 [0.75, 1.66]
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5.3 Fibrin sealant vs collagen 2 189 Rate Ratio (Fixed, 95% CI) 1.13 [0.90, 1.42]
5.4 Fibrin sealant vs
cyanoacrylate
1 30 Rate Ratio (Fixed, 95% CI) 1.50 [0.25, 8.98]
5.5 Oxidised cellulose vs
cyanoacrylate
1 30 Rate Ratio (Fixed, 95% CI) 3.50 [0.73, 16.85]
5.6 Oxidised cellulose vs
fibrin sealant
1 30 Rate Ratio (Fixed, 95% CI) 2.33 [0.60, 9.02]
6 Blood transfusion (proportion) 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Fibrin sealant vs control 2 392 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.61, 1.76]
6.2 Fibrin sealant and collagen
vs control
1 300 Odds Ratio (M-H, Fixed, 95% CI) 1.52 [0.88, 2.61]
6.3 Fibrin sealant vs
cyanoacrylate
1 30 Odds Ratio (M-H, Fixed, 95% CI) 3.25 [0.52, 20.37]
6.4 Oxidised cellulose vs
cyanoacrylate
1 30 Odds Ratio (M-H, Fixed, 95% CI) 2.36 [0.36, 15.45]
6.5 Oxidised cellulose vs
fibrin sealant
1 30 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.15, 3.49]
7 Blood transfusion (red blood
cell)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Fibrin sealant vs control 2 122 Mean Difference (IV, Random, 95% CI) -0.53 [-1.00, -0.06]
7.2 Fibrin sealant and collagen
vs control
1 300 Mean Difference (IV, Random, 95% CI) -0.01 [-0.16, 0.14]
7.3 Fibrin sealant vs collagen 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Fibrin sealant vs
cyanoacrylate
1 30 Mean Difference (IV, Random, 95% CI) 2.2 [1.59, 2.81]
7.5 Oxidised cellulose vs
cyanoacrylate
1 30 Mean Difference (IV, Random, 95% CI) -0.27 [-0.81, 0.27]
7.6 Oxidised cellulose vs
fibrin sealant
2 80 Mean Difference (IV, Random, 95% CI) -1.76 [-2.00, 0.47]
8 Blood transfusion (fresh frozen
plasma)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Fibrin sealant vs
cyanoacrylate
1 30 Mean Difference (IV, Fixed, 95% CI) -0.8 [-1.01, -0.59]
8.2 Oxidised cellulose vs
cyanoacrylate
1 30 Mean Difference (IV, Fixed, 95% CI) -0.27 [-0.55, 0.01]
8.3 Oxidised cellulose vs
fibrin sealant
2 80 Mean Difference (IV, Fixed, 95% CI) 0.53 [0.35, 0.71]
9 Blood loss 5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 Fibrin sealant vs control 2 350 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.13, 0.33]
9.2 Fibrin sealant and collagen
vs control
1 300 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.06, 0.19]
9.3 Fibrin sealant vs collagen 1 62 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.54, 0.68]
9.4 Fibrin sealant vs
cyanoacrylate
1 30 Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.20, 0.43]
9.5 Oxidised cellulose vs
cyanoacrylate
1 30 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.35, 0.19]
9.6 Oxidised cellulose vs
fibrin sealant
1 30 Mean Difference (IV, Fixed, 95% CI) -0.19 [-0.45, 0.06]
10 Total hospital stay 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 Fibrin sealant vs control 1 82 Mean Difference (IV, Fixed, 95% CI) -0.5 [-2.45, 1.45]
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10.2 Fibrin sealant and
collagen vs control
1 300 Mean Difference (IV, Fixed, 95% CI) 0.70 [-1.83, 3.23]
10.3 Fibrin sealant vs
cyanoacrylate
1 30 Mean Difference (IV, Fixed, 95% CI) -1.34 [-3.61, 0.93]
10.4 Oxidised cellulose vs
cyanoacrylate
1 30 Mean Difference (IV, Fixed, 95% CI) -0.67 [-3.12, 1.78]
10.5 Oxidised cellulose vs
fibrin sealant
2 80 Mean Difference (IV, Fixed, 95% CI) 0.25 [-1.84, 2.33]
11 ITU stay 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Oxidised cellulose vs
fibrin sealant
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Operating time 5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 Fibrin sealant vs control 2 122 Mean Difference (IV, Fixed, 95% CI) -14.55 [-52.86, 23.
76]
12.2 Fibrin sealant and
collagen vs control
1 300 Mean Difference (IV, Fixed, 95% CI) 19.0 [2.09, 35.91]
12.3 Fibrin sealant vs collagen 1 62 Mean Difference (IV, Fixed, 95% CI) -4.0 [-44.33, 36.33]
12.4 Oxidised cellulose vs
fibrin sealant
1 50 Mean Difference (IV, Fixed, 95% CI) 5.40 [-70.13, 80.93]
Comparison 6. Methods of vascular occlusion
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (perioperative) 14 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Continuous portal triad
clamping vs control
1 15 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Intermittent portal triad
clamping vs control
4 392 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.16, 2.44]
1.3 Continuous portal triad
clamping vs continuous hepatic
vascular exclusion
2 170 Odds Ratio (M-H, Fixed, 95% CI) 3.39 [0.34, 33.33]
1.4 Continuous selective
hepatic vascular exclusion
vs continuous portal triad
clamping
1 160 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Continuous selective
portal triad clamping vs
continuous portal triad
clamping
1 120 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Intermittent portal triad
clamping vs continuous portal
triad clamping
2 121 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.02, 1.64]
1.7 Intermittent portal triad
clamping vs continuous
selective portal triad clamping
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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1.8 Intermittent selective
portal triad clamping vs
intermittent portal triad
clamping
2 138 Odds Ratio (M-H, Fixed, 95% CI) 2.93 [0.12, 74.00]
2 Serious adverse events
(proportion)
8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Intermittent portal triad
clamping vs control
3 302 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.55, 2.44]
2.2 Continuous portal triad
clamping vs continuous hepatic
vascular exclusion
1 118 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.11, 4.22]
2.3 Continuous selective
hepatic vascular exclusion
vs continuous portal triad
clamping
1 160 Odds Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.13]
2.4 Continuous selective
portal triad clamping vs
continuous portal triad
clamping
1 120 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.19, 0.98]
2.5 Intermittent portal triad
clamping vs continuous portal
triad clamping
1 35 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.07, 2.96]
2.6 Intermittent portal triad
clamping vs continuous
selective portal triad clamping
1 80 Odds Ratio (M-H, Fixed, 95% CI) 4.33 [0.46, 40.61]
3 Serious adverse events (number) 5 Rate Ratio (Fixed, 95% CI) Subtotals only
3.1 Intermittent portal triad
clamping vs control
1 100 Rate Ratio (Fixed, 95% CI) 1.50 [0.42, 5.32]
3.2 Continuous portal triad
clamping vs continuous hepatic
vascular exclusion
1 52 Rate Ratio (Fixed, 95% CI) 0.23 [0.03, 2.00]
3.3 Intermittent portal triad
clamping vs continuous portal
triad clamping
1 86 Rate Ratio (Fixed, 95% CI) 0.12 [0.01, 0.95]
3.4 Intermittent selective
portal triad clamping vs
intermittent portal triad
clamping
2 138 Rate Ratio (Fixed, 95% CI) 1.26 [0.53, 2.99]
4 Adverse events (proportion) 12 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Intermittent portal triad
clamping vs control
4 392 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [0.83, 1.94]
4.2 Continuous portal triad
clamping vs continuous hepatic
vascular exclusion
1 118 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.41, 1.96]
4.3 Continuous selective
hepatic vascular exclusion
vs continuous portal triad
clamping
1 160 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.20, 1.13]
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4.4 Continuous selective
portal triad clamping vs
continuous portal triad
clamping
1 120 Odds Ratio (M-H, Fixed, 95% CI) 0.41 [0.19, 0.93]
4.5 Intermittent portal triad
clamping vs continuous portal
triad clamping
2 121 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.29, 1.56]
4.6 Intermittent portal triad
clamping vs continuous
selective portal triad clamping
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.29, 2.52]
4.7 Intermittent selective
portal triad clamping vs
intermittent portal triad
clamping
2 138 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.42, 1.75]
5 Adverse events (number) 6 Rate Ratio (Fixed, 95% CI) Subtotals only
5.1 Intermittent portal triad
clamping vs control
2 226 Rate Ratio (Fixed, 95% CI) 1.19 [0.80, 1.76]
5.2 Continuous portal triad
clamping vs continuous hepatic
vascular exclusion
1 52 Rate Ratio (Fixed, 95% CI) 0.61 [0.29, 1.32]
5.3 Intermittent portal triad
clamping vs continuous portal
triad clamping
1 86 Rate Ratio (Fixed, 95% CI) 0.64 [0.31, 1.32]
5.4 Intermittent selective
portal triad clamping vs
intermittent portal triad
clamping
2 138 Rate Ratio (Fixed, 95% CI) 1.17 [0.72, 1.91]
6 Blood transfusion (proportion) 13 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Continuous portal triad
clamping vs control
1 34 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.80]
6.2 Intermittent portal triad
clamping vs control
4 392 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.50, 1.35]
6.3 Continuous portal triad
clamping vs continuous hepatic
vascular exclusion
1 118 Odds Ratio (M-H, Fixed, 95% CI) 5.66 [2.29, 14.00]
6.4 Continuous selective
hepatic vascular exclusion
vs continuous portal triad
clamping
1 160 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.24, 1.11]
6.5 Continuous selective
portal triad clamping vs
continuous portal triad
clamping
1 120 Odds Ratio (M-H, Fixed, 95% CI) 1.56 [0.42, 5.82]
6.6 Intermittent portal triad
clamping vs continuous portal
triad clamping
2 121 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.52, 2.49]
6.7 Intermittent portal triad
clamping vs continuous
selective portal triad clamping
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.36, 2.23]
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6.8 Intermittent selective
portal triad clamping vs
intermittent portal triad
clamping
2 138 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.25, 1.36]
7 Blood transfusion (red blood
cell)
10 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Continuous portal triad
clamping vs control
1 15 Mean Difference (IV, Fixed, 95% CI) -0.60 [-3.20, 2.00]
7.2 Intermittent portal triad
clamping vs control
1 100 Mean Difference (IV, Fixed, 95% CI) -1.5 [-2.75, -0.25]
7.3 Continuous portal triad
clamping vs continuous hepatic
vascular exclusion
1 52 Mean Difference (IV, Fixed, 95% CI) 0.40 [-1.61, 2.41]
7.4 Continuous selective
hepatic vascular exclusion
vs continuous portal triad
clamping
1 160 Mean Difference (IV, Fixed, 95% CI) -1.20 [-2.38, -0.02]
7.5 Continuous selective
portal triad clamping vs
continuous portal triad
clamping
1 120 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.31, -0.09]
7.6 Intermittent portal triad
clamping vs continuous portal
triad clamping
2 121 Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.60, 0.34]
7.7 Intermittent portal triad
clamping vs continuous
selective portal triad clamping
1 80 Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.23, 0.46]
7.8 Intermittent selective
portal triad clamping vs
intermittent portal triad
clamping
2 138 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.45, 0.32]
8 Blood loss 16 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Continuous portal triad
clamping vs control
3 131 Mean Difference (IV, Random, 95% CI) -0.24 [-0.76, 0.27]
8.2 Intermittent portal triad
clamping vs control
4 402 Mean Difference (IV, Random, 95% CI) -0.02 [-0.19, 0.15]
8.3 Continuous portal triad
clamping vs continuous hepatic
vascular exclusion
2 170 Mean Difference (IV, Random, 95% CI) 0.17 [-0.35, 0.68]
8.4 Continuous selective
hepatic vascular exclusion
vs continuous portal triad
clamping
1 160 Mean Difference (IV, Random, 95% CI) -0.25 [-0.49, -0.00]
8.5 Continuous selective
portal triad clamping vs
continuous portal triad
clamping
1 120 Mean Difference (IV, Random, 95% CI) 0.10 [-0.19, 0.39]
8.6 Intermittent portal triad
clamping vs continuous portal
triad clamping
2 121 Mean Difference (IV, Random, 95% CI) 0.06 [-0.20, 0.32]
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8.7 Intermittent portal triad
clamping vs continuous
selective portal triad clamping
1 80 Mean Difference (IV, Random, 95% CI) -0.08 [-0.20, 0.05]
8.8 Intermittent selective
portal triad clamping vs
intermittent portal triad
clamping
2 138 Mean Difference (IV, Random, 95% CI) -0.17 [-0.74, 0.39]
9 Major blood loss (proportion) 3 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 Intermittent portal triad
clamping vs control
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Continuous selective
hepatic vascular exclusion
vs continuous portal triad
clamping
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Continuous selective
portal triad clamping vs
continuous portal triad
clamping
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Total hospital stay 10 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 Intermittent portal triad
clamping vs control
4 402 Mean Difference (IV, Fixed, 95% CI) 0.32 [-0.64, 1.28]
10.2 Continuous portal triad
clamping vs continuous hepatic
vascular exclusion
1 52 Mean Difference (IV, Fixed, 95% CI) -8.0 [-13.05, -2.95]
10.3 Continuous selective
hepatic vascular exclusion
vs continuous portal triad
clamping
1 160 Mean Difference (IV, Fixed, 95% CI) -2.80 [-4.13, -1.47]
10.4 Intermittent portal triad
clamping vs continuous portal
triad clamping
1 86 Mean Difference (IV, Fixed, 95% CI) 1.0 [-2.82, 4.82]
10.5 Intermittent portal
triad clamping vs continuous
selective portal triad clamping
1 80 Mean Difference (IV, Fixed, 95% CI) -0.27 [-1.60, 1.06]
10.6 Intermittent selective
portal triad clamping vs
intermittent portal triad
clamping
2 138 Mean Difference (IV, Fixed, 95% CI) -0.67 [-2.40, 1.06]
11 ITU stay 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Continuous selective
hepatic vascular exclusion
vs continuous portal triad
clamping
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Operating time 12 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 Continuous portal triad
clamping vs control
2 40 Mean Difference (IV, Random, 95% CI) -45.87 [-95.61, 3.
87]
12.2 Intermittent portal triad
clamping vs control
2 176 Mean Difference (IV, Random, 95% CI) 25.66 [-31.57, 82.
89]
12.3 Continuous portal triad
clamping vs continuous hepatic
vascular exclusion
2 170 Mean Difference (IV, Random, 95% CI) -29.32 [-82.75, 24.
10]
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12.4 Continuous selective
hepatic vascular exclusion
vs continuous portal triad
clamping
1 160 Mean Difference (IV, Random, 95% CI) -7.20 [-63.42, 49.
02]
12.5 Continuous selective
portal triad clamping vs
continuous portal triad
clamping
1 120 Mean Difference (IV, Random, 95% CI) 20.0 [-0.00, 40.00]
12.6 Intermittent portal triad
clamping vs continuous portal
triad clamping
1 35 Mean Difference (IV, Random, 95% CI) 13.40 [-41.28, 68.
08]
12.7 Intermittent portal
triad clamping vs continuous
selective portal triad clamping
1 80 Mean Difference (IV, Random, 95% CI) -32.17 [-51.50, -12.
84]
12.8 Intermittent selective
portal triad clamping vs
intermittent portal triad
clamping
2 138 Mean Difference (IV, Random, 95% CI) 8.64 [-10.16, 27.45]
Comparison 7. Pharmacological interventions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (perioperative) 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Recombinant factor VIIa
vs control
1 185 Odds Ratio (M-H, Fixed, 95% CI) 0.61 [0.13, 2.83]
1.2 Tranexamic acid vs control 1 214 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events
(proportion)
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Anti-thrombin III vs
control
1 24 Odds Ratio (M-H, Fixed, 95% CI) 1.19 [0.20, 6.99]
2.2 Recombinant factor VIIa
vs control
2 432 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.58, 2.09]
3 Serious adverse events (number) 3 Rate Ratio (Fixed, 95% CI) Subtotals only
3.1 Recombinant factor VIIa
vs control
2 432 Rate Ratio (Fixed, 95% CI) 1.46 [0.75, 2.84]
3.2 Tranexamic acid vs control 1 214 Rate Ratio (Fixed, 95% CI) 0.86 [0.31, 2.37]
4 Adverse events (proportion) 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Anti-thrombin III vs
control
1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.10, 2.84]
4.2 Recombinant factor VIIa
vs control
1 232 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.34, 3.21]
4.3 Tranexamic acid vs control 1 214 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.36, 1.67]
5 Adverse events (number) 3 Rate Ratio (Fixed, 95% CI) Subtotals only
5.1 Recombinant factor VIIa
vs control
2 432 Rate Ratio (Fixed, 95% CI) 0.98 [0.87, 1.10]
5.2 Tranexamic acid vs control 1 214 Rate Ratio (Fixed, 95% CI) 0.78 [0.43, 1.42]
6 Blood transfusion (proportion) 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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6.1 Aprotinin vs control 1 97 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.12, 0.82]
6.2 Desmopressin vs control 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.12, 2.57]
6.3 Recombinant factor VIIa
vs control
2 416 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.62, 1.43]
6.4 Tranexamic acid vs control 1 214 Odds Ratio (M-H, Fixed, 95% CI) 0.02 [0.00, 0.40]
7 Blood transfusion (fresh frozen
plasma)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Desmopressin vs control 1 60 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.39, 0.19]
8 Blood loss 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Aprotinin vs control 1 97 Mean Difference (IV, Fixed, 95% CI) -0.44 [-0.87, 0.00]
9 Hospital stay 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 Tranexamic acid vs control 1 214 Mean Difference (IV, Fixed, 95% CI) -1.0 [-3.06, 1.06]
10 Operating time 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 Aprotinin vs control 1 97 Mean Difference (IV, Fixed, 95% CI) -1.0 [-30.08, 28.08]
Analysis 1.1. Comparison 1 Anterior approach vs conventional approach, Outcome 1 Mortality
(perioperative).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 1 Anterior approach vs conventional approach
Outcome: 1 Mortality (perioperative)
Study or subgroup Anterior approach
Conventional
approach Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Anterior approach vs conventional approach
Capussotti 2012 1/33 1/32 14.3 % 0.97 [ 0.06, 16.18 ]
Liu 2006 1/60 6/60 85.7 % 0.15 [ 0.02, 1.31 ]
Subtotal (95% CI) 93 92 100.0 % 0.27 [ 0.05, 1.32 ]
Total events: 2 (Anterior approach), 7 (Conventional approach)
Heterogeneity: Chi2 = 1.06, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 1.61 (P = 0.11)
0.01 0.1 1 10 100
Favours anterior approach Favours conventional approach
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Analysis 1.2. Comparison 1 Anterior approach vs conventional approach, Outcome 2 Serious adverse
events (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 1 Anterior approach vs conventional approach
Outcome: 2 Serious adverse events (proportion)
Study or subgroup Anterior approach
Conventional
approach Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Anterior approach vs conventional approach
Capussotti 2012 5/33 4/32 1.25 [ 0.30, 5.15 ]
0.1 0.2 0.5 1 2 5 10
Favours anterior approach Favours conventional approach
Analysis 1.3. Comparison 1 Anterior approach vs conventional approach, Outcome 3 Adverse events
(proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 1 Anterior approach vs conventional approach
Outcome: 3 Adverse events (proportion)
Study or subgroup Anterior approach
Conventional
approach Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Anterior approach vs conventional approach
Capussotti 2012 15/33 13/32 32.9 % 1.22 [ 0.46, 3.26 ]
Liu 2006 16/60 20/60 67.1 % 0.73 [ 0.33, 1.59 ]
Subtotal (95% CI) 93 92 100.0 % 0.89 [ 0.48, 1.64 ]
Total events: 31 (Anterior approach), 33 (Conventional approach)
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.71)
0.1 0.2 0.5 1 2 5 10
Favours anterior approach Favours conventional approach
208Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Anterior approach vs conventional approach, Outcome 4 Adverse events
(number).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 1 Anterior approach vs conventional approach
Outcome: 4 Adverse events (number)
Study or subgroup Anterior approach
Conventional
approach log [Rate Ratio] Rate Ratio Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior approach vs conventional approach
Capussotti 2012 33 32 -0.08793 (0.3382) 0.92 [ 0.47, 1.78 ]
0.5 0.7 1 1.5 2
Favours anterior approach Favours conventional approach
Analysis 1.5. Comparison 1 Anterior approach vs conventional approach, Outcome 5 Blood transfusion
(proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 1 Anterior approach vs conventional approach
Outcome: 5 Blood transfusion (proportion)
Study or subgroup Anterior approach
Conventional
approach Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anterior approach vs conventional approach
Capussotti 2012 6/33 3/32 48.2 % 2.15 [ 0.49, 9.45 ]
Liu 2006 4/60 17/60 51.8 % 0.18 [ 0.06, 0.58 ]
Subtotal (95% CI) 93 92 100.0 % 0.60 [ 0.05, 6.74 ]
Total events: 10 (Anterior approach), 20 (Conventional approach)
Heterogeneity: Tau2 = 2.61; Chi2 = 6.66, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours anterior approach Favours conventional approach
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Analysis 1.6. Comparison 1 Anterior approach vs conventional approach, Outcome 6 Major blood loss
(proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 1 Anterior approach vs conventional approach
Outcome: 6 Major blood loss (proportion)
Study or subgroup Anterior approach
Conventional
approach Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anterior approach vs conventional approach
Capussotti 2012 7/33 5/32 48.3 % 1.45 [ 0.41, 5.17 ]
Liu 2006 5/60 17/60 51.7 % 0.23 [ 0.08, 0.67 ]
Subtotal (95% CI) 93 92 100.0 % 0.56 [ 0.09, 3.41 ]
Total events: 12 (Anterior approach), 22 (Conventional approach)
Heterogeneity: Tau2 = 1.34; Chi2 = 4.74, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours anterior approach Favours conventional approach
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Analysis 2.1. Comparison 2 Autologous blood donation vs control, Outcome 1 Adverse events (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 2 Autologous blood donation vs control
Outcome: 1 Adverse events (proportion)
Study or subgroup
Autologous
blood
donation Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Autologous blood donation vs control
Kostopanagiotou 2007 5/15 5/13 0.80 [ 0.17, 3.77 ]
0.1 0.2 0.5 1 2 5 10
Favours autologous blood donation Favours control
Analysis 2.2. Comparison 2 Autologous blood donation vs control, Outcome 2 Blood transfusion
(proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 2 Autologous blood donation vs control
Outcome: 2 Blood transfusion (proportion)
Study or subgroup
Autologous
blood
donation Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Autologous blood donation vs control
Kajikawa 1994 5/21 13/21 0.19 [ 0.05, 0.73 ]
0.05 0.2 1 5 20
Favours autologous blood donation Favours control
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Analysis 2.3. Comparison 2 Autologous blood donation vs control, Outcome 3 Blood transfusion (red blood
cell).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 2 Autologous blood donation vs control
Outcome: 3 Blood transfusion (red blood cell)
Study or subgroup
Autologous
blood
donation Control
Mean
Difference
Mean
Difference
N Mean(SD)[units] N Mean(SD)[units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Autologous blood donation vs control
Kostopanagiotou 2007 15 1.6 (0.7) 13 1.7 (0.6) -0.10 [ -0.58, 0.38 ]
-0.5 -0.25 0 0.25 0.5
Favours autologous blood donation Favours control
Analysis 2.4. Comparison 2 Autologous blood donation vs control, Outcome 4 Blood loss.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 2 Autologous blood donation vs control
Outcome: 4 Blood loss
Study or subgroup
Autologous
blood
donation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[litres] N Mean(SD)[litres] IV,Fixed,95% CI IV,Fixed,95% CI
1 Autologous blood donation vs control
Kajikawa 1994 21 1.272 (0.88) 21 1.19 (0.82) 46.7 % 0.08 [ -0.44, 0.59 ]
Kostopanagiotou 2007 15 0.68 (0.7) 13 0.78 (0.6) 53.3 % -0.10 [ -0.58, 0.38 ]
Subtotal (95% CI) 36 34 100.0 % -0.02 [ -0.37, 0.34 ]
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
-0.5 -0.25 0 0.25 0.5
Favours autologous blood donation Favours control
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Analysis 2.5. Comparison 2 Autologous blood donation vs control, Outcome 5 Major blood loss
(proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 2 Autologous blood donation vs control
Outcome: 5 Major blood loss (proportion)
Study or subgroup
Autologous
blood
donation Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Autologous blood donation vs control
Kajikawa 1994 4/21 2/21 2.24 [ 0.36, 13.78 ]
0.05 0.2 1 5 20
Favours autologous blood donation Favours control
Analysis 2.6. Comparison 2 Autologous blood donation vs control, Outcome 6 Total hospital stay.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 2 Autologous blood donation vs control
Outcome: 6 Total hospital stay
Study or subgroup
Autologous
blood
donation Control
Mean
Difference
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
1 Autologous blood donation vs control
Kostopanagiotou 2007 15 11 (2) 13 10 (3) 1.00 [ -0.92, 2.92 ]
-2 -1 0 1 2
Favours autologous blood donation Favours control
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Analysis 2.7. Comparison 2 Autologous blood donation vs control, Outcome 7 Operating time.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 2 Autologous blood donation vs control
Outcome: 7 Operating time
Study or subgroup
Autologous
blood
donation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[minutes] N Mean(SD)[minutes] IV,Fixed,95% CI IV,Fixed,95% CI
1 Autologous blood donation vs control
Kajikawa 1994 21 318 (105) 21 290 (92) 26.1 % 28.00 [ -31.71, 87.71 ]
Kostopanagiotou 2007 15 175 (45) 13 190 (50) 73.9 % -15.00 [ -50.46, 20.46 ]
Subtotal (95% CI) 36 34 100.0 % -3.79 [ -34.28, 26.70 ]
Heterogeneity: Chi2 = 1.47, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours autologous blood donation Favours control
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Analysis 3.1. Comparison 3 Cardiopulmonary interventions, Outcome 1 Mortality (perioperative).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 1 Mortality (perioperative)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hypoventilation vs control
Hasegawa 2002 0/40 0/39 Not estimable
Subtotal (95% CI) 40 39 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low central venous pressure vs control
Kato 2008 0/43 0/42 Not estimable
Subtotal (95% CI) 43 42 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Jarnagin 2008 3/67 1/63 100.0 % 2.91 [ 0.29, 28.70 ]
Matot 2002 0/39 0/39 Not estimable
Subtotal (95% CI) 106 102 100.0 % 2.91 [ 0.29, 28.70 ]
Total events: 3 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
0.01 0.1 1 10 100
Favours intervention Favours control
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Analysis 3.2. Comparison 3 Cardiopulmonary interventions, Outcome 2 Serious adverse events
(proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 2 Serious adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hypoventilation vs control
Hasegawa 2002 2/40 1/39 2.00 [ 0.17, 23.00 ]
2 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Jarnagin 2008 19/67 19/63 0.92 [ 0.43, 1.95 ]
0.05 0.2 1 5 20
Favours intervention Favours control
Analysis 3.3. Comparison 3 Cardiopulmonary interventions, Outcome 3 Serious adverse events (number).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 3 Serious adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low central venous pressure vs control
El-Kharboutly 2004 21 21 -1.60944 (1.549193) 0.20 [ 0.01, 4.17 ]
2 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Matot 2002 39 39 -0.28768 (0.763763) 0.75 [ 0.17, 3.35 ]
0.01 0.1 1 10 100
Favours intervention Favours control
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Analysis 3.4. Comparison 3 Cardiopulmonary interventions, Outcome 4 Adverse events (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 4 Adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hypoventilation vs control
Hasegawa 2002 16/40 13/39 100.0 % 1.33 [ 0.53, 3.34 ]
Subtotal (95% CI) 40 39 100.0 % 1.33 [ 0.53, 3.34 ]
Total events: 16 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Low central venous pressure vs control
Wang 2006 5/25 6/25 100.0 % 0.79 [ 0.21, 3.03 ]
Subtotal (95% CI) 25 25 100.0 % 0.79 [ 0.21, 3.03 ]
Total events: 5 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
3 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Jarnagin 2008 22/67 28/63 73.0 % 0.61 [ 0.30, 1.25 ]
Matot 2002 8/39 9/39 27.0 % 0.86 [ 0.29, 2.52 ]
Subtotal (95% CI) 106 102 100.0 % 0.68 [ 0.37, 1.23 ]
Total events: 30 (Intervention), 37 (Control)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
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Analysis 3.5. Comparison 3 Cardiopulmonary interventions, Outcome 5 Adverse events (number).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 5 Adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low central venous pressure vs control
El-Kharboutly 2004 20 20 -0.69315 (0.707107) 0.50 [ 0.13, 2.00 ]
2 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Matot 2002 39 39 0 (0.408248) 1.00 [ 0.45, 2.23 ]
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Analysis 3.6. Comparison 3 Cardiopulmonary interventions, Outcome 6 Blood transfusion (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 6 Blood transfusion (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hypoventilation vs control
Hasegawa 2002 3/40 4/39 100.0 % 0.71 [ 0.15, 3.40 ]
Subtotal (95% CI) 40 39 100.0 % 0.71 [ 0.15, 3.40 ]
Total events: 3 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Low central venous pressure vs control
El-Kharboutly 2004 9/20 11/20 38.9 % 0.67 [ 0.19, 2.33 ]
Kato 2008 0/43 0/42 Not estimable
Wang 2006 8/25 14/25 61.1 % 0.37 [ 0.12, 1.17 ]
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(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 88 87 100.0 % 0.49 [ 0.21, 1.13 ]
Total events: 17 (Intervention), 25 (Control)
Heterogeneity: Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
3 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Jarnagin 2008 17/67 8/63 70.6 % 2.34 [ 0.93, 5.89 ]
Matot 2002 14/39 4/39 29.4 % 4.90 [ 1.44, 16.66 ]
Subtotal (95% CI) 106 102 100.0 % 3.09 [ 1.49, 6.42 ]
Total events: 31 (Intervention), 12 (Control)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
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Analysis 3.7. Comparison 3 Cardiopulmonary interventions, Outcome 7 Blood transfusion (red blood cell).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 7 Blood transfusion (red blood cell)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[Units] N Mean(SD)[Units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Acute normovolemic haemodilution vs control
Yao 2006 10 0.4175 (0.515) 10 1.66 (0.62) 100.0 % -1.25 [ -1.74, -0.75 ]
Subtotal (95% CI) 10 10 100.0 % -1.25 [ -1.74, -0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.88 (P < 0.00001)
2 Acute normovolemic haemodilution plus hypotension vs control
Yao 2006 10 0 (0.01) 10 1.66 (0.62) 100.0 % -1.66 [ -2.05, -1.28 ]
Subtotal (95% CI) 10 10 100.0 % -1.66 [ -2.05, -1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.48 (P < 0.00001)
3 Acute normovolemic haemodilution plus low central venous pressure vs control
Guo 2013 15 1.145 (0.45) 15 0.88 (0.18) 100.0 % 0.27 [ 0.02, 0.51 ]
Subtotal (95% CI) 15 15 100.0 % 0.27 [ 0.02, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.033)
4 Low central venous pressure vs control
El-Kharboutly 2004 20 1.3 (0.325) 20 2.75 (1.825) 67.1 % -1.45 [ -2.26, -0.64 ]
Wang 2006 25 1.3125 (0.6) 25 3.22 (2.9) 32.9 % -1.90 [ -3.06, -0.74 ]
Subtotal (95% CI) 45 45 100.0 % -1.60 [ -2.26, -0.93 ]
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 4.71 (P < 0.00001)
5 Acute normovolemic haemodilution plus hypotension vs acute normovolemic haemodilution
Yao 2006 10 0 (0.01) 10 0.42 (0.515) 100.0 % -0.42 [ -0.74, -0.10 ]
Subtotal (95% CI) 10 10 100.0 % -0.42 [ -0.74, -0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
6 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Jarnagin 2008 67 0.7 (2.9) 63 0.44 (2.9) 62.5 % 0.26 [ -0.74, 1.26 ]
Matot 2002 39 0 (2.9) 39 0 (2.9) 37.5 % 0.0 [ -1.29, 1.29 ]
Subtotal (95% CI) 106 102 100.0 % 0.16 [ -0.63, 0.95 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
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Analysis 3.8. Comparison 3 Cardiopulmonary interventions, Outcome 8 Blood transfusion (fresh frozen
plasma).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 8 Blood transfusion (fresh frozen plasma)
Study or subgroup Intervention Control
Mean
Difference
Mean
Difference
N Mean(SD)[units] N Mean(SD)[units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Low central venous pressure vs control
Wang 2006 25 1.752 (1) 25 4.23 (2.63) -2.48 [ -3.58, -1.37 ]
2 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Jarnagin 2008 67 0.28 (2.63) 63 0.17 (2.63) 0.11 [ -0.79, 1.01 ]
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Analysis 3.9. Comparison 3 Cardiopulmonary interventions, Outcome 9 Blood transfusion
(cryoprecipitate).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 9 Blood transfusion (cryoprecipitate)
Study or subgroup Intervention Control
Mean
Difference
Mean
Difference
N Mean(SD)[units] N Mean(SD)[units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Hypoventilation vs control
Hasegawa 2002 40 0.052 (0.19) 39 0.08 (0.23) -0.02 [ -0.12, 0.07 ]
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Analysis 3.10. Comparison 3 Cardiopulmonary interventions, Outcome 10 Blood loss.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 10 Blood loss
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[litres] N Mean(SD)[litres] IV,Fixed,95% CI IV,Fixed,95% CI
1 Acute normovolemic haemodilution vs control
Yao 2006 10 0.654 (0.16) 10 0.65 (0.04) 100.0 % 0.00 [ -0.10, 0.11 ]
Subtotal (95% CI) 10 10 100.0 % 0.00 [ -0.10, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
2 Acute normovolemic haemodilution plus hypotension vs control
Yao 2006 10 0.404 (0.17) 10 0.65 (0.04) 100.0 % -0.25 [ -0.36, -0.14 ]
Subtotal (95% CI) 10 10 100.0 % -0.25 [ -0.36, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.47 (P < 0.00001)
3 Acute normovolemic haemodilution plus low central venous pressure vs control
Guo 2013 15 0.735 (0.08) 15 0.71 (0.08) 100.0 % 0.02 [ -0.03, 0.08 ]
Subtotal (95% CI) 15 15 100.0 % 0.02 [ -0.03, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
4 Hypoventilation vs control
Hasegawa 2002 40 0.63 (2.54) 39 0.63 (2.54) 100.0 % 0.0 [ -1.12, 1.12 ]
Subtotal (95% CI) 40 39 100.0 % 0.0 [ -1.12, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Low central venous pressure vs control
Choi 2007 30 0.589 (0.38) 32 0.78 (0.47) 35.0 % -0.19 [ -0.41, 0.02 ]
El-Kharboutly 2004 20 0.49 (0.29) 20 1.02 (0.32) 44.0 % -0.53 [ -0.72, -0.34 ]
Kato 2008 43 0.499 (0.67) 42 0.58 (0.67) 19.4 % -0.08 [ -0.37, 0.20 ]
Wang 2006 25 0.904 (0.18) 25 2.33 (2.54) 1.6 % -1.43 [ -2.42, -0.43 ]
Subtotal (95% CI) 118 119 100.0 % -0.34 [ -0.47, -0.22 ]
Heterogeneity: Chi2 = 13.35, df = 3 (P = 0.004); I2 =78%
Test for overall effect: Z = 5.32 (P < 0.00001)
6 Acute normovolemic haemodilution plus hypotension vs acute normovolemic haemodilution
Yao 2006 10 0.404 (0.17) 10 0.65 (0.16) 100.0 % -0.25 [ -0.39, -0.11 ]
Subtotal (95% CI) 10 10 100.0 % -0.25 [ -0.39, -0.11 ]
Heterogeneity: not applicable
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Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[litres] N Mean(SD)[litres] IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 3.39 (P = 0.00071)
7 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Jarnagin 2008 67 0.7 (0.7) 63 0.8 (0.7) 95.6 % -0.10 [ -0.34, 0.14 ]
Matot 2002 39 0.89 (2.54) 39 0.75 (2.54) 4.4 % 0.14 [ -0.99, 1.27 ]
Subtotal (95% CI) 106 102 100.0 % -0.09 [ -0.32, 0.15 ]
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.46)
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Analysis 3.11. Comparison 3 Cardiopulmonary interventions, Outcome 11 Major blood loss (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 11 Major blood loss (proportion)
Study or subgroup Intervention Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Jarnagin 2008 29/67 33/63 0.69 [ 0.35, 1.39 ]
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Analysis 3.12. Comparison 3 Cardiopulmonary interventions, Outcome 12 Hospital stay.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 12 Hospital stay
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
1 Hypoventilation vs control
Hasegawa 2002 40 20 (8.6) 39 20 (8.6) 100.0 % 0.0 [ -3.79, 3.79 ]
Subtotal (95% CI) 40 39 100.0 % 0.0 [ -3.79, 3.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Low central venous pressure vs control
Choi 2007 30 12.8 (2.8) 32 14.4 (4.2) 71.3 % -1.60 [ -3.37, 0.17 ]
Kato 2008 43 26 (8.6) 42 30 (8.6) 16.6 % -4.00 [ -7.66, -0.34 ]
Wang 2006 25 16.3 (6.8) 25 21.5 (8.6) 12.1 % -5.20 [ -9.50, -0.90 ]
Subtotal (95% CI) 98 99 100.0 % -2.43 [ -3.93, -0.94 ]
Heterogeneity: Chi2 = 3.15, df = 2 (P = 0.21); I2 =37%
Test for overall effect: Z = 3.20 (P = 0.0014)
3 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Jarnagin 2008 67 7 (8.6) 63 7 (8.6) 100.0 % 0.0 [ -2.96, 2.96 ]
Subtotal (95% CI) 67 63 100.0 % 0.0 [ -2.96, 2.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 3.13. Comparison 3 Cardiopulmonary interventions, Outcome 13 Operating time.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 3 Cardiopulmonary interventions
Outcome: 13 Operating time
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[minutes] N Mean(SD)[minutes] IV,Fixed,95% CI IV,Fixed,95% CI
1 Acute normovolemic haemodilution plus low central venous pressure vs control
Guo 2014 20 179 (34) 20 196 (48) 100.0 % -17.00 [ -42.78, 8.78 ]
Subtotal (95% CI) 20 20 100.0 % -17.00 [ -42.78, 8.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
2 Hypoventilation vs control
Hasegawa 2002 40 498 (200) 39 498 (200) 100.0 % 0.0 [ -88.21, 88.21 ]
Subtotal (95% CI) 40 39 100.0 % 0.0 [ -88.21, 88.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Low central venous pressure vs control
Choi 2007 30 257.5 (68.5) 32 265.2 (35.1) 25.2 % -7.70 [ -35.06, 19.66 ]
El-Kharboutly 2004 20 164 (42) 20 190.1 (24) 42.0 % -26.10 [ -47.30, -4.90 ]
Guo 2014 20 183 (39) 20 196 (48) 25.7 % -13.00 [ -40.10, 14.10 ]
Wang 2006 25 229.6 (67.33) 25 246 (112.36) 7.2 % -16.40 [ -67.75, 34.95 ]
Subtotal (95% CI) 95 97 100.0 % -17.41 [ -31.14, -3.67 ]
Heterogeneity: Chi2 = 1.23, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
4 Low central venous pressure vs acute normovolemic haemodilution plus low central venous pressure
Guo 2014 20 183 (39) 20 179 (34) 61.2 % 4.00 [ -18.68, 26.68 ]
Jarnagin 2008 67 288 (200) 63 255 (200) 6.7 % 33.00 [ -35.79, 101.79 ]
Matot 2002 39 321 (79) 39 293 (61) 32.1 % 28.00 [ -3.32, 59.32 ]
Subtotal (95% CI) 126 122 100.0 % 13.63 [ -4.11, 31.38 ]
Heterogeneity: Chi2 = 1.81, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
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Analysis 4.1. Comparison 4 Methods of parenchymal transection, Outcome 1 Mortality (perioperative).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 4 Methods of parenchymal transection
Outcome: 1 Mortality (perioperative)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cavitron ultrasonic surgical aspirator vs clamp-crush method
Doklestic 2012 0/20 2/20 100.0 % 0.18 [ 0.01, 4.01 ]
Takayama 2001 0/66 0/66 Not estimable
Subtotal (95% CI) 86 86 100.0 % 0.18 [ 0.01, 4.01 ]
Total events: 0 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Radiofrequency dissecting sealer vs clamp-crush method
Arita 2005 0/40 0/40 Not estimable
Doklestic 2012 1/20 2/20 80.3 % 0.47 [ 0.04, 5.69 ]
Ikeda 2009 0/60 0/60 Not estimable
Lupo 2007 0/24 0/26 Not estimable
Muratore 2014 3/50 0/50 19.7 % 7.44 [ 0.37, 147.92 ]
Subtotal (95% CI) 194 196 100.0 % 1.85 [ 0.38, 8.97 ]
Total events: 4 (Intervention), 2 (Control)
Heterogeneity: Chi2 = 1.99, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.76 (P = 0.45)
3 Sharp transection method vs clamp-crush method
Smyrniotis 2005 0/41 0/41 Not estimable
Subtotal (95% CI) 41 41 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Stapler vs clamp-crush method
Rahbari 2014 4/65 2/65 100.0 % 2.07 [ 0.36, 11.69 ]
Subtotal (95% CI) 65 65 100.0 % 2.07 [ 0.36, 11.69 ]
Total events: 4 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
5 Hydrojet vs cavitron ultrasonic surgical aspirator
Lesurtel 2005 2/25 2/25 65.2 % 1.00 [ 0.13, 7.72 ]
Rau 2001 1/31 1/30 34.8 % 0.97 [ 0.06, 16.19 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 56 55 100.0 % 0.99 [ 0.19, 5.17 ]
Total events: 3 (Intervention), 3 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
6 Radiofrequency dissecting sealer vs cavitron ultrasonic surgical aspirator
Doklestic 2012 1/20 0/20 15.9 % 3.15 [ 0.12, 82.16 ]
Lesurtel 2005 0/25 2/25 84.1 % 0.18 [ 0.01, 4.04 ]
Subtotal (95% CI) 45 45 100.0 % 0.66 [ 0.11, 4.05 ]
Total events: 1 (Intervention), 2 (Control)
Heterogeneity: Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.45 (P = 0.65)
7 Stapler vs cavitron ultrasonic surgical aspirator
Savlid 2013 0/50 0/50 Not estimable
Subtotal (95% CI) 50 50 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Radiofrequency dissecting sealer vs hydrojet
Lesurtel 2005 0/25 2/25 100.0 % 0.18 [ 0.01, 4.04 ]
Subtotal (95% CI) 25 25 100.0 % 0.18 [ 0.01, 4.04 ]
Total events: 0 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
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Analysis 4.2. Comparison 4 Methods of parenchymal transection, Outcome 2 Serious adverse events
(proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 4 Methods of parenchymal transection
Outcome: 2 Serious adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cavitron ultrasonic surgical aspirator vs clamp-crush method
Doklestic 2012 1/20 5/20 62.0 % 0.16 [ 0.02, 1.50 ]
Takayama 2001 2/66 3/66 38.0 % 0.66 [ 0.11, 4.06 ]
Subtotal (95% CI) 86 86 100.0 % 0.35 [ 0.09, 1.35 ]
Total events: 3 (Intervention), 8 (Control)
Heterogeneity: Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
2 Radiofrequency dissecting sealer vs clamp-crush method
Arita 2005 5/40 2/40 26.9 % 2.71 [ 0.49, 14.90 ]
Doklestic 2012 1/20 5/20 73.1 % 0.16 [ 0.02, 1.50 ]
Ikeda 2009 0/60 0/60 Not estimable
Subtotal (95% CI) 120 120 100.0 % 0.85 [ 0.27, 2.63 ]
Total events: 6 (Intervention), 7 (Control)
Heterogeneity: Chi2 = 3.94, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.29 (P = 0.77)
3 Sharp transection method vs clamp-crush method
Smyrniotis 2005 4/41 2/41 100.0 % 2.11 [ 0.36, 12.20 ]
Subtotal (95% CI) 41 41 100.0 % 2.11 [ 0.36, 12.20 ]
Total events: 4 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
4 Stapler vs clamp-crush method
Rahbari 2014 19/65 16/65 100.0 % 1.26 [ 0.58, 2.75 ]
Subtotal (95% CI) 65 65 100.0 % 1.26 [ 0.58, 2.75 ]
Total events: 19 (Intervention), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
5 Hydrojet vs cavitron ultrasonic surgical aspirator
Rau 2001 2/31 3/30 100.0 % 0.62 [ 0.10, 4.00 ]
Subtotal (95% CI) 31 30 100.0 % 0.62 [ 0.10, 4.00 ]
Total events: 2 (Intervention), 3 (Control)
Heterogeneity: not applicable
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.50 (P = 0.62)
6 Radiofrequency dissecting sealer vs cavitron ultrasonic surgical aspirator
Doklestic 2012 1/20 1/20 100.0 % 1.00 [ 0.06, 17.18 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.06, 17.18 ]
Total events: 1 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 4.3. Comparison 4 Methods of parenchymal transection, Outcome 3 Serious adverse events
(number).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 4 Methods of parenchymal transection
Outcome: 3 Serious adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cavitron ultrasonic surgical aspirator vs clamp-crush method
Takayama 2001 66 66 -0.40547 (0.912871) 100.0 % 0.67 [ 0.11, 3.99 ]
Subtotal (95% CI) 66 66 100.0 % 0.67 [ 0.11, 3.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
2 Radiofrequency dissecting sealer vs clamp-crush method
Arita 2005 40 40 0.916291 (0.83666) 47.2 % 2.50 [ 0.49, 12.89 ]
Lupo 2007 24 26 1.466337 (0.790569) 52.8 % 4.33 [ 0.92, 20.41 ]
Subtotal (95% CI) 64 66 100.0 % 3.34 [ 1.08, 10.31 ]
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
3 Hydrojet vs cavitron ultrasonic surgical aspirator
Lesurtel 2005 25 25 0.405465 (0.912871) 100.0 % 1.50 [ 0.25, 8.98 ]
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(. . . Continued)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 25 25 100.0 % 1.50 [ 0.25, 8.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
4 Radiofrequency dissecting sealer vs cavitron ultrasonic surgical aspirator
Lesurtel 2005 25 25 0.405465 (0.912871) 100.0 % 1.50 [ 0.25, 8.98 ]
Subtotal (95% CI) 25 25 100.0 % 1.50 [ 0.25, 8.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
5 Stapler vs cavitron ultrasonic surgical aspirator
Savlid 2013 50 50 0.287682 (0.440959) 100.0 % 1.33 [ 0.56, 3.16 ]
Subtotal (95% CI) 50 50 100.0 % 1.33 [ 0.56, 3.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
6 Radiofrequency dissecting sealer vs hydrojet
Lesurtel 2005 25 25 0 (0.816497) 100.0 % 1.00 [ 0.20, 4.95 ]
Subtotal (95% CI) 25 25 100.0 % 1.00 [ 0.20, 4.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 4.4. Comparison 4 Methods of parenchymal transection, Outcome 4 Adverse events (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 4 Methods of parenchymal transection
Outcome: 4 Adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cavitron ultrasonic surgical aspirator vs clamp-crush method
Doklestic 2012 7/20 15/20 49.1 % 0.18 [ 0.05, 0.70 ]
Koo 2005 25/25 17/25 1.7 % 24.77 [ 1.34, 457.61 ]
Takayama 2001 20/66 14/66 49.2 % 1.61 [ 0.73, 3.56 ]
Subtotal (95% CI) 111 111 100.0 % 1.30 [ 0.73, 2.34 ]
Total events: 52 (Intervention), 46 (Control)
Heterogeneity: Chi2 = 12.28, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 0.88 (P = 0.38)
2 Radiofrequency dissecting sealer vs clamp-crush method
Arita 2005 9/40 7/40 22.8 % 1.37 [ 0.45, 4.12 ]
Doklestic 2012 10/20 15/20 31.5 % 0.33 [ 0.09, 1.27 ]
Muratore 2014 18/50 17/50 45.7 % 1.09 [ 0.48, 2.48 ]
Subtotal (95% CI) 110 110 100.0 % 0.92 [ 0.51, 1.64 ]
Total events: 37 (Intervention), 39 (Control)
Heterogeneity: Chi2 = 2.87, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 0.30 (P = 0.77)
3 Sharp transection method vs clamp-crush method
Smyrniotis 2005 17/41 16/41 100.0 % 1.11 [ 0.46, 2.68 ]
Subtotal (95% CI) 41 41 100.0 % 1.11 [ 0.46, 2.68 ]
Total events: 17 (Intervention), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
4 Stapler vs clamp-crush method
Rahbari 2014 31/65 30/65 100.0 % 1.06 [ 0.53, 2.12 ]
Subtotal (95% CI) 65 65 100.0 % 1.06 [ 0.53, 2.12 ]
Total events: 31 (Intervention), 30 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
5 Hydrojet vs cavitron ultrasonic surgical aspirator
Rau 2001 3/31 8/30 100.0 % 0.29 [ 0.07, 1.24 ]
Subtotal (95% CI) 31 30 100.0 % 0.29 [ 0.07, 1.24 ]
Total events: 3 (Intervention), 8 (Control)
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(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.096)
6 Radiofrequency dissecting sealer vs cavitron ultrasonic surgical aspirator
Doklestic 2012 10/20 7/20 100.0 % 1.86 [ 0.52, 6.61 ]
Subtotal (95% CI) 20 20 100.0 % 1.86 [ 0.52, 6.61 ]
Total events: 10 (Intervention), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
0.002 0.1 1 10 500
Favours intervention Favours control
Analysis 4.5. Comparison 4 Methods of parenchymal transection, Outcome 5 Adverse events (number).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 4 Methods of parenchymal transection
Outcome: 5 Adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cavitron ultrasonic surgical aspirator vs clamp-crush method
Takayama 2001 66 66 0.446287 (0.320156) 100.0 % 1.56 [ 0.83, 2.93 ]
Subtotal (95% CI) 66 66 100.0 % 1.56 [ 0.83, 2.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
2 Radiofrequency dissecting sealer vs clamp-crush method
Arita 2005 40 40 0.251314 (0.503953) 32.8 % 1.29 [ 0.48, 3.45 ]
Ikeda 2009 60 60 0.310155 (0.396958) 52.9 % 1.36 [ 0.63, 2.97 ]
Lupo 2007 24 26 1.871802 (0.763763) 14.3 % 6.50 [ 1.45, 29.04 ]
Subtotal (95% CI) 124 126 100.0 % 1.67 [ 0.95, 2.94 ]
Heterogeneity: Chi2 = 3.70, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.78 (P = 0.075)
3 Sharp transection method vs clamp-crush method
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Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Smyrniotis 2005 41 41 0.117783 (0.343592) 100.0 % 1.12 [ 0.57, 2.21 ]
Subtotal (95% CI) 41 41 100.0 % 1.12 [ 0.57, 2.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
4 Hydrojet vs cavitron ultrasonic surgical aspirator
Lesurtel 2005 25 25 -0.13353 (0.517549) 100.0 % 0.88 [ 0.32, 2.41 ]
Subtotal (95% CI) 25 25 100.0 % 0.88 [ 0.32, 2.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
5 Radiofrequency dissecting sealer vs cavitron ultrasonic surgical aspirator
Lesurtel 2005 25 25 0.117783 (0.485913) 100.0 % 1.12 [ 0.43, 2.92 ]
Subtotal (95% CI) 25 25 100.0 % 1.12 [ 0.43, 2.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
6 Stapler vs cavitron ultrasonic surgical aspirator
Savlid 2013 50 50 0.146603 (0.313187) 100.0 % 1.16 [ 0.63, 2.14 ]
Subtotal (95% CI) 50 50 100.0 % 1.16 [ 0.63, 2.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
7 Radiofrequency dissecting sealer vs hydrojet
Lesurtel 2005 25 25 0.251314 (0.503953) 100.0 % 1.29 [ 0.48, 3.45 ]
Subtotal (95% CI) 25 25 100.0 % 1.29 [ 0.48, 3.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
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Analysis 4.6. Comparison 4 Methods of parenchymal transection, Outcome 6 Blood transfusion
(proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 4 Methods of parenchymal transection
Outcome: 6 Blood transfusion (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cavitron ultrasonic surgical aspirator vs clamp-crush method
Doklestic 2012 3/20 2/20 63.3 % 1.59 [ 0.24, 10.70 ]
Takayama 2001 1/66 1/66 36.7 % 1.00 [ 0.06, 16.33 ]
Subtotal (95% CI) 86 86 100.0 % 1.37 [ 0.29, 6.59 ]
Total events: 4 (Intervention), 3 (Control)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
2 Radiofrequency dissecting sealer vs clamp-crush method
Arita 2005 2/40 0/40 2.2 % 5.26 [ 0.24, 113.11 ]
Doklestic 2012 4/20 2/20 7.6 % 2.25 [ 0.36, 13.97 ]
Ikeda 2009 2/60 2/60 9.1 % 1.00 [ 0.14, 7.34 ]
Lupo 2007 8/24 13/26 39.3 % 0.50 [ 0.16, 1.57 ]
Muratore 2014 16/50 13/50 41.8 % 1.34 [ 0.56, 3.19 ]
Subtotal (95% CI) 194 196 100.0 % 1.13 [ 0.63, 2.03 ]
Total events: 32 (Intervention), 30 (Control)
Heterogeneity: Chi2 = 3.62, df = 4 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
3 Sharp transection method vs clamp-crush method
Smyrniotis 2005 13/41 15/41 100.0 % 0.80 [ 0.32, 2.01 ]
Subtotal (95% CI) 41 41 100.0 % 0.80 [ 0.32, 2.01 ]
Total events: 13 (Intervention), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
4 Hydrojet vs cavitron ultrasonic surgical aspirator
Lesurtel 2005 8/25 8/25 100.0 % 1.00 [ 0.30, 3.28 ]
Subtotal (95% CI) 25 25 100.0 % 1.00 [ 0.30, 3.28 ]
Total events: 8 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Radiofrequency dissecting sealer vs cavitron ultrasonic surgical aspirator
Doklestic 2012 4/20 3/20 27.3 % 1.42 [ 0.27, 7.34 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lesurtel 2005 5/25 8/25 72.7 % 0.53 [ 0.15, 1.93 ]
Subtotal (95% CI) 45 45 100.0 % 0.77 [ 0.29, 2.09 ]
Total events: 9 (Intervention), 11 (Control)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
6 Radiofrequency dissecting sealer vs hydrojet
Lesurtel 2005 5/25 8/25 100.0 % 0.53 [ 0.15, 1.93 ]
Subtotal (95% CI) 25 25 100.0 % 0.53 [ 0.15, 1.93 ]
Total events: 5 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
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Analysis 4.7. Comparison 4 Methods of parenchymal transection, Outcome 7 Blood transfusion (red blood
cell).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 4 Methods of parenchymal transection
Outcome: 7 Blood transfusion (red blood cell)
Study or subgroup Intervention Control
Mean
Difference
Mean
Difference
N Mean(SD)[units] N Mean(SD)[units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Sharp transection method vs clamp-crush method
Smyrniotis 2005 41 0 (2.3) 41 0 (2.3) 0.0 [ -1.00, 1.00 ]
2 Stapler vs clamp-crush method
Rahbari 2014 65 1.1 (1.6) 65 1.2 (2.3) -0.10 [ -0.78, 0.58 ]
3 Hydrojet vs cavitron ultrasonic surgical aspirator
Rau 2001 31 1.5 (1.69) 30 2.48 (1.99) -0.98 [ -1.91, -0.05 ]
4 Stapler vs cavitron ultrasonic surgical aspirator
Savlid 2013 50 4 (2.3) 50 4 (2.3) 0.0 [ -0.90, 0.90 ]
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Analysis 4.8. Comparison 4 Methods of parenchymal transection, Outcome 8 Blood transfusion (fresh
frozen plasma).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 4 Methods of parenchymal transection
Outcome: 8 Blood transfusion (fresh frozen plasma)
Study or subgroup Intervention Control
Mean
Difference
Mean
Difference
N Mean(SD)[units] N Mean(SD)[units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Stapler vs clamp-crush method
Rahbari 2014 65 0.3 (0.9) 65 0.5 (1.7) -0.20 [ -0.67, 0.27 ]
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Analysis 4.9. Comparison 4 Methods of parenchymal transection, Outcome 9 Blood loss.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 4 Methods of parenchymal transection
Outcome: 9 Blood loss
Study or subgroup Intervention Control
Mean
Difference
Mean
Difference
N Mean(SD)[litres] N Mean(SD)[litres] IV,Fixed,95% CI IV,Fixed,95% CI
1 Cavitron ultrasonic surgical aspirator vs clamp-crush method
Koo 2005 25 0.875 (0.58) 25 0.79 (0.47) 0.08 [ -0.21, 0.38 ]
2 Hydrojet vs cavitron ultrasonic surgical aspirator
Rau 2001 31 1.479 (1) 30 1.8 (1) -0.32 [ -0.82, 0.18 ]
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Analysis 4.10. Comparison 4 Methods of parenchymal transection, Outcome 10 Operating time.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 4 Methods of parenchymal transection
Outcome: 10 Operating time
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[minutes] N Mean(SD)[minutes] IV,Fixed,95% CI IV,Fixed,95% CI
1 Cavitron ultrasonic surgical aspirator vs clamp-crush method
Doklestic 2012 20 270 (196) 20 240 (196) 6.2 % 30.00 [ -91.48, 151.48 ]
Koo 2005 25 258.7 (45.1) 25 231.4 (66) 93.8 % 27.30 [ -4.03, 58.63 ]
Subtotal (95% CI) 45 45 100.0 % 27.47 [ -2.87, 57.81 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.076)
2 Radiofrequency dissecting sealer vs clamp-crush method
Doklestic 2012 20 295 (196) 20 240 (196) 5.1 % 55.00 [ -66.48, 176.48 ]
Lupo 2007 24 292 (51) 26 278 (51) 94.9 % 14.00 [ -14.30, 42.30 ]
Subtotal (95% CI) 44 46 100.0 % 16.11 [ -11.45, 43.67 ]
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
3 Sharp transection method vs clamp-crush method
Smyrniotis 2005 41 205 (196) 41 211 (196) 100.0 % -6.00 [ -90.85, 78.85 ]
Subtotal (95% CI) 41 41 100.0 % -6.00 [ -90.85, 78.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
4 Stapler vs clamp-crush method
Rahbari 2014 65 190 (85) 65 221 (86) 100.0 % -31.00 [ -60.40, -1.60 ]
Subtotal (95% CI) 65 65 100.0 % -31.00 [ -60.40, -1.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
5 Radiofrequency dissecting sealer vs cavitron ultrasonic surgical aspirator
Doklestic 2012 20 295 (196) 20 270 (196) 100.0 % 25.00 [ -96.48, 146.48 ]
Subtotal (95% CI) 20 20 100.0 % 25.00 [ -96.48, 146.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
6 Stapler vs cavitron ultrasonic surgical aspirator
Savlid 2013 50 272 (196) 50 298 (101) 100.0 % -26.00 [ -87.12, 35.12 ]
Subtotal (95% CI) 50 50 100.0 % -26.00 [ -87.12, 35.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
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Analysis 5.1. Comparison 5 Methods of dealing with cut surface, Outcome 1 Mortality (perioperative).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 1 Mortality (perioperative)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fibrin sealant vs control
Bektas 2014 1/35 1/35 50.1 % 1.00 [ 0.06, 16.65 ]
De Boer 2012 6/156 1/154 49.9 % 6.12 [ 0.73, 51.44 ]
Subtotal (95% CI) 191 189 100.0 % 3.56 [ 0.73, 17.35 ]
Total events: 7 (Intervention), 2 (Control)
Heterogeneity: Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 1.57 (P = 0.12)
2 Fibrin sealant and collagen vs control
Figueras 2007 6/150 2/150 100.0 % 3.08 [ 0.61, 15.53 ]
Subtotal (95% CI) 150 150 100.0 % 3.08 [ 0.61, 15.53 ]
Total events: 6 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
3 Fibrin sealant vs argon beam
Fischer 2011 2/54 4/52 69.1 % 0.46 [ 0.08, 2.64 ]
Frilling 2005 6/59 2/62 30.9 % 3.40 [ 0.66, 17.55 ]
Subtotal (95% CI) 113 114 100.0 % 1.37 [ 0.46, 4.03 ]
Total events: 8 (Intervention), 6 (Control)
Heterogeneity: Chi2 = 2.67, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.57 (P = 0.57)
4 Fibrin sealant vs collagen
Chapman 2000 0/38 2/29 58.9 % 0.14 [ 0.01, 3.09 ]
Kohno 1992 1/31 1/31 20.4 % 1.00 [ 0.06, 16.74 ]
Moench 2014 3/65 1/62 20.6 % 2.95 [ 0.30, 29.16 ]
Subtotal (95% CI) 134 122 100.0 % 0.90 [ 0.24, 3.32 ]
Total events: 4 (Intervention), 4 (Control)
Heterogeneity: Chi2 = 2.41, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.16 (P = 0.87)
5 Oxidised cellulose vs fibrin sealant
Ollinger 2013 1/32 1/18 100.0 % 0.55 [ 0.03, 9.33 ]
Subtotal (95% CI) 32 18 100.0 % 0.55 [ 0.03, 9.33 ]
Total events: 1 (Intervention), 1 (Control)
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(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
6 Plasmajet vs fibrin sealant
Gugenheim 2011 2/29 3/29 100.0 % 0.64 [ 0.10, 4.16 ]
Subtotal (95% CI) 29 29 100.0 % 0.64 [ 0.10, 4.16 ]
Total events: 2 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
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Analysis 5.2. Comparison 5 Methods of dealing with cut surface, Outcome 2 Serious adverse events
(proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 2 Serious adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fibrin sealant vs control
Bektas 2014 9/35 11/35 24.1 % 0.76 [ 0.27, 2.14 ]
De Boer 2012 28/156 23/154 56.0 % 1.25 [ 0.68, 2.28 ]
Noun 1996 6/35 9/42 20.0 % 0.76 [ 0.24, 2.39 ]
Subtotal (95% CI) 226 231 100.0 % 1.03 [ 0.64, 1.65 ]
Total events: 43 (Intervention), 43 (Control)
Heterogeneity: Chi2 = 1.00, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
2 Fibrin sealant vs argon beam
Fischer 2011 10/54 14/52 100.0 % 0.62 [ 0.25, 1.55 ]
Subtotal (95% CI) 54 52 100.0 % 0.62 [ 0.25, 1.55 ]
Total events: 10 (Intervention), 14 (Control)
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(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
3 Fibrin sealant vs collagen
Moench 2014 23/65 16/62 100.0 % 1.57 [ 0.73, 3.38 ]
Subtotal (95% CI) 65 62 100.0 % 1.57 [ 0.73, 3.38 ]
Total events: 23 (Intervention), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
4 Oxidised cellulose vs fibrin sealant
Ollinger 2013 10/32 8/18 100.0 % 0.57 [ 0.17, 1.87 ]
Subtotal (95% CI) 32 18 100.0 % 0.57 [ 0.17, 1.87 ]
Total events: 10 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
5 Plasmajet vs fibrin sealant
Gugenheim 2011 1/29 6/29 100.0 % 0.14 [ 0.02, 1.22 ]
Subtotal (95% CI) 29 29 100.0 % 0.14 [ 0.02, 1.22 ]
Total events: 1 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
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Analysis 5.3. Comparison 5 Methods of dealing with cut surface, Outcome 3 Serious adverse events
(number).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 3 Serious adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Fibrin sealant vs control
Bektas 2014 35 35 -0.06062 (0.348315) 100.0 % 0.94 [ 0.48, 1.86 ]
Subtotal (95% CI) 35 35 100.0 % 0.94 [ 0.48, 1.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
2 Fibrin sealant and collagen vs control
Figueras 2007 150 150 0.276253 (0.282732) 100.0 % 1.32 [ 0.76, 2.29 ]
Subtotal (95% CI) 150 150 100.0 % 1.32 [ 0.76, 2.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
3 Fibrin sealant vs argon beam
Frilling 2005 59 62 1.496516 (0.555719) 100.0 % 4.47 [ 1.50, 13.27 ]
Subtotal (95% CI) 59 62 100.0 % 4.47 [ 1.50, 13.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0071)
4 Fibrin sealant vs collagen
Kohno 1992 31 31 0 (0.471405) 27.0 % 1.00 [ 0.40, 2.52 ]
Moench 2014 65 62 0.275521 (0.286534) 73.0 % 1.32 [ 0.75, 2.31 ]
Subtotal (95% CI) 96 93 100.0 % 1.22 [ 0.76, 1.98 ]
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
5 Fibrin sealant vs cyanoacrylate
Kakaei 2013 15 15 0 (1.414214) 100.0 % 1.00 [ 0.06, 15.99 ]
Subtotal (95% CI) 15 15 100.0 % 1.00 [ 0.06, 15.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Oxidised cellulose vs cyanoacrylate
Kakaei 2013 15 15 1.386294 (1.118034) 100.0 % 4.00 [ 0.45, 35.79 ]
Subtotal (95% CI) 15 15 100.0 % 4.00 [ 0.45, 35.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
7 Oxidised cellulose vs fibrin sealant
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(. . . Continued)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Kakaei 2013 15 15 1.386294 (1.118034) 100.0 % 4.00 [ 0.45, 35.79 ]
Subtotal (95% CI) 15 15 100.0 % 4.00 [ 0.45, 35.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
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Analysis 5.4. Comparison 5 Methods of dealing with cut surface, Outcome 4 Adverse events (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 4 Adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fibrin sealant versus control
Bektas 2014 26/35 27/35 11.7 % 0.86 [ 0.29, 2.56 ]
De Boer 2012 82/156 89/154 71.8 % 0.81 [ 0.52, 1.27 ]
Noun 1996 10/35 15/42 16.5 % 0.72 [ 0.27, 1.89 ]
Subtotal (95% CI) 226 231 100.0 % 0.80 [ 0.55, 1.17 ]
Total events: 118 (Intervention), 131 (Control)
Heterogeneity: Chi2 = 0.06, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Fibrin sealant and collagen vs control
Figueras 2007 35/150 35/150 100.0 % 1.00 [ 0.59, 1.71 ]
Subtotal (95% CI) 150 150 100.0 % 1.00 [ 0.59, 1.71 ]
Total events: 35 (Intervention), 35 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Fibrin sealant vs argon beam
Fischer 2011 25/54 28/52 53.9 % 0.74 [ 0.34, 1.59 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frilling 2005 26/59 24/62 46.1 % 1.25 [ 0.60, 2.58 ]
Subtotal (95% CI) 113 114 100.0 % 0.97 [ 0.58, 1.64 ]
Total events: 51 (Intervention), 52 (Control)
Heterogeneity: Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
4 Fibrin sealant vs collagen
Moench 2014 39/65 38/62 100.0 % 0.95 [ 0.46, 1.93 ]
Subtotal (95% CI) 65 62 100.0 % 0.95 [ 0.46, 1.93 ]
Total events: 39 (Intervention), 38 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
5 Oxidised cellulose vs fibrin sealant
Genyk 2014 4/110 5/114 48.4 % 0.82 [ 0.22, 3.15 ]
Ollinger 2013 23/32 14/18 51.6 % 0.73 [ 0.19, 2.82 ]
Subtotal (95% CI) 142 132 100.0 % 0.77 [ 0.30, 2.01 ]
Total events: 27 (Intervention), 19 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
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Analysis 5.5. Comparison 5 Methods of dealing with cut surface, Outcome 5 Adverse events (number).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 5 Adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Fibrin sealant vs control
Bektas 2014 35 35 0.011173 (0.149489) 100.0 % 1.01 [ 0.75, 1.36 ]
Subtotal (95% CI) 35 35 100.0 % 1.01 [ 0.75, 1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
2 Fibrin sealant vs argon beam
Frilling 2005 59 62 0.111472 (0.203166) 100.0 % 1.12 [ 0.75, 1.66 ]
Subtotal (95% CI) 59 62 100.0 % 1.12 [ 0.75, 1.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
3 Fibrin sealant vs collagen
Kohno 1992 31 31 -0.07411 (0.385164) 9.2 % 0.93 [ 0.44, 1.98 ]
Moench 2014 65 62 0.140563 (0.122938) 90.8 % 1.15 [ 0.90, 1.46 ]
Subtotal (95% CI) 96 93 100.0 % 1.13 [ 0.90, 1.42 ]
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
4 Fibrin sealant vs cyanoacrylate
Kakaei 2013 15 15 0.405465 (0.912871) 100.0 % 1.50 [ 0.25, 8.98 ]
Subtotal (95% CI) 15 15 100.0 % 1.50 [ 0.25, 8.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
5 Oxidised cellulose vs cyanoacrylate
Kakaei 2013 15 15 1.252763 (0.801784) 100.0 % 3.50 [ 0.73, 16.85 ]
Subtotal (95% CI) 15 15 100.0 % 3.50 [ 0.73, 16.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
6 Oxidised cellulose vs fibrin sealant
Kakaei 2013 15 15 0.847298 (0.690066) 100.0 % 2.33 [ 0.60, 9.02 ]
Subtotal (95% CI) 15 15 100.0 % 2.33 [ 0.60, 9.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
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Analysis 5.6. Comparison 5 Methods of dealing with cut surface, Outcome 6 Blood transfusion (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 6 Blood transfusion (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fibrin sealant vs control
De Boer 2012 26/156 22/154 68.9 % 1.20 [ 0.65, 2.22 ]
Noun 1996 7/38 11/44 31.1 % 0.68 [ 0.23, 1.97 ]
Subtotal (95% CI) 194 198 100.0 % 1.04 [ 0.61, 1.76 ]
Total events: 33 (Intervention), 33 (Control)
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Fibrin sealant and collagen vs control
Figueras 2007 40/150 29/150 100.0 % 1.52 [ 0.88, 2.61 ]
Subtotal (95% CI) 150 150 100.0 % 1.52 [ 0.88, 2.61 ]
Total events: 40 (Intervention), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
3 Fibrin sealant vs cyanoacrylate
Kakaei 2013 5/15 2/15 100.0 % 3.25 [ 0.52, 20.37 ]
Subtotal (95% CI) 15 15 100.0 % 3.25 [ 0.52, 20.37 ]
Total events: 5 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
4 Oxidised cellulose vs cyanoacrylate
Kakaei 2013 4/15 2/15 100.0 % 2.36 [ 0.36, 15.45 ]
Subtotal (95% CI) 15 15 100.0 % 2.36 [ 0.36, 15.45 ]
Total events: 4 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
5 Oxidised cellulose vs fibrin sealant
Kakaei 2013 4/15 5/15 100.0 % 0.73 [ 0.15, 3.49 ]
Subtotal (95% CI) 15 15 100.0 % 0.73 [ 0.15, 3.49 ]
Total events: 4 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
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Analysis 5.7. Comparison 5 Methods of dealing with cut surface, Outcome 7 Blood transfusion (red blood
cell).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 7 Blood transfusion (red blood cell)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[units] N Mean(SD)[units] IV,Random,95% CI IV,Random,95% CI
1 Fibrin sealant vs control
Liu 1993 20 5.9375 (4.06) 20 8.13 (6.49) 2.0 % -2.19 [ -5.54, 1.17 ]
Noun 1996 38 3 (1) 44 3.5 (1.2) 98.0 % -0.50 [ -0.98, -0.02 ]
Subtotal (95% CI) 58 64 100.0 % -0.53 [ -1.00, -0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.027)
2 Fibrin sealant and collagen vs control
Figueras 2007 150 0.3 (0.74) 150 0.31 (0.53) 100.0 % -0.01 [ -0.16, 0.14 ]
Subtotal (95% CI) 150 150 100.0 % -0.01 [ -0.16, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.89)
3 Fibrin sealant vs collagen
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Fibrin sealant vs cyanoacrylate
Kakaei 2013 15 4.33 (1.07) 15 2.13 (0.55) 100.0 % 2.20 [ 1.59, 2.81 ]
Subtotal (95% CI) 15 15 100.0 % 2.20 [ 1.59, 2.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.08 (P < 0.00001)
5 Oxidised cellulose vs cyanoacrylate
Kakaei 2013 15 1.86 (0.92) 15 2.13 (0.55) 100.0 % -0.27 [ -0.81, 0.27 ]
Subtotal (95% CI) 15 15 100.0 % -0.27 [ -0.81, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
6 Oxidised cellulose vs fibrin sealant
Kakaei 2013 15 1.86 (0.92) 15 4.33 (1.07) 72.2 % -2.47 [ -3.18, -1.76 ]
Ollinger 2013 32 4.35 (6.48) 18 4.28 (5.52) 27.8 % 0.07 [ -3.32, 3.47 ]
Subtotal (95% CI) 47 33 100.0 % -1.76 [ -4.00, 0.47 ]
Heterogeneity: Tau2 = 1.67; Chi2 = 2.06, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 1.54 (P = 0.12)
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Analysis 5.8. Comparison 5 Methods of dealing with cut surface, Outcome 8 Blood transfusion (fresh frozen
plasma).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 8 Blood transfusion (fresh frozen plasma)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[units] N Mean(SD)[units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Fibrin sealant vs cyanoacrylate
Kakaei 2013 15 0 (0.01) 15 0.8 (0.42) 100.0 % -0.80 [ -1.01, -0.59 ]
Subtotal (95% CI) 15 15 100.0 % -0.80 [ -1.01, -0.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.38 (P < 0.00001)
2 Oxidised cellulose vs cyanoacrylate
Kakaei 2013 15 0.53 (0.36) 15 0.8 (0.42) 100.0 % -0.27 [ -0.55, 0.01 ]
Subtotal (95% CI) 15 15 100.0 % -0.27 [ -0.55, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
3 Oxidised cellulose vs fibrin sealant
Kakaei 2013 15 0.53 (0.36) 15 0 (0.01) 99.9 % 0.53 [ 0.35, 0.71 ]
Ollinger 2013 32 20.12 (6.84) 18 17.64 (10.64) 0.1 % 2.48 [ -2.98, 7.94 ]
Subtotal (95% CI) 47 33 100.0 % 0.53 [ 0.35, 0.71 ]
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 5.73 (P < 0.00001)
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Analysis 5.9. Comparison 5 Methods of dealing with cut surface, Outcome 9 Blood loss.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 9 Blood loss
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[litres] N Mean(SD)[litres] IV,Fixed,95% CI IV,Fixed,95% CI
1 Fibrin sealant vs control
De Boer 2012 156 0.675 (1.13) 154 0.55 (0.95) 98.1 % 0.13 [ -0.11, 0.36 ]
Liu 1993 20 3.047 (2.14) 20 4.05 (3.18) 1.9 % -1.00 [ -2.68, 0.67 ]
Subtotal (95% CI) 176 174 100.0 % 0.10 [ -0.13, 0.33 ]
Heterogeneity: Chi2 = 1.71, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.88 (P = 0.38)
2 Fibrin sealant and collagen vs control
Figueras 2007 150 0.884 (0.61) 150 0.82 (0.52) 100.0 % 0.06 [ -0.06, 0.19 ]
Subtotal (95% CI) 150 150 100.0 % 0.06 [ -0.06, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
3 Fibrin sealant vs collagen
Kohno 1992 31 1.098 (1.45) 31 1.03 (0.95) 100.0 % 0.07 [ -0.54, 0.68 ]
Subtotal (95% CI) 31 31 100.0 % 0.07 [ -0.54, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
4 Fibrin sealant vs cyanoacrylate
Kakaei 2013 15 0.767 (0.42) 15 0.65 (0.45) 100.0 % 0.11 [ -0.20, 0.43 ]
Subtotal (95% CI) 15 15 100.0 % 0.11 [ -0.20, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
5 Oxidised cellulose vs cyanoacrylate
Kakaei 2013 15 0.573 (0.28) 15 0.65 (0.45) 100.0 % -0.08 [ -0.35, 0.19 ]
Subtotal (95% CI) 15 15 100.0 % -0.08 [ -0.35, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
6 Oxidised cellulose vs fibrin sealant
Kakaei 2013 15 0.573 (0.28) 15 0.77 (0.42) 100.0 % -0.19 [ -0.45, 0.06 ]
Subtotal (95% CI) 15 15 100.0 % -0.19 [ -0.45, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
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Analysis 5.10. Comparison 5 Methods of dealing with cut surface, Outcome 10 Total hospital stay.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 10 Total hospital stay
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
1 Fibrin sealant vs control
Noun 1996 38 10.8 (4) 44 11.3 (5) 100.0 % -0.50 [ -2.45, 1.45 ]
Subtotal (95% CI) 38 44 100.0 % -0.50 [ -2.45, 1.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
2 Fibrin sealant and collagen vs control
Figueras 2007 150 13.3 (13) 150 12.6 (9) 100.0 % 0.70 [ -1.83, 3.23 ]
Subtotal (95% CI) 150 150 100.0 % 0.70 [ -1.83, 3.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
3 Fibrin sealant vs cyanoacrylate
Kakaei 2013 15 7.46 (2.79) 15 8.8 (3.5) 100.0 % -1.34 [ -3.61, 0.93 ]
Subtotal (95% CI) 15 15 100.0 % -1.34 [ -3.61, 0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
4 Oxidised cellulose vs cyanoacrylate
Kakaei 2013 15 8.13 (3.35) 15 8.8 (3.5) 100.0 % -0.67 [ -3.12, 1.78 ]
Subtotal (95% CI) 15 15 100.0 % -0.67 [ -3.12, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
5 Oxidised cellulose vs fibrin sealant
Kakaei 2013 15 8.13 (3.35) 15 7.46 (2.79) 89.4 % 0.67 [ -1.54, 2.88 ]
Ollinger 2013 32 15.2 (9.2) 18 18.5 (12) 10.6 % -3.30 [ -9.69, 3.09 ]
Subtotal (95% CI) 47 33 100.0 % 0.25 [ -1.84, 2.33 ]
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.23 (P = 0.82)
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Analysis 5.11. Comparison 5 Methods of dealing with cut surface, Outcome 11 ITU stay.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 11 ITU stay
Study or subgroup Intervention Control
Mean
Difference
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
1 Oxidised cellulose vs fibrin sealant
Ollinger 2013 32 2.8 (6.3) 18 2.2 (2.1) 0.60 [ -1.79, 2.99 ]
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Analysis 5.12. Comparison 5 Methods of dealing with cut surface, Outcome 12 Operating time.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 5 Methods of dealing with cut surface
Outcome: 12 Operating time
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[minutes] N Mean(SD)[minutes] IV,Fixed,95% CI IV,Fixed,95% CI
1 Fibrin sealant vs control
Liu 1993 20 294.5 (64.3) 20 343 (184) 20.1 % -48.50 [ -133.92, 36.92 ]
Noun 1996 38 252 (90) 44 258 (108) 79.9 % -6.00 [ -48.86, 36.86 ]
Subtotal (95% CI) 58 64 100.0 % -14.55 [ -52.86, 23.76 ]
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Fibrin sealant and collagen vs control
Figueras 2007 150 282 (76.3) 150 263 (73.1) 100.0 % 19.00 [ 2.09, 35.91 ]
Subtotal (95% CI) 150 150 100.0 % 19.00 [ 2.09, 35.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
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(. . . Continued)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[minutes] N Mean(SD)[minutes] IV,Fixed,95% CI IV,Fixed,95% CI
3 Fibrin sealant vs collagen
Kohno 1992 31 165 (82) 31 169 (80) 100.0 % -4.00 [ -44.33, 36.33 ]
Subtotal (95% CI) 31 31 100.0 % -4.00 [ -44.33, 36.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
4 Oxidised cellulose vs fibrin sealant
Ollinger 2013 32 252.5 (159.7) 18 247.1 (111.3) 100.0 % 5.40 [ -70.13, 80.93 ]
Subtotal (95% CI) 32 18 100.0 % 5.40 [ -70.13, 80.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
-100 -50 0 50 100
Favours intervention Favours control
Analysis 6.1. Comparison 6 Methods of vascular occlusion, Outcome 1 Mortality (perioperative).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 1 Mortality (perioperative)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Continuous portal triad clamping vs control
Clavien 1996 0/8 0/7 Not estimable
Subtotal (95% CI) 8 7 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Intermittent portal triad clamping vs control
Capussotti 2006 1/63 1/63 18.2 % 1.00 [ 0.06, 16.35 ]
Lee 2012 1/63 1/63 18.2 % 1.00 [ 0.06, 16.35 ]
Man 1997 1/50 2/50 36.3 % 0.49 [ 0.04, 5.58 ]
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(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Man 2003 0/20 1/20 27.2 % 0.32 [ 0.01, 8.26 ]
Subtotal (95% CI) 196 196 100.0 % 0.63 [ 0.16, 2.44 ]
Total events: 3 (Intervention), 5 (Control)
Heterogeneity: Chi2 = 0.42, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
3 Continuous portal triad clamping vs continuous hepatic vascular exclusion
Belghiti 1996 1/24 0/28 47.6 % 3.64 [ 0.14, 93.54 ]
Chen 2006 1/58 0/60 52.4 % 3.16 [ 0.13, 79.07 ]
Subtotal (95% CI) 82 88 100.0 % 3.39 [ 0.34, 33.33 ]
Total events: 2 (Intervention), 0 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.30)
4 Continuous selective hepatic vascular exclusion vs continuous portal triad clamping
Si-Yuan 2014 0/80 0/80 Not estimable
Subtotal (95% CI) 80 80 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Continuous selective portal triad clamping vs continuous portal triad clamping
Ni 2013 0/60 0/60 Not estimable
Subtotal (95% CI) 60 60 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Intermittent portal triad clamping vs continuous portal triad clamping
Belghiti 1999 0/44 2/42 51.7 % 0.18 [ 0.01, 3.91 ]
Capussotti 2003 0/17 2/18 48.3 % 0.19 [ 0.01, 4.23 ]
Subtotal (95% CI) 61 60 100.0 % 0.19 [ 0.02, 1.64 ]
Total events: 0 (Intervention), 4 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
7 Intermittent portal triad clamping vs continuous selective portal triad clamping
Liang 2009 0/40 0/40 Not estimable
Subtotal (95% CI) 40 40 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Intermittent selective portal triad clamping vs intermittent portal triad clamping
Figueras 2005 1/41 0/39 100.0 % 2.93 [ 0.12, 74.00 ]
Wu 2002 0/30 0/28 Not estimable
Subtotal (95% CI) 71 67 100.0 % 2.93 [ 0.12, 74.00 ]
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(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 1 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
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Analysis 6.2. Comparison 6 Methods of vascular occlusion, Outcome 2 Serious adverse events (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 2 Serious adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intermittent portal triad clamping vs control
Capussotti 2006 2/63 4/63 30.3 % 0.48 [ 0.09, 2.74 ]
Lee 2012 14/63 9/63 54.7 % 1.71 [ 0.68, 4.31 ]
Park 2012 1/25 2/25 15.0 % 0.48 [ 0.04, 5.65 ]
Subtotal (95% CI) 151 151 100.0 % 1.16 [ 0.55, 2.44 ]
Total events: 17 (Intervention), 15 (Control)
Heterogeneity: Chi2 = 2.16, df = 2 (P = 0.34); I2 =7%
Test for overall effect: Z = 0.38 (P = 0.70)
2 Continuous portal triad clamping vs continuous hepatic vascular exclusion
Chen 2006 2/58 3/60 100.0 % 0.68 [ 0.11, 4.22 ]
Subtotal (95% CI) 58 60 100.0 % 0.68 [ 0.11, 4.22 ]
Total events: 2 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
3 Continuous selective hepatic vascular exclusion vs continuous portal triad clamping
Si-Yuan 2014 0/80 2/80 100.0 % 0.20 [ 0.01, 4.13 ]
Subtotal (95% CI) 80 80 100.0 % 0.20 [ 0.01, 4.13 ]
Total events: 0 (Intervention), 2 (Control)
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
4 Continuous selective portal triad clamping vs continuous portal triad clamping
Ni 2013 12/60 22/60 100.0 % 0.43 [ 0.19, 0.98 ]
Subtotal (95% CI) 60 60 100.0 % 0.43 [ 0.19, 0.98 ]
Total events: 12 (Intervention), 22 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.045)
5 Intermittent portal triad clamping vs continuous portal triad clamping
Capussotti 2003 2/17 4/18 100.0 % 0.47 [ 0.07, 2.96 ]
Subtotal (95% CI) 17 18 100.0 % 0.47 [ 0.07, 2.96 ]
Total events: 2 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
6 Intermittent portal triad clamping vs continuous selective portal triad clamping
Liang 2009 4/40 1/40 100.0 % 4.33 [ 0.46, 40.61 ]
Subtotal (95% CI) 40 40 100.0 % 4.33 [ 0.46, 40.61 ]
Total events: 4 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
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Analysis 6.3. Comparison 6 Methods of vascular occlusion, Outcome 3 Serious adverse events (number).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 3 Serious adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Intermittent portal triad clamping vs control
Man 1997 50 50 0.405465 (0.645497) 100.0 % 1.50 [ 0.42, 5.32 ]
Subtotal (95% CI) 50 50 100.0 % 1.50 [ 0.42, 5.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 Continuous portal triad clamping vs continuous hepatic vascular exclusion
Belghiti 1996 24 28 -1.45529 (1.095445) 100.0 % 0.23 [ 0.03, 2.00 ]
Subtotal (95% CI) 24 28 100.0 % 0.23 [ 0.03, 2.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
3 Intermittent portal triad clamping vs continuous portal triad clamping
Belghiti 1999 44 42 -2.12596 (1.06066) 100.0 % 0.12 [ 0.01, 0.95 ]
Subtotal (95% CI) 44 42 100.0 % 0.12 [ 0.01, 0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.045)
4 Intermittent selective portal triad clamping vs intermittent portal triad clamping
Figueras 2005 41 39 0.286462 (0.58554) 56.8 % 1.33 [ 0.42, 4.20 ]
Wu 2002 30 28 0.154151 (0.67082) 43.2 % 1.17 [ 0.31, 4.34 ]
Subtotal (95% CI) 71 67 100.0 % 1.26 [ 0.53, 2.99 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
0.01 0.1 1 10 100
Favours intervention Favours control
256Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.4. Comparison 6 Methods of vascular occlusion, Outcome 4 Adverse events (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 4 Adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intermittent portal triad clamping vs control
Capussotti 2006 21/63 16/63 28.6 % 1.47 [ 0.68, 3.18 ]
Lee 2012 26/63 15/63 23.6 % 2.25 [ 1.04, 4.84 ]
Man 1997 13/50 15/50 29.7 % 0.82 [ 0.34, 1.97 ]
Man 2003 5/20 9/20 18.1 % 0.41 [ 0.11, 1.56 ]
Subtotal (95% CI) 196 196 100.0 % 1.27 [ 0.83, 1.94 ]
Total events: 65 (Intervention), 55 (Control)
Heterogeneity: Chi2 = 5.99, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 1.09 (P = 0.28)
2 Continuous portal triad clamping vs continuous hepatic vascular exclusion
Chen 2006 17/58 19/60 100.0 % 0.89 [ 0.41, 1.96 ]
Subtotal (95% CI) 58 60 100.0 % 0.89 [ 0.41, 1.96 ]
Total events: 17 (Intervention), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
3 Continuous selective hepatic vascular exclusion vs continuous portal triad clamping
Si-Yuan 2014 9/80 17/80 100.0 % 0.47 [ 0.20, 1.13 ]
Subtotal (95% CI) 80 80 100.0 % 0.47 [ 0.20, 1.13 ]
Total events: 9 (Intervention), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
4 Continuous selective portal triad clamping vs continuous portal triad clamping
Ni 2013 13/60 24/60 100.0 % 0.41 [ 0.19, 0.93 ]
Subtotal (95% CI) 60 60 100.0 % 0.41 [ 0.19, 0.93 ]
Total events: 13 (Intervention), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
5 Intermittent portal triad clamping vs continuous portal triad clamping
Belghiti 1999 11/44 13/42 74.4 % 0.74 [ 0.29, 1.91 ]
Capussotti 2003 2/17 4/18 25.6 % 0.47 [ 0.07, 2.96 ]
Subtotal (95% CI) 61 60 100.0 % 0.67 [ 0.29, 1.56 ]
Total events: 13 (Intervention), 17 (Control)
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
6 Intermittent portal triad clamping vs continuous selective portal triad clamping
Liang 2009 8/40 9/40 100.0 % 0.86 [ 0.29, 2.52 ]
Subtotal (95% CI) 40 40 100.0 % 0.86 [ 0.29, 2.52 ]
Total events: 8 (Intervention), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
7 Intermittent selective portal triad clamping vs intermittent portal triad clamping
Figueras 2005 12/41 15/39 66.3 % 0.66 [ 0.26, 1.68 ]
Wu 2002 10/30 8/28 33.7 % 1.25 [ 0.41, 3.82 ]
Subtotal (95% CI) 71 67 100.0 % 0.86 [ 0.42, 1.75 ]
Total events: 22 (Intervention), 23 (Control)
Heterogeneity: Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
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Analysis 6.5. Comparison 6 Methods of vascular occlusion, Outcome 5 Adverse events (number).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 5 Adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Intermittent portal triad clamping vs control
Lee 2012 63 63 0.519875 (0.269224) 56.1 % 1.68 [ 0.99, 2.85 ]
Man 1997 50 50 -0.27444 (0.304354) 43.9 % 0.76 [ 0.42, 1.38 ]
Subtotal (95% CI) 113 113 100.0 % 1.19 [ 0.80, 1.76 ]
Heterogeneity: Chi2 = 3.82, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.85 (P = 0.40)
2 Continuous portal triad clamping vs continuous hepatic vascular exclusion
Belghiti 1996 24 28 -0.4877 (0.390681) 100.0 % 0.61 [ 0.29, 1.32 ]
Subtotal (95% CI) 24 28 100.0 % 0.61 [ 0.29, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
3 Intermittent portal triad clamping vs continuous portal triad clamping
Belghiti 1999 44 42 -0.45199 (0.372678) 100.0 % 0.64 [ 0.31, 1.32 ]
Subtotal (95% CI) 44 42 100.0 % 0.64 [ 0.31, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
4 Intermittent selective portal triad clamping vs intermittent portal triad clamping
Figueras 2005 41 39 0.05535 (0.324893) 59.2 % 1.06 [ 0.56, 2.00 ]
Wu 2002 30 28 0.305701 (0.391675) 40.8 % 1.36 [ 0.63, 2.93 ]
Subtotal (95% CI) 71 67 100.0 % 1.17 [ 0.72, 1.91 ]
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 6.6. Comparison 6 Methods of vascular occlusion, Outcome 6 Blood transfusion (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 6 Blood transfusion (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Continuous portal triad clamping vs control
Chouker 2004 1/19 6/15 100.0 % 0.08 [ 0.01, 0.80 ]
Subtotal (95% CI) 19 15 100.0 % 0.08 [ 0.01, 0.80 ]
Total events: 1 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.031)
2 Intermittent portal triad clamping vs control
Capussotti 2006 8/63 1/63 2.6 % 9.02 [ 1.09, 74.41 ]
Lee 2012 14/63 9/63 20.6 % 1.71 [ 0.68, 4.31 ]
Man 1997 18/50 29/50 54.5 % 0.41 [ 0.18, 0.91 ]
Man 2003 12/20 19/20 22.3 % 0.08 [ 0.01, 0.71 ]
Subtotal (95% CI) 196 196 100.0 % 0.82 [ 0.50, 1.35 ]
Total events: 52 (Intervention), 58 (Control)
Heterogeneity: Chi2 = 14.66, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 0.76 (P = 0.45)
3 Continuous portal triad clamping vs continuous hepatic vascular exclusion
Chen 2006 27/58 8/60 100.0 % 5.66 [ 2.29, 14.00 ]
Subtotal (95% CI) 58 60 100.0 % 5.66 [ 2.29, 14.00 ]
Total events: 27 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.75 (P = 0.00018)
4 Continuous selective hepatic vascular exclusion vs continuous portal triad clamping
Si-Yuan 2014 13/80 22/80 100.0 % 0.51 [ 0.24, 1.11 ]
Subtotal (95% CI) 80 80 100.0 % 0.51 [ 0.24, 1.11 ]
Total events: 13 (Intervention), 22 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.088)
5 Continuous selective portal triad clamping vs continuous portal triad clamping
Ni 2013 6/60 4/60 100.0 % 1.56 [ 0.42, 5.82 ]
Subtotal (95% CI) 60 60 100.0 % 1.56 [ 0.42, 5.82 ]
Total events: 6 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Intermittent portal triad clamping vs continuous portal triad clamping
Belghiti 1999 14/44 12/42 70.9 % 1.17 [ 0.46, 2.93 ]
Capussotti 2003 5/17 5/18 29.1 % 1.08 [ 0.25, 4.70 ]
Subtotal (95% CI) 61 60 100.0 % 1.14 [ 0.52, 2.49 ]
Total events: 19 (Intervention), 17 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
7 Intermittent portal triad clamping vs continuous selective portal triad clamping
Liang 2009 14/40 15/40 100.0 % 0.90 [ 0.36, 2.23 ]
Subtotal (95% CI) 40 40 100.0 % 0.90 [ 0.36, 2.23 ]
Total events: 14 (Intervention), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
8 Intermittent selective portal triad clamping vs intermittent portal triad clamping
Figueras 2005 6/41 4/39 25.3 % 1.50 [ 0.39, 5.78 ]
Wu 2002 5/30 12/28 74.7 % 0.27 [ 0.08, 0.90 ]
Subtotal (95% CI) 71 67 100.0 % 0.58 [ 0.25, 1.36 ]
Total events: 11 (Intervention), 16 (Control)
Heterogeneity: Chi2 = 3.47, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.26 (P = 0.21)
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Analysis 6.7. Comparison 6 Methods of vascular occlusion, Outcome 7 Blood transfusion (red blood cell).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 7 Blood transfusion (red blood cell)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[units] N Mean(SD)[units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Continuous portal triad clamping vs control
Clavien 1996 8 1.3 (2.4) 7 1.9 (2.7) 100.0 % -0.60 [ -3.20, 2.00 ]
Subtotal (95% CI) 8 7 100.0 % -0.60 [ -3.20, 2.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 Intermittent portal triad clamping vs control
Man 1997 50 0 (3.18) 50 1.5 (3.18) 100.0 % -1.50 [ -2.75, -0.25 ]
Subtotal (95% CI) 50 50 100.0 % -1.50 [ -2.75, -0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
3 Continuous portal triad clamping vs continuous hepatic vascular exclusion
Belghiti 1996 24 2.9 (3.9) 28 2.5 (3.4) 100.0 % 0.40 [ -1.61, 2.41 ]
Subtotal (95% CI) 24 28 100.0 % 0.40 [ -1.61, 2.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
4 Continuous selective hepatic vascular exclusion vs continuous portal triad clamping
Si-Yuan 2014 80 1 (3.8) 80 2.2 (3.8) 100.0 % -1.20 [ -2.38, -0.02 ]
Subtotal (95% CI) 80 80 100.0 % -1.20 [ -2.38, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
5 Continuous selective portal triad clamping vs continuous portal triad clamping
Ni 2013 60 1.2 (0.2) 60 1.4 (0.4) 100.0 % -0.20 [ -0.31, -0.09 ]
Subtotal (95% CI) 60 60 100.0 % -0.20 [ -0.31, -0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.46 (P = 0.00053)
6 Intermittent portal triad clamping vs continuous portal triad clamping
Belghiti 1999 44 2.3 (2.6) 42 3 (2.6) 18.6 % -0.70 [ -1.80, 0.40 ]
Capussotti 2003 17 0.5 (1.1) 18 0.5 (0.1) 81.4 % 0.0 [ -0.52, 0.52 ]
Subtotal (95% CI) 61 60 100.0 % -0.13 [ -0.60, 0.34 ]
Heterogeneity: Chi2 = 1.27, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 0.54 (P = 0.59)
7 Intermittent portal triad clamping vs continuous selective portal triad clamping
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Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[units] N Mean(SD)[units] IV,Fixed,95% CI IV,Fixed,95% CI
Liang 2009 40 1.4825 (0.95) 40 1.37 (0.58) 100.0 % 0.11 [ -0.23, 0.46 ]
Subtotal (95% CI) 40 40 100.0 % 0.11 [ -0.23, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
8 Intermittent selective portal triad clamping vs intermittent portal triad clamping
Figueras 2005 41 0.34 (0.9) 39 0.36 (1) 83.6 % -0.02 [ -0.44, 0.40 ]
Wu 2002 30 2.24 (2.2) 28 2.54 (1.4) 16.4 % -0.30 [ -1.25, 0.64 ]
Subtotal (95% CI) 71 67 100.0 % -0.07 [ -0.45, 0.32 ]
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
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Analysis 6.8. Comparison 6 Methods of vascular occlusion, Outcome 8 Blood loss.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 8 Blood loss
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[litres] N Mean(SD)[litres] IV,Random,95% CI IV,Random,95% CI
1 Continuous portal triad clamping vs control
Chouker 2004 19 1.38 (0.71) 15 2.17 (0.85) 30.5 % -0.79 [ -1.33, -0.25 ]
Dayangac 2010 36 0.328 (0.13) 36 0.32 (0.29) 44.6 % 0.01 [ -0.10, 0.11 ]
Pietsch 2010 14 0.65 (0.58) 11 0.67 (1.06) 24.9 % -0.02 [ -0.72, 0.68 ]
Subtotal (95% CI) 69 62 100.0 % -0.24 [ -0.76, 0.27 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 8.22, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 0.92 (P = 0.36)
2 Intermittent portal triad clamping vs control
Capussotti 2006 63 0.184 (0.25) 63 0.2 (0.19) 34.1 % -0.02 [ -0.10, 0.06 ]
Lee 2012 63 0.488 (0.53) 63 0.49 (0.49) 26.2 % 0.00 [ -0.18, 0.18 ]
Man 1997 50 1.28 (1.26) 50 1.99 (1.26) 9.1 % -0.71 [ -1.20, -0.22 ]
Park 2012 25 0.486 (0.29) 25 0.32 (0.14) 30.6 % 0.16 [ 0.04, 0.29 ]
Subtotal (95% CI) 201 201 100.0 % -0.02 [ -0.19, 0.15 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 14.30, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 0.25 (P = 0.80)
3 Continuous portal triad clamping vs continuous hepatic vascular exclusion
Belghiti 1996 24 0.989 (1.25) 28 1.2 (1.1) 32.9 % -0.21 [ -0.85, 0.44 ]
Chen 2006 58 0.77 (0.32) 60 0.42 (0.25) 67.1 % 0.35 [ 0.25, 0.45 ]
Subtotal (95% CI) 82 88 100.0 % 0.17 [ -0.35, 0.68 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 2.78, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.64 (P = 0.52)
4 Continuous selective hepatic vascular exclusion vs continuous portal triad clamping
Si-Yuan 2014 80 0.529 (0.79) 80 0.78 (0.79) 100.0 % -0.25 [ -0.49, 0.00 ]
Subtotal (95% CI) 80 80 100.0 % -0.25 [ -0.49, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.047)
5 Continuous selective portal triad clamping vs continuous portal triad clamping
Ni 2013 60 0.3 (0.8) 60 0.2 (0.8) 100.0 % 0.10 [ -0.19, 0.39 ]
Subtotal (95% CI) 60 60 100.0 % 0.10 [ -0.19, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
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Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[litres] N Mean(SD)[litres] IV,Random,95% CI IV,Random,95% CI
6 Intermittent portal triad clamping vs continuous portal triad clamping
Belghiti 1999 44 1.29 (0.9) 42 1.18 (0.8) 53.8 % 0.11 [ -0.25, 0.47 ]
Capussotti 2003 17 0.732 (0.64) 18 0.73 (0.52) 46.2 % 0.00 [ -0.39, 0.39 ]
Subtotal (95% CI) 61 60 100.0 % 0.06 [ -0.20, 0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
7 Intermittent portal triad clamping vs continuous selective portal triad clamping
Liang 2009 40 0.57 (0.29) 40 0.65 (0.28) 100.0 % -0.08 [ -0.20, 0.05 ]
Subtotal (95% CI) 40 40 100.0 % -0.08 [ -0.20, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
8 Intermittent selective portal triad clamping vs intermittent portal triad clamping
Figueras 2005 41 0.735 (0.4) 39 0.67 (0.53) 59.6 % 0.06 [ -0.14, 0.27 ]
Wu 2002 30 1.159 (1.21) 28 1.69 (0.9) 40.4 % -0.53 [ -1.07, 0.02 ]
Subtotal (95% CI) 71 67 100.0 % -0.17 [ -0.74, 0.39 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 3.92, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 6.9. Comparison 6 Methods of vascular occlusion, Outcome 9 Major blood loss (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 9 Major blood loss (proportion)
Study or subgroup Intervention Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intermittent portal triad clamping vs control
Lee 2012 5/63 4/63 1.27 [ 0.33, 4.97 ]
2 Continuous selective hepatic vascular exclusion vs continuous portal triad clamping
Si-Yuan 2014 2/80 7/80 0.27 [ 0.05, 1.33 ]
3 Continuous selective portal triad clamping vs continuous portal triad clamping
Ni 2013 0/60 1/60 0.33 [ 0.01, 8.21 ]
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Analysis 6.10. Comparison 6 Methods of vascular occlusion, Outcome 10 Total hospital stay.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 10 Total hospital stay
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
1 Intermittent portal triad clamping vs control
Capussotti 2006 63 8.9 (4.7) 63 8.6 (3.4) 44.9 % 0.30 [ -1.13, 1.73 ]
Lee 2012 63 8 (4.2) 63 7 (4.2) 42.8 % 1.00 [ -0.47, 2.47 ]
Man 1997 50 11 (12) 50 10 (12) 4.2 % 1.00 [ -3.70, 5.70 ]
Park 2012 25 15.8 (4.6) 25 19.3 (7.2) 8.2 % -3.50 [ -6.85, -0.15 ]
Subtotal (95% CI) 201 201 100.0 % 0.32 [ -0.64, 1.28 ]
Heterogeneity: Chi2 = 5.90, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 0.65 (P = 0.52)
2 Continuous portal triad clamping vs continuous hepatic vascular exclusion
Belghiti 1996 24 14 (6) 28 22 (12) 100.0 % -8.00 [ -13.05, -2.95 ]
Subtotal (95% CI) 24 28 100.0 % -8.00 [ -13.05, -2.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.10 (P = 0.0019)
3 Continuous selective hepatic vascular exclusion vs continuous portal triad clamping
Si-Yuan 2014 80 9.8 (3.7) 80 12.6 (4.8) 100.0 % -2.80 [ -4.13, -1.47 ]
Subtotal (95% CI) 80 80 100.0 % -2.80 [ -4.13, -1.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.13 (P = 0.000036)
4 Intermittent portal triad clamping vs continuous portal triad clamping
Belghiti 1999 44 15 (10) 42 14 (8) 100.0 % 1.00 [ -2.82, 4.82 ]
Subtotal (95% CI) 44 42 100.0 % 1.00 [ -2.82, 4.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
5 Intermittent portal triad clamping vs continuous selective portal triad clamping
Liang 2009 40 9.85 (3.55) 40 10.12 (2.41) 100.0 % -0.27 [ -1.60, 1.06 ]
Subtotal (95% CI) 40 40 100.0 % -0.27 [ -1.60, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
6 Intermittent selective portal triad clamping vs intermittent portal triad clamping
Figueras 2005 41 8.15 (3.8) 39 9.38 (4.9) 80.2 % -1.23 [ -3.16, 0.70 ]
Wu 2002 30 16.4 (7.7) 28 14.8 (7.4) 19.8 % 1.60 [ -2.29, 5.49 ]
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(. . . Continued)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 71 67 100.0 % -0.67 [ -2.40, 1.06 ]
Heterogeneity: Chi2 = 1.63, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 0.76 (P = 0.45)
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Analysis 6.11. Comparison 6 Methods of vascular occlusion, Outcome 11 ITU stay.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 11 ITU stay
Study or subgroup Intervention Control
Mean
Difference
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
1 Continuous selective hepatic vascular exclusion vs continuous portal triad clamping
Si-Yuan 2014 80 1.2 (0.5) 80 1.5 (1) -0.30 [ -0.54, -0.06 ]
-0.5 -0.25 0 0.25 0.5
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Analysis 6.12. Comparison 6 Methods of vascular occlusion, Outcome 12 Operating time.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 6 Methods of vascular occlusion
Outcome: 12 Operating time
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[minutes]N Mean(SD)[minutes] IV,Random,95% CI IV,Random,95% CI
1 Continuous portal triad clamping vs control
Clavien 1996 8 280 (76.4) 7 332.1 (58.2) 53.1 % -52.10 [ -120.38, 16.18 ]
Pietsch 2010 14 200.36 (71.1) 11 239.18 (105.5) 46.9 % -38.82 [ -111.44, 33.80 ]
Subtotal (95% CI) 22 18 100.0 % -45.87 [ -95.61, 3.87 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.071)
2 Intermittent portal triad clamping vs control
Lee 2012 63 240 (181.4) 63 252 (181.4) 37.5 % -12.00 [ -75.35, 51.35 ]
Park 2012 25 387.2 (44) 25 338.9 (39.3) 62.5 % 48.30 [ 25.17, 71.43 ]
Subtotal (95% CI) 88 88 100.0 % 25.66 [ -31.57, 82.89 ]
Heterogeneity: Tau2 = 1226.12; Chi2 = 3.07, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.88 (P = 0.38)
3 Continuous portal triad clamping vs continuous hepatic vascular exclusion
Belghiti 1996 24 301 (103) 28 366 (106) 36.9 % -65.00 [ -121.92, -8.08 ]
Chen 2006 58 124.5 (10.7) 60 133 (11.8) 63.1 % -8.50 [ -12.56, -4.44 ]
Subtotal (95% CI) 82 88 100.0 % -29.32 [ -82.75, 24.10 ]
Heterogeneity: Tau2 = 1172.31; Chi2 = 3.77, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 1.08 (P = 0.28)
4 Continuous selective hepatic vascular exclusion vs continuous portal triad clamping
Si-Yuan 2014 80 131.2 (181.4) 80 138.4 (181.4) 100.0 % -7.20 [ -63.42, 49.02 ]
Subtotal (95% CI) 80 80 100.0 % -7.20 [ -63.42, 49.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
5 Continuous selective portal triad clamping vs continuous portal triad clamping
Ni 2013 60 136 (45) 60 116 (65) 100.0 % 20.00 [ 0.00, 40.00 ]
Subtotal (95% CI) 60 60 100.0 % 20.00 [ 0.00, 40.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
6 Intermittent portal triad clamping vs continuous portal triad clamping
Capussotti 2003 17 241.7 (78.1) 18 228.3 (86.9) 100.0 % 13.40 [ -41.28, 68.08 ]
Subtotal (95% CI) 17 18 100.0 % 13.40 [ -41.28, 68.08 ]
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(. . . Continued)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[minutes]N Mean(SD)[minutes] IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
7 Intermittent portal triad clamping vs continuous selective portal triad clamping
Liang 2009 40 203.98 (38.36) 40 236.15 (49.2) 100.0 % -32.17 [ -51.50, -12.84 ]
Subtotal (95% CI) 40 40 100.0 % -32.17 [ -51.50, -12.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.26 (P = 0.0011)
8 Intermittent selective portal triad clamping vs intermittent portal triad clamping
Figueras 2005 41 219 (45) 39 207 (48) 84.9 % 12.00 [ -8.41, 32.41 ]
Wu 2002 30 399 (85.2) 28 409.2 (101.4) 15.1 % -10.20 [ -58.58, 38.18 ]
Subtotal (95% CI) 71 67 100.0 % 8.64 [ -10.16, 27.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
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Analysis 7.1. Comparison 7 Pharmacological interventions, Outcome 1 Mortality (perioperative).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 7 Pharmacological interventions
Outcome: 1 Mortality (perioperative)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Recombinant factor VIIa vs control
Lodge 2005 4/126 3/59 100.0 % 0.61 [ 0.13, 2.83 ]
Subtotal (95% CI) 126 59 100.0 % 0.61 [ 0.13, 2.83 ]
Total events: 4 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 Tranexamic acid vs control
Wu 2006 0/108 0/106 Not estimable
Subtotal (95% CI) 108 106 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Pharmacological interventions, Outcome 2 Serious adverse events (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 7 Pharmacological interventions
Outcome: 2 Serious adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Anti-thrombin III vs control
Shimada 1994 4/13 3/11 100.0 % 1.19 [ 0.20, 6.99 ]
Subtotal (95% CI) 13 11 100.0 % 1.19 [ 0.20, 6.99 ]
Total events: 4 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
2 Recombinant factor VIIa vs control
Lodge 2005 104/132 54/68 85.9 % 0.96 [ 0.47, 1.98 ]
Shao 2006 7/151 2/81 14.1 % 1.92 [ 0.39, 9.47 ]
Subtotal (95% CI) 283 149 100.0 % 1.10 [ 0.58, 2.09 ]
Total events: 111 (Intervention), 56 (Control)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
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Analysis 7.3. Comparison 7 Pharmacological interventions, Outcome 3 Serious adverse events (number).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 7 Pharmacological interventions
Outcome: 3 Serious adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Recombinant factor VIIa vs control
Lodge 2005 132 68 0.212175 (0.376386) 80.7 % 1.24 [ 0.59, 2.59 ]
Shao 2006 151 81 1.081917 (0.768706) 19.3 % 2.95 [ 0.65, 13.31 ]
Subtotal (95% CI) 283 149 100.0 % 1.46 [ 0.75, 2.84 ]
Heterogeneity: Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 1.13 (P = 0.26)
2 Tranexamic acid vs control
Wu 2006 108 106 -0.15222 (0.517549) 100.0 % 0.86 [ 0.31, 2.37 ]
Subtotal (95% CI) 108 106 100.0 % 0.86 [ 0.31, 2.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
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Analysis 7.4. Comparison 7 Pharmacological interventions, Outcome 4 Adverse events (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 7 Pharmacological interventions
Outcome: 4 Adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Anti-thrombin III vs control
Shimada 1994 4/13 5/11 100.0 % 0.53 [ 0.10, 2.84 ]
Subtotal (95% CI) 13 11 100.0 % 0.53 [ 0.10, 2.84 ]
Total events: 4 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
2 Recombinant factor VIIa vs control
Shao 2006 142/151 76/81 100.0 % 1.04 [ 0.34, 3.21 ]
Subtotal (95% CI) 151 81 100.0 % 1.04 [ 0.34, 3.21 ]
Total events: 142 (Intervention), 76 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
3 Tranexamic acid vs control
Wu 2006 14/108 17/106 100.0 % 0.78 [ 0.36, 1.67 ]
Subtotal (95% CI) 108 106 100.0 % 0.78 [ 0.36, 1.67 ]
Total events: 14 (Intervention), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.43, df = 2 (P = 0.80), I2 =0.0%
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Analysis 7.5. Comparison 7 Pharmacological interventions, Outcome 5 Adverse events (number).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 7 Pharmacological interventions
Outcome: 5 Adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Recombinant factor VIIa vs control
Lodge 2005 132 68 0.042199 (0.096326) 37.4 % 1.04 [ 0.86, 1.26 ]
Shao 2006 151 81 -0.05414 (0.074526) 62.6 % 0.95 [ 0.82, 1.10 ]
Subtotal (95% CI) 283 149 100.0 % 0.98 [ 0.87, 1.10 ]
Heterogeneity: Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
2 Tranexamic acid vs control
Wu 2006 108 106 -0.25231 (0.30708) 100.0 % 0.78 [ 0.43, 1.42 ]
Subtotal (95% CI) 108 106 100.0 % 0.78 [ 0.43, 1.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 0.56, df = 1 (P = 0.45), I2 =0.0%
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Analysis 7.6. Comparison 7 Pharmacological interventions, Outcome 6 Blood transfusion (proportion).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 7 Pharmacological interventions
Outcome: 6 Blood transfusion (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Aprotinin vs control
Lentschener 1997 8/48 19/49 100.0 % 0.32 [ 0.12, 0.82 ]
Subtotal (95% CI) 48 49 100.0 % 0.32 [ 0.12, 0.82 ]
Total events: 8 (Intervention), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
2 Desmopressin vs control
Wong 2003 3/30 5/30 100.0 % 0.56 [ 0.12, 2.57 ]
Subtotal (95% CI) 30 30 100.0 % 0.56 [ 0.12, 2.57 ]
Total events: 3 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
3 Recombinant factor VIIa vs control
Lodge 2005 41/126 23/59 47.8 % 0.75 [ 0.40, 1.44 ]
Shao 2006 63/155 29/76 52.2 % 1.11 [ 0.63, 1.95 ]
Subtotal (95% CI) 281 135 100.0 % 0.94 [ 0.62, 1.43 ]
Total events: 104 (Intervention), 52 (Control)
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.78)
4 Tranexamic acid vs control
Wu 2006 0/108 17/106 100.0 % 0.02 [ 0.00, 0.40 ]
Subtotal (95% CI) 108 106 100.0 % 0.02 [ 0.00, 0.40 ]
Total events: 0 (Intervention), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0093)
Test for subgroup differences: Chi2 = 10.15, df = 3 (P = 0.02), I2 =70%
0.002 0.1 1 10 500
Favours intervention Favours control
276Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.7. Comparison 7 Pharmacological interventions, Outcome 7 Blood transfusion (fresh frozen
plasma).
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 7 Pharmacological interventions
Outcome: 7 Blood transfusion (fresh frozen plasma)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[units] N Mean(SD)[units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Desmopressin vs control
Wong 2003 30 0.2 (0.7) 30 0.8 (2.1) 100.0 % -0.60 [ -1.39, 0.19 ]
Subtotal (95% CI) 30 30 100.0 % -0.60 [ -1.39, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 7.8. Comparison 7 Pharmacological interventions, Outcome 8 Blood loss.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 7 Pharmacological interventions
Outcome: 8 Blood loss
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[litres] N Mean(SD)[litres] IV,Fixed,95% CI IV,Fixed,95% CI
1 Aprotinin vs control
Lentschener 1997 48 1.217 (0.97) 49 1.65 (1.22) 100.0 % -0.44 [ -0.87, 0.00 ]
Subtotal (95% CI) 48 49 100.0 % -0.44 [ -0.87, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Not applicable
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Analysis 7.9. Comparison 7 Pharmacological interventions, Outcome 9 Hospital stay.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 7 Pharmacological interventions
Outcome: 9 Hospital stay
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
1 Tranexamic acid vs control
Wu 2006 108 8 (7.7) 106 9 (7.7) 100.0 % -1.00 [ -3.06, 1.06 ]
Subtotal (95% CI) 108 106 100.0 % -1.00 [ -3.06, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 7.10. Comparison 7 Pharmacological interventions, Outcome 10 Operating time.
Review: Methods to decrease blood loss during liver resection: a network meta-analysis
Comparison: 7 Pharmacological interventions
Outcome: 10 Operating time
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[minutes] N Mean(SD)[minutes] IV,Fixed,95% CI IV,Fixed,95% CI
1 Aprotinin vs control
Lentschener 1997 48 232 (75) 49 233 (71) 100.0 % -1.00 [ -30.08, 28.08 ]
Subtotal (95% CI) 48 49 100.0 % -1.00 [ -30.08, 28.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Different methods of cardiopulmonary interventions
Acute normovolemic haemodilution (ANH)
Low central venous pressure (central venous pressure)
Hypoventilation
Combination of ANH with central venous pressure or hypotension
Table 2. Different methods of parenchymal transection
Finger-fracture method
Clamp-crush method
Cavitron ultrasonic surgical aspirator
Sharp dissection
Radiofrequency dissecting sealer
Ultrasonic shears
Stapler
Waterjet (Hydrojet)
Table 3. Different methods of dealing with raw surface
Suturing for large and medium vessels and ducts and performing electrocauterisation of small vessels and ducts
Suturing for large vessels and performing ultrasonic shears for medium-sized and small vessels and ducts
Suturing and argon beam coagulator
Suturing and fibrin sealant
Suturing and collagen
Suturing and oxidised cellulose
Suturing and cyanoacrylate
Suturing and combination of fibrin sealant with collagen or oxidised cellulose
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Table 4. Different methods of vascular occlusion
No vascular occlusion
Portal triad clamping (continuous) (occlusion of inflow alone)
Portal triad clamping (intermittent) (occlusion of inflow alone)
Hepatic vascular exclusion (occlusion of inflow and outflow) (continuous or intermittent)
Selective portal trial clamping (occlusion of inflow to the hemi-liver that is being resected) (continuous or intermittent)
Selective hepatic vascular exclusion (occlusion of inflow to the hemi-liver and outflow from the hemi-liver that is being resected)
(continuous or intermittent)
Table 5. Clavien-Dindo classification of postoperative complications
Grades Definitions Examples
I Any deviation from the normal postoperative course with-
out the need for pharmacological treatment or surgical, en-
doscopic, or radiological interventions
Drugs such as antiemetics, antipyretics, analgesics, diuretics,
and electrolytes; physiotherapy; wound infections opened at
the bedside
II Requiring pharmacological treatment with drugs other than
those allowed for grade I complications
Blood transfusions, total parenteral nutrition
III Requiring surgical, endoscopic, or radiological intervention Bile leak requiring endoscopic stent; re-operation for any
cause; drainage of infected intra-abdominal collection
IV Life-threatening complication requiring high dependency or
intensive care management
Dialysis
V Death of patient -
Suffix d If the patient suffers from a complication at the time of dis-
charge and needs further follow-up to evaluate the compli-
cation fully
-
Adapted from Dindo 2004; Clavien 2009.
Table 6. Cardiopulmonary interventions: choice of model results
Blood transfusion (red blood cell) (units)
Treatment number Treatment name
1 Control
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Table 6. Cardiopulmonary interventions: choice of model results (Continued)
2 Acute normovolemic haemodilution
3 Acute normovolemic haemodilution plus hypotension
4 Acute normovolemic haemodilution plus low central venous pressure
5 Low central venous pressure
Fixed-effect model Random-effects model Inconsistency model
Dbara 2.68 −8.90 −9.80
pDb 10.05 12.67 11.96
DICc 12.73 3.77 2.17
d[2]d −1.23 (95% CrI−1.74 to−0.
73)
−1.26 (95% CrI −4.92 to 2.
39)
-
d[3]e −1.65 (95% CrI−2.06 to−1.
25)
−1.68 (95% CrI −5.33 to 1.
98)
-
d[4]f 0.15 (95% CrI −0.10 to 0.40) −0.57 (95% CrI −3.35 to 1.
88)
-
d[5]g −0.81 (95% CrI−1.33 to−0.
30)
−1.08 (95% CrI −3.43 to 1.
13)
-
Between-study standard devia-
tion
- 1.446
Model used Random-effects model
Evidence of inconsistency There is no evidence of inconsistency since the difference in DIC between consistency and incon-
sistency models was not significant
Blood loss (litres)
Treatment number Treatment name
1 Control
2 Acute normovolemic haemodilution
3 Acute normovolemic haemodilution plus hypotension
4 Acute normovolemic haemodilution plus low central venous pressure
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Table 6. Cardiopulmonary interventions: choice of model results (Continued)
5 Hypoventilation
6 Low central venous pressure
Fixed-effect model Random-effects model Inconsistency model
Dbara −24.73 −36.06 −36.65
pDb 14.00 17.77 18.26
DICc −10.73 −18.29 −18.39
d[2]d 0.00 (95% CrI −0.10 to 0.10) 0.00 (95% CrI −0.95 to 0.96) -
d[3]e −0.25 (95% CrI−0.37 to−0.
13)
−0.25 (95% CrI −1.20 to 0.
71)
-
d[4]f 0.01 (95% CrI −0.04 to 0.07) −0.10 (95% CrI −0.88 to 0.
46)
-
d[5]g 0.00 (95% CrI −1.12 to 1.12) −0.01 (95% CrI −1.44 to 1.
43)
-
d[6]h −0.29 (95% CrI−0.40 to−0.
18)
−0.32 (95% CrI −0.86 to 0.
09)
-
Between-study standard devia-
tion
- 0.3734 -
Model used Random-effects model
Evidence of inconsistency There is no evidence of inconsistency since the difference in DIC between consistency and incon-
sistency models was not significant
aDbar = posterior mean of deviance.
bpD = effective number of parameters.
cDIC = deviance information criterion.
dd[2] indicates effect estimate (mean difference) of treatment 2 versus treatment 1.
ed[3] indicates effect estimate (mean difference) of treatment 3 versus treatment 1.
f d[4] indicates effect estimate (mean difference) of treatment 4 versus treatment 1.
gd[5] indicates effect estimate (mean difference) of treatment 5 versus treatment 1.
hd[6] indicates effect estimate (mean difference) of treatment 6 versus treatment 1.
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Table 7. Parenchymal transection methods: choice of model results
Adverse events (proportion)
Treatment number Treatment name
1 Clamp-crush method
2 Cavitron ultrasonic surgical aspirator
3 Hydrojet
4 Radiofrequency dissecting sealer
5 Sharp transection method
6 Stapler
Fixed-effect model Random-effects model Inconsistency model*
Dbara 95.62 80.26 81.67
pDb 13.05 17.04 16.71
DICc 108.67 97.30 98.37
d[2]d 0.32 (95% CrI −0.28 to 0.92) 0.76 (95% CrI −2.18 to 4.69) -
d[3]e −0.99 (95% CrI −2.76 to 0.
54)
−0.56 (95% CrI −6.84 to 6.
60)
-
d[4]f 0.11 (95% CrI −0.46 to 0.68) 0.19 (95% CrI −2.95 to 3.50) -
d[5]g 0.10 (95% CrI −0.79 to 1.00) 0.1 (95% CrI −5.59 to 5.80) -
d[6]h 0.06 (95% CrI −0.63 to 0.76) 0.06 (95% CrI −5.59 to 5.76) -
Between-study standard devia-
tion
- 2.436 -
Model used Random-effects model
Evidence of inconsistency There is no evidence of inconsistency since the difference in DIC between consistency and incon-
sistency models was not significant
Adverse events (number)
Treatment number Treatment name
1 Clamp-crush method
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Table 7. Parenchymal transection methods: choice of model results (Continued)
2 Cavitron ultrasonic surgical aspirator
3 Hydrojet
4 Radiofrequency dissecting sealer
5 Sharp transection method
6 Stapler
Fixed-effect model Random-effects model Inconsistency model*
Dbara 80.99 80.94 79.59
pDb 11.93 11.88 14.76
DICc 92.92 92.83 94.35
d[2]d 0.47 (95% CrI −0.08 to 1.03) 0.47 (95% CrI −0.08 to 1.03) -
d[3]e 0.34 (95% CrI −0.71 to 1.29) 0.33 (95% CrI −0.71 to 1.28) -
d[4]f 0.61 (95% CrI 0.12 to 1.12) 0.61 (95% CrI 0.12 to 1.11) -
d[5]g 0.12 (95% CrI −0.56 to 0.81) 0.12 (95% CrI −0.56 to 0.81) -
d[6]h 0.62 (95% CrI −0.21 to 1.48) 0.62 (95% CrI −0.20 to 1.45) -
Between-study standard devia-
tion
- 2.499 -
Model used Fixed-effect model -
Evidence of inconsistency There is no evidence of inconsistency since the difference in DIC between consistency and incon-
sistency models was not significant
Blood transfusion (proportion)
Treatment number Treatment name
1 Clamp-crush method
2 Cavitron ultrasonic surgical aspirator
3 Hydrojet
4 Radiofrequency dissecting sealer
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Table 7. Parenchymal transection methods: choice of model results (Continued)
5 Sharp transection method
Fixed-effect model Random-effects model Inconsistency model*
Dbara 72.41 71.86 72.23
pDb 11.91 13.99 14.98
DICc 84.33 85.85 87.21
d[2]d 0.39 (95% CrI −0.62 to 1.42) 0.42 (95% CrI −1.09 to 1.96) -
d[3]e 0.55 (95% CrI −0.75 to 1.83) 0.60 (95% CrI −1.47 to 2.83) -
d[4]f 0.09 (95% CrI −0.50 to 0.68) 0.14 (95% CrI −0.77 to 1.32) -
d[5]g −0.22 (95% CrI −1.16 to 0.
71)
−0.22 (95% CrI −2.21 to 1.
75)
-
Between-study standard devia-
tion
- 0.6464 -
Model used Fixed-effect model -
Evidence of inconsistency There is no evidence of inconsistency since the difference in DIC between consistency and incon-
sistency models was not significant
aDBar = posterior mean of deviance.
bpD = effective number of parameters.
cDIC = deviance information criterion.
dd[2] indicates log transformed effect estimate (odds ratio or rate ratio) of treatment 2 versus treatment 1.
ed[3] indicates log transformed effect estimate (odds ratio or rate ratio) of treatment 3 versus treatment 1.
f d[4] indicates log transformed effect estimate (odds ratio or rate ratio) of treatment 4 versus treatment 1.
gd[5] indicates log transformed effect estimate (odds ratio or rate ratio) of treatment 5 versus treatment 1.
hd[6] indicates log transformed effect estimate (odds ratio or rate ratio) of treatment 6 versus treatment 1.
Table 8. Vascular occlusion methods: choice of model results
Serious adverse events (proportion)
Treatment number Treatment name
1 Control
2 ConHVE
3 ConPTC
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Table 8. Vascular occlusion methods: choice of model results (Continued)
4 ConSelectiveHVE
5 ConSelectivePTC
6 IntPTC
Fixed-effect model Random-effects model Inconsistency model
Dbara 64.25 63.57 64.03
pDb 12.54 14.37 14.83
DICc 76.79 77.95 78.86
d[2]d 0.82 (95% CrI −1.70 to 3.50) 0.62 (95% CrI −5.00 to 5.89) -
d[3]e 0.35 (95% CrI −1.26 to 1.96) 0.16 (95% CrI −3.87 to 3.71) -
d[4]f −1.98 (95% CrI −8.24 to 1.
48)
−2.25 (95% CrI −9.99 to 3.
38)
-
d[5]g −0.63 (95% CrI −2.29 to 0.
97)
−1.01 (95% CrI −5.35 to 2.
36)
-
d[6]h 0.15 (95% CrI −0.61 to 0.92) −0.07 (95% CrI −2.53 to 1.
85)
-
Between-study standard devia-
tion
- 1.216 -
Model used Fixed-effect model
Evidence of inconsistency There is no evidence of inconsistency since the difference in DIC between consistency and incon-
sistency models was not significant
Adverse events (proportion)
Treatment number Treatment name
1 Control
2 ConHVE
3 ConPTC
4 ConSelectiveHVE
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Table 8. Vascular occlusion methods: choice of model results (Continued)
5 ConSelectivePTC
6 IntPTC
7 IntSelectivePTC
Fixed-effect model Random-effects model Inconsistency model
Dbara 120.82 118.76 119.07
pDb 18.10 21.01 21.93
DICc 138.92 139.77 141.00
d[2]d 0.95 (95% CrI −0.21 to 2.12) 0.90 (95% CrI −1.12 to 2.84) -
d[3]e 0.83 (95% CrI 0.00 to 1.69) 0.78 (95% CrI −0.58 to 2.09) -
d[4]f 0.05 (95% CrI −1.19 to 1.27) 0.00 (95% CrI −2.05 to 1.96) -
d[5]g 0.10 (95% CrI −0.81 to 1.01) 0.07 (95% CrI −1.42 to 1.50) -
d[6]h 0.24 (95% CrI −0.19 to 0.68) 0.18 (95% CrI −0.66 to 0.88) -
d[7]i 0.09 (95% CrI −0.75 to 0.93) 0.04 (95% CrI −1.37 to 1.35) -
Between-study standard devia-
tion
- 0.4825 -
Model used Fixed-effect model
Evidence of inconsistency There is no evidence of inconsistency since the difference in DIC between consistency and incon-
sistency models was not significant
Blood transfusion (proportion)
Treatment number Treatment name
1 Control
2 ConHVE
3 ConPTC
4 ConSelectiveHVE
5 ConSelectivePTC
6 IntPTC
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Table 8. Vascular occlusion methods: choice of model results (Continued)
7 IntSelectivePTC
Fixed-effect model Random-effects model Inconsistency model
Dbara 139.87 120.00 120.10
pDb 19.04 25.25 25.72
DICc 158.91 145.25 145.82
d[2]d −2.55 (95% CrI−3.80 to−1.
36)
−2.88 (95% CrI −7.47 to 1.
47)
-
d[3]e −0.77 (95% CrI −1.56 to 0.
01)
−1.11 (95% CrI −3.72 to 1.
28)
-
d[4]f −1.46 (95% CrI−2.58 to−0.
36)
−1.79 (95% CrI −6.38 to 2.
53)
-
d[5]g −0.26 (95% CrI −1.18 to 0.
67)
−0.48 (95% CrI −3.83 to 2.
72)
-
d[6]h −0.34 (95% CrI −0.84 to 0.
16)
−0.47 (95% CrI −2.32 to 1.
28)
-
d[7]i −0.92 (95% CrI −1.96 to 0.
08)
−0.97 (95% CrI −4.24 to 2.
24)
-
Between study standard devia-
tion
- 1.613 -
Model used Random-effects model
Evidence of inconsistency There is no evidence of inconsistency since the difference in DIC between consistency and incon-
sistency models was not significant
Blood transfusion (red blood cell) (units)
Treatment number Treatment name
1 Control
2 ConHVE
3 ConPTC
4 ConSelectiveHVE
5 ConSelectivePTC
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Table 8. Vascular occlusion methods: choice of model results (Continued)
6 IntPTC
7 IntSelectivePTC
Fixed-effect model Random-effects model Inconsistency model
Dbara −1.55 −1.05 0.24
pDb 15.99 17.36 19.34
DICc 14.44 16.32 19.58
d[2]d −1.65 (95% CrI −3.96 to 0.
67)
−1.56 (95% CrI −4.18 to 1.
14)
-
d[3]e −1.25 (95% CrI−2.39 to−0.
10)
−1.18 (95% CrI −2.54 to 0.
31)
-
d[4]f −2.45 (95% CrI−4.08 to−0.
82)
−2.37 (95% CrI−4.33 to−0.
30)
-
d[5]g −1.45 (95% CrI−2.59 to−0.
31)
−1.41 (95% CrI −2.86 to 0.
12)
-
d[6]h −1.36 (95% CrI−2.48 to−0.
23)
−1.35 (95% CrI −2.69 to 0.
01)
-
d[7]i −1.43 (95% CrI−2.61 to−0.
24)
−1.43 (95% CrI −3.01 to 0.
08)
-
Between-study standard devia-
tion
- 0.3149 -
Model used Fixed-effect model
Evidence of inconsistency There is no evidence of inconsistency since the difference in DIC between consistency and incon-
sistency models was not significant
Blood loss (litres)
Treatment number Treatment name
1 Control
2 ConHVE
3 ConPTC
4 ConSelectiveHVE
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Table 8. Vascular occlusion methods: choice of model results (Continued)
5 ConSelectivePTC
6 IntPTC
7 IntSelectivePTC
Fixed-effect model Random-effects model Inconsistency model
Dbara −45.73 −61.66 −63.13
pDb 22.01 29.37 30.58
DICc −23.72 −32.29 −32.55
d[2]d −0.36 (95% CrI−0.50 to−0.
23)
−0.37 (95% CrI −0.94 to 0.
22)
-
d[3]e −0.02 (95% CrI −0.12 to 0.
07)
−0.14 (95% CrI −0.52 to 0.
14)
-
d[4]f −0.27 (95% CrI−0.54 to−0.
01)
−0.39 (95% CrI −1.16 to 0.
27)
-
d[5]g 0.09 (95% CrI −0.04 to 0.21) 0.00 (95% CrI −0.57 to 0.45) -
d[6]h 0.01 (95% CrI −0.05 to 0.07) −0.06 (95% CrI −0.39 to 0.
17)
-
d[7]i 0.00 (95% CrI −0.21 to 0.2) −0.18 (95% CrI −0.84 to 0.
30)
-
Between-study standard devia-
tion
- 0.2539 -
Model used Random-effects model
Evidence of inconsistency There is no evidence of inconsistency since the difference in DIC between consistency and incon-
sistency models was not significant
Con: continuous; Int: intermittent; HVE: hepatic vascular exclusion; PTC: portal triad clamping.
aDBar = posterior mean of deviance.
bpD = effective number of parameters.
cDIC = deviance information criterion.
dd[2] indicates effect estimate (mean difference) of treatment 2 versus treatment 1.
ed[3] indicates effect estimate (mean difference) of treatment 3 versus treatment 1.
f d[4] indicates effect estimate (mean difference) of treatment 4 versus treatment 1.
gd[5] indicates effect estimate (mean difference) of treatment 5 versus treatment 1.
hd[6] indicates effect estimate (mean difference) of treatment 6 versus treatment 1.
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id[7] indicates effect estimate (mean difference) of treatment 7 versus treatment 1.
Table 9. Cardiopulmonary interventions: pair-wise comparisonsa,b
Blood transfusion (red blood cell) (units)
Acute normovolemic
haemodilution
Acute normo-
volemic haemodilution
plus hypotension
Acute normo-
volemic haemodilution
plus low central venous
pressure
Low central venous
pressure
Control MD −1.26; 95% CrI
−4.92 to 2.39
MD −1.68; 95% CrI
−5.33 to 1.98
MD −0.57; 95% CrI
−3.35 to 1.88
MD −1.08; 95% CrI
−3.43 to 1.13
Acute normovolemic
haemodilution
- MD −0.42; 95% CrI
−5.59 to 4.75
MD 0.69; 95% CrI −3.
80 to 5.18
MD 0.18; 95% CrI −4.
12 to 4.49
Acute normo-
volemic haemodilution
plus hypotension
- - MD 1.11; 95% CrI −3.
39 to 5.60
MD 0.60; 95% CrI −3.
71 to 4.91
Acute normo-
volemic haemodilution
plus low central venous
pressure
- - - MD −0.51; 95% CrI
−3.97 to 2.96
Blood loss (litres)
Acute normovolemic
haemodilution
Acute normo-
volemic haemodilution
plus hypotension
Acute normo-
volemic haemodilution
plus low central venous
pressure
Hypoventilation
Control MD 0.00; 95% CrI −0.
95 to 0.96
MD −0.25; 95% CrI
−1.20 to 0.71
MD −0.10; 95% CrI
−0.88 to 0.46
MD −0.01; 95% CrI
−1.44 to 1.43
Acute normovolemic
haemodilution
- MD −0.25; 95% CrI
−1.60 to 1.10
MD −0.11; 95% CrI
−1.27 to 1.06
MD −0.01; 95% CrI
−1.73 to 1.71
Acute normo-
volemic haemodilution
plus hypotension
- - MD 0.14; 95% CrI −1.
02 to 1.31
MD 0.24; 95% CrI −1.
48 to 1.96
Acute normo-
volemic haemodilution
plus low central venous
pressure
- - - MD 0.10; 95% CrI −1.
49 to 1.68
Hypoventilation - - - -
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aThe table provides the effect estimate of each pair-wise comparison. To identify the effect estimate of a comparison (e.g. A versus B),
look at the cell that occupies the column corresponding to treatment A and the row corresponding to treatment B. This gives the
information directly. If that cell is empty (indicated by a ’-’, you have to look at column corresponding to treatment B and row
corresponding to treatment A. You will have to take the inverse of this number (i.e. 1/number) to get the treatment effect.
bTreatment effects with evidence of difference are shown by italics (not applicable).
Table 10. Parenchymal transection methods: pair-wise comparisonsa,b
Adverse events (proportion)
Cavitron ultrasonic
surgical aspirator
Hydrojet Radiofrequency
dissecting sealer
Sharp transection
method
Clamp-crush method OR 2.15; 95% CrI 0.11
to 108.74
OR 0.57; 95% CrI 0.00
to 732.89
OR 1.20; 95% CrI 0.05
to 33.05
OR 1.11; 95% CrI 0.00
to 331.29
Cavitron ultrasonic
surgical aspirator
- OR 0.27; 95% CrI 0.00
to 501.34
OR 0.56; 95% CrI 0.01
to 62.38
OR 0.52; 95% CrI 0.00
to 398.54
Hydrojet - - OR 2.12; 95% CrI 0.00
to 3638.36
OR 1.94; 95% CrI 0.00
to 12959.09
Radiofrequency
dissecting sealer
- - - OR 0.92; 95% CrI 0.00
to 638.06
Sharp transection
method
- - - -
Adverse events (number)
Cavitron ultrasonic
surgical aspirator
Hydrojet Radiofrequency
dissecting sealer
Sharp transection
method
Clamp-crush method rate ratio 1.60; 95% CrI
0.92 to 2.79
rate ratio 1.40; 95% CrI
0.49 to 3.63
rate ratio 1.84; 95% CrI
1.13 to 3.06
rate ratio 1.13; 95% CrI
0.57 to 2.24
Cavitron ultrasonic
surgical aspirator
- rate ratio 0.88; 95% CrI
0.28 to 2.75
rate ratio 1.15; 95% CrI
0.54 to 2.42
rate ratio 0.71; 95% CrI
0.29 to 1.71
Hydrojet - - rate ratio 1.31; 95% CrI
0.43 to 4.01
rate ratio 0.81; 95% CrI
0.24 to 2.71
Radiofrequency
dissecting sealer
- - - rate ratio 0.62; 95% CrI
0.26 to 1.44
Sharp transection
method
- - - -
Blood transfusion (proportion)
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Table 10. Parenchymal transection methods: pair-wise comparisonsa,b (Continued)
Cavitron ultrasonic
surgical aspirator
Hydrojet Radiofrequency
dissecting sealer
Sharp transection
method
Clamp-crush method OR 1.48; 95% CrI 0.54
to 4.13
OR 1.73; 95% CrI 0.47
to 6.25
OR 1.09; 95% CrI 0.61
to 1.97
OR 0.80; 95% CrI 0.31
to 2.03
Cavitron ultrasonic
surgical aspirator
- OR 1.17; 95% CrI 0.23
to 6.05
OR 0.74; 95% CrI 0.23
to 2.39
OR 0.54; 95% CrI 0.14
to 2.15
Hydrojet - - OR 0.63; 95% CrI 0.15
to 2.61
OR 0.46; 95% CrI 0.09
to 2.27
Radiofrequency
dissecting sealer
- - - OR 0.73; 95% CrI 0.24
to 2.21
aThe table provides the effect estimate of each pair-wise comparison. To identify the effect estimate of a comparison (e.g. A versus B),
look at the cell that occupies the column corresponding to treatment A and the row corresponding to treatment B. This gives the
information directly. If that cell is empty (indicated by a ’-’, you have to look at column corresponding to treatment B and row
corresponding to treatment A. You will have to take the inverse of this number (i.e. 1/number) to get the treatment effect.
bTreatment effects with evidence of difference are shown by italics (not applicable).
Table 11. Vascular occlusion methods: pair-wise comparisonsa,b
Serious adverse events (proportion)
ConHVE ConPTC ConSelectiveHVE ConSelectivePTC IntPTC
Control OR 2.27; 95% CrI
0.18 to 33.05
OR 1.42; 95% CrI
0.28 to 7.09
OR 0.14; 95% CrI
0.00 to 4.37
OR 0.53; 95% CrI
0.10 to 2.65
OR 1.16; 95% CrI
0.54 to 2.51
ConHVE - OR 0.63; 95% CrI
0.03 to 13.31
OR 0.06; 95% CrI
0.00 to 15.06
OR 0.23; 95% CrI
0.01 to 5.02
OR 0.51; 95% CrI
0.03 to 7.68
ConPTC - - OR 0.10; 95% CrI
0.00 to 16.28
OR 0.37; 95% CrI
0.04 to 3.70
OR 0.82; 95% CrI
0.14 to 4.86
ConSelectiveHVE - - - Not estimable Not estimable
ConSelectivePTC - - - - OR 2.19; 95% CrI
0.36 to 13.26
Adverse events (proportion)
ConHVE ConPTC ConSelectiveHVE ConSelectivePTC IntPTC
Control OR 2.58; 95% CrI
0.81 to 8.30
OR 2.30; 95% CrI
1.00 to 5.41
OR 1.06; 95% CrI
0.31 to 3.58
OR 1.11; 95% CrI
0.45 to 2.75
OR 1.28; 95% CrI
0.83 to 1.97
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Table 11. Vascular occlusion methods: pair-wise comparisonsa,b (Continued)
ConHVE - OR 0.89; 95% CrI
0.21 to 3.75
OR 0.41; 95% CrI
0.08 to 2.22
OR 0.43; 95% CrI
0.10 to 1.88
OR 0.49; 95% CrI
0.14 to 1.71
ConPTC - - OR 0.46; 95% CrI
0.10 to 2.04
OR 0.48; 95% CrI
0.14 to 1.67
OR 0.55; 95% CrI
0.21 to 1.43
ConSelectiveHVE - - - OR 1.05; 95% CrI
0.23 to 4.84
OR 1.21; 95% CrI
0.33 to 4.45
ConSelectivePTC - - - - OR 1.15; 95% CrI
0.42 to 3.16
IntPTC - - - - -
Blood transfusion (proportion)
ConHVE ConPTC ConSelectiveHVE ConSelectivePTC IntPTC
Control OR 0.06; 95% CrI
0.00 to 4.33
OR 0.33; 95% CrI
0.02 to 3.59
OR 0.17; 95% CrI
0.00 to 12.59
OR 0.62; 95% CrI
0.02 to 15.18
OR 0.63; 95% CrI
0.10 to 3.59
ConHVE - Not estimable Not estimable Not estimable Not estimable
ConPTC - - OR 0.51; 95% CrI
0.00 to 83.52
Not estimable OR 1.89; 95% CrI
0.09 to 41.17
ConSelectiveHVE - - - Not estimable Not estimable
ConSelectivePTC - - - - OR 1.01; 95% CrI
0.02 to 42.32
IntPTC - - - - -
Blood transfusion (red blood cell)
ConHVE ConPTC ConSelectiveHVE ConSelectivePTC IntPTC
Control MD −1.65; 95%
CrI −3.96 to 0.67
MD −1.25; 95%
CrI−2.39 to−0.10
MD −2.45; 95%
CrI−4.08 to−0.82
MD −1.45; 95%
CrI−2.59 to−0.31
MD −1.36; 95%
CrI−2.48 to−0.23
ConHVE - MD 0.40; 95% CrI
−2.18 to 2.98
MD −0.80; 95%
CrI −3.64 to 2.03
MD 0.20; 95% CrI
−2.39 to 2.78
MD 0.29; 95% CrI
−2.29 to 2.86
ConPTC - - MD −1.20; 95%
CrI −3.20 to 0.79
MD −0.20; 95%
CrI −1.82 to 1.42
MD −0.11; 95%
CrI −1.72 to 1.50
ConSelectiveHVE - - - MD 1.00; 95% CrI
−0.99 to 2.99
MD 1.09; 95% CrI
−0.89 to 3.07
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Table 11. Vascular occlusion methods: pair-wise comparisonsa,b (Continued)
ConSelectivePTC - - - - MD 0.09; 95% CrI
−1.51 to 1.70
IntPTC - - - - -
Blood loss
- ConHVE ConPTC ConSelectiveHVE ConSelectivePTC IntPTC
Control MD −0.37; 95%
CrI −0.94 to 0.22
MD −0.14; 95%
CrI −0.52 to 0.14
MD −0.39; 95%
CrI −1.16 to 0.27
MD 0.00; 95% CrI
−0.57 to 0.45
MD −0.06; 95%
CrI −0.39 to 0.17
ConHVE - MD 0.23; 95% CrI
−0.44 to 0.90
MD −0.02; 95%
CrI −0.94 to 0.90
MD 0.37; 95% CrI
−0.41 to 1.14
MD 0.31; 95% CrI
−0.34 to 0.95
ConPTC - - MD −0.25; 95%
CrI −1.04 to 0.54
MD 0.14; 95% CrI
−0.47 to 0.74
MD 0.08; 95% CrI
−0.35 to 0.52
ConSelectiveHVE - - - MD 0.39; 95% CrI
−0.49 to 1.26
MD 0.33; 95% CrI
−0.44 to 1.10
ConSelectivePTC - - - - MD −0.06; 95%
CrI −0.64 to 0.52
IntPTC - - - - -
Con: continuous; Int: intermittent; HVE: hepatic vascular exclusion; PTC: portal triad clamping.
aThe table provides the effect estimate of each pair-wise comparison. To identify the effect estimate of a comparison (e.g. A versus B),
look at the cell that occupies the column corresponding to treatment A and the row corresponding to treatment B. This gives the
information directly. If that cell is empty (indicated by a ’ -’, you have to look at column corresponding to treatment B and row
corresponding to treatment A. You will have to take the inverse of this number (i.e. 1/number) to get the treatment effect.
bTreatment effects with evidence of difference are shown by italics.
Table 12. Intervention and control (ordered by category and comparisons)
Study Intervention Co-interventions
Interven-
tion
Control Other in-
forma-
tion
Type
of inter-
vention
Vascu-
lar occlu-
sion
Parenchy-
mal tran-
section
method
Raw sur-
face
Pharma-
cological
methods
Car-
diopul-
monary
methods
Autolo-
gous
transfu-
sion
Capus-
sotti
2012
Anterior
approach
Control - Anterior
approach
Not
stated
Clamp-
crush,
bipolar
dissecting
Not
stated
Not
stated
Not
stated
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
sealer
Liu 2006 Anterior
approach
Control - Anterior
approach
Not
stated
Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Not
stated
Not
stated
Not
stated
Not
stated
Kajikawa
1994
Autolo-
gous
blood do-
nation
Control Note: au-
tologous
blood do-
nation
group
was fur-
ther ran-
domised
to recom-
bi-
nant ery-
thropoi-
etin and
no
erythro-
poietin
Autolo-
gous
transfu-
sion
Not
stated
Not
stated
Not
stated
Not
stated
Not
stated
Factor be-
ing ran-
domised
Kostopana-
giotou
2007
Autolo-
gous
blood do-
nation
Control Autolo-
gous
blood do-
nation: 2
units
of blood
were
with-
drawn be-
fore
surgery
Autolo-
gous
transfu-
sion
Hepatic
vascular
exclusion
Not
stated
Not
stated
Not
stated
Not
stated
Factor be-
ing ran-
domised
Guo
2013
Acute
normov-
olemic
haemodi-
lu-
tion plus
low cen-
tral
venous
pressure
Control Acute
normo-
volemic
dilution
plus low
central
venous
pressure:
blood
with-
drawn to
a target
Car-
diopul-
monary
methods
Not
stated
Not
stated
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
of 28%
haemat-
ocrit and
replaced
with
fluid.
Target for
central
venous
pressure
was not
reported
Jarnagin
2008
Acute
normov-
olemic
haemodi-
lu-
tion plus
low cen-
tral
venous
pressure
Low cen-
tral
venous
pressure
Acute
normov-
olemic
haemodi-
lution:
blood was
with-
drawn
and re-
placed by
colloids
and crys-
talloids to
reach
a haema-
tocrit tar-
get of 8
gm/dL.
Low cen-
tral
venous
pres-
sure was
main-
tained <
5 H20 us-
ing fluid
restric-
tion
and phar-
maco-
logic ma-
nipula-
tion
Car-
diopul-
monary
methods
Intermit-
tent por-
tal triad
clamping
Not
stated
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
Matot
2002
Acute
normov-
olemic
haemodi-
lu-
tion plus
low cen-
tral
venous
pressure
Low cen-
tral
venous
pressure
Acute
normo-
volemic
haemod-
ilution:
blood
was with-
drawn
and re-
placed by
colloids
to reach
a haema-
tocrit
target of
24%.
Low cen-
tral
venous
pres-
sure was
achieved
by fluid
restric-
tion
Car-
diopul-
monary
methods
Not
stated
Not
stated
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Yao 2006 Acute
normov-
olemic
haemodi-
lution
Acute
normov-
olemic
haemodi-
lu-
tion with
hypoten-
sion
3rd
group:
control
Acute
normo-
volemic
haemod-
ilution:
with-
drawal
of blood
and
replace-
ment
with
fluids to
maintain
a target
haemat-
ocrit of
30%.
Acute
normo-
volemic
haemod-
Car-
diopul-
monary
methods
Not
stated
Not
stated
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
ilution
with con-
trolled
hypoten-
sion: in
addition
to acute
normo-
volemic
haemod-
ilution,
sodium
nitro-
prusside
was used.
Target
blood
pressure
not
known
Hasegawa
2002
Hy-
poventi-
lation
Control - Car-
diopul-
monary
methods
Intermit-
tent por-
tal triad
clamp-
ing or se-
lective oc-
clusion
Clamp
crush
or cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Not
stated
Not
stated
Factor be-
ing ran-
domised
None
Choi
2007
Low cen-
tral
venous
pressure
Control Low cen-
tral
venous
pressure:
by re-
stricting
flow from
legs
Car-
diopul-
monary
methods
Not
stated
Not
stated
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
El-
Khar-
boutly
2004
Low cen-
tral
venous
pressure
Control Low cen-
tral
venous
pressure:
nitroglyc-
erine
Car-
diopul-
monary
interven-
tion
Intermit-
tent por-
tal triad
clamping
Not
stated
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Kato
2008
Low cen-
tral
venous
pressure
Control Low cen-
tral
venous
pressure:
by infe-
Car-
diopul-
monary
methods
Intermit-
tent por-
tal triad
clamping
Cavit-
ron ultra-
sonic sur-
gical aspi-
Fibrin
glue used
Not
stated
Factor be-
ing ran-
domised
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
rior IVC
clamping
rator
Wang
2006
Low cen-
tral
venous
pressure
Control Low
central
venous
pressure:
by limit-
ing fluid,
nitroglyc-
erine, and
furosemide
Car-
diopul-
monary
methods
Varied Clamp-
crush
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Guo
2014
Low cen-
tral
venous
pressure
Low cen-
tral
venous
pressure +
acute
normov-
olemic
haemodi-
lution.
3rd
group:
control
Low cen-
tral
venous
pressure:
fluid re-
striction
andnitro-
glycerine.
Acute
normo-
volemic
haemod-
ilution
plus low
central
venous
pressure:
with-
drawal of
blood to
a target
haemat-
ocrit of
30% and
replace-
ment
with
colloids
Car-
diopul-
monary
methods
Not
stated
Not
stated
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Rahbari
2014
Stapler Clamp-
crush
method
Sta-
pler: Au-
tosuture
Endo-
GIA sta-
pler (Co-
vidien)
Parenchu-
mal tran-
section
Variable Factor be-
ing ran-
domised
Variable Not
stated
Low cen-
tral
venous
pressure
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
Koo 2005 Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Clamp-
crush
method
-
Parenchy-
mal tran-
section
No vascu-
lar occlu-
sion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
Takayama
2001
Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Clamp-
crush
method
-
Parenchy-
mal tran-
section
Intermit-
tent total
or selec-
tive por-
tal triad
clamping
Factor be-
ing ran-
domised
Fibrin
glue used
Not
stated
Not
stated
Not
stated
Doklestic
2012
Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Clamp-
crush
method
3rd
group: ra-
diofre-
quency
dissecting
sealer
Ultra-
sonic dis-
sec-
tor: cavit-
ron ultra-
sonic sur-
gical aspi-
rator.
Radiofre-
quency
dissect-
ing sealer:
Ligasure
Parenchy-
mal tran-
section
Intermit-
tent por-
tal triad
clamping
Factor be-
ing ran-
domised
Not
stated
Not
stated
Low cen-
tral
venous
pressure
Not
stated
Rau 2001 Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Hydrojet Hydrojet:
Jet Cutter Parenchy-
mal tran-
section
Portal
triad
clamping
Factor be-
ing ran-
domised
Variable Not
stated
Not
stated
Not
stated
Savlid
2013
Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Stapler Stapler:
Endosta-
pler (Co-
vidien)
Parenchy-
mal tran-
section
Variable Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
Lesurtel
2005
Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Radiofre-
quency
dissecting
sealer.
3rd
group:
hydrojet
Radiofre-
quency
dissect-
ing sealer:
Tissue
Link
Hydrojet:
HelixHy-
dro-Jet
A
Parenchy-
mal tran-
section
No vascu-
lar occlu-
sion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
4th group
with
clamp-
crush and
vascu-
lar occlu-
sion was
excluded
since
there was
difference
in the co-
interven-
tion be-
tween the
groups
Ikeda
2009
Radiofre-
quency
dissecting
sealer
Clamp-
crush
method
Radiofre-
quency
dissect-
ing sealer:
Ligasure
Parenchy-
mal tran-
section
Intermit-
tent por-
tal triad
clamping
or hemi-
hepatic
occlusion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
No
Lupo
2007
Radiofre-
quency
dissecting
sealer
Clamp-
crush
method
Radiofre-
quency
dissect-
ing sealer:
Radion-
ics
needles
Parenchy-
mal tran-
section
No vascu-
lar occlu-
sion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
Muratore
2014
Radiofre-
quency
dissecting
sealer
Clamp-
crush
method
Radiofre-
quency
dissect-
ing sealer:
Liga-
sure (Co-
vidien)
Parenchy-
mal tran-
section
Not
stated
Factor be-
ing ran-
domised
No fibrin
glue used
Not
stated
Low cen-
tral
venous
pressure
Not
stated
Arita
2005
Radio-
frequency
dissecting
sealer
Clamp-
crush
method
Radio-
frequency
dissect-
ing sealer:
Tis-
sue Link
(Valley
Lab)
Parenchy-
mal tran-
section
Variable Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
Smyrnio-
tis
2005
Sharp
transec-
tion
Clamp-
crush
method
Sharp
transec-
tion: us-
ing
scalpel
Parenchy-
mal tran-
section
Selec-
tive hep-
atic vas-
cular ex-
clusion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Low cen-
tral
venous
pressure
Not
stated
Shimada
1994
Anti-
thrombin
III con-
centrate
Control Anti-
throm-
bin con-
centrate:
1500 IU
IV over
30
min: im-
mediately
before the
oper-
ation, just
be-
fore hep-
atic divi-
sion, and
immedi-
ately after
operation
Pharma-
cological
methods
Not
stated
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Lentsch-
ener
1997
Aprotinin Control Apro-
tinin:
Loading
dose: 2 X
106 kIU
of apro-
tinin over
a 20 min
period af-
ter induc-
tion
of anaes-
thesia.
Continu-
ous infu-
sion: 5 x
105 kIU
per hour
admin-
istered by
an
infusion
Pharma-
cological
methods
Intermit-
tent por-
tal triad
clamping
Kelly
clamp
Fibrin
glue used
Factor be-
ing ran-
domised
None Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
pump
until skin
closure
Addi-
tional bo-
lus: 5 X
105 KIU
of apro-
tinin was
in-
fused ev-
ery three
trans-
fused red
b10od
cell (red
blood
cell)
packs
Control:
placebo
Wong
2003
Desmo-
pressin
Control Desmo-
pressin:
30 mcg/
kg shortly
after
induction
Control:
placebo
Pharma-
cological
methods
Varied Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Lodge
2005
Recombi-
nant fac-
tor VIIa
Control Recombi-
nant fac-
tor VIIa:
1st dose:
slow in-
travenous
injection
(20 mcg/
kg or 80
mcg/kg)
within
5 min be-
fore inci-
sion.
2nd dose:
identical
dose was
Pharma-
cological
methods
Mixture
of meth-
ods
Not
stated
No fibrin
glue used
Factor be-
ing ran-
domised
Not
stated
No
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
given 5 h
after inci-
sion if the
surgery
time
was antic-
ipated to
exceed 6
hours
Control:
placebo
Shao
2006
Recombi-
nant fac-
tor VIIa
Control Recombi-
nant fac-
tor VIIa:
brand not
stated
Dose: 50
or
100 mcg/
kg before
skin inci-
sion over
2 minutes
and
repeated
every 2
hours un-
til a maxi-
mum of 4
doses
Control:
placebo
Pharma-
cological
methods
Not
stated
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Wu 2006 Tranex-
amic acid
Control Tranex-
amic
acid: 500
mg just
before the
surgery
followed
by 250
mg 4x/
day for 3
days
Pharma-
cological
methods
Varied Clamp-
crush
method
Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Chap-
man
2000
Collagen Fibrin
sealant
Collagen:
Instat
(Johnson
Raw sur-
face
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
& John-
son)
Fibrin
sealant:
Costa-
sis (Cohe-
sion
Tech-
nologies)
- bovine
thrombin
and colla-
gen com-
bined
with pa-
tient’s
own
plasma
Franceschi
2006
Collagen Fibrin
sealant
Collagen:
Instat
(Ethicon)
Fibrin
sealant:
CryoSeal
FS
Raw sur-
face
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Kohno
1992
Collagen Fibrin
sealant
Collagen:
Avitene
(Alcon
Inc).
Fibrin
sealant:
Beriplast
P
(Bering-
werke
AB)
Raw sur-
face
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Moench
2014
Collagen Fibrin
sealant
Colla-
gen: San-
gustop
fleece
(Aesculap
AG).
Fibrin-
based
haemo-
stat:
Raw sur-
face
Not
stated
A num-
ber of
parenchy-
mal tran-
section
tech-
niques
Factor be-
ing ran-
domised
None Not
stated
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
Tachosil
(Ny-
comed)
Fischer
2011
Fibrin
sealant
Argon
beam co-
agulator
Fibrin
sealant:
Tacchosil
(Ny-
comed)
Raw sur-
face
Amixture
of ap-
proaches
Amixture
of ap-
proaches
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Frilling
2005
Fibrin
sealant
Argon
beam co-
agulator
Fibrin
sealant:
Tacchosil
Raw sur-
face
Not
stated
Amixture
of ap-
proaches
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Bektas
2014
Fibrin
sealant
Control Fibrin
sealant:
TISSEEL
(Baxter
Health
Corpora-
tion)
Spray; 5
mL of fib-
rinogen
with syn-
thetic
aprotinin
and 5 mL
of throm-
bin (500
IU/mL)
Raw sur-
face
Intermit-
tent por-
tal triad
clamping
Differ-
ent types
of liver re-
section
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
De Boer
2012
Fibrin
sealant
Control Fibrin
sealant:
Quixil
(Johnson
& John-
son Med-
i-
cal) spray;
5 mL of
fibrino-
gen and
tranex-
amic acid
and 5 mL
of throm-
bin
Raw sur-
face
With and
without
inflowoc-
clusion
Clamp-
crush,
cavit-
ron ultra-
sonic sur-
gical aspi-
ra-
tor, elec-
tric coag-
ulation
based,
com-
bined
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
Liu 1993 Fibrin
sealant
Control Fibrin
sealant:
name not
available
Raw sur-
face
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Noun
1996
Fibrin
sealant
Control Fibrin
sealant:
Biocol
Raw sur-
face
Varied Clamp-
crush
method
or cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Porte
2012
Fibrin
sealant
Gelatin Fibrin
sealant:
Fibrocaps
(ProFib-
rix)
Raw sur-
face
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Genyk
2014
Fibrin
sealant
Oxidised
cellulose
Fibrin
sealant:
Tacchosil
Oxidised
cellulose:
Surgicel
Raw sur-
face
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Koea
2013
Fibrin
sealant
Oxidised
cellulose
Fibrin
sealant:
Fibrin
Pad
Ox-
idised cel-
lulose: no
further
details
Raw sur-
face
Not
stated
Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Ollinger
2013
Fibrin
sealant
Oxidised
cellulose
Fibrin
sealant:
Tachosil
(Ny-
comed)
Oxidised
cellulose:
Veriset
(Covi-
dien)
Raw sur-
face
Varied Not
stated
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
Kakaei
2013
Fibrin
sealant
Oxidised
cellulose
3rd
group:
cyanoacry-
late
Oxidised
cellulose:
Surgicel
(Ethicon
Inc)
Cyanoacry-
late:
Glubran
2 (GEM
SRL)
Fibrin
sealant:
Tachosil
(Takeda
Pharma-
ceuticals)
Raw sur-
face
Not
stated
Clamp-
crush
method
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Gugen-
heim
2011
Fibrin
sealant
Plasma-
Jet coagu-
lator
Fibrin
sealant:
fibrin
glue (no
further
details)
Raw sur-
face
Not
stated
Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Figueras
2007
Fibrin
sealant
plus col-
lagen
Control Fibrin
sealant
spray:
Tissucol
Collagen:
collagen
sponge
(Johnson
& John-
son)
Note: In
both
groups,
bleeding
from raw
surface
was con-
trolled
using ar-
gon beam
coagula-
tor or Tis-
suelink
Raw sur-
face
Intermit-
tent por-
tal triad
or selec-
tive
clamping
Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
Belghiti
1996
Continu-
ous portal
triad
clamping
Contin-
uous hep-
atic vas-
cular ex-
clusion
Hepatic
vascu-
lar exclu-
sion by
encircling
the entire
retrohep-
atic infe-
rior vena
cava
Vascular
occlusion
Factor be-
ing ran-
domised
Clamp-
crush
or cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Fibrin
glue used
Not
stated
Not
stated
Not
stated
Chen
2006
Continu-
ous portal
triad
clamping
Contin-
uous hep-
atic vas-
cular ex-
clusion
Hepatic
vascular
exclusion
by encir-
cling the
entire in-
frahep-
atic infe-
rior vena
cava
Vascular
occlusion
Factor be-
ing ran-
domised
Clamp-
crush
method
Not
stated
Not
stated
Not
stated
Not
stated
Si-Yuan
2014
Continu-
ous portal
triad
clamping
Continu-
ous selec-
tive hep-
atic vas-
cular ex-
clusion
- Vascular
occlusion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Low cen-
tral
venous
pressure
Not
stated
Ni 2013 Continu-
ous portal
triad
clamping
Continu-
ous selec-
tive por-
tal triad
clamping
- Vascular
occlusion
Factor be-
ing ran-
domised
Clamp-
crush
method
Not
stated
Not
stated
Low cen-
tral
venous
pressure
Not
stated
Chouker
2004
Continu-
ous portal
triad
clamping
Control - Vascular
occlusion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
Not
stated
Clavien
1996
Continu-
ous portal
triad
clamping
Control Note: Af-
ter every
1 hour of
continu-
ous portal
triad
clamp-
ing (or 30
minutes
Vascular
occlusion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
for cir-
rhotic pa-
tients),
the clamp
was re-
leased for
10 min-
utes
before
reclamp-
ing
Dayangac
2010
Continu-
ous portal
triad
clamping
Control - Vascular
occlusion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
Not
stated
Pietsch
2010
Continu-
ous portal
triad
clamping
Control - Vascular
occlusion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
Not
stated
Belghiti
1999
Continu-
ous portal
triad
clamping
Intermit-
tent por-
tal triad
clamping
Continu-
ous portal
triad
clamp-
ing: un-
til end of
transec-
tion
Intermit-
tent por-
tal triad
clamp-
ing: 15
minutes
on and
5 minutes
off
until hep-
atectomy
Vascular
occlusion
Factor be-
ing ran-
domised
Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Not
stated
Not
stated
Low cen-
tral
venous
pressure
Not
stated
Capus-
sotti
2003
Continu-
ous portal
triad
clamping
Intermit-
tent por-
tal triad
clamping
Intermit-
tent por-
tal triad
clamp-
ing: 15
minutes
on and
Vascular
occlusion
Factor be-
ing ran-
domised
Clamp-
crush
Fibrin
glue used
Not
stated
Not
stated
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
5 minutes
off
Liang
2009
Continu-
ous selec-
tive por-
tal triad
clamping
Intermit-
tent por-
tal triad
clamping
Intermit-
tent por-
tal triad
clamp-
ing: 20
minutes
on and
5 minutes
off
Vascular
occlusion
Factor be-
ing ran-
domised
Clamp
crush
Not
stated
None Not
stated
Not
stated
Capus-
sotti
2006
Intermit-
tent por-
tal triad
clamping
Control Intermit-
tent por-
tal triad
clamp-
ing: 15
minutes
on and
5 minutes
off
Vascular
occlusion
Factor be-
ing ran-
domised
Clamp-
crush
or bipolar
dissecting
sealer
Not
stated
Not
stated
Low cen-
tral
venous
pressure
Not
stated
Lee 2012 Intermit-
tent por-
tal triad
clamping
Control Intermit-
tent por-
tal triad
clamp-
ing: 15
minutes
on and
5 minutes
off
Vascular
occlusion
Factor be-
ing ran-
domised
Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Fibrin
glue used
Not
stated
Low cen-
tral
venous
pressure
Not
stated
Man
1997
Intermit-
tent por-
tal triad
clamping
Control Intermit-
tent por-
tal triad
clamp-
ing: 20
minutes
on and
5 minutes
off
Vascular
occlusion
Factor be-
ing ran-
domised
Cavit-
ron ultra-
sonic sur-
gical aspi-
rator
Not
stated
Not
stated
Not
stated
Not
stated
Man
2003
Intermit-
tent por-
tal triad
clamping
Control Intermit-
tent por-
tal triad
clamp-
ing: 20
minutes
on and
Vascular
occlusion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
Not
stated
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Table 12. Intervention and control (ordered by category and comparisons) (Continued)
5 minutes
off (until
resection
is com-
pleted
or a maxi-
mum of 6
cycles)
Park
2012
Intermit-
tent por-
tal triad
clamping
Control Intermit-
tent por-
tal triad
clamp-
ing: 15
minutes
on and
5 minutes
off
Vascular
occlusion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
Not
stated
Figueras
2005
Intermit-
tent por-
tal triad
clamping
Intermit-
tent selec-
tive por-
tal triad
clamping
Intermit-
tent
clamp-
ing: 15
minutes
on and
5 minutes
off
Vascular
occlusion
Factor be-
ing ran-
domised
Not
stated
Not
stated
Not
stated
Not
stated
Not
stated
Wu 2002 Intermit-
tent por-
tal triad
clamping
Intermit-
tent selec-
tive por-
tal triad
clamping
Intermit-
tent por-
tal triad
clamp-
ing: 15
minutes
on and
5 minutes
off
Intermit-
tent selec-
tive por-
tal triad
clamp-
ing: 30
minutes
on and
5 minutes
off
Vascular
occlusion
Factor be-
ing ran-
domised
Clamp-
crush
method
Not
stated
Not
stated
Not
stated
Not
stated
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Table 13. Risk of bias (ordered by category and comparisons)
Study Inter-
vention
Control Se-
quence
genera-
tion
Alloca-
tion
conceal-
ment
Blind-
ing of
partic-
ipants
and
health-
care
providers
Blind-
ing
of out-
come
asses-
sors
Miss-
ing out-
come
bias
Selec-
tive re-
porting
bias
Source
of fund-
ing bias
Other
bias
Over-
all risk
of bias
Capus-
sotti
2012
Ante-
rior ap-
proach
Control Low Unclear Unclear Unclear High Low Low Low Unclear
or high
Liu
2006
Ante-
rior ap-
proach
Control Unclear Unclear High High High High Low Low Unclear
or high
Ka-
jikawa
1994
Autolo-
gous
blood
dona-
tion
Control Unclear Unclear Unclear Unclear Unclear High Unclear Low Unclear
or high
Kostopana-
giotou
2007
Autolo-
gous
blood
dona-
tion
Control Unclear Unclear Unclear Unclear High High Unclear Low Unclear
or high
Guo
2013
Acute
normo-
volemic
haemod-
ilution
plus low
central
venous
pressure
Control Unclear Unclear Unclear Unclear Unclear High Low Low Unclear
or high
Jarnagin
2008
Acute
normo-
volemic
haemod-
ilution
plus low
central
venous
pressure
Low
central
venous
pressure
Unclear Unclear Unclear Unclear High Low Unclear Low Unclear
or high
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Table 13. Risk of bias (ordered by category and comparisons) (Continued)
Matot
2002
Acute
normo-
volemic
haemod-
ilution
plus low
central
venous
pressure
Low
central
venous
pressure
Low Unclear High Unclear Low High Low Low Unclear
or high
Yao
2006
Acute
normo-
volemic
haemod-
ilution
Acute
normo-
volemic
haemod-
ilution
with hy-
poten-
sion
3rd
group:
control
Unclear Unclear Unclear Unclear Unclear High Unclear Low Unclear
or high
Hasegawa
2002
Hy-
poventi-
lation
Control Low Low Low High Low High Low Low Unclear
or high
Choi
2007
Low
central
venous
pressure
Control Unclear Unclear Unclear Unclear Unclear High Unclear Low Unclear
or high
El-
Khar-
boutly
2004
Low
central
venous
pressure
Control Unclear Unclear Unclear Unclear Unclear High Unclear Low Unclear
or high
Kato
2008
Low
central
venous
pressure
Control Low Low Unclear Unclear Low High Unclear Low Unclear
or high
Wang
2006
Low
central
venous
pressure
Control Unclear Unclear Unclear Unclear High High Unclear Low Unclear
or high
Guo
2014
Low
central
venous
Low
central
venous
Unclear Unclear Unclear Unclear Unclear High Low Low Unclear
or high
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Table 13. Risk of bias (ordered by category and comparisons) (Continued)
pressure pressure
+ acute
normo-
volemic
haemod-
ilution.
3rd
group:
control
Rahbari
2014
Stapler Clamp-
crush
method
Low Low High Low Low Low High Low Unclear
or high
Koo
2005
Cav-
itron ul-
trasonic
surgical
aspirator
Clamp-
crush
method
Unclear Unclear Unclear Unclear Unclear High Unclear Low Unclear
or high
Takayama
2001
Cav-
itron ul-
trasonic
surgical
aspirator
Clamp-
crush
method
Unclear Unclear Unclear Unclear Low Low Unclear Low Unclear
or high
Dok-
lestic
2012
Cav-
itron ul-
trasonic
surgical
aspirator
Clamp-
crush
method.
3rd
group:
radiofre-
quency
dissect-
ing
sealer
Unclear Unclear Unclear Unclear Unclear Low Low Low Unclear
or high
Rau
2001
Cav-
itron ul-
trasonic
surgical
aspirator
Hydro-
jet
Unclear Unclear Unclear Unclear Unclear High Unclear Low Unclear
or high
Savlid
2013
Cav-
itron ul-
trasonic
surgical
aspirator
Stapler Low Low Unclear Unclear Low Low High Low Unclear
or high
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Table 13. Risk of bias (ordered by category and comparisons) (Continued)
Lesurtel
2005
Cav-
itron ul-
trasonic
surgical
aspirator
Ra-
diofre-
quency
dissect-
ing
sealer.
3rd
group:
hydrojet
Unclear Unclear Unclear Unclear Low Low High Low Unclear
or high
Ikeda
2009
Ra-
diofre-
quency
dissect-
ing
sealer
Clamp-
crush
method
Low Unclear High High Low Low Low Low Unclear
or high
Lupo
2007
Ra-
diofre-
quency
dissect-
ing
sealer
Clamp-
crush
method
Low Unclear Unclear Unclear Low High Low Low Unclear
or high
Mura-
tore
2014
Ra-
diofre-
quency
dissect-
ing
sealer
Clamp-
crush
method
Low Low Unclear High Low Low Low Low Unclear
or high
Arita
2005
Radio-
fre-
quency
dissect-
ing
sealer
Clamp-
crush
method
Low Low High High Low Low Low Low Unclear
or high
Smyrni-
otis
2005
Sharp
transec-
tion
Clamp-
crush
method
Unclear Unclear Unclear Unclear Low High Unclear Low Unclear
or high
Shimada
1994
Anti-
throm-
bin
III con-
centrate
Control Unclear Unclear Unclear Unclear Unclear High Unclear Low Unclear
or high
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Table 13. Risk of bias (ordered by category and comparisons) (Continued)
Lentsch-
ener
1997
Apro-
tinin
Control Low Unclear Unclear Low High High High Low Unclear
or high
Wong
2003
Desmo-
pressin
Control Unclear Unclear Low Low High High Low Low Unclear
or high
Lodge
2005
Recom-
bi-
nant fac-
tor VIIa
Control Low Low Low Low High Low High Low Unclear
or high
Shao
2006
Recom-
bi-
nant fac-
tor VIIa
Control Unclear Unclear Unclear Unclear High High High Low Unclear
or high
Wu
2006
Tranex-
amic
acid
Control Unclear Unclear Low Low Low High Unclear Low Unclear
or high
Chap-
man
2000
Colla-
gen
Fibrin
sealant
Low Unclear Unclear Unclear High High High Low Unclear
or high
Franceschi
2006
Colla-
gen
Fibrin
sealant
Unclear Unclear Unclear Unclear Unclear High Unclear Low Unclear
or high
Kohno
1992
Colla-
gen
Fibrin
sealant
Unclear Unclear Unclear Unclear Low Low Unclear Low Unclear
or high
Moench
2014
Colla-
gen
Fibrin
sealant
Low Low High High High Low High Low Unclear
or high
Fischer
2011
Fibrin
sealant
Argon
beam
coagula-
tor
Unclear Low High High High Low High Low Unclear
or high
Frilling
2005
Fibrin
sealant
Argon
beam
coagula-
tor
Unclear Unclear High High Low Low Unclear Low Unclear
or high
Bektas
2014
Fibrin
sealant
Control Low Low High High Low Low High Low Unclear
or high
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Table 13. Risk of bias (ordered by category and comparisons) (Continued)
De Boer
2012
Fibrin
sealant
Control Low Low High High Low Low High Low Unclear
or high
Liu
1993
Fibrin
sealant
Control Unclear Unclear Unclear Unclear Low High Unclear Low Unclear
or high
Noun
1996
Fibrin
sealant
Control Unclear Unclear Unclear Unclear High High Unclear Low Unclear
or high
Porte
2012
Fibrin
sealant
Gelatin Unclear Unclear Unclear Unclear Unclear High Unclear Low Unclear
or high
Genyk
2014
Fibrin
sealant
Oxi-
dised
cellulose
Unclear Unclear Unclear Unclear Unclear High Unclear Low Unclear
or high
Koea
2013
Fibrin
sealant
Oxi-
dised
cellulose
Low Low High High High High High Low Unclear
or high
Ollinger
2013
Fibrin
sealant
Oxi-
dised
cellulose
Unclear Unclear High High Low Low High Low Unclear
or high
Kakaei
2013
Fibrin
sealant
Oxi-
dised
cellulose
3rd
group:
cyanoacry-
late
Low Unclear High Unclear Unclear High Low Low Unclear
or high
Gugen-
heim
2011
Fibrin
sealant
Plasma-
Jet coag-
ulator
Unclear Unclear Unclear Unclear Low High Unclear Low Unclear
or high
Figueras
2007
Fibrin
sealant
plus col-
lagen
Control Low Low Unclear Unclear Low Low Low Low Unclear
or high
Belghiti
1996
Contin-
u-
ous por-
tal triad
clamp-
ing
Contin-
u-
ous hep-
atic vas-
cular ex-
clusion
Unclear Unclear Unclear Unclear High High Unclear Low Unclear
or high
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Table 13. Risk of bias (ordered by category and comparisons) (Continued)
Chen
2006
Contin-
u-
ous por-
tal triad
clamp-
ing
Contin-
u-
ous hep-
atic vas-
cular ex-
clusion
Unclear Unclear Unclear Unclear Unclear Low Low Low Unclear
or high
Si-Yuan
2014
Contin-
u-
ous por-
tal triad
clamp-
ing
Contin-
uous se-
lec-
tive hep-
atic vas-
cular ex-
clusion
Unclear Low Unclear Unclear Low High Unclear Low Unclear
or high
Ni 2013 Contin-
u-
ous por-
tal triad
clamp-
ing
Contin-
uous se-
lec-
tive por-
tal triad
clamp-
ing
Unclear Low Unclear Unclear Low Low Low Low Unclear
or high
Chouker
2004
Contin-
u-
ous por-
tal triad
clamp-
ing
Control Unclear Unclear High Unclear High High Unclear Low Unclear
or high
Clavien
1996
Contin-
u-
ous por-
tal triad
clamp-
ing
Control Unclear Unclear Unclear Unclear High High Low Low Unclear
or high
Dayan-
gac
2010
Contin-
u-
ous por-
tal triad
clamp-
ing
Control Low Low High Low Low High Low Low Unclear
or high
Pietsch
2010
Contin-
u-
ous por-
tal triad
clamp-
Control Unclear Unclear Unclear Unclear Unclear High Unclear Low Unclear
or high
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Table 13. Risk of bias (ordered by category and comparisons) (Continued)
ing
Belghiti
1999
Contin-
u-
ous por-
tal triad
clamp-
ing
Inter-
mit-
tent por-
tal triad
clamp-
ing
Unclear Unclear Unclear Unclear Low High Unclear Low Unclear
or high
Capus-
sotti
2003
Contin-
u-
ous por-
tal triad
clamp-
ing
Inter-
mit-
tent por-
tal triad
clamp-
ing
Low Unclear Unclear Unclear Low Low Unclear Low Unclear
or high
Liang
2009
Contin-
uous se-
lec-
tive por-
tal triad
clamp-
ing
Inter-
mit-
tent por-
tal triad
clamp-
ing
Unclear Unclear Unclear Unclear Low Low Low Low Unclear
or high
Capus-
sotti
2006
Inter-
mit-
tent por-
tal triad
clamp-
ing
Control Low Unclear Unclear Unclear Low High Unclear Low Unclear
or high
Lee
2012
Inter-
mit-
tent por-
tal triad
clamp-
ing
Control Low Low High High Low Low Low Low Unclear
or high
Man
1997
Inter-
mit-
tent por-
tal triad
clamp-
ing
Control Unclear Unclear Unclear Unclear Low High Low Low Unclear
or high
Man
2003
Inter-
mit-
tent por-
tal triad
Control Unclear Unclear Unclear Unclear Low High Unclear Low Unclear
or high
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Table 13. Risk of bias (ordered by category and comparisons) (Continued)
clamp-
ing
Park
2012
Inter-
mit-
tent por-
tal triad
clamp-
ing
Control Low Low Unclear Unclear High High Low Low Unclear
or high
Figueras
2005
Inter-
mit-
tent por-
tal triad
clamp-
ing
Inter-
mittent
selec-
tive por-
tal triad
clamp-
ing
Unclear Unclear Unclear Unclear Low High Low Low Unclear
or high
Wu
2002
Inter-
mit-
tent por-
tal triad
clamp-
ing
Inter-
mittent
selec-
tive por-
tal triad
clamp-
ing
Unclear Unclear Unclear Unclear Low Low Low Low Unclear
or high
Table 14. Detailed ’Summary of findings’ table: anterior approach vs conventional approach
Outcomes Illustrative comparative risks* (95%
CrI)
Relative effect
(95% CrI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Control Intervention
Mortality (periop-
erative)
76 per 1000 19 per 1000
(2 to 82)
OR 0.23
(0.03 to 1.08)
185
(2 studies)
⊕©©©
Very low1,2,3
Mortality (longest
follow-up)
None of the trials reported this outcome.
Seri-
ous adverse events
(proportion)
125 per 1000 154 per 1000
(40 to 457)
OR 1.27
(0.29 to 5.89)
65
(1 study)
⊕©©©
Very low1,2,3
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Table 14. Detailed ’Summary of findings’ table: anterior approach vs conventional approach (Continued)
Serious adverse
events (number)
None of the trials reported this outcome.
Health-related
quality of life (30
days, 3 months)
None of the trials reported this outcome.
Health-
related quality of
life (maximal fol-
low-up)
None of the trials reported this outcome.
*The basis for the assumed risk is the mean control group proportion. The corresponding risk (and its 95% credible interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CrI).
Network meta-analysis was not performed for any of the outcomes since there were only two treatments
CrI: credible intervals; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was unclear or high in the trial(s) (downgraded by 1 point).
2 Sample size was low (total number of participants fewer than 400 for continuous outcomes and fewer than 300 events in total in
both groups for other outcomes) (downgraded by 1 point).
3 Credible intervals spanned no effect and clinically significant effect (20% relative risk reduction for binary outcomes; standardised
mean difference of 0.5 for health-related quality of life) (downgraded by 1 point).
Table 15. Detailed ’Summary of findings’ table: autologous blood donation vs control
Outcomes Illustrative comparative risks* (95%
CrI)
Relative effect
(95% CrI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Control Intervention
Mortality (periop-
erative)
There was no mortality in either group. 28
(1 study)
⊕©©©
Very low1,2,3
Mortal-
ity (longest follow-
up): reported at 1
There was no mortality in either group. 28
(1 study)
⊕©©©
Very low1,2,3
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Table 15. Detailed ’Summary of findings’ table: autologous blood donation vs control (Continued)
year
Seri-
ous adverse events
(proportion)
None of the trials reported this outcome.
Serious adverse
events (number)
None of the trials reported this outcome.
Health-related
quality of life (30
days, 3 months)
None of the trials reported this outcome.
Health-
related quality of
life (longest fol-
low-up)
None of the trials reported this outcome.
*The basis for the assumed risk is the mean control group proportion. The corresponding risk (and its 95% credible interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CrI).
Network meta-analysis was not performed for any of the outcomes since there were only two treatments
CrI: credible intervals; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was unclear or high in the trial(s) (downgraded by 1 point).
2 Sample size was low (total number of participants fewer than 400 for continuous outcomes and fewer than 300 events in total in
both groups for other outcomes) (downgraded by 1 point).
3Credible intervals spanned no effect and clinically significant effect (20% relative risk reduction for binary outcomes; standardised
mean difference of 0.5 for health-related quality of life) (downgraded by 1 point).
Table 16. Detailed ’Summary of findings’ table: cardiopulmonary interventions
Outcomes Illustrative comparative risks* (95%
CrI)
Relative effect
(95% CrI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Control Intervention
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Table 16. Detailed ’Summary of findings’ table: cardiopulmonary interventions (Continued)
Mortality (perioperative)
Hypoventilation vs
control
There was no mortality in either group. 79
(1 study)
⊕©©©
Very low1,2,3
Low central venous
pressure vs control
There was no mortality in either group. 85
(1 study)
⊕©©©
Very low1,2,3
Mortality (longest
follow-up)
None of the trials reported this outcome.
Serious adverse events (proportion)
Hypoventilation vs
control
26 per 1000 60 per 1000
(5 to 679)
OR 2.41
(0.18 to 80.4)
79
(1 study)
⊕©©©
Very low1,2,3
Low
central venous pres-
sure vs acute normo-
volemic haemodilu-
tion plus low CVP
302 per 1000 284 per 1000
(157 to 460)
OR 0.92
(0.43 to 1.97)
63
(1 study)
⊕©©©
Very low1,2,3
Serious adverse events (number)
Low central venous
pressure vs control
100 per 1000 0 per 1000
(0 to 2)
Rate ratio 0.00
(0 to 0.02)
42
(1 study)
⊕©©©
Very lowa,b,c
Low
central venous pres-
sure vs acute normo-
volemic haemodilu-
tion plus low central
venous pressure
103 per 1000 77 per 1000
(15 to 287)
Rate ratio 0.73
(0.13 to 3.53)
78
(1 study)
⊕©©©
Very lowa,b,c
Health-related
quality of life (30
days, 3 months)
None of the trials reported this outcome.
Health-
related quality of
life (longest fol-
low-up)
None of the trials reported this outcome.
*The basis for the assumed risk is the mean control group proportion. The corresponding risk (and its 95% credible interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CrI).
Networkmeta-analysis was not performed for any of the outcomes because of the lack of availability of direct and indirect comparisons
in the network
CrI: credible intervals; OR: odds ratio.
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Table 16. Detailed ’Summary of findings’ table: cardiopulmonary interventions (Continued)
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1aRisk of bias was unclear or high in the trial(s) (downgraded by 1 point).
2 Sample size was low (total number of participants fewer than 400 for continuous outcomes and fewer than 300 events in total in
both groups for other outcomes) (downgraded by 1 point).
3Credible intervals spanned no effect and clinically significant effect (20% relative risk reduction for binary outcomes; standardised
mean difference of 0.5 for health-related quality of life) (downgraded by 1 point).
Table 17. Detailed ’Summary of findings’ table: methods of parenchymal transection
Outcomes Illustrative comparative risks* (95%
CrI)
Relative effect
(95% CrI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Control Intervention
Mortality (perioperative)
CUSA vs clamp-
crush method
23 per 1000 6 per 1000
(0 to 54)
OR 0.24
(0.01 to 2.41)
172
(2 studies)
⊕©©©
Very low1,2,3
Radiofrequency dis-
sect-
ing sealer vs clamp-
crush method
10 per 1000 16 per 1000
(4 to 65)
OR 1.60
(0.43 to 6.7)
390
(5 studies)
⊕©©©
Very low1,2,3
Sharp transection
method vs clamp-
crush method
There was no mortality in either group. 82
(1 study)
⊕©©©
Very low1,2,3
Stapler vs clamp-
crush method
31 per 1000 67 per 1000
(12 to 375)
OR 2.26
(0.39 to 18.93)
130
(1 study)
⊕©©©
Very low1,2,3
Hydrojet vs CUSA 55 per 1000 54 per 1000
(9 to 258)
OR 0.98
(0.16 to 6.04)
111
(2 studies)
⊕©©©
Very low1,2,3
Radiofrequency dis-
secting sealer vs
CUSA
44 per 1000 28 per 1000
(3 to 166)
OR 0.61
(0.07 to 4.28)
90
(2 studies)
⊕©©©
Very low1,2,3
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Table 17. Detailed ’Summary of findings’ table: methods of parenchymal transection (Continued)
Stapler vs CUSA There was no mortality in either group. 79
(1 study)
⊕©©©
Very low1,2,3
Radiofrequency dis-
secting sealer vs hy-
drojet
80 per 1000 9 per 1000
(0 to 145)
OR 0.10
(0 to 1.95)
50
(1 study)
⊕©©©
Very low1,2,3
Mortality (longest
follow-up)
None of the trials reported this outcome.
Serious adverse events (proportion)
CUSA vs clamp-
crush method
93 per 1000 31 per 1000
(6 to 110)
OR 0.31
(0.06 to 1.2)
172
(2 studies)
⊕©©©
Very low1,2,3
Radiofrequency dis-
sect-
ing sealer vs clamp-
crush method
58 per 1000 49 per 1000
(15 to 145)
OR 0.83
(0.24 to 2.74)
240
(3 studies)
⊕©©©
Very low1,2,3
Sharp transection
method vs clamp-
crush method
49 per 1000 106 per 1000
(20 to 502)
OR 2.31
(0.39 to 19.69)
82
(1 study)
⊕©©©
Very low1,2,3
Hydrojet vs CUSA 100 per 1000 124 per 1000
(61 to 238)
OR 1.27
(0.58 to 2.81)
61
(1 study)
⊕©©©
Very low1,2,3
Radiofrequency dis-
secting sealer vs
CUSA
50 per 1000 30 per 1000
(3 to 180)
OR 0.58
(0.06 to 4.16)
40
(1 study)
⊕©©©
Very low1,2,3
Stapler vs CUSA 246 per 1000 246 per 1000
(6 to 931)
OR 1.00
(0.02 to 41.22)
130
(1 study)
⊕©©©
Very low1,2,3
Serious adverse events (number)
CUSA vs clamp-
crush method
45 per 1000 29 per 1000
(3 to 166)
Rate ratio 0.63
(0.07 to 4.17)
132
(1 study)
⊕©©©
Very low1,2,3
Radiofrequency dis-
sect-
ing sealer vs clamp-
crush method
61 per 1000 190 per 1000
(75 to 474)
Rate ratio 3.64
(1.25 to 13.97)
130
(2 studies)
⊕⊕©©
Low1,2
Hydrojet vs CUSA 80 per 1000 121 per 1000
(20 to 546)
Rate ratio 1.59
(0.24 to 13.83)
50
(1 study)
⊕©©©
Very low1,2,3
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Table 17. Detailed ’Summary of findings’ table: methods of parenchymal transection (Continued)
Radiofrequency dis-
secting sealer vs
CUSA
80 per 1000 121 per 1000
(20 to 546)
Rate ratio 1.59
(0.24 to 13.83)
50
(1 study)
⊕©©©
Very low1,2,3
Stapler vs CUSA 180 per 1000 230 per 1000
(109 to 424)
Rate ratio 1.36
(0.56 to 3.36)
100
(1 study)
⊕©©©
Very low1,2,3
Radiofrequency dis-
secting sealer vs hy-
drojet
120 per 1000 120 per 1000
(23 to 445)
Rate ratio 1.00
(0.17 to 5.88)
50
(1 study)
⊕©©©
Very low1,2,3
Health-related
quality of life (30
days, 3 months)
None of the trials reported this outcome.
Health-
related quality of
life (maximal fol-
low-up)
None of the trials reported this outcome.
*The basis for the assumed risk is the mean control group proportion. The corresponding risk (and its 95% credible interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CrI).
Networkmeta-analysis was not performed for any of the outcomes because of the lack of availability of direct and indirect comparisons
in the network
CrI: credible intervals; CUSA: cavitron ultrasonic surgical aspirator; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was unclear or high in the trial(s) (downgraded by 1 point).
2 Sample size was low (total number of participants fewer than 400 for continuous outcomes and fewer than 300 events in total in
both groups for other outcomes) (downgraded by 1 point).
3 Credible intervals spanned no effect and clinically significant effect (20% relative risk reduction for binary outcomes; standardised
mean difference of 0.5 for health-related quality of life) (downgraded by 1 point).
Table 18. Detailed ’Summary of findings’ Table: methods of dealing with cut surface
Outcomes Illustrative comparative risks* (95%
CrI)
Relative effect
(95% CrI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
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Table 18. Detailed ’Summary of findings’ Table: methods of dealing with cut surface (Continued)
Assumed risk Corresponding
risk
Control Intervention
Mortality (perioperative)
Fibrin sealant vs
control
11 per 1000 41 per 1000
(10 to 253)
OR 4.03
(0.9 to 31.72)
380
(2 studies)
⊕©©©
Very low1,2,3
Fibrin sealant and
collagen vs control
13 per 1000 45 per 1000
(10 to 268)
OR 3.48
(0.74 to 27.03)
300
(1 study)
⊕©©©
Very low1,2,3
Fibrin sealant vs ar-
gon beam
53 per 1000 72 per 1000
(25 to 198)
OR 1.39
(0.46 to 4.45)
227
(2 studies)
⊕©©©
Very low1,2,3
Fibrin sealant vs col-
lagen
33 per 1000 30 per 1000
(7 to 123)
OR 0.91
(0.2 to 4.14)
256
(3 studies)
⊕©©©
Very low1,2,3
Oxidised cellulose
vs fibrin sealant
56 per 1000 31 per 1000
(1 to 565)
OR 0.54
(0.01 to 22.09)
50
(1 study)
⊕©©©
Very low1,2,3
Plasmajet vs fibrin
sealant
103 per 1000 65 per 1000
(7 to 332)
OR 0.60
(0.06 to 4.31)
58
(1 study)
⊕©©©
Very low1,2,3
Mortality (longest
follow-up)
None of the trials reported this outcome.
Serious adverse events (proportion)
Fibrin sealant vs
control
186 per 1000 191 per 1000
(128 to 275)
OR 1.03
(0.64 to 1.66)
457
(3 studies)
⊕©©©
Very low1,2,3
Fibrin sealant vs ar-
gon beam
269 per 1000 183 per 1000
(78 to 360)
OR 0.61
(0.23 to 1.53)
106
(1 study)
⊕©©©
Very low1,2,3
Fibrin sealant vs col-
lagen
258 per 1000 356 per 1000
(205 to 547)
OR 1.59
(0.74 to 3.47)
127
(1 study)
⊕©©©
Very low1,2,3
Oxidised cellulose
vs fibrin sealant
444 per 1000 309 per 1000
(113 to 603)
OR 0.56
(0.16 to 1.9)
50
(1 study)
⊕©©©
Very low1,2,3
Plasmajet vs fibrin
sealant
207 per 1000 25 per 1000
(0 to 165)
OR 0.10
(0 to 0.76)
58
(1 study)
⊕©©©
Very low1,2,3
Serious adverse events (number)
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Table 18. Detailed ’Summary of findings’ Table: methods of dealing with cut surface (Continued)
Fibrin sealant vs
control
486 per 1000 470 per 1000
(307 to 640)
Rate ratio 0.94
(0.47 to 1.88)
70
(1 study)
⊕©©©
Very low1,2,3
Fibrin sealant&col-
lagen vs control
147 per 1000 186 per 1000
(116 to 286)
Rate ratio 1.33
(0.76 to 2.33)
300
(1 study)
⊕©©©
Very low1,2,3
Fibrin sealant vs ar-
gon beam
65 per 1000 249 per 1000
(107 to 547)
Rate ratio 4.81
(1.73 to 17.5)
121
(1 study)
⊕⊕©©
Low1,2
Fibrin sealant vs col-
lagen
323 per 1000 369 per 1000
(266 to 488)
Rate ratio 1.23
(0.76 to 2)
189
(2 studies)
⊕©©©
Very low1,2,3
Fibrin sealant vs
cyanoacrylate
67 per 1000 67 per 1000
(2 to 733)
Rate ratio 1.01
(0.03 to 38.36)
30
(1 study)
⊕©©©
Very low1,2,3
Oxidised cellulose
vs cyanoacrylate
67 per 1000 277 per 1000
(46 to 921)
Rate ratio 5.37
(0.67 to 163.2)
30
(1 study)
⊕©©©
Very low1,2,3
Oxidised cellulose
vs fibrin sealant
67 per 1000 278 per 1000
(46 to 926)
Rate ratio 5.40
(0.67 to 174.86)
30
(1 study)
⊕©©©
Very low1,2,3
Health-related
quality of life (30
days, 3 months)
None of the trials reported this outcome.
Health-
related quality of
life (longest fol-
low-up)
None of the trials reported this outcome.
*The basis for the assumed risk is the mean control group proportion. The corresponding risk (and its 95% credible interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CrI).
Networkmeta-analysis was not performed for any of the outcomes because of the lack of availability of direct and indirect comparisons
in the network
CrI: credible intervals; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was unclear or high in the trial(s) (downgraded by 1 point).
2 Sample size was low (total number of participants fewer than 400 for continuous outcomes and fewer than 300 events in total in
both groups for other outcomes) (downgraded by 1 point).
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3Credible intervals spanned no effect and clinically significant effect (20% relative risk reduction for binary outcomes; standardised
mean difference of 0.5 for health-related quality of life) (downgraded by 1 point).
Table 19. Detailed ’Summary of findings’ table: methods of vascular occlusion
Outcomes Illustrative comparative risks* (95%
CrI)
Relative effect
(95% CrI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Control Intervention
Mortality (perioperative)
Continuous portal
triad clamping vs
control
There was no mortality in either group. 15
(1 study)
⊕©©©
Very low1,2,3
Intermittent portal
triad clamping vs
control
26 per 1000 15 per 1000
(3 to 60)
OR 0.60
(0.13 to 2.42)
392
(4 studies)
⊕©©©
Very low1,2,3
Continuous portal
triad clamping vs
continuous hepatic
vascular exclusion
1 per 1000 5 per 1000
(4 to 15)
OR 4.91
(3.68 to 15.64)
170
(2 studies)
⊕©©©
Very low1,2,3
Contin-
uous selective hep-
atic vascular exclu-
sion vs continuous
portal triad clamp-
ing
There was no mortality in either group. 160
(1 study)
⊕©©©
Very low1,2,3
Contin-
uous selective por-
tal triad clamping
vs continuous portal
triad clamping
There was no mortality in either group. 120
(1 study)
⊕©©©
Very low1,2,3
Intermittent portal
triad clamping
vs continuous portal
triad clamping
67 per 1000 10 per 1000
(0 to 70)
OR 0.14
(0 to 1.05)
121
(2 studies)
⊕©©©
Very low1,2,3
Intermittent portal
triad clamping vs
continuous selective
portal triad clamp-
There was no mortality in either group. 80
(1 study)
⊕©©©
Very low1,2,3
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Table 19. Detailed ’Summary of findings’ table: methods of vascular occlusion (Continued)
ing
Intermittent
selective portal triad
clamping vs inter-
mittent portal triad
clamping
1 per 1000 2 per 1000
(0 to 69)
OR 2.27
(0.17 to 74)
138
(2 studies)
⊕©©©
Very low1,2,3
Mortality (longest
follow-up)
None of the trials reported this outcome.
Serious adverse events (proportion)*
Continuous hepatic
vascular exclusion vs
control
99 per 1000 200 per 1000
(19 to 785)
Rate ratio 2.27
(0.18 to 33.05)
815
(6 studies)
⊕©©©
Very low1,2,3
Continuous portal
triad clamping vs
control
99 per 1000 135 per 1000
(30 to 439)
Rate ratio 1.42
(0.28 to 7.09)
815
(6 studies)
⊕©©©
Very low1,2,3
Continuous selec-
tive hepatic vascular
exclusion vs control
99 per 1000 15 per 1000
(0 to 325)
Rate ratio 0.14
(0 to 4.37)
815
(6 studies)
⊕©©©
Very low1,2,3
Continuous
selective portal triad
clamping vs control
99 per 1000 55 per 1000
(11 to 226)
Rate ratio 0.53
(0.1 to 2.65)
815
(6 studies)
⊕©©©
Very low1,2,3
Intermittent portal
triad clamping vs
control
99 per 1000 113 per 1000
(56 to 217)
Rate ratio 1.16
(0.54 to 2.51)
815
(6 studies)
⊕©©©
Very low1,2,3
Continuous portal
triad clamping vs
continuous hepatic
vascular exclusion
50 per 1000 32 per 1000
(2 to 412)
Rate ratio 0.63
(0.03 to 13.31)
815
(6 studies)
⊕©©©
Very low1,2,3
Continuous selec-
tive hepatic vascular
exclusion vs contin-
uous hepatic vascu-
lar exclusion
50 per 1000 3 per 1000
(0 to 442)
Rate ratio 0.06
(0 to 15.06)
815
(6 studies)
⊕©©©
Very low1,2,3
Continuous
selective portal triad
clamping vs contin-
uous hepatic vascu-
lar exclusion
50 per 1000 12 per 1000
(1 to 209)
Rate ratio 0.23
(0.01 to 5.02)
815
(6 studies)
⊕©©©
Very low1,2,3
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Table 19. Detailed ’Summary of findings’ table: methods of vascular occlusion (Continued)
Intermittent portal
triad clamping vs
continuous hepatic
vascular exclusion
50 per 1000 26 per 1000
(2 to 288)
Rate ratio 0.51
(0.03 to 7.68)
815
(6 studies)
⊕©©©
Very low1,2,3
Contin-
uous selective hep-
atic vascular exclu-
sion vs continuous
portal triad clamp-
ing
139 per 1000 16 per 1000
(0 to 724)
Rate ratio 0.10
(0 to 16.28)
815
(6 studies)
⊕©©©
Very low1,2,3
Contin-
uous selective por-
tal triad clamping
vs continuous portal
triad clamping
139 per 1000 56 per 1000
(6 to 374)
Rate ratio 0.37
(0.04 to 3.7)
815
(6 studies)
⊕©©©
Very low1,2,3
Intermittent portal
triad clamping
vs continuous portal
triad clamping
139 per 1000 117 per 1000
(22 to 439)
Rate ratio 0.82
(0.14 to 4.86)
815
(6 studies)
⊕©©©
Very low1,2,3
Continuous
selective portal triad
clamping vs contin-
uous selective hep-
atic vascular exclu-
sion
As there were no serious adverse events in either group, the credible
intervals were extremely wide. This is equivalent to not estimable
in direct comparisons
815
(6 studies)
⊕©©©
Very low1,2,3
Intermittent portal
triad clamping vs
continuous selective
hepatic vascular ex-
clusion
As there were no serious adverse events in either group, the credible
intervals were extremely wide. This is equivalent to not estimable
in direct comparisons
815
(6 studies)
⊕©©©
Very low1,2,3
Intermittent portal
triad clamping vs
continuous selective
portal triad clamp-
ing
130 per 1000 247 per 1000
(51 to 665)
Rate ratio 2.19
(0.36 to 13.26)
815
(6 studies)
⊕©©©
Very low1,2,3
Serious adverse events (number)
Intermittent portal
triad clamping vs
control
80 per 1000 119 per 1000
(36 to 358)
Rate ratio 1.55
(0.43 to 6.4)
100
(1 study)
⊕©©©
Very lowa,b,c
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Table 19. Detailed ’Summary of findings’ table: methods of vascular occlusion (Continued)
Continuous portal
triad clamping vs
continuous hepatic
vascular exclusion
179 per 1000 36 per 1000
(2 to 218)
Rate ratio 0.17
(0.01 to 1.28)
52
(1 study)
⊕©©©
Very lowa,b,c
Intermittent portal
triad clamping
vs continuous portal
triad clamping
190 per 1000 21 per 1000
(0 to 116)
Rate ratio 0.09
(0 to 0.56)
86
(1 study)
⊕⊕©©
Lowa,b
Intermittent
selective portal triad
clamping vs inter-
mittent portal triad
clamping
134 per 1000 165 per 1000
(76 to 328)
Rate ratio 1.27
(0.53 to 3.15)
138
(2 studies)
⊕©©©
Very lowa,b,c
Health-related
quality of life (30
days, 3 months)
None of the trials reported this outcome.
Health-
related quality of
life (longest fol-
low-up)
None of the trials reported this outcome.
*The basis for the assumed risk is the mean control group proportion. The corresponding risk (and its 95% credible interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CrI).
Network meta-analysis was not performed for any of the outcomes other than serious adverse events (proportion) because of the lack
of availability of direct and indirect comparisons in the network
CrI: credible intervals; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was unclear or high in the trial(s) (downgraded by 1 point).
2 Sample size was low (total number of participants fewer than 400 for continuous outcomes and fewer than 300 events in total in
both groups for other outcomes) (downgraded by 1 point).
3 Credible intervals spanned no effect and clinically significant effect (20% relative risk reduction for binary outcomes; standardised
mean difference of 0.5 for health-related quality of life) (downgraded by 1 point).
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Table 20. Detailed ’Summary of findings’ table: pharmacological interventions
Outcomes Illustrative comparative risks* (95%
CrI)
Relative effect
(95% CrI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Control Intervention
Mortality (perioperative)
Recombinant factor
VIIa vs control
51 per 1000 33 per 1000
(7 to 158)
OR 0.63
(0.13 to 3.51)
185
(1 study)
⊕©©©
Very low1,2,3
Tranexamic acid vs
control
There was no mortality in either group. 214
(1 study)
⊕©©©
Very low1,2,3
Mortality (longest
follow-up)
None of the trials reported this outcome.
Serious adverse events (proportion)
Anti-thrombin III
vs control
273 per 1000 312 per 1000
(67 to 761)
OR 1.21
(0.19 to 8.49)
24
(1 study)
⊕©©©
Very low1,2,3
Recombinant Fac-
tor VIIa vs control
376 per 1000 396 per 1000
(256 to 555)
OR 1.09
(0.57 to 2.07)
432
(2 studies)
⊕©©©
Very low1,2,3
Serious adverse events (number)
Recombinant Fac-
tor VIIa vs control
81 per 1000 120 per 1000
(68 to 217)
Rate ratio 1.55
(0.83 to 3.16)
432
(2 studies)
⊕©©©
Very low1,2,3
Tranexamic acid vs
control
75 per 1000 65 per 1000
(23 to 164)
Rate ratio 0.85
(0.29 to 2.41)
214
(1 study)
⊕©©©
Very low1,2,3
Health-related
quality of life (30
days, 3 months)
None of the trials reported this outcome.
Health-
related quality of
life (maximal fol-
low-up)
None of the trials reported this outcome.
*The basis for the assumed risk is the mean control group proportion. The corresponding risk (and its 95% credible interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CrI).
Networkmeta-analysis was not performed for any of the outcomes because of the lack of availability of direct and indirect comparisons
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Table 20. Detailed ’Summary of findings’ table: pharmacological interventions (Continued)
in the network
CrI: credible intervals; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was unclear or high in the trial(s) (downgraded by 1 point).
2 Sample size was low (total number of participants fewer than 400 for continuous outcomes and fewer than 300 events in total in
both groups for other outcomes) (downgraded by 1 point).
3 Credible intervals spanned no effect and clinically significant effect (20% relative risk reduction for binary outcomes; standardised
mean difference of 0.5 for health-related quality of life) (downgraded by 1 point).
A P P E N D I C E S
Appendix 1. Search strategies
Database Time span Search strategy
The Central Register of Controlled Trials
(CENTRAL)
2015, Issue 9 1. Blood loss OR bleeding OR hemorrhage OR
haemorrhage OR hemorrhages OR haemorrhages
OR hemostasis OR haemostasis OR transfusion
2. MeSH descriptor Hemorrhage explode all trees
3. MeSH descriptor Blood Transfusion explode all
trees
4. (#1 OR #2 OR #3)
5. Liver OR hepatic OR hepato*
6. MeSH descriptor Liver explode all trees
7. (5 OR 6)
8. ResectionOR resectionsOR segmentectomyOR
segmentectomies
9. (7 AND 8)
10. Hepatectomy OR hepatectomies
11.MeSHdescriptorHepatectomy explode all trees
12. (9 OR 10 OR 11)
13. (4 AND 12)
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(Continued)
MEDLINE (PubMed) January 1947 to September 2015 (Blood loss OR bleeding OR hemorrhage OR
haemorrhage OR hemorrhages OR haemorrhages
OR hemostasis OR haemostasis OR transfusion
OR “Hemorrhage” [MeSH] OR “Blood Transfu-
sion” [MeSH]) AND (((liver OR hepatic OR hep-
ato* OR “liver” [MeSH]) AND (resection OR re-
sections OR segmentectomy OR segmentectomies)
) OR hepatectomy OR hepatectomies OR “hepa-
tectomy” [MeSH]) AND ((randomized controlled
trial [pt] OR controlled clinical trial [pt] OR ran-
domized [tiab] OR placebo [tiab] OR drug therapy
[sh] OR randomly [tiab] OR trial [tiab] OR groups
[tiab]) NOT (animals [mh] NOT humans [mh]))
Embase (OvidSP) January 1974 to September 2015 1. (Blood loss or bleeding or hemorrhage or haemor-
rhage or hemorrhages or haemorrhages or hemosta-
sis or haemostasis or transfusion).af
2. Exp bleeding/or exp blood transfusion/
3 .1 or 2
4. (Liver or hepatic or hepato*).af
5. (Resectionor resections or segmentectomyor seg-
mentectomies).af
6. 4 and 5
7. (Hepatectomy or hepatectomies).af
8. Exp Liver Resection/
9. 6 or 7 or 8
10. 3 and 9
11. Exp crossover-procedure/or exp double-blind
procedure/or exp randomized controlled trial/or
single-blind procedure/
12. (Random* OR factorial* OR crossover* OR
cross over* OR cross-over* OR placebo* OR dou-
ble* adj blind* OR single* adj blind* OR assign*
OR allocat* OR volunteer*).af
13. 11 OR 12
14. 10 AND 13
Science Citation Index Expanded (Web of
Science)
January 1945 to September 2015 1. TS=(Blood loss OR bleeding OR hemorrhage
OR haemorrhage OR hemorrhages OR haemor-
rhages OR hemostasis OR haemostasis OR trans-
fusion)
2. TS=((liver OR hepatic OR hepato*) AND (re-
section OR resections OR segmentectomy OR
segmentectomies) OR hepatectomy OR hepatec-
tomies)
3. TS=(random*OR rct*OR crossoverORmasked
OR blind* OR placebo* ORmeta-analysis OR sys-
tematic review* OR meta-analys*)
4. 1 AND 2 AND 3
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(Continued)
World Health Organization International
Clinical Trials Registry Platform Search
Portal (www.who.int/ictrp)
September 2015 Liver resection OR hepatectomy
Appendix 2. WinBUGS code
Binary outcome
Binary outcome - fixed-effect model
# Binomial likelihood, logit link
# Fixed effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH trials
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood
# model for linear predictor
logit(p[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]
# expected value of the numerators
rhat[i,k] <- p[i,k] * n[i,k]
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))
}
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
# pair wise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
338Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
} # *** PROGRAM ENDS
Binary outcome - random-effects model
# Binomial likelihood, logit link
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH trials
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood
logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions (with multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment for multi-arm randomised clinical trialss
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# pair wise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
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}} # *** PROGRAM ENDS
Binary outcome - inconsistency model (random-effects)
# Binomial likelihood, logit link, inconsistency model
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH trials
delta[i,1]<-0 # treatment effect is zero in control arm
mu[i] ~ dnorm(0,.0001) # vague priors for trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood
logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor
#Deviance contribution
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))
}
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ~ dnorm(d[t[i,1],t[i,k]] ,tau)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
for (c in 1:(nt-1)) { # priors for all mean treatment effects
for (k in (c+1):nt) { d[c,k] ~ dnorm(0,.0001) }
}
sd ~ dunif(0,5) # vague prior for between-trial standard deviation
var <- pow(sd,2) # between-trial variance
tau <- 1/var # between-trial precision
} # *** PROGRAM ENDS
Continuous outcome (mean difference)
Continuous outcome (mean difference) - fixed-effect model
# Normal likelihood, identity link
# Fixed effect model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH trials
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
y[i,k] ~ dnorm(theta[i,k],prec[i,k])
# model for linear predictor
theta[i,k] <- mu[i] + d[t[i,k]] - d[t[i,1]]
#Deviance contribution
340Methods to decrease blood loss during liver resection: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k]
}
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for control arm
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- rank(d[],k) # assumes lower is better
# rk[k] <- nt+1-rank(d[],k) # assumes lower outcome is worse
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Continuous outcome (mean difference) - random-effects model
# Normal likelihood, identity link
# Random effects model for multi-arm trials
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH trials
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
y[i,k] ~ dnorm(theta[i,k],prec[i,k])
theta[i,k] <- mu[i] + delta[i,k] # model for linear predictor
#Deviance contribution
dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k]
}
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific MD distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of MD distributions, with multi-arm trial correction
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of MD distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment, multi-arm randomised clinical trialss
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for control arm
# vague priors for treatment effects
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for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- rank(d[],k) # assumes lower is better
# rk[k] <- nt+1-rank(d[],k) # assumes lower outcome is worse
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Continuous outcome (mean difference) - inconsistency model (random-effects)
# Normal likelihood, identity link
# Random effects model for multi-arm trials
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH trials
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # binomial likelihood
theta[i,k] <- mu[i] + delta[i,k] # model for linear predictor
#Deviance contribution
dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k]
}
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific MD distributions
delta[i,k] ~ dnorm(d[t[i,1],t[i,k]] ,tau)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
for (c in 1:(nt-1)) { # priors for all mean treatment effects
for (k in (c+1):nt) { d[c,k] ~ dnorm(0,.0001) }
}
sd ~ dunif(0,5) # vague prior for between-trial standard deviation
tau <- pow(sd,-2) # between-trial precision
} # *** PROGRAM ENDS
Continuous outcome (standardised mean difference)
We will calculate the standardised mean difference and its standard error for each treatment comparison using the statistical algorithms
used by RevMan 2014.
Continuous outcome (standardised mean difference) - fixed-effect model
# Normal likelihood, identity link
# Trial-level data given as treatment differences
# Fixed effects model
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model{ # *** PROGRAM STARTS
for(i in 1:ns2) { # LOOP THROUGH 2-ARM trials
y[i,2] ~ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials
#Deviance contribution for trial i
resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]
}
for(i in (ns2+1):(ns2+ns3)) { # LOOP THROUGH THREE-ARM trials
for (k in 1:(na[i]-1)) { # set variance-covariance matrix
for (j in 1:(na[i]-1)) {
Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)
}
}
Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i„]) #Precision matrix
# multivariate normal likelihood for 3-arm trials
y[i,2:na[i]] ~ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)])
#Deviance contribution for trial i
for (k in 1:(na[i]-1)){ # multiply vector & matrix
ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)]
z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)])
}
resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)])
}
for(i in 1:(ns2+ns3)){ # LOOP THROUGH ALL trials
for (k in 2:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
delta[i,k] <- d[t[i,k]] - d[t[i,1]]
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- nt+1-rank(d[],k) # assumes higher HRQoL is “good”
#rk[k] <- rank(d[],k) # assumes higher outcome is “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Continuous outcome (standardised mean difference) - random-effects model
# Normal likelihood, identity link
# Trial-level data given as treatment differences
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns2) { # LOOP THROUGH 2-ARM trials
y[i,2] ~ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials
#Deviance contribution for trial i
resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]
}
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for(i in (ns2+1):(ns2+ns3)) { # LOOP THROUGH THREE-ARM trials
for (k in 1:(na[i]-1)) { # set variance-covariance matrix
for (j in 1:(na[i]-1)) {
Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)
}
}
Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i„]) #Precision matrix
# multivariate normal likelihood for 3-arm trials
y[i,2:na[i]] ~ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)])
#Deviance contribution for trial i
for (k in 1:(na[i]-1)){ # multiply vector & matrix
ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)]
z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)])
}
resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)])
}
for(i in 1:(ns2+ns3)){ # LOOP THROUGH ALL trials
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
for (k in 2:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
}
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific SMD distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of random effects distributions, with multi-arm trial correction
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of random effects distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment, multi-arm randomised clinical trialss
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- nt+1-rank(d[],k) # assumes higher HRQoL is “good”
# rk[k] <- rank(d[],k) # assumes higher outcome is “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Continuous outcome (standardised mean difference) - inconsistency model (random-effects)
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# Normal likelihood, identity link
# Trial-level data given as treatment differences
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns2) { # LOOP THROUGH 2-ARM trials
y[i,2] ~ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials
#Deviance contribution for trial i
resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]
}
for(i in (ns2+1):(ns2+ns3)) { # LOOP THROUGH THREE-ARM trials
for (k in 1:(na[i]-1)) { # set variance-covariance matrix
for (j in 1:(na[i]-1)) {
Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)
}
}
Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i„]) #Precision matrix
# multivariate normal likelihood for 3-arm trials
y[i,2:na[i]] ~ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)])
#Deviance contribution for trial i
for (k in 1:(na[i]-1)){ # multiply vector & matrix
ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)]
z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)])
}
resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)])
}
for(i in 1:(ns2+ns3)){ # LOOP THROUGH ALL trials
for (k in 2:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
}
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific SMD distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of random effects distributions
md[i,k] <- d[t[i,k]] - d[t[i,1]]
# precision of random effects distributions
taud[i,k] <- tau *2*(k-1)/k
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
} # *** PROGRAM ENDS
Count outcome
Count outcome - fixed-effect model
# Poisson likelihood, log link
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# Fixed effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH trials
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dpois(theta[i,k]) # Poisson likelihood
theta[i,k] <- lambda[i,k]*E[i,k] # failure rate * exposure
# model for linear predictor
log(lambda[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]
#Deviance contribution
dev[i,k] <- 2*((theta[i,k]-r[i,k]) + r[i,k]*log(r[i,k]/theta[i,k])) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
# pair wise RRs and LRRs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
rater[c,k] <- exp(d[k] - d[c])
lrater[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Count outcome - random-effects model
# Poisson likelihood, log link
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH trials
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dpois(theta[i,k]) # Poisson likelihood
theta[i,k] <- lambda[i,k]*E[i,k] # failure rate * exposure
# model for linear predictor
log(lambda[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]
#Deviance contribution
dev[i,k] <- 2*((theta[i,k]-r[i,k]) + r[i,k]*log(r[i,k]/theta[i,k])) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
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for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions (with multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment for multi-arm randomised clinical trialss
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# pair wise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Count outcome - inconsistency model (random-effects)
# Poisson likelihood, log link
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH trials
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dpois(theta[i,k]) # Poisson likelihood
theta[i,k] <- lambda[i,k]*E[i,k] # failure rate * exposure
# model for linear predictor
log(lambda[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]
#Deviance contribution
dev[i,k] <- 2*((theta[i,k]-r[i,k]) + r[i,k]*log(r[i,k]/theta[i,k])) }
# summed residual deviance contribution for this trial
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resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of LRR distributions (without multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]]
# precision of LOR distributions (without multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
} # *** PROGRAM ENDS
Appendix 3. Raw data
Legend
Binary outcomes
# ns= number of studies; nt=number of treatments; t[,1] indicates control and t[,2] indicates intervention. In a three-arm trial, t[,3]
indicates the second intervention. r[,1] indicates the number with events in the control group; n[,1] indicates the total number of
people in the control group. r[,2], n[,2], r[,3], and n[,3] indicate the corresponding numbers for intervention and second intervention.
In two-arm trials, r[,3] and n[,3] will be entered as ’NA’ to indicate empty cells. na[] indicates the number of arms in the trial. Study
indicates the study name and is for reference only.
# Continuous outcomes
# ns= number of studies; nt=number of treatments; t[,1] indicates control and t[,2] indicates intervention. In a three-arm trial, t[,3]
indicates the second intervention. y[,1] indicates the mean in the control group; se[,1] indicates the standard error in the control group.
y[,2], se[,2], y[,3], and se[,3] indicate the corresponding numbers for intervention and second intervention. In two-arm trials, y[,3]
and se[,3] will be entered as ’NA’ to indicate empty cells. na[] indicates the number of arms in the trial. Study indicates the study name
and is for reference only.
# Count outcomes
# ns= number of studies; nt=number of treatments; t[,1] indicates control and t[,2] indicates intervention. In a three-arm trial, t[,3]
indicates the second intervention. r[,1] indicates the number of events in the control group; E[,1] indicates the total number of people
in the control group. r[,2], E[,2], r[,3], and E[,3] indicate the corresponding numbers for intervention and second intervention. In
two-arm trials, r[,3] and E[,3] will be entered as ’NA’ to indicate empty cells. na[] indicates the number of arms in the trial. Study
indicates the study name and is for reference only.
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Cardiopulmonary interventions
#Blood transfusion red blood cell; treatment codes: 1 = Control; 2 = ANH; 3 = ANH Hypotension; 4 = ANH Lowcentral venous
pressure; 5 = Lowcentral venous pressure
list(nt=5,ns=6)
y[,1] se[,1] y[,2] se[,2] y[,3] se[,3] t[,1] t[,2] t[,3] na[] #study
1.6625 0.2 0.4175 0.16 0 0.01 1 2 3 3 #Yao 2006
0.8775 0.05 1.145 0.12 NA NA 1 4 NA 2 #Guo 2013
2.75 0.4 1.3 0.075 NA NA 1 5 NA 2 #El-Kharboutly 2004
3.215 0.58 1.3125 0.12 NA NA 1 5 NA 2 #Wang 2006
0.44 0.37 0.7 0.35 NA NA 4 5 NA 2 #Jarnagin 2008
0 0.47 0 0.47 NA NA 4 5 NA 2 #Matot 2002
END
#Blood loss; treatment codes: 1 = Control; 2 = ANH; 3 = ANH Hypotension; 4 = ANH Lowcentral venous pressure; 5 = Hypoven-
tilation; 6 = Lowcentral venous pressure
list(nt=6,ns=9)
y[,1] se[,1] y[,2] se[,2] y[,3] se[,3] t[,1] t[,2] t[,3] na[] #study
0.651 0.01 0.654 0.05 0.404 0.06 1 2 3 3 #Yao 2006
0.711 0.02 0.735 0.02 NA NA 1 4 NA 2 #Guo 2013
0.63 0.41 0.63 0.4 NA NA 1 5 NA 2 #Hasegawa 2002
0.783 0.08 0.589 0.07 NA NA 1 6 NA 2 #Choi 2007
1.021 0.07 0.49 0.06 NA NA 1 6 NA 2 #El-Kharboutly 2004
0.584 0.1 0.499 0.1 NA NA 1 6 NA 2 #Kato 2008
2.329 0.51 0.904 0.04 NA NA 1 6 NA 2 #Wang 2006
0.8 0.09 0.7 0.09 NA NA 4 6 NA 2 #Jarnagin 2008
0.75 0.41 0.89 0.41 NA NA 4 6 NA 2 #Matot 2002
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(Continued)
END
Methods of parenchymal transection
#Adverse events proportion; treatment codes: 1 = ClampCrush; 2 = cavitron ultrasonic surgical aspirator; 3 = Hydrojet; 4 = RFDS;
5 = SharpTransection; 6 = Stapler
list(nt=6,ns=8)
r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] t[,1] t[,2] t[,3] na[] #study
15 20 7 20 10 20 1 2 4 3 #Doklestic 2012
17 25 25 25 NA NA 1 2 NA 2 #Koo 2005
14 66 20 66 NA NA 1 2 NA 2 #Takayama 2001
7 40 9 40 NA NA 1 4 NA 2 #Arita 2005
17 50 18 50 NA NA 1 4 NA 2 #Muratore 2014
16 41 17 41 NA NA 1 5 NA 2 #Smyrniotis 2005
30 65 31 65 NA NA 1 6 NA 2 #Rahbari 2014
8 30 3 31 NA NA 2 3 NA 2 #Rau 2001
END
#Adverse events number; treatment codes: 1 = ClampCrush; 2 = Cavitron ultrasonic surgical aspirator; 3 = Hydrojet; 4 = RFDS; 5
= SharpTransection; 6 = Stapler
list(nt=6,ns=7)
r[,1] E[,1] r[,2] E[,2] r[,3] E[,3] t[,1] t[,2] t[,3] na[] #study
16 66 25 66 NA NA 1 2 NA 2 #Takayama 2001
7 40 9 40 NA NA 1 4 NA 2 #Arita 2005
11 60 15 60 NA NA 1 4 NA 2 #Ikeda 2009
2 26 12 24 NA NA 1 4 NA 2 #Lupo 2007
16 41 18 41 NA NA 1 5 NA 2 #Smyrniotis 2005
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8 25 7 25 9 25 2 3 4 3 #Lesurtel 2005
19 50 22 50 NA NA 2 6 NA 2 #Savlid 2013
END
#Blood transfusion proportion; treatment codes: 1 = ClampCrush; 2 = Cavitron ultrasonic surgical aspirator; 3 = Hydrojet; 4 =
RFDS; 5 = SharpTransection
list(nt=5,ns=8)
r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] t[,1] t[,2] t[,3] na[] #study
2 20 3 20 4 20 1 2 4 3 #Doklestic 2012
1 66 1 66 NA NA 1 2 NA 2 #Takayama 2001
0 40 2 40 NA NA 1 4 NA 2 #Arita 2005
2 60 2 60 NA NA 1 4 NA 2 #Ikeda 2009
13 26 8 24 NA NA 1 4 NA 2 #Lupo 2007
13 50 16 50 NA NA 1 4 NA 2 #Muratore 2014
15 41 13 41 NA NA 1 5 NA 2 #Smyrniotis 2005
8 25 8 25 5 25 2 3 4 3 #Lesurtel 2005
END
Methods of vascular occlusion
#Serious adverse events proportion; treatment codes: 1 = Control; 2 = ConHVE; 3 = ConPTC; 4 = ConSelectiveHVE; 5 = ConSe-
lectivePTC; 6 = IntPTC
list(nt=6,ns=8)
r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] t[,1] t[,2] t[,3] na[] #study
4 63 2 63 NA NA 1 6 NA 2 #Capussotti 2006
9 63 14 63 NA NA 1 6 NA 2 #Lee 2012
2 25 1 25 NA NA 1 6 NA 2 #Park 2012
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3 60 2 58 NA NA 2 3 NA 2 #Chen 2006
2.5 81 0.5 81 NA NA 3 4 NA 2 #Si-Yuan 2014
22 60 12 60 NA NA 3 5 NA 2 #Ni 2013
4 18 2 17 NA NA 3 6 NA 2 #Capussotti 2003
1 40 4 40 NA NA 5 6 NA 2 #Liang 2009
END
#Adverse events proportion; treatment codes: 1 =Control; 2 =ConHVE; 3 =ConPTC; 4 =ConSelectiveHVE; 5 =ConSelectivePTC;
6 = IntPTC; 7 = IntSelectivePTC
list(nt=7,ns=12)
r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] t[,1] t[,2] t[,3] na[] #study
16 63 21 63 NA NA 1 6 NA 2 #Capussotti 2006
15 63 26 63 NA NA 1 6 NA 2 #Lee 2012
15 50 13 50 NA NA 1 6 NA 2 #Man 1997
9 20 5 20 NA NA 1 6 NA 2 #Man 2003
19 60 17 58 NA NA 2 3 NA 2 #Chen 2006
17 80 9 80 NA NA 3 4 NA 2 #Si-Yuan 2014
24 60 13 60 NA NA 3 5 NA 2 #Ni 2013
13 42 11 44 NA NA 3 6 NA 2 #Belghiti 1999
4 18 2 17 NA NA 3 6 NA 2 #Capussotti 2003
9 40 8 40 NA NA 5 6 NA 2 #Liang 2009
15 39 12 41 NA NA 6 7 NA 2 #Figueras 2005
8 28 10 30 NA NA 6 7 NA 2 #Wu 2002
END
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#Blood transfusion proportion; treatment codes: 1 = Control; 2 = ConHVE; 3 = ConPTC; 4 = ConSelectiveHVE; 5 = ConSelec-
tivePTC; 6 = IntPTC; 7 = IntSelectivePTC
list(nt=7,ns=13)
r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] t[,1] t[,2] t[,3] na[] #study
6 15 1 19 NA NA 1 3 NA 2 #Chouker 2004
1 63 8 63 NA NA 1 6 NA 2 #Capussotti 2006
9 63 14 63 NA NA 1 6 NA 2 #Lee 2012
29 50 18 50 NA NA 1 6 NA 2 #Man 1997
19 20 12 20 NA NA 1 6 NA 2 #Man 2003
8 60 27 58 NA NA 2 3 NA 2 #Chen 2006
22 80 13 80 NA NA 3 4 NA 2 #Si-Yuan 2014
4 60 6 60 NA NA 3 5 NA 2 #Ni 2013
12 42 14 44 NA NA 3 6 NA 2 #Belghiti 1999
5 18 5 17 NA NA 3 6 NA 2 #Capussotti 2003
15 40 14 40 NA NA 5 6 NA 2 #Liang 2009
4 39 6 41 NA NA 6 7 NA 2 #Figueras 2005
12 28 5 30 NA NA 6 7 NA 2 #Wu 2002
END
#Blood transfusion red blood cell; treatment codes: 1 = Control; 2 = ConHVE; 3 = ConPTC; 4 = ConSelectiveHVE; 5 = ConSelec-
tivePTC; 6 = IntPTC; 7 = IntSelectivePTC
list(nt=7,ns=10)
y[,1] se[,1] y[,2] se[,2] y[,3] se[,3] t[,1] t[,2] t[,3] na[] #study
1.9 1.02 1.3 0.85 NA NA 1 3 NA 2 #Clavien 1996
1.5 0.45 0 0.45 NA NA 1 6 NA 2 #Man 1997
2.5 0.64 2.9 0.8 NA NA 2 3 NA 2 #Belghiti 1996
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2.2 0.42 1 0.42 NA NA 3 4 NA 2 #Si-Yuan 2014
1.4 0.05 1.2 0.03 NA NA 3 5 NA 2 #Ni 2013
3 0.4 2.3 0.39 NA NA 3 6 NA 2 #Belghiti 1999
0.5 0.02 0.5 0.27 NA NA 3 6 NA 2 #Capussotti 2003
1.3675 0.09 1.4825 0.15 NA NA 5 6 NA 2 #Liang 2009
0.36 0.16 0.34 0.14 NA NA 6 7 NA 2 #Figueras 2005
2.5425 0.26 2.24 0.4 NA NA 6 7 NA 2 #Wu 2002
END
#Blood loss; treatment codes: 1 = Control; 2 = ConHVE; 3 = ConPTC; 4 = ConSelectiveHVE; 5 = ConSelectivePTC; 6 = IntPTC;
7 = IntSelectivePTC
list(nt=7,ns=16)
y[,1] se[,1] y[,2] se[,2] y[,3] se[,3] t[,1] t[,2] t[,3] na[] #study
2.17 0.22 1.38 0.16 NA NA 1 3 NA 2 #Chouker 2004
0.32 0.05 0.328 0.02 NA NA 1 3 NA 2 #Dayangac 2010
0.671 0.32 0.65 0.16 NA NA 1 3 NA 2 #Pietsch 2010
0.204 0.02 0.184 0.03 NA NA 1 6 NA 2 #Capussotti 2006
0.489 0.06 0.488 0.07 NA NA 1 6 NA 2 #Lee 2012
1.99 0.18 1.28 0.18 NA NA 1 6 NA 2 #Man 1997
0.324 0.03 0.486 0.06 NA NA 1 6 NA 2 #Park 2012
1.195 0.21 0.989 0.26 NA NA 2 3 NA 2 #Belghiti 1996
0.42 0.03 0.77 0.04 NA NA 2 3 NA 2 #Chen 2006
0.777 0.09 0.529 0.09 NA NA 3 4 NA 2 #Si-Yuan 2014
0.2 0.1 0.3 0.1 NA NA 3 5 NA 2 #Ni 2013
1.18 0.12 1.29 0.14 NA NA 3 6 NA 2 #Belghiti 1999
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0.733 0.12 0.732 0.15 NA NA 3 6 NA 2 #Capussotti 2003
0.649 0.04 0.57 0.05 NA NA 5 6 NA 2 #Liang 2009
0.671 0.09 0.735 0.06 NA NA 6 7 NA 2 #Figueras 2005
1.685 0.17 1.159 0.22 NA NA 6 7 NA 2 #Wu 2002
END
Appendix 4. Technical details of network meta-analysis
The posterior probabilities (effect estimates or values) of the treatment contrast (i.e., log odds ratio or mean difference) may vary
depending upon the priors and initial values to start the simulations.
We used non-informative priors for all distributions. For distributions of effect estimates for different studies and different treatments,
normal distribution with mean = 0 and variance = 10,000 were used. For between-study standard deviation in random-effects models, a
uniform distribution with limits of 0 and 5was used for all analyses. The only exception was adverse events proportion in the comparison
of parenchymal transection methods, where we chose the random-effects model based on the fit, but the posterior distribution was
determined by the prior distribution. For this comparison, the distribution for between-study standard deviation was changed to a
uniform distribution with limits of 0 and 2.
In order to control the random error due to the choice of initial values, we performed the network analysis for three different initial
values (priors) as per the guidance from the National Institute for Health and Care Excellence (NICE) Decision Support Unit (DSU)
documents (Dias 2013a). If the results from three different initial values (’chains’) are similar (convergence), then the results are reliable.
It is important to discard the results of the initial simulations as they can be significantly affected by the choice of the initial values and
only include the results of the simulations obtained after the convergence. The discarding of the initial simulations is called ’burn in’.
We ran the models for all outcomes for 30,000 simulations for ’burn in’ for three different chains (a set of initial values). We ran the
models for another 100,000 simulations to obtain the effect estimates. We obtained the effect estimates from the results of all the three
chains (different initial values). We ensured that the results in the three different chains were similar in order to control for random
error due to the choice of initial values. This was done in addition to the visual inspection of convergence obtained after simulations in
the burn in. The mean effect estimate and 95% credible intervals were the median and 2.5% percentile and 97.5% credible intervals.
We ran three different models for each outcome. Fixed-effect model assumes that the treatment effect is the same across studies. The
random-effects consistency model assumes that the treatment effect is distributed normally across the studies but assumes that the
transitivity assumption is satisfied (i.e., the population studied, the definition of outcomes, and the methods used were similar across
studies and that there is consistency between the direct comparison and indirect comparison). A random-effects inconsistency model
does not assume transitivity assumption. If the inconsistency model resulted in a better model fit than the consistency model, the
results of the network meta-analysis can be unreliable and so should be interpreted with extreme caution. If there was evidence of
inconsistency, we planned to identify areas in the network where substantial inconsistency might be present in terms of clinical and
methodological diversities between trials and, when appropriate, limit network meta-analysis to a more compatible subset of trials.
The choice of the model between fixed-effect model and random-effects model was based on the model fit as per the guidelines of the
NICE TSU (Dias 2013a). The model fit was assessed by deviance residuals and Deviance Information Criteria (DIC) according to
NICE TSU guidelines (Dias 2013a). A difference of three or five in the DIC is not generally considered important (Dias 2012b). We
used the simpler model, that is, fixed-effect model was used if the DIC were similar between the fixed-effect model and random-effects
model. We used the random-effects model if it resulted in a better model fit as indicated by a DIC lower than that of fixed-effect model
by at least three.
We have calculated the effect estimates of the treatment and the 95% credible intervals using the formulae for calculating the effect
estimates in indirect comparisons (Bucher 1997):
ln(ORAC) = ln(ORAB) - ln(ORCB ) and
Var(ln ORAC) = Var (ln ORAB) + Var (ln ORCB )
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where ln indicates natural logarithm; OR indicates odds ratio; Var indicates variance; and A, B, and C are three different treatments.
Appendix 5. Simulated data
#Simulation used for analysis; treatments 1,2,3,4; ln effect estimates: 2 vs 1 = 0, 3 vs 1 = 0.1, 4 vs 1 =- 0.15, 3 vs 2 = 0.1, 4 vs 2 = -0.
15; 4 vs 3 = 0.25)
Methods of simulating data: We have simulated the data using Excel. For this purpose, we have fixed the ln (natural logarithm) odds
of the comparisons at the predetermined values. We have then added or subtracted a random value between -0.25 and 0.25 from
the resulting odds ratio to determine the odds ratio of the individual study. We simulated the odds ratio for 15 studies. We then
performed the network meta-analysis using the codes provided in Appendix 2. We also performed a meta-analysis of the simulated
data using frequentist meta-analysis in RevMan; this showed the effect estimates obtained by the frquentist estimates included the
predetermined effect estimate and was close but not the same to the predetermined effect estimate
list(nt=4,ns=15)
r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] t[,1] t[,2] t[,3] na[] #study
22 23 22 23 NA NA 1 2 NA 2 #1
12 30 20 60 NA NA 1 2 NA 2 #2
4 20 7 40 NA NA 1 2 NA 2 #3
12 22 13 22 NA NA 1 2 NA 2 #4
20 24 19 24 NA NA 1 3 NA 2 #5
24 26 24 26 NA NA 1 3 NA 2 #6
16 20 16 20 NA NA 1 4 NA 2 #7
9 22 9 22 NA NA 1 4 NA 2 #8
5 26 6 26 NA NA 1 4 NA 2 #9
27 28 27 28 NA NA 1 4 NA 2 #10
9 21 9 21 NA NA 1 4 NA 2 #11
4 20 4 20 NA NA 2 3 NA 2 #12
18 22 18 22 NA NA 2 4 NA 2 #13
5 27 11 54 NA NA 3 4 NA 2 #14
5 27 13 54 NA NA 3 4 NA 2 #15
END
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Appendix 6. Results of simulation
Frequentist direct1 Network (fixed-effect model)2 Network (random-effects model)2
0.89 [0.48, 1.66] 0.90 [0.51,1.58] 0.90 [0.49,1.67]
0.83 [0.26, 2.72] 0.83 [0.40,1.69] 0.84 [0.39,1.81]
1.05 [0.56, 1.99] 1.04 [0.60,1.81] 1.05 [0.58,1.92]
1.00 [0.21, 4.71] 0.93 [0.41,2.08] 0.93 [0.39,2.20]
1.00 [0.22, 4.63] 1.16 [0.57,2.36] 1.16 [0.53,2.54]
1.26 [0.55, 2.86] 1.25 [0.65,2.48] 1.25 [0.60,2.56]
Footnotes:
1Mean estimate and 95% confidence intervals
2Mean estimate and 95% credible intervals
Appendix 7. Sample size calculation
The overall mortality in the control groups (conventional approach in the comparison ’anterior approach versus conventional approach’;
no autologous blood transfusion in the comparison autologous blood transfusion in the comparison ’autologous blood transfusion
versus control’; no active intervention or control group in the ’cardiopulmonary interventions’; ’clamp-crush method’ for ’parenchymal
transection methods’; no active intervention or control group in the ’methods of dealing with raw surface’; no vascular occlusion in the
’methods of vascular occlusion’; and no active intervention or control group in the ’pharmacological interventions’), in which mortality
was reported, was 1.8% (21/1196). Based on this control group proportion, a relative risk reduction of 20% in the experimental group,
type I error of 5%, and type II error of 20%, the required information size for the outcome measure of perioperative mortality was
38,614 participants. This is the sample size required in a meta-analysis if there was no heterogeneity. In the presence of I2 of 25%, the
required sample size is 38,614/(1-0.25) = 51,485; In the presence of I2 of 50%, the required sample size is 38,614/(1-0.5) = 77,228.
Network analyses may be more prone to the risk of random errors than direct comparisons (Del Re 2013). Accordingly, a greater sample
size is required in indirect comparisons than direct comparisons (Thorlund 2012). The power and precision in indirect comparisons
depends upon various factors such as the number of participants included under each comparison and the heterogeneity between the
trials (Thorlund 2012). If there were no heterogeneity across the trials, the sample size in indirect comparisons would be equivalent to
the sample size in direct comparisons. The effective indirect sample size can be calculated using the number of participants included
in each direct comparison (Thorlund 2012). For example, a sample size of 2500 participants in the direct comparison A versus C
(nAC ) and a sample size of 7500 participants in the direct comparison B versus C (nBC ) results in an effective indirect sample size of
1876 participants. However, in the presence of heterogeneity within the comparisons, the sample size required is higher. In the above
scenario, for an I2 statistic for each of the comparisons A versus C (IAC
2) and B versus C (IBC
2) of 25%, the effective indirect sample
size is 1407 participants. For an I2 statistic for each of the comparisons A versus C and B versus C of 50%, the effective indirect sample
size is 938 participants (Thorlund 2012). We planned to calculate the effective indirect sample size using the following generic formula
(Thorlund 2012):
((nAC x (1 - IAC
2)) x (nBC x (1-IBC
2))/((nAC x (1 - IAC
2)) + (nBC x (1-IBC
2)).
However, we did not perform this as the number of participants included in this network analysis is less than that needed in a direct
comparison. In addition, there is currently no method to calculate the effective indirect sample size for a network analysis involving
more than three treatment groups.
Sample size calculations for serious adverse events and blood transfusion (proportion) for a relative risk reduction of 20% in the
experimental group, type I error of 5%, and type II error of 20% are shown below.
Control group proportion for serious adverse events = 16.7% (151/905)
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Required information size for serious adverse events = 3592
Required information size for serious adverse events with I2 of 25% = 3592/(1-0.25) = 4789
Required information size for serious adverse events with I2 of 50% = 3592/(1-0.5) = 7184
Control group proportion for blood transfusion = 21.8% (327/1500)
Required information size for blood transfusion = 2602
Required information size for blood transfusion with I2 of 25% = 3592/(1-0.25) = 3469
Required information size for blood transfusion with I2 of 50% = 3592/(1-0.5) = 5204
Appendix 8. WinBUGS code for subgroup analysis
We have only shown the code for the random-effects model for a binary outcome. The differences in the code are underlined. We
planned to make similar changes for other outcomes.
# Binomial likelihood, logit link, subgroup
# Random effects model for multi-arm trials
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH trials
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood
# model for linear predictor, covariate effect relative to treat in arm 1
logit(p[i,k]) <- mu[i] + delta[i,k] + (beta[t[i,k]]-beta[t[i,1]]) * x[i]
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions (with multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment for multi-arm randomised clinical trialss
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
beta[1] <- 0 # covariate effect is zero for reference treatment
for (k in 2:nt){ # LOOP THROUGH TREATMENTS
d[k] ~ dnorm(0,.0001) # vague priors for treatment effects
beta[k] <- B # common covariate effect
}
B ~ dnorm(0,.0001) # vague prior for covariate effect
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
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# treatment effect when covariate = z[j]
for (k in 1:nt){ # LOOP THROUGH TREATMENTS
for (j in 1:nz) { dz[j,k] <- d[k] + (beta[k]-beta[1])*z[j] }
}
# *** PROGRAM ENDS
Appendix 9. Summary of findings (secondary outcomes): blood transfusion requirements
Methods to decrease blood loss during liver resection: a network meta-analysis: blood transfusion requirements
Patient or population: people undergoing liver resection
Settings: secondary or tertiary setting
Intervention and control: various treatments
Follow-up: perioperative period
Outcomes Anterior ap-
proach versus
conventional
approach
Autol-
ogous blood
donation ver-
sus control
Cardiopul-
monary
interventions
Methods
of parenchy-
mal transec-
tion
Meth-
ods of dealing
with raw sur-
face
Meth-
ods of vascu-
lar occlusion
Pharmaco-
logical inter-
ventions
Treatments
The first treat-
ment listed
is the control.
The
remaining are
interventions
1. Conventional
approach
2. Anterior
approach
1. Control
2. Autologous
blood
donation
1. Control
2. Acute
normov-
olemic
haemodilu-
tion plus low
central venous
pressure
3. Hypoventilation
4. Low
central venous
pressure
1. Clamp-
crush method
2. Cavitron
ultrasonic
surgical
aspirator
3. Hydrojet
4. Radiofrequency
dissecting
sealer
5. Sharp
transection
method
6. Stapler
1. Control
2. Argon
beam
3. Collagen
4. Cyanoacrylate
5. Fibrin
sealant
6. Fibrin
sealant plus
collagen
7. Oxidised
cellulose
8. Plasmajet
1. Control
2. Continuous
hepatic
vascular
exclusion
3. Continuous
portal triad
clamping
4. Continuous
selective
hepatic
vascular
exclusion
5. Continuous
selective
portal triad
clamping
6. Intermittent
portal triad
clamping
1. Control
2. Anti-
thrombin III
3. Recombinant
factor VIIa
4. Tranexamic
acid
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7. Intermittent
selective
portal triad
clamping
Blood transfu-
sion (propor-
tion)
There was
no evidence of
differences in
blood transfu-
sion (propor-
tion) between
the 2 groups
(quality of ev-
idence = very
low)1,2,3,4.
The
blood transfu-
sion (propor-
tion) was
lower in autol-
ogous blood
donation than
control.
Proportion re-
quiring blood
transfusion in
control group:
619 per 1000
Proportion re-
quiring blood
transfusion in
autologous
blood do-
nation group:
111 per 1000
(25 to 409)
Relative ef-
fect: OR 0.18,
95% CrI 0.04
to 0.66
42 partici-
pants; 1.
Quality of ev-
idence = low
1,2.
The
blood transfu-
sion (propor-
tion) was
higher in low
central venous
pressure than
acute normov-
olemic
haemodilu-
tion plus low
central venous
pressure.
Proportion re-
quiring blood
transfusion in
acute normov-
olemic
haemodilu-
tion plus low
central venous
pressure: 118
per 1000
Proportion re-
quiring blood
transfusion in
low central ve-
nous pressure
group: 376per
1000 (184 to
820)
Relative ef-
fect: OR 3.19,
95% CrI 1.56
to 6.95
208 partici-
pants; 2.
Quality of ev-
idence = low
1,2.
There was
no evidence of
*There was no
evidence of
differences in
blood transfu-
sion (propor-
tion) for any
of the compar-
isons
(quality of ev-
idence = very
low)1,2,3,4.
There was
no evidence of
differences in
blood transfu-
sion (propor-
tion) for any
of the compar-
isons
(quality of ev-
idence = very
low)1,2,3,4.
* The
blood transfu-
sion (propor-
tion) was
lower in con-
tinuous portal
triad clamping
than control.
Proportion re-
quiring blood
transfusion in
control group:
300 per 1000
Proportion re-
quiring blood
trans-
fusion in con-
tinuous portal
triad
clamping: 18
per 1000 (0 to
148)
Relative ef-
fect: OR 0.06,
95% CrI 0.00
to 0.49
34 partici-
pants; 1.
Quality of ev-
idence = low
1,2.
The
blood transfu-
sion (propor-
tion) was
higher in con-
tinuous portal
triad clamping
than continu-
ous hepatic
vascular exclu-
The
blood transfu-
sion (propor-
tion)
was lower in
aprotinin than
control.
Proportion re-
quiring blood
transfusion in
control group:
291 per 1000
Proportion re-
quiring blood
transfusion in
aprotinin
group: 90 per
1000 (32 to
227)
Relative ef-
fect: OR 0.31,
95% CrI 0.11
to 0.78.
97 partici-
pants; 1.
Quality of ev-
idence = low
1,2.
The
blood transfu-
sion (propor-
tion) was
lower
in tranexamic
acid than con-
trol
Proportion re-
quiring blood
transfusion in
tranexamic
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differences in
other compar-
isons (quality
of evidence =
very low)1,2,3.
sion
Proportion re-
quiring blood
transfusion
in continuous
hepatic vascu-
lar exclusion:
133 per 1000
Proportion re-
quiring blood
trans-
fusion in con-
tinuous portal
triad clamping
group: 785per
1000 (326 to
2072)
Relative ef-
fect: OR 5.90,
95% CrI 2.45
to 15.58
118 partici-
pants; 1.
Quality of ev-
idence = low
1,2.
There was
no evidence of
differences in
other compar-
isons
(quality of ev-
idence = very
low)1,2,3,4.
acid group: 3
per 1000 (0 to
38)
Relative ef-
fect: OR 0.01,
95% CrI 0.00
to 0.13.
214 partici-
pants; 1.
Quality of ev-
idence = low
1,2.
There was
no evidence of
differences in
other compar-
isons (quality
of evidence =
very low)1,2,3.
Blood transfu-
sion (red
blood cells)
None of the
trials reported
this outcome.
There was no
evidence
of differences
in blood trans-
fusion quan-
tity (red blood
cells) between
the groups
(quality of ev-
idence = very
low)1,2,3.
* The blood
transfusion
quantity (red
blood cells)
was lower in
acute normov-
olemic
haemodilu-
tion.
The mean
blood transfu-
sion quan-
tity (red blood
cells)
The
blood transfu-
sion quan-
tity (red blood
cells)
was lower in
hydrojet than
cavitron ultra-
sonic surgical
aspirator.
The mean
blood transfu-
sion quan-
tity (red blood
The
blood transfu-
sion quan-
tity (red blood
cells)
was lower in
fibrin sealant
than control.
The mean
blood transfu-
sion quan-
tity (red blood
cells) in the
* The blood
trans-
fusion quan-
tity (red blood
cells) was
lower in con-
tinuous portal
triad clamping
than control.
The mean
blood transfu-
sion quan-
tity (red blood
The
blood transfu-
sion quan-
tity (red blood
cells)
was lower in
aprotinin than
control.
The mean
blood transfu-
sion quan-
tity (red blood
cells)
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in the control
group was 1.
38 units.
The mean
blood transfu-
sion quantity
(red
blood cells) in
the acute nor-
movolemic
haemod-
ilution was 1.
25 lower (1.74
to 0.75 lower)
.
20 partici-
pants; 1.
Quality of evi-
dence: very
low)1,2,3.
The mean
blood transfu-
sion quantity
(red
blood cells) in
the acute nor-
movolemic
haemodi-
lution plus hy-
potension was
1.66
lower (2.06 to
1.32 lower).
20 partici-
pants; 1.
Quality of evi-
dence: low1,2.
The mean
blood transfu-
sion quantity
(red
blood cells) in
the acute nor-
movolemic
haemodilu-
tion plus low
central venous
cell)
in the cavitron
ultrasonic sur-
gical aspirator
group was 2.
48 units.
The mean
blood transfu-
sion quan-
tity (red blood
cells)
in the hydrojet
group was 0.
98 lower (1.90
to 0.06 lower)
.
61 partici-
pants; 1.
Quality of ev-
idence = very
low1,2,3.
There was
no evidence of
difference
in blood trans-
fusion quan-
tity (red blood
cells) in the re-
maining com-
parisons
(quality of ev-
idence = very
low)1,2,3.
control group
was 3.5 units.
The mean
blood transfu-
sion quan-
tity (red blood
cells) in the
fibrin sealant
group was 0.
53 lower (1.00
to 0.07 lower)
.
122 partici-
pants; 2.
Quality of ev-
idence = very
low1,2,3.
The
blood transfu-
sion quan-
tity (red blood
cells)
was higher in
fibrin sealant
than
cyanoacrylate.
The mean
blood transfu-
sion quantity
(red
blood cells) in
the cyanoacry-
late group was
2.13 units.
The mean
blood transfu-
sion quan-
tity (red blood
cells) in the
fibrin sealant
group was 2.
20 higher
(1.59 to 2.81
higher).
30 partici-
pants; 1.
cells) in the
control group
was 1.7 units.
The mean
blood transfu-
sion quan-
tity (red blood
cells) in the in-
ter-
mittent portal
triad clamping
was 1.25 lower
(2.39 to 0.10
lower).
(network
meta-analysis)
786 partici-
pants; 10.
Quality of ev-
idence = very
low1,2,3.
The
blood transfu-
sion quan-
tity (red blood
cells) was
lower in inter-
mittent portal
triad clamping
than control.
The mean
blood transfu-
sion quan-
tity (red blood
cells) in the in-
ter-
mittent portal
triad clamping
was 1.50 lower
(2.75 to 0.26
lower).
100 partici-
pants; 1.
Quality of ev-
idence = very
in the control
group was 2.
10 units.
The mean
blood transfu-
sion quantity
(red
blood cells) in
the aprotinin
group was 0.
94
lower (no in-
formation to
calculate con-
fidence inter-
vals; P = 0.
015).
97 partici-
pants; 1.
Quality of ev-
idence = very
lowa,b,c .
There was
no evidence of
difference
in blood trans-
fusion quan-
tity (red blood
cells) in the re-
maining com-
parisons
(quality of ev-
idence = very
low)1,2,3.
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pressure was 0.
27 higher
(0.01 to 0.52
higher).
30 partici-
pants; 1.
Quality of evi-
dence: very
low1,2,3.
There was
no evidence of
differences in
other compar-
isons (quality
of evidence =
very low)1,2,3.
Quality of ev-
idence = low
1,2.
There was
no evidence of
difference
in blood trans-
fusion quan-
tity (red blood
cells) in the re-
maining com-
parisons
(quality of evi-
dence =very
low)1,2,3,4.
low1,2,3.
The
blood transfu-
sion quan-
tity (red blood
cells)
was lower in
continuous se-
lective hepatic
vascular exclu-
sion than con-
tinuous portal
triad
clamping.
The mean
blood transfu-
sion quantity
(red
blood cells) in
the con-
tinuous portal
triad clamping
group was 1.
125 units.
The mean
blood transfu-
sion quan-
tity (red blood
cells) in the
continuous se-
lective hepatic
vascular exclu-
sion was 1.20
lower (2.37 to
0.04 lower).
160 partici-
pants; 1.
Quality of ev-
idence = very
low1,2,3.
The
blood transfu-
sion quan-
tity (red blood
cells)
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was lower in
continuous se-
lective portal
triad clamping
than con-
tinuous portal
triad
clamping.
The mean
blood transfu-
sion quan-
tity (red blood
cells) in the
continuous se-
lective portal
triad clamping
was 0.20 lower
(0.31 to 0.09
lower).
120 partici-
pants; 1.
Quality of ev-
idence = very
low1,2,3.
There was
no evidence of
difference
in blood trans-
fusion quan-
tity (red blood
cells) in the re-
maining com-
parisons
(quality of ev-
idence = very
low)1,2,3,4.
Blood transfu-
sion (platelets)
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
There was
no evidence of
differences in
blood transfu-
sion quantity
(platelets) be-
tween the
groups (qual-
ity of evidence
= very low)
1,2,3.
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Blood transfu-
sion (fresh
frozen plasma)
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
The blood
transfusion
quantity (fresh
frozen plasma)
was lower in
low central ve-
nous pressure
than control
The mean
blood transfu-
sion
quantity (fresh
frozen plasma)
in the control
group was 4.
23 units.
The mean
blood transfu-
sion quan-
tity (red blood
cells) in the
low central ve-
nous pressure
was 2.48 lower
(3.58 to 1.37
lower).
50 partici-
pants; 1.
Quality of ev-
idence = low
1,2.
There was
no evidence of
differences in
the other com-
parison (qual-
ity of evidence
= very low)
1,2,3.
There was
no evidence of
differences in
blood transfu-
sion
quantity (fresh
frozen plasma)
between the
groups (qual-
ity of evidence
= very low)
1,2,3.
The blood
transfusion
quantity (fresh
frozen plasma)
was lower in
fibrin sealant
than
cyanoacrylate.
The mean
blood transfu-
sion
quantity (fresh
frozen plasma)
in
the cyanoacry-
late group was
0.8 units.
The mean
blood transfu-
sion
quantity (fresh
frozen plasma)
in the fibrin
sealant group
was 0.81 lower
(1.04 to 0.62
lower).
30 partici-
pants; 1.
Quality of ev-
idence = very
low1,2,3.
The blood
transfusion
quantity (fresh
frozen plasma)
was higher in
oxidised cellu-
lose than fib-
rin sealant.
The mean
blood transfu-
sion
quantity (fresh
frozen plasma)
None of the
trials reported
this outcome.
There was
no evidence of
differences in
blood transfu-
sion
quantity (fresh
frozen plasma)
between the
groups (qual-
ity of evidence
= very low)
1,2,3.
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in the fibrin
sealant group
was 8.8 units.
The mean
blood transfu-
sion quantity
(fresh frozen
plasma) in the
oxidised cellu-
lose group was
0.53 higher
(0.36 to 0.71
higher).
80 partici-
pants; 2.
Quality of ev-
idence = very
low1,2,3.
There was
no evidence of
difference in
blood transfu-
sion
quantity (fresh
frozen plasma)
in the remain-
ing compar-
isons (quality
of evidence =
very low)1,2,3.
Blood transfu-
sion (cryopre-
cipitate)
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
There was
no evidence of
differences in
blood transfu-
sion quantity
(cryoprecip-
itate) between
the groups
(quality of ev-
idence = very
low)1,2,3.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
Blood loss There was
no evidence of
differences in
blood loss be-
tween the
groups (qual-
There was
no evidence of
differences in
blood loss be-
tween the
groups (qual-
* The blood
loss was lower
in acute nor-
movolemic
haemodi-
lution plus hy-
There was
no evidence of
differences in
blood loss be-
tween the
groups (qual-
There was
no evidence of
differences in
blood loss be-
tween the
groups (qual-
There was
no evidence of
differences in
blood loss be-
tween the
groups (qual-
The blood loss
was lower
in tranexamic
acid than con-
trol (dif-
ference in me-
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ity of evidence
= very low)
1,2,3.
ity of evidence
= very low)
1,2,3.
potension
than control
The mean
blood
loss in the con-
trol group was
0.71 litres.
The mean
blood loss in
the acute nor-
movolemic
haemodi-
lution plus hy-
potension was
0.25
lower (0.37 to
0.13 lower).
20 partici-
pants; 1.
Quality of ev-
idence = very
low1,2,3.
The mean
blood
loss in the low
central venous
pressure was 0.
34 lower (0.46
to 0.22 lower)
.
237 partici-
pants; 4.
Quality of ev-
idence = very
low1,2,3.
The mean
blood loss in
the acute nor-
movolemic
haemodilu-
tion groupwas
0.65 litres.
The blood loss
in acute nor-
movolemic
haemodi-
lution plus hy-
ity of evidence
= very low)
1,2,3.
ity of evidence
= very low)
1,2,3.
ity of evidence
= very low)
1,2,3,4.
dian:
-0.30 litres, P
< 0.001; 214
participants; 1
study).
The mean
blood
loss in the con-
trol group was
0.45 litres.
The mean
blood loss
in the tranex-
amic acid was
0.30 lower (no
in-
formation to
calculate con-
fidence inter-
vals; P < 0.
001).
214 partici-
pants; 1.
Quality of ev-
idence = low
1,2.
There was
no evidence of
difference
in blood trans-
fusion quan-
tity (red blood
cells) in the re-
maining com-
parisons
(quality of ev-
idence = very
low)1,2,3.
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potension was
0.25
lower (0.40 to
0.10 lower)
20 partici-
pants; 1.
Quality of ev-
idence = very
low1,2,3.
There was
no evidence of
differences in
other compar-
isons (quality
of evidence =
very low)1,2,3.
Ma-
jor blood loss
(proportion)
There was no
evidence
of differences
inmajor blood
loss (propor-
tion) between
the 2 groups
(quality of ev-
idence = very
low)1,2,3,4.
There was no
evidence
of differences
inmajor blood
loss (propor-
tion) between
the 2 groups
(quality of ev-
idence = very
low)1,2,3.
There was no
evidence
of differences
inmajor blood
loss (propor-
tion) between
the groups
(quality of ev-
idence = very
low)1,2,3.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
There was no
evidence
of differences
inmajor blood
loss (propor-
tion) between
the groups
(quality of ev-
idence = very
low)1,2,3.
None of the
trials reported
this outcome.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1 Risk of bias was unclear or high in the trial[s) (downgraded by 1 point).
2 Sample size was low (total number of participants fewer than 400 for continuous outcomes and fewer than 300 events in total in
both groups for other outcomes) (downgraded by 1 point).
3 Credible intervals overlapped no effect and clinically significant effect (20% relative risk reduction for binary outcomes;1 unit of
transfusion quantity; 500 ml blood loss) (downgraded by 1 point)
4 There was considerable or substantial heterogeneity in the pair-wise comparison or at least 1 of the comparisons in the network
(downgrade by 2 points)
*Networkmeta-analysis was performed for these outcome because of the availability of direct and indirect comparisons in the network.
The remaining outcomes were analysed by direct comparisons
CrI: credible intervals;MD: mean difference; OR: odds ratio.
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Appendix 10. Summary of findings (secondary outcomes): operating time, hospital stay, and time
needed to return to work
Methods to decrease blood loss during liver resection: a network meta-analysis: operating time, hospital stay, and time-to-
return to work
Patient or population: people undergoing liver resection
Settings: secondary or tertiary setting
Intervention and control: various treatments
Follow-up: peri-operative period
Outcomes Anterior ap-
proach versus
conventional
approach
Autol-
ogous blood
donation ver-
sus control
Cardiopul-
monary
interventions
Methods
of parenchy-
mal transec-
tion
Meth-
ods of dealing
with raw sur-
face
Meth-
ods of vascu-
lar occlusion
Pharmaco-
logical inter-
ventions
Treatments
The first treat-
ment listed
is the control.
The
remaining are
interventions
1. Conventional
approach
2. Anterior
approach
1. Control
2. Autologous
blood
donation
1. Control
2. Acute
normov-
olemic
haemodilu-
tion plus low
central venous
pressure
3. Hypoventilation
4. Low
central venous
pressure
1. Clamp-
crush method
2. Cavitron
ultrasonic
surgical
aspirator
3. Hydrojet
4. Radiofrequency
dissecting
sealer
5. Sharp
transection
method
6. Stapler
1. Control
2. Argon
beam
3. Collagen
4. Cyanoacrylate
5. Fibrin
sealant
6. Fibrin
sealant plus
collagen
7. Oxidised
cellulose
8. Plasmajet
1. Control
2. Continuous
hepatic
vascular
exclusion
3. Continuous
portal triad
clamping
4. Continuous
selective
hepatic
vascular
exclusion
5. Continuous
selective
portal triad
clamping
6. Intermittent
portal triad
clamping
7. Intermittent
selective
portal triad
clamping
1. Control
2. Anti-
thrombin III
3. Recombinant
factor VIIa
4. Tranexamic
acid
Total hospital
stay
There was
no evidence of
differ-
There was
no evidence of
differ-
The total hos-
pital stay was
lower in low
There was
no evidence of
differ-
There was
no evidence of
differ-
The total hos-
pital stay was
lower in con-
There was
no evidence of
differ-
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ences in hos-
pital stay be-
tween the
groups (qual-
ity of evidence
= very low)
1,2,3.
ences in hos-
pital stay be-
tween the
groups (qual-
ity of evidence
= very low)
1,2,3.
central venous
pressure than
control.
The mean
hospital stay
in the control
group was 20.
75 days.
The
mean hospital
stay in the low
central venous
pressure was 2.
42 lower (3.91
to 0.94 lower)
.
197 partici-
pants; 3.
Quality of ev-
idence = very
low1,2,3.
There were no
evidence of
differences in
the remaining
comparisons
(quality of ev-
idence = very
low)a,b,c .
ences in hos-
pital stay be-
tween the
groups (qual-
ity of evidence
= very low)
1,2,3.
ences in hos-
pital stay be-
tween the
groups (qual-
ity of evidence
= very low)
1,2,3.
tinuous portal
triad clamping
than continu-
ous hepatic
vascular exclu-
sion.
The mean
hospital stay
in the contin-
uous hepatic
vascular exclu-
sion groupwas
22 days.
The mean
hospital stay
in the con-
tinuous portal
triad clamping
was 8.00 lower
(13.03 to 2.95
lower).
52 partici-
pants; 1.
Quality of ev-
idence = low
1,2.
The mean
hospital stay
in the con-
tinuous portal
triad clamping
group was 14
days.
The mean
hospi-
tal stay in the
continuous se-
lective hepatic
vascular exclu-
sion was 2.80
lower (4.13 to
1.47 lower).
160 partici-
pants; 1.
Quality of ev-
ences in hos-
pital stay be-
tween the
groups (qual-
ity of evidence
= very low)
1,2,3.
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idence = low
1,2.
There were no
evidence of
differences in
the remaining
comparisons
(quality of ev-
idence = very
low)1,2,3.
ITU stay There was no
evidence
of differences
in ITU stay
between the 2
groups (qual-
ity of evidence
= very low)
1,2,3.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
There was no
evidence
of differences
in ITU stay
between the 2
groups (qual-
ity of evidence
= very low)
1,2,3.
There was no
evidence
of differences
in ITU stay
between the 2
groups (qual-
ity of evidence
= very low)
1,2,3.
The ITU stay
was lower in
continuous se-
lective hepatic
vascular exclu-
sion than con-
tinuous portal
triad
clamping.
The mean
ITU stay in
the con-
tinuous portal
triad clamping
group was 1.5
days.
The mean
ITU stay
in the contin-
uous selective
hepatic vascu-
lar exclusion
group was 0.3
lower (0.55 to
0.06 lower).
160 partici-
pants; 1.
Quality of ev-
idence = very
low1,2,3.
There was
no evidence of
differences in
other compar-
isons (quality
of evidence =
very low)1,2,3.
None of the
trials reported
this outcome.
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Operating
time
There was
no evidence of
differences in
operating time
between the 2
groups (qual-
ity of evidence
= very low)
1,2,3.
There was
no evidence of
differences in
operating time
between the 2
groups (qual-
ity of evidence
= very low)
1,2,3.
The operating
timewas lower
in low central
venous pres-
sure than con-
trol.
The mean op-
erating time in
the control
group was 246
minutes.
The mean op-
erating time in
the low central
venous pres-
sure was 15.32
lower (29.03
to 1.69 lower)
.
192 partici-
pants; 4.
Quality of ev-
idence = very
low1,2,3.
There was
no evidence of
differences in
other compar-
isons (quality
of evidence =
very low)1,2,3.
There was
no evidence of
differences in
operating time
between the
groups (qual-
ity of evidence
= very low)
1,2,3.
The operating
time was
higher in fib-
rin sealant &
collagen than
control.
The mean op-
erating time in
the control
group was 263
minutes.
The mean op-
erating time in
the fibrin
sealant & col-
lagen was 19.
72 higher (2.
93 to 36.57
higher).
300 partici-
pants; 1.
Quality of ev-
idence = very
low1,2,3.
There was
no evidence of
differences in
other compar-
isons (quality
of evidence =
very low)1,2,3.
The operating
time was
lower in inter-
mittent portal
triad clamping
than continu-
ous selective
portal triad
clamping.
The mean op-
erating time in
the
continuous se-
lective portal
triad clamping
group was 236
minutes.
The mean op-
erating time in
the inter-
mittent portal
triad clamping
group was 30.
53 lower (49.
68 to 11.29
lower).
80 partici-
pants; 1.
Quality of ev-
idence = very
low1,2,3.
There was
no evidence of
differences in
other compar-
isons
(quality of ev-
idence = very
low)1,2,3,4.
The operating
timewas lower
in tranexamic
acid than con-
trol.
The mean op-
erating time in
the control
group was 261
minutes.
The mean op-
erating time in
the
tranexamic
acid was 52.20
lower (no in-
formation to
calculate con-
fidence inter-
vals; P = 0.
003).
214 partici-
pants; 1.
Quality of ev-
idence = low
1,2.
There was
no evidence of
differences in
other compar-
isons (quality
of evidence =
very low)1,2,3.
Time needed
to return to
work
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
None of the
trials reported
this outcome.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
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change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1 Risk of bias was unclear or high in the trial[s) (downgraded by 1 point).
2 Sample size was low (total number of participants fewer than 400 for continuous outcomes and fewer than 300 events in total in
both groups for other outcomes) (downgraded by 1 point).
3 Credible intervals overlapped no effect and clinically significant effect (20% relative risk reduction for binary outcomes; 1 day of
hospital stay, intensive therapy unit stay, and time-to-return to work; 15 minutes of operating time) (downgraded by 1 point)
4 There was considerable or substantial heterogeneity in the pair-wise comparison or at least 1 of the comparisons in the network
(downgrade by 2 points)
*Networkmeta-analysis was not performed for any of the outcomes because of the lack of availability of direct and indirect comparisons
in the network
CrI:credible intervals; ITU: intensive therapy unit;MD: mean difference; OR: odds ratio.
WH A T ’ S N E W
Last assessed as up-to-date: 23 September 2015.
Date Event Description
18 July 2016 New citation required and conclusions have changed The conclusions changed from “Very low quality evidence
suggested that liver resection using a radiofrequency dissect-
ing sealer without vascular occlusion or fibrin sealant may in-
crease serious adverse events, and this should be evaluated in
further randomised clinical trials. The risk of serious adverse
events with liver resection using no special equipment com-
pared with more complex methods requiring special equip-
ment was uncertain due to the very low quality of the ev-
idence. The credible intervals were wide and considerable
benefit or harm with a specific method of liver resection can-
not be ruled out” into “Low-quality evidence suggests that
liver resection using a radiofrequency dissecting sealer may
be associated with more adverse events than with the clamp-
crush method. Low-quality evidence also suggests that the
proportion of participants requiring a blood transfusion was
higher in the groups receiving low central venous pressure
than in those receiving acute normovolemic haemodilution
plus low central venous pressure; very low-quality evidence
suggests that blood transfusion quantity (red blood cells) was
lower in the fibrin sealant group than in the control; blood
transfusion quantity (fresh frozen plasma) was higher in the
oxidised cellulose group than in the fibrin sealant group; and
blood loss, total hospital stay, and operating time were lower
with low central venous pressure than control. There is no
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evidence to suggest that using special equipment for liver re-
section is of any benefit in decreasing the mortality, morbid-
ity, or blood transfusion requirements (very low-quality evi-
dence). Radiofrequency dissecting sealer should not be used
outside the clinical trial setting since there is low-quality ev-
idence for increased harm without any evidence of benefits.
In addition, it should be noted that the sample size was small
and the credible intervals were wide, and considerable benefit
or harm with a specific method of liver resection cannot be
ruled out.”
18 July 2016 New search has been performed We performed a new search on 23 September 2015. Because
of the revised inclusion criteria, we could include 67 trials,
compared to 9 trials in the previous version
16 July 2016 Amended We revised the inclusion criteria and methods. This allowed
the inclusion of 67 trials, compared to 9 trials in the previous
version. This also led to changes in the conclusions
C O N T R I B U T I O N S O F A U T H O R S
Elisabetta Moggia identified the studies, extracted the data, and completed sections of the review.
Benjamin Rousse re-analysed the network meta-analysis and revised the errors in the analysis.
Constantinos Simillis identified the studies, extracted the data, performed part of the analysis, and drafted the previous version of
review (Simillis 2014).
Tianjing Li critically reviewed the content, particularly in relation to the network meta-analysis.
Brian R Davidson critically commented on the review.
Kurinchi S Gurusamy performed the analysis and revised the review.
All review authors agreed on this review version before publication.
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Review authors perform research related to decreasing blood loss in liver resection. This includes clinical studies. No other conflicts of
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. We calculated the odds ratios (OR) rather than the risk ratios (RR) since it is easier to model the OR for network meta-analysis.
Although ORs are more difficult to interpret than RRs, we overcame this problem by presenting the results as illustrative comparative
risks for mortality, serious adverse events, and proportion of people requiring blood transfusion.
2. We calculated the mean difference (MD) and 95% credible interval (CrI) for quantity of blood transfused rather than the
standardised mean difference (SMD) and 95% CrI. We expected some authors to report quantity of blood transfused in litres
transfused and others to report this as number of units transfused. However, all the trials included in this review reported the quantity
of blood transfused in units enabling us to calculate the MD and 95% CrI, which is easier to interpret than SMD.
3. We planned to calculate the rate ratio with 95% CrI. However, the trials reported the proportion of people with serious adverse
events. So we calculated the OR with 95% CrI rather than the rate ratio with 95% CrI.
4. We used the residual deviance and Deviance Information Criteria (DIC) for assessing between-study heterogeneity as per the
guidance from the National Institute for Health and Care Excellence (NICE) Decision Support Unit (DSU) Technical Support
Documents (Dias 2012b; Dias 2013a).
5. We reported the network meta-analysis on all the outcomes although we planned to perform the network analysis for the
primary outcomes and one secondary outcome on blood transfusion requirements. This was to obtain and report the maximum
information from the available data.
6. We planned to report the random-effects model for network meta-analysis. However, we decided to report the fixed-effects
model or random-effects model based on residual deviance and DIC statistics as recommended by the NICE DSU Technical Support
Documents (Dias 2013a).
7. We did not fit the inconsistency model that uses the design-by-treatment approach proposed by Higgins and White (Higgins
2012; White 2012), since we used the assessment of inconsistency using the approach suggested by NICE DSU.
8. We did not first calculate all pair-wise meta-analysis estimates and then compare them with indirect comparison estimates
(Bucher 1997) for each loop, as the method that we used is an extension of the Bucher et al. (Bucher 1997) method to assess
inconsistency (Dias 2012c; Dias 2013e).
9. We did not perform the direct comparison. This was because of the exclusion of many trials that might have been suitable for
direct comparison but were unsuitable for the overview.
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Differences between first version and second version (current version)
1. We included all the interventions aimed at limiting blood loss and blood transfusion requirements. This was because of requests
for this information by stakeholders, which resulted in a directly commissioned report that included all interventions aimed at
decreasing blood loss and blood transfusion requirements.
2. We included the outcome ’any adverse event’ in addition to the serious adverse events since it was not possible to assess the
severity of the outcomes in many trials, for example, bile leak could be a mild adverse event or a serious adverse event depending upon
whether an additional intervention was needed to resolve it.
3. Unlike in the previous version, where we considered a combination of one method from each of Table 2, Table 3, and Table 4 as
a treatment strategy, in this review, we considered each of these interventions (different methods of cardiopulmonary interventions,
parenchymal transection methods, methods of dealing with raw surface, vascular occlusion methods, and pharmacological
interventions) as separate networks. This approach was in response to the lack of information on the details of co-interventions in the
trials and the design of the trials, which limited the number of trials included in the previous analysis. In many of the trials, the
surgeons involved in the trial were allowed to choose their method of liver resection apart from the factor being randomised. This is
based on an assumption that the factors are independent of each other, that is, there is no interaction between the factors, or the
choice of one factor is not dependent on the choice of another factor. There is no evidence to support or refute this assumption.
However, if we planned to include only trials in which all the intervention variables were adequately reported and none were left to
the choice of the surgeons, we would not even have been able to include as many trials as we did in the previous version, as we have
now included all the interventions aimed at decreasing blood loss and blood transfusion requirements during liver resection.
4. We performed a network meta-analysis only when it was possible to compare the direct and indirect estimates because one
cannot assess consistency between the direct and indirect estimates unless both are available.
5. We presented the direct estimates as those performed using Bayesian and frequentist analyses. For frequentist analysis, we
presented the results of the model that was used for Bayesian analysis (which was determined by the model fit).
6. We planned to perform subgroup analysis using WinBUGS rather than RevMan.
7. We did not perform sensitivity analysis considering some adverse events as serious and mild, since we included ’any adverse
events’ as an outcome. This captured the adverse events for which we were unable to assess the severity.
8. We modified the ’Summary of findings’ table from the original format because of the presence of many comparisons and many
outcomes. We presented only the comparisons in which there was evidence of differences with the illustrative examples. For other
comparisons, we simply mentioned that there was no evidence of differences. This is to ensure that the most important information is
available in the ’Summary of findings’ table.
9. We have provided links in the ’Summary of findings’ table to tables with a more traditional ’Summary of findings’ format.
10. In addition to this ’Summary of findings’ table, we also provided the ’Summary of findings’ table for network meta-analysis in a
graphical format (in the form of forest plots along with the quality of evidence), in which we used the methodology of grading the
quality of evidence in network meta-analysis suggested by the GRADE Working group (Puhan 2014). The first step is to estimate the
evidence from direct and indirect effect estimates. Further steps included rating the quality of evidence from direct and indirect effect
estimates, presenting the estimate combined from the direct estimate and indirect estimate, and rating the quality of the network
meta-analysis effect estimates (Puhan 2014). Although codes are available for node splitting, they resulted in numerical errors because
of the data,so we calculated the direct estimates (including only the trials that compared the specific intervention and control) and
indirect estimates (after removing the trials that compared the specific intervention and control).
11. We provided the minimal clinically important differences that we used or planned to use in an explicit manner. We considered a
20% relative risk reduction as minimal clinically important differences for binary outcomes and count outcomes. For continuous
outcomes, we used or planned to use the following minimal clinically important differences: a standardised mean difference of 0.5 for
health-related quality of life, a mean difference of one unit for blood transfusion quantity, a mean difference of 500 mL for blood loss,
a mean difference of one day of hospital stay and time-to-return to activity, and a mean difference of 15 min for operating time.
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N O T E S
Considerable overlap is evident in the Background and Methods sections of this review and those of several other reviews written by
the same group of authors.
Author order was changed inAugust 2013 as follows: Constantinos Simillis, Tianjing Li, Jessica Vaughan, Lorne Becker, BrianDavidson,
Kurinchi Gurusamy.
Author order was changed in October 2016 as follows: Elisabetta Moggia, Benjamin Rouse, Constantinos Simillis, Tianjing Li, Jessica
Vaughan, Brian Davidson, Kurinchi Gurusamy.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Bayes Theorem; Blood Loss, Surgical [∗prevention & control]; Blood Transfusion [utilization]; Catheter Ablation [methods]; Fibrin
Tissue Adhesive [administration & dosage]; Hemostasis, Surgical [∗methods]; Hepatectomy [adverse effects; ∗methods]; Randomized
Controlled Trials as Topic; Suction [instrumentation; methods]
MeSH check words
Humans
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